---
document_datetime: 2025-12-08 10:52:44
document_pages: 158
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/scemblix-vr-0000265010-epar-assessment-report-variation_en.pdf
document_name: scemblix-vr-0000265010-epar-assessment-report-variation_en.pdf
version: success
processing_time: 298.5677783
conversion_datetime: 2025-12-25 00:57:55.095671
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 October 2025 EMADOC-1700519818-2475374 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Invented name: Scemblix

International non-proprietary name: Asciminib

Procedure No. EMA/VR/0000265010

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                              |                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ..................................................................................     | 7                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 8                                                |
| 2. Scientific discussion                                                                                                | ................................................................................9                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 9 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 9             |
| 2.1.2. About the product .........................................................................................      | 11                                                                                                       |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 11                                                                                                 |
| 2.2. Non-clinical aspects..........................................................................................     | 12                                                                                                       |
| 2.2.1. Toxicology....................................................................................................   | 12                                                                                                       |
| 2.2.2. Ecotoxicity/environmental risk assessment........................................................                | 12                                                                                                       |
| 2.2.3. Discussion on non-clinical aspects....................................................................           | 12                                                                                                       |
| 2.2.4. Conclusion on the non-clinical aspects..............................................................             | 12                                                                                                       |
| 2.3. Clinical aspects ................................................................................................  | 13                                                                                                       |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 13     |
| 2.3.2. Pharmacokinetics ..........................................................................................      | 14                                                                                                       |
| 2.3.1. Methods.......................................................................................................   | 14                                                                                                       |
| 2.3.2. Pharmacokinetics in the target population.........................................................               | 16                                                                                                       |
| 2.3.3. Special populations........................................................................................      | 20                                                                                                       |
| 2.3.4. Genetic differences in pharmacokinetics............................................................              | 21                                                                                                       |
| 2.3.5. Pharmacodynamics........................................................................................         | 22                                                                                                       |
| 2.3.6. PK/PD modelling / exposure-response relationships............................................                    | 26                                                                                                       |
| 2.3.7. Discussion on clinical pharmacology .................................................................            | 29                                                                                                       |
| 2.3.8. Conclusions on clinical pharmacology                                                                             | ............................................................... 32                                       |
| 2.4. Clinical efficacy ................................................................................................ | 32                                                                                                       |
| 2.4.1. Main study                                                                                                       | ................................................................................................... 32   |
| 2.4.2. Discussion on clinical efficacy ..........................................................................       | 97                                                                                                       |
| 2.4.3. Conclusions on the clinical efficacy..................................................................102        |                                                                                                          |
| 2.5. Clinical safety                                                                                                    | .................................................................................................103     |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................141                           |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................143                             |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................143    |
| 2.6. Risk management plan.....................................................................................143       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................148                                 |
| 2.7.1. User consultation..........................................................................................148   |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................149                  |                                                                                                          |
| 3.1. Therapeutic Context ........................................................................................149    |                                                                                                          |
| 3.1.1. Disease or condition......................................................................................149    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................149                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................149                |
| 3.2. Favourable effects...........................................................................................150   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................151                                                            |
| 3.4. Unfavourable effects........................................................................................151    |                                                                                                          |

<div style=\"page-break-after: always\"></div>

3.5. Uncertainties and limitations about unfavourable effects .......................................  153

3.6. Effects Table ..................................................................................................  153

3.7. Benefit-risk assessment and discussion ..............................................................  154

3.7.1. Importance of favourable and unfavourable effects ...........................................  154

3.7.2. Balance of benefits and risks  ..........................................................................  155

3.7.3. Additional considerations on the benefit-risk balance .........................................  156

3.8. Conclusions  ....................................................................................................  156

4. Recommendations ...............................................................................  156

5. EPAR changes  ......................................................................................  157

Assessment report

<div style=\"page-break-after: always\"></div>

## List of abbreviations

2G

Second generation

1L

First line

2L

Second line

ABL1 /ABL1

Abelson oncogene; non-italicized: Abelson protein

ABL2 /ABL2

Abelson related oncogene; non-italicized: Abelson related protein

ADME

Absorption, distribution, metabolism, and excretion

ADR

Adverse drug reaction

AE

Adverse event

AESI

Adverse event of special interest

aGFR

Adjusted glomerular filtration rate

ALL

Acute lymphoblastic leukemia

ALLG

Australian Leukemia Lymphoma Group

Allo-SCT

Allogeneic stem cell transplantation

ALT

Alanine aminotransferase

AOEs

Arterial occlusive events

AP

Accelerated phase

AST

Aspartate aminotransferase

AUC

Area under curve

AUCinf

AUC from time zero to infinity

AUClast

AUC from time zero to the time of the last quantifiable concentration

AUCtau

AUC from time zero to the end of the dosing interval tau

BC

Blast crisis

BCR

Breakpoint Cluster Region

BCR::ABL1

Chimeric BCR::ABL1

oncogene

BCR::ABL1

BCR::ABL1 oncoprotein with dysregulated ABL1 kinase activity

BID

bis in diem /twice a day

BMA

Bone marrow aspirate

BP

Blast phase

BP

Systolic blood pressure/diastolic blood pressure

CBC

Complete blood count

CCI

Charlson Comorbidity Index

CCyR

Complete Cytogenetic Response

CHMP

Committee for Medicinal Products for Human Use

CHR

Complete hematological response

CI

Confidence Interval

Cmax

Observed maximum plasma (or serum or blood) concentration following drug

administration

CMH

Cochran-Mantel-Haenszel

Cmin

Trough concentration

CL

Systemic (or total body) clearance from plasma (or serum or blood) following

intravenous

administration

CL/F

Apparent systemic (or total body) clearance from plasma (or serum or blood) following

extravascular administration

CLr

Renal clearance from plasma (or serum or blood) [volume / time]

CML

Chronic Myeloid Leukemia

CML-AP

Chronic myeloid leukemia in accelerated phase

CML-CP

Chronic myeloid leukemia in chronic phase

COVID-19

Coronavirus Disease of 2019

CRF

Case report form

CSR

Clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

Ctrough/Cmin

Plasma concentration (measured concentration at the end of a dosing interval at steady state

[taken directly before next administration])

CV

Coefficient of variation

CVD

Cardiovascular disease

CYP

Cytochromes P450

DDI

Drug-drug interaction

<div style=\"page-break-after: always\"></div>

DMR Deep molecular response EAIR Exposure-adjusted incidence rate ECOG Eastern Cooperative Oncology Group EFS Event Free Survival ELN European Leukemia Net ELTS EUTOS Long-Term Survival EMA European Medicines Agency EORTC QLQC30     European organization for research and treatment of cancer - quality of life questionnaire EORTC QLQCML24    European organization for research and treatment of cancer CML module EOT End of treatment EQ VAS EuroQol Visual Analogue Scale EUTOS European Treatment Outcome Study EWOC Escalation with overdose control FAS Full Analysis Set FCT Film-coated tablet FDA Food and Drug Administration FFS Failure Free Survival FIH First in human FMI Final market image GGT Gamma-glutamyltransferase HRQoL Health-related quality of life ICH International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use IRT Interactive Response Technology that includes Interactive Voice Response System and Interactive Web Response System IS International scale IS-TKI Investigator selected-TKI KM Kaplan-Meier LPLV Last patient last visit MCyR Major cytogenetic response mCyR Minor Cytogenetic Response MedDRA Medical Dictionary for Regulatory Activities MMR Major molecular response MoA Mechanism of action MTD Maximum tolerated dose NCCN National Comprehensive Cancer Network NCI National Cancer Institute NE Not estimable OS Overall survival PA Primary analysis Ph+ CML Philadelphia chromosome-positive chronic myelogenous leukemia Papp Apparent permeability coefficient PBPK Physiologically based pharmacokinetic PCR Polymerase Chain Reaction PCyR Partial Cytogenetic response PD Pharmacodynamic(s) PFS Progression-free survival Ph+ Philadelphia chromosome positive PK Pharmacokinetics PopPK Population PK PRAC Pharmacovigilance Risk Assessment Committee PRO Patient-reported outcomes PRS-TKI Pre-randomization selected-TKI QD Once daily RDE Recommended dose for expansion RQ-PCR Real time quantitative polymerase chain reaction RT-PCR Reverse transcription polymerase chain reaction SAE Serious adverse event SBP Summary of biopharmaceutics SCP Summary of clinical pharmacology SD Standard deviation

<div style=\"page-break-after: always\"></div>

SOC System organ class SOP Standard operating procedure sNDA Supplementary New Drug Application TEAE Treatment-emergent adverse event T1/2 Terminal elimination half-life TFR Treatment-free remission TKI Tyrosine kinase inhibitors Tmax Time to reach the maximum concentration after drug administration TTF Time to treatment failure ULN Upper limit of normal

Assessment report

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Novartis Europharm Limited submitted to the European Medicines Agency on 07 April 2025 an application for group of variations.

The following changes were proposed:

| Variation(s) requested   | Variation(s) requested                                                                                                                                      | Type              |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| C.I.6.a                  | C.I.6.a Addition of a new therapeutic indication or modification of an approved one                                                                         | Variation type II |
| C.I.4                    | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data | Variation type II |

A grouped application consisting of:

C.I.6.a: Extension of indication to include treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) for SCEMBLIX, based on primary and key secondary analysis results from study CABL001J12301 (ASC4FIRST, J12301); this is an ongoing Phase III, multi-center, open-label, randomized study of oral asciminib (80 mg once daily, QD) versus Investigator selected tyrosine kinase inhibitor (TKI) in patients with newly diagnosed Ph+ CML-CP, with the primary and key secondary objectives to compare the major molecular response (MMR) rates at Week 48 and Week 96, respectively. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. RMP version 4.0 was also submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.

C.I.4: Update of sections 4.2, 4.5, 5.1, 5.2 and 5.3 of the SmPC in order to introduce a new posology regimen based on results from studies CABL001J12301 and CABL001A2302 (ASC4OPT, A2302). CABL001A2302 is an ongoing Phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib (80 mg daily, randomized to 40 mg BID or 80 mg QD) in patients with Ph+ CML-CP previously treated with two or more TKIs, with the primary objective to estimate the MMR rate at Week 48 of all the patients (40 mg BID and 80 mg QD) with no evidence of MMR at baseline. The Package Leaflet is updated accordingly. RMP version 4.0 has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Scemblix was designated as an orphan medicinal product EU/3/20/2261 on 24 March 2020. Scemblix was designated as an orphan medicinal product in the following indication: Treatment of chronic myeloid leukaemia.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation for the treatment of chronic myeloid leukaemia as

<div style=\"page-break-after: always\"></div>

an orphan medicinal product in the approved indication. The outcome of the COMP review can be found here https://www.ema.europa.eu/en/medicines/human/Scemblix

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision EMEA-002347-PIP01-18 on the agreement of a paediatric investigation plan (PIP) .

At the time of submission of the application, the PIP EMEA-002347-PIP01-18 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Scemblix as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/scemblix

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 25 March 2021 (EMA/SA/0000047632), on 19 September 2025 (EMA/SA/0000181795). The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Martin Mengel

Co-Rapporteur:  n/a

| Timetable                                                     | Actual dates   |
|---------------------------------------------------------------|----------------|
| Submission date                                               | 7 April 2025   |
| Start of procedure:                                           | 26 April 2025  |
| CHMP Rapporteur's preliminary assessment report circulated on | 26 June 2025   |
| PRAC RMP advice and assessment overview adopted by PRAC on    | 10 July 2025   |
| CHMP Rapporteur's updated assessment report circulated on     | 18 July 2025   |

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                                                                  | Actual dates      |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Request for supplementary information and extension of timetable adopted by the CHMP on                                                    | 24 July 2025      |
| MAH's responses submitted to the CHMP on                                                                                                   | 13 August 2025    |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on                                                       | 19 September 2025 |
| PRAC RMP advice and assessment overview adopted by PRAC on                                                                                 | 2 October 2025    |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on                                                           | 10 October 2025   |
| CHMP opinion:                                                                                                                              | 16 October 2025   |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Scemblix in comparison with existing therapies | 16 October 2025   |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The newly claimed indication is:

Scemblix is indicated for the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+CML-CP)

## Epidemiology

The disease has an annual incidence of one to two cases per 100000, with a median age of 66 years at presentation. Prevalence is steadily increasing due to improved survival.

## Aetiology and pathogenesis

Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm and is characterised by uncontrolled proliferation of mature and maturing granulocytes in blood and bone marrow.  CML is caused by a reciprocal translocation of chromosomes 9 and 22 (t(9;22)(q34;q11)), generating a BCR::ABL1 fusion gene, which is translated into a constitutively active kinase protein, promoting cell growth and replication via downstream signalling pathways such as RAS, RAF; MYC and STAT.

## Clinical presentation, diagnosis and prognosis

The natural history of CML is characterized by a triphasic course. In most of the patients, the disease is diagnosed in the chronic phase (CP), which is characterized by overproduction and accumulation of immature myelogenous cells and mature granulocytes in the spleen, bone marrow, and peripheral blood. If CML-CP remains untreated, or it is not controlled with available therapies, patients will progress to an intermediate phase known as accelerated phase (AP), marked by the presence of primitive blast cells in the bone marrow and peripheral blood.

<div style=\"page-break-after: always\"></div>

Most patients with CML-AP eventually progress to a blastic phase (BP), a condition resembling acute leukaemia in which myeloid or lymphoid blasts proliferate in an uncontrolled manner (Apperley 2015). Based on the experience with TKIs, the best approach to avoid advanced CML (CML-AP/-BP) is preventing progression and keeping patients in the well-controlled chronic phase.

The prognosis of CML has changed during the past two decades from a disease with an overall survival of only 5-7 years to one in which patients responding to TKI treatment can expect a near to normal life expectancy (Apperley 2015) with 1% CML associated mortality. However, some patients do not respond to the treatment (primary resistance), lose their response (secondary resistance), or experience tolerability issues. Also, the detection of BCR-ABL1 mutations in CML-CP, in particular T315I mutation, are associated with a greater likelihood of resistance to TKI treatment and consequent disease progression (Soverini 2005).

## Management

Since the approval of imatinib in 2001, the 10-year survival rates for patients with CML have improved from approximately 20% to around 80-90%, and targeted therapy with TKIs has become the gold standard of treatment (Jabbour and Kantarjian 2018). There are four TKIs approved in the EU for the treatment of newly diagnosed CML in the chronic phase (1 st  generation: imatinib; 2 nd  generation: nilotinib, dasatinib, bosutinib).

The two main goals of CML treatment are to normalise survival and to achieve durable deep molecular responses (DMR, including MR4 and MR4.5 lasting for 2-5+ years) allowing for a treatment free remission (TFR). The choice of the TKI depends on 1) the patient's age and comorbidities 2) the CML risk profile 3) the cost and affordability of the TKI 4) the treatment goal, as imatinib is considered to be equally effective for prolongation of survival to 2 nd  generation TKI. Achievement of deep molecular remissions is potentially faster with 2 nd  generation TKI, possibly reaching the criteria for a discontinuation attempt in a TFR faster.

Achievement of major molecular response (MMR, MR3.0, BCR-ABL1 ≤ 0.1%) is, following clinical guidelines, predictive for CML-specific survival, as disease progression is uncommon, once this level of cytoreduction has been achieved (European Leukemia Net GL, 2020).

Clinical decision making in 1 st  and 2 nd  line treatment is guided by monitoring milestones of BCR-ABL1 transcript levels on the international scale (IS). Here, optimal response implies treatment continuation, failure implies a change in treatment and warranting careful consideration, considering treatment goals, tolerance and comorbidities.

<div style=\"page-break-after: always\"></div>

Table 1 Milestones for treating CML

|           | Optimal   | Warning                             | Failure                                  |
|-----------|-----------|-------------------------------------|------------------------------------------|
| Baseline  | NA        | High-risk ACA, high-risk ELTS score | NA                                       |
| 3 months  | ≤10%      | >10%                                | >10%if confirmedwithin1-3 months         |
| 6 months  | ≤1%       | >1-10%                              | >10%                                     |
| 12 months | ≤0.1%     | >0.1-1%                             | >1%                                      |
| Any time  | ≤0.1%     | >0.1-1%, loss of ≤0.1% (MMR)        | >1%, resistance mutations, high-risk ACA |

For patients aiming at TFR, the optimal response (at any time) is BCR-ABL1 ≤ 0.01% (MR4). A change of treatment may be considered if MMR is not reached by 36 -48 months. NA not applicable, ACA additional chromosome abnormalities in Ph + cells, ELTS EUTOS long term survival score.  a Loss of MMR (BCR-ABL1 &gt; 0.1%) indicates failure after TFR

A respectable number of patients fail to reach or maintain deep remissions due to primary or secondary resistance or have difficulties in the tolerability of the drug. The optimal sequence of TKI therapy remains controversial in respect to safety of a long-term treatment, especially in patients with comorbidities. Ponatinib is approved after treatment with dasatinib or nilotinib or in the presence of a T315I mutation.

Asciminib is currently approved in the EU for adults after treatment with two or more TKIs and recommended by the National Comprehensive Cancer Network (NCCN) 2025 guideline and 2025 European LeukemiaNet.

## 2.1.2. About the product

Asciminib (ABL001), administered orally, is a potent allosteric inhibitor of ABL/BCR-ABL1 tyrosine kinase by specifically targeting the ABL myristoyl pocket (STAMP).BCR-ABL1 is a chimeric oncoprotein with the constitutively active ABL1 tyrosine kinase domain. Asciminib inhibits the ABL1 kinase activity of the BCR-ABL1 fusion protein, by specifically targeting the ABL myristoyl pocket. Asciminib (ABL001) is an inhibitor that targets the myristoyl pocket of BCR-ABL1, in contrast to the currently available TKIs that target the BCR-ABL1 ATP binding site. By virtue of asciminib not interacting with the ATP-binding site, asciminib maintains activity against cells expressing clinically observed ATP-binding TKI resistant mutations. Asciminib was approved in the EU for adults with Ph+ CML-CP after treatment with two or more TKIs on 25 August 2022.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Advice for the development of asciminib monotherapy as 1L treatment was received from CHMP on 25 March 2021 and included the following aspects:

- -Population: Including patients with moderate renal - and hepatic impairment was endorsed. Excluding patients with a history of acute pancreatitis within one year prior to randomisation or with chronic pancreatitis or chronic liver disease was considered acceptable.

<div style=\"page-break-after: always\"></div>

- -Endpoints: 1) in this context, it was accepted that only activity to measure positive effects, supported by endpoints that reflect changes in clinical management (loss of or not obtaining activity), and favourable safety are acceptable to support an extension of the indication. 2) The endpoint 'MMR at 48 weeks' was considered early but was in line with other recently approved TKI (nilotinib, bosutinib), although EMA Anticancer guideline recommends MMR at 18 months. 3) EFS as a secondary endpoint, including treatment change could further justify the clinical relevance of the primary endpoint 4) 'Region' should be noted in the randomisation or analysis to provide information about regional differences.
- -Statistical design: 1) The proposed global comparison of activity (MRR) in an 'overall population' against a multi-comparator-control was considered less useful due to heterogeneous populations, heterogeneous activity/tolerability profiles and that the comparison might be driven by the effect of imatinib rather than 2G TKIs. 2) The difficulty to define a non-inferiority margin in case the applicant favours a comparison with 2G TKI in terms of favourable safety.

## 2.2. Non-clinical aspects

## 2.2.1. Toxicology

No new non-clinical data were submitted other than for the new posology, 80 mg QD additional safety margins were calculated and section 5.3. of the SmPC was updated accordingly.

## 2.2.2. Ecotoxicity/environmental risk assessment

In a parallel submission for the indication CML-CP with T315I mutation (EMA/X/0000256688) for which the assessment is ongoing, a phase II ERA for the active substance asciminib was provided. As this revised ERA is based on prevalence data for CML, the applicant claimed that the already approved ERA (provided with the initial MAA) also covers the patient population applied for in the current authorisation application. Furthermore, the maximum daily dose of 400 mg/day used in the respective ERA is higher than in the current submission (80 mg/day). Therefore, the MAH stated that the conclusions from the recently submitted assessment remain conservative and valid and the ERA does not warrant an update.

## 2.2.3. Discussion on non-clinical aspects

No new nonclinical data were submitted which is considered acceptable as this extension of indication relates to the same condition and is therefore covered by previously submitted data.

As for this type II variation, the recommended daily dose of 80 mg/day is less than the maximum daily dose of 400 mg/day used in the already provided ERA and therefore an increase in the environmental exposure is not anticipated. Consequently, the MAH's conclusion can be followed and an update of the existing ERA is deemed not required. Furthermore, for this type II variation the calculation of PECSW (under consideration of a maximum daily dose of 80 mg/day and the refined Fpen of 0.00013) results in a value of 0.0052 µg/l and does not exceed the trigger value of 0.01 µg/l.

## 2.2.4. Conclusion on the non-clinical aspects

The new/extended indication does not lead to a significant increase in environmental exposure further to the use of asciminib hydrochloride.

<div style=\"page-break-after: always\"></div>

Considering the above, asciminib hydrochloride is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 2 Overview of key clinical studies

| Studies/ Population/ No. of participants (N) No. of participants included                  | Study description                                                                                                                                                      | Dose schedule                                                             | Data cut- off date                                                    | Completion status                                   |
|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------|
| CABL001J12301 Adult participants with newly diagnosed Ph+ CML-CP N=405 n=200               | A phase III, multi-center, open-label, randomised study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Ph+ CML-CP                 | 80 mg QD                                                                  | 28-Nov-2023 (Week 48 Primary CSR) 22-Oct-2024 (Week 96 Secondary CSR) | Ongoing                                             |
| Supportive studies in the All Asciminib Safety pool                                        | Supportive studies in the All Asciminib Safety pool                                                                                                                    | Supportive studies in the All Asciminib Safety pool                       | Supportive studies in the All Asciminib Safety pool                   | Supportive studies in the All Asciminib Safety pool |
| CABL001A2301 Adult participants withPh+ CML-CP previously treated with ≥2 TKIs N=233 n=156 | Aphase III, multi- center, open- label, randomised study of oral ABL001 (asciminib) versus bosutinib in patients with CML-CP, previously treated with two or more TKIs | 40 mg BID                                                                 | 22-Mar-2023 (EOT CSR)                                                 | Ongoing                                             |
| CABL001X2101 Adult participants with Ph+ CML or ALL,                                       | A phase I, multicenter, open-label study of oral ABL001in                                                                                                              | 10, 20, 40, 80, 150, 160, 200, 280 mg BID and 40, 60 80, 120, 160, 200 mg | 14-Mar-2023 (final CSR)                                               | Completed                                           |

<div style=\"page-break-after: always\"></div>

| relapsed, refractory to or intolerant of TKIs N=326 n=200   | patients with Ph+ CML or Ph+ALL a                                                                                                                     | QD as single agent or in combination with imatinib, nilotinib or dasatinib   |                                                             |         |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------|---------|
| Additional study in 2L                                      |                                                                                                                                                       |                                                                              |                                                             |         |
| CABL001AUS08 N=101 (2L cohort)                              | A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1 st Line Chronic Phase- Chronic Myelogenous | 80 mg QD                                                                     | 15-Nov-2024 (IA 4 including efficacy set=63 safety set=101) | Ongoing |

## 2.3.2. Pharmacokinetics

For the requested extension of indication, PK data from the pivotal ongoing Phase III study J12301 in newly diagnosed Ph+ CML-CP patients (1L) were submitted.

In addition, new PopPK analyses based on study X2101 (completed FIH study (N=326) including adult patients with cytogenetically confirmed, previously diagnosed CML or Ph+ ALL), J12301 (N=405; n=201 in asciminib arm), A2103 (hepatic impairment study), and A2105 (renal impairment study) were presented.

Exposure-response analyses based on studies J12301, A2301 (pivotal phase III study in 3L+ CML for initial MAA), and X2101, as well as PK-pharmacogenomics analyses for UGT2B7 and UGT2B17 based on J12301 were also included.

In addition, the current variation also concerned the addition of the 80 mg QD regimen as alternative dosing for the previously approved 3L+ CML population. In this respect, the new PopPK model was also used for an updated PK profile comparison of the asciminib 40 mg BID and 80 mg QD dosing regimens and by exposure-efficacy analyses.

An intrapolation to second-line treatment with a total-daily dose regimen of 80 mg (either 40 mg BID or 80 mg QD) based on ER modelling was also included.

## 2.3.1. Methods

## PopPK modelling

The newly submitted revised popPK model comprised the following studies: A2103 (renal impairment in HV), A2105 (hepatic impairment in HV), X2101 (FIH), A2301, and J12301. The starting model was a combination of the original popPK model and the model developed by the FDA, incorporating all interaction terms and all covariates retained in either one of those models. The total number of subjects in the updated popPK pool was 637. During model refinement, formulation on Tlag and the correlation between ka and Tlag was deleted. Thus, the final model was a 2-compartment model with first order absorption, lag time for absorption, clearance from central compartment and total daily dose as a structural covariate on clearance. The final covariate model included race on Tlag (Asian or nonAsian), formulation on Ka (capsule versus table), total daily dose, baseline age, sex, baseline weight, and baseline aGFR on CL, and formulation, sex and baseline weight on V1. Inter-individual variabilities

<div style=\"page-break-after: always\"></div>

were applied following a log-normal distribution on the parameters Tlag, Ka, CL, V1 and V2, with correlation terms between CL and V1, CL and V2, and between V1 and V2. The residual error model selected combined both additive and proportional residual error model.

With the update of the dataset, also more data on the dosing regimen of 80 mg QD were available. The original popPK analysis included only n=18 patients receiving 80 mg QD in study X2101. The updated popPK dataset now includes n=197 patients from Study J12301 where the 80 mg QD dosing regimen was studied. In order to further compare the two-dosing regimen 40mg BID and 80 mg QD, the final popPK model was used to update the PK profile comparison of the two regimens simulating 500 subjects in each dosing regimen. PcVPCs for the different dosing regimens 80mg QD and 40 mg BID are depicted below.

<!-- image -->

Blue dots:observations.Blackdashed lines:5th,50th,and 95thpercentiles of the observations.Blue solid lines: 5th,50th,and 95thpercentilesofthepredictions.Blueshades:95%confidence intervalof5thand 95th percentilesof thepredictions.Red shade:95%confidence intervalof5othpercentileof thepredictions. Source:vob/CABL001A/mas/mas\\_3/model/pgm\\_001/pcVPC.R-&gt;pcVPC.png Model:vob/CABL001A//mas/mas3/model/pgm001/PopPK/Runfinal0.mlxtran

Figure 1 Prediction-corrected visual predictive checks (pcVPC) on first dosing day of asciminib, stratified by dosing regimen- QD left panel, BID right panel

Results of the simulated PK metrics for the 40 mg BID and 80 mg QD dosing regimens are summarized below (see Table 3).

Table 3 Summary of simulated PK metrics of 40 mg BID and 80 mg QD

| Regimen      | Cmax (ng/mL)   | AUC0-24h (ng*h/mL)   | Cmin (ng/mL)   |
|--------------|----------------|----------------------|----------------|
| 40 mg b.i.d. | 829 (33%)      | 12564 (39%)          | 320 (53%)      |
| 80 mg q.d.   | 1289 (35%)     | 12558 (41%)          | 222 (71%)      |

Arithmetic mean and %CV are presented

Source:vob/CABL001A/mas/mas\\_3/simulation/pgm\\_001/Comp\\_40BID\\_80QD.R

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics in the target population

## Newly diagnosed Ph+ CML-CP (1L)

## Study J12301 in newly diagnosed Ph+ CML-CP (1L)

Study J12301 is the pivotal ongoing Phase III, multi-centre, open-label, randomised study of asciminib 80 mg QD vs. investigator selected TKI (imatinib, nilotinib, dasatinib, or bosutinib) in patients with newly diagnosed (ND) Ph+ CML-CP (1L). 405 patients were randomised, of which 201 received asciminib.

Full PK sampling was performed in 25 patients over 12 hours on week 2/day 14 at selected sites. All patients had sparse sampling pre-dose at weeks 2 /day 14 and at weeks 4, 12, 24 and 48 and analysed by a validated LC-MS/MS method with a LLOQ of 1.00 ng/ml. No PK samples were collected after Week 48 visit.

The primary Week 48 data cut-off was on 28-Nov-2023. The data cut-off date (30-Oct-2023) for the PK analysis (Week 2 / Day 14) was different from the primary analysis DCO date. There were 6 additional samples (Week 48 sparse samples) that were collected between 30-Oct-2023 and 28-Nov2023. Therefore, these additional data were included in the Week 96 CSR. However, the MAH identified that at the time of the PK analysis DCO that dosing information were improperly merged with PK concentration data which led to errors in the PK data in the Week 48 primary analysis CSR. In total, data from 59 samples from 51 unique participants were impacted. All impacted data were for participants with sparse PK samples.

As a consequence of these corrected PK data outputs and additional 6 samples, there was a minor change in the trough concentration (Ctrough) geo-mean range to 161 - 192 ng/mL (from the previously reported 160 - 182 ng/mL) (Figure 3).

Plasma concentrations of asciminib increased rapidly after oral administration of asciminib 80 mg QD with a median Tmax of 2.0 hr. The steady-state geo-mean Cmax was 1470 ng/mL (geo-mean CV% 38.2%), geo-mean of AUClast was 8590 ng*hr/mL (geo-mean CV% 42.2%; note: Tlast was 12 hr post-dose).

<div style=\"page-break-after: always\"></div>

Figure 2: Asciminib steady-state plasma concentration-time profiles in 1L Ph+ CML-CP, study J12301

<!-- image -->

Figure 14.2-3.1

Figure 3: Asciminib trough concentration-time profiles in 1L Ph+ CML-CP, study J12301 - Full and sparse PK sampling

<!-- image -->

TKI-pretreated patients with CML-CP (3L+)

## Study A2301 in TKI-pretreated patients with 3L+ CML-CP

Study A2301 is an ongoing Phase IIIb, multi-centre, open-label, active-controlled randomised of oral asciminib 40 mg BID vs. bosutinib 500 mg QD in the treatment of TKI-pretreated patients with 3L+ CML-CP, submitted as pivotal study for the initial MAA. Of 233 patients randomised in a 2:1 ratio 157 were randomised to asciminib. PK data were included in the popPK and ERR analyses.

Time (hr)

<div style=\"page-break-after: always\"></div>

## PopPK modelling

The newly submitted revised popPK model comprised of the following studies: A2103 (renal impairment in HV), A2105 (hepatic impairment in HV), X2101 (FIH), A2301, and J12301.

## Lines of TKI pre-treatment

Relationships between these potential covariates and asciminib clearance were investigated. The typical individual in the initially submitted model was a 51.6-year-old and 70 kg non-Asian male patient whose baseline aGFR is 90 mL/min, on a total daily dose of 80 mg using the FMI formulation. Asciminib clearance for this typical individual was 6.89 L/h, and the combined volumes of central and peripheral compartments were approximately 109 L (V1 of 56.7 L and V2 of 51.9 L). The clearance of 6.89 L/h predicted by the final model was in line with both the clearance predicted by the original popPK model (6.31 L/h), and by the independent model developed by the FDA (9.48 L/h).

From this popPK model, no correlation was seen between clearance and number of prior TKI treatments, suggesting that there is no difference in asciminib PK between 1L and 3L+ patients (Figure 4).

Figure 4: Correlation between clearance and number of TKI pre-treatments

<!-- image -->

## Alternative dosing 80 mg QD vs. 40 mg BID in 3L+ CML-CP

The 80 mg QD dosing regimen was originally proposed as an alternative regimen to 40 mg BID in 3L+ CML-CP, based on simulations from the dataset with a limited number of patients treated with 80 mg QD (n=18) in study X2101. As the popPK dataset now includes n=197 patients from 1L CML-CP Study J12301 where the 80 mg QD dosing regimen was studied, the final popPK model was used to update the PK profile comparison of the two regimens.

In the initially submitted model, the simulated average AUC0-24h values were comparable between the two regimens, while the average Cmax and Cmin at steady state of 80 mg QD were 1.62-fold and 0.71-fold of that of 40 mg BID, respectively, consistent with the results described in the original popPK analysis.

Clearance was very similar between the 40 mg BID (n=192) and 80 mg QD (n=215) dose regimens.

Upon request, the MAH further revised the model to include regimen as covariate to account for potential differences between dosing frequencies using only the 80mg QD and 40mg BID data to avoid confounding by higher doses with nonlinear PK (Table 4).

<div style=\"page-break-after: always\"></div>

Table 4 Summary of PopPK vs NCA derived asciminib PK parameters at 40 mg BID and 80 mg QD at steady state

|                       | PopPK simulated 40 mg b.i.d.   | PopPK simulated 40 mg b.i.d.        |               |               | PopPK simulated 80 mg QD      |                      |              |
|-----------------------|--------------------------------|-------------------------------------|---------------|---------------|-------------------------------|----------------------|--------------|
|                       | AUC 0-12h = AUC tau (ng.h/m L) | AUC 0-24h (ng.h/mL) (2*AUC 0- 12h ) | Cmax (ng/m L) | Cmin (ng/m L) | AUC 0-24h = AUC tau (ng.h/mL) | Cmax (ng/mL)         | Cmin (ng/mL) |
| Geomean (geomean %CV) | 5422 (43)                      | 10844 (43)                          | 624 (41)      | 270 (63)      | 11639 (43)                    | 956 (42)             | 142 (99)     |
| Mean ± SD             | 5902 ± 2556                    | 11804 ± 5111                        | 675 ± 280     | 315 ± 180     | 12672 ± 5491                  | 1036 ± 426           | 194 ± 164    |
| Median                | 5441                           | 10881                               | 631           | 273           | 11692                         | 959                  | 145          |
| 90% CI                | [2755, 10363]                  | [5511, 20725]                       | [325, 1207]   | [107, 650]    | [5910, 22278]                 | [483, 1799]          | [39, 499]    |
|                       | NCA 40 mg BID (X2101)          | NCA 40 mg BID (X2101)               |               |               | NCA 80 mg QD (X2101)          | NCA 80 mg QD (X2101) |              |
|                       | AUC tau (ng.h/m L)             | AUC 0-24h (ng.h/mL) (2*AUC tau )    | Cmax (ng/m L) | Cmin (ng/m L) | AUC tau (ng.h/mL)             | Cmax (ng/mL)         | Cmin (ng/mL) |
| Geomean (geomean      | 5262 (48.49)                   | 10524                               | 793 (48.92)   | 263 (67.53)   | 15112 (27.85)                 | 1781 (23.34)         | 193 (39.58)  |

%CV)

Figure 5: Visual predictive check showing overlay of observed and predicted PK profiles

<!-- image -->

vob/CABL001A/mas/mas\\_3/model/pgm\\_008/PlotOverlayObsVsPred2.R -&gt; /output\\_008/VPCABL001PK3A.png Model:vob/CABL001A/mas/mas\\_3/model/pgm\\_008/PopPK/Run13A.mlxtran

Grey dots: observations. Blue solid lines: 50th percentiles of the observed PK data; red solid lines: 2.5th and 97.5th percentiles of observed PK data. Blue shades: 95% confidence interval of 50th percentiles of the predictions from 200 replicates. Red shades: 95% confidence interval of 2.5th and 97.5th percentiles of the predictions.

<div style=\"page-break-after: always\"></div>

Figure 6: Boxplots comparing PopPK-predicted PK parameters of asciminib 40 mg BID and 80 mg QD  at steady state

<!-- image -->

vob/CABL001A/mas/mas\\_3/model/pgm\\_008/Compute40mgBID80mgQDPK1.R -&gt;BoxplotsPKparameters.png

## 2.3.3. Special populations

## Renal impairment

The revised PopPK analysis included 348 subjects with normal renal function, 233 subjects with mild renal impairment, 48 subjects with moderate renal impairment, and 8 subjects with severe renal impairment, based on aGFR (absolute GFR) at baseline by MDRD.

Clearance was lower in patients with mild, moderate and severe renal impairment compared to those with normal renal function (Figure 7). However, these results should be interpreted with caution, given the limited number of subjects in the moderate (n=48, 7.5%) and severe (n=8, 1.3%) renal impairment categories. The impact of renal function was not statistically significant, suggesting that no dose adjustment is necessary.

<div style=\"page-break-after: always\"></div>

Figure 7: Correlation between renal impairment category and clearance

<!-- image -->

## Hepatic impairment / liver function

The patients in the CML studies were enrolled based on liver function tests and classified according to NCI liver function criteria.

The popPK report highlighted that while for the primary analysis of the dedicated hepatic impairment study A2103 subjects were assigned to hepatic function groups based on the Child-Pugh classification, for the purposes of exploratory analysis in phase III study A2301 and for the analyses in the popPK report, subjects were (re-)classified according to the NCI-ODWG liver function criteria. There seemed to be a low degree of concordance between the assessments made by Child-Pugh classification and NCI criteria in study A2301 which led to discrepancies in the popPK in proportions of A2103 subjects in the various hepatic function categories (subject numbers enrolled by Child-Pugh per severity class 8:8:8:8; re-classified by NCI 17:6:4:5 normal/mild/moderate/severe subjects).

No correlation between liver function by NCI-ODWG criteria and clearance was observed in the popPK model.

## 2.3.4. Genetic differences in pharmacokinetics

As asciminib is mainly metabolized via UGTs (UGT2B7 [28%], UGT2B17 [16%], UGT1A3/4 [14%]) (in total ~60%) and CYP3A4 (~35%), previously the effect of UGT2B7 and UGT2B17 genetic variants on the PK of asciminib (Ctrough) in samples from study A2301 was analysed and polymorphisms for both UGTs did not have a clinically relevant effect on PK.

In study J12301 (report DMPK-RC4009521-OTHER), of 200 patients 149 patients had valid data for UGT2B7 and 151 patients had valid data for UGT2B17. For UGT2B7 there were four different phenotypes: intermediate (5/149, 3%), normal (58/149, 39%), rapid (58/149, 39%), and ultrarapid metabolizer (28/149, 19%). For UGT2B17 there were three different phenotypes: intermediate (66/151, 44%), normal (44/151, 29%), and poor metabolizer (41/151, 27%).

<div style=\"page-break-after: always\"></div>

Among the different UGT2B7 phenotypes, no statistically significant difference was observed (KruskalWallis test, p-value of 0.064), neither for different UGT2B7 allele combinations (Table 5).

Table 5 Summary statistics of Ctrough levels (ng/mL) by UGT2B7 phenotype, study J12301

| Statistics               | Intermediate Metabolizer   | Normal Metabolizer   | Rapid Metabolizer   | Ultrarapid Metabolizer   |
|--------------------------|----------------------------|----------------------|---------------------|--------------------------|
| N                        | 5                          | 57                   | 55                  | 28                       |
| QC pass                  | 5 (100%)                   | 57 (100%)            | 55 (100%)           | 28 (100%)                |
| Mean (SD)                | 165 (178)                  | 195 (109)            | 222 (136)           | 232 (110)                |
| Median (Min- Max)        | 117 (56-245)               | 168 (146-194)        | 196 (172-222)       | 209 (175-249)            |
| Geometric mean           | 108                        | 161                  | 182                 | 209                      |
| 95% CI for geometricmean | 61-480                     | 50-496               | 91-866              | 80-480                   |

Among the different UGT2B17 phenotypes, no statistically significant difference was observed (KruskalWallis test, p -value = 0.762) neither for different UGT2B17 allele combinations (Table 6).

Table 6 Summary statistics of Ctrough (ng/mL) levels by UGT2B17 phenotype, study J12301

| Statistics                | Intermediate Metabolizer   | Normal Metabolizer   | Poor Metabolizer   |
|---------------------------|----------------------------|----------------------|--------------------|
| N                         | 64                         | 42                   | 41                 |
| Mean (SD)                 | 214 (114)                  | 216 (154)            | 198 (96)           |
| Median (Min-Max)          | 186 (163-213)              | 183 (155-215)        | 177 (153-206)      |
| Geometric mean            | 179                        | 161                  | 185                |
| 95% CI for geometric mean | 50-487                     | 80-866               | 60-456             |

## 2.3.5. Pharmacodynamics

## Mechanism of action

Asciminib is a potent inhibitor of BCR::ABL1 tyrosine kinase. BCR::ABL1 is a chimeric oncoprotein with the constitutively active ABL1 tyrosine kinase domain. Asciminib, by specifically targeting the allosteric myristoyl binding pocket on the SH1 domain of ABL1, inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein.

## Primary and secondary pharmacology

## Primary pharmacology

1L study J12301 evaluated BCR::ABL ratio IS (%) change from baseline vs. average trough asciminib concentration at week 48 ( Figure 8 a).

<div style=\"page-break-after: always\"></div>

Figure 8a: BCR::ABL ratio IS (%) change from baseline vs. average trough asciminib concentration at week 48 - 1L study J12301

<!-- image -->

Average trough asciminib concentration (ng/mL)

Updated CSR J12301 w96 Figure 14.2-6.1

In Figure 8b, the individual BCR::ABL IS (%) values at Week 48 vs. average trough concentrations (Cmin) are provided. In line with change from baseline, a shallow correlation (rho = -0.121) is apparent between BCR::ABL IS (%) and average Cmin.

Figure 8b: Average asciminib trough concentrations vs. BCR::ABL1 ratio (IS%) at week 48 1L study J12301

<!-- image -->

Source: Response to 1. RSI, Figure 2-3

## Study A2302 in TKI-pretreated 3L+CML-CP patients - 40 mg BID vs. 80 mg QD

Study A2302 was a phase IIIb, multi-centre, open-label, treatment optimization study of oral asciminib in TKI-pretreated patients with CML-CP (3L+) to estimate the MMR rate at Week 48 of all subjects (40 mg BID and 80 mg QD) with CML-CP following two or more prior TKI treatments and with no evidence of MMR at baseline. No PK sampling was performed but sampling for biomarkers.

For the patients without MMR at baseline the BCR::ABL1 (%IS) ratio plot in MMR (≤ 0.1%) at Week 48 in each dose group is shown in Figure 9 . The BCR::ABL1 ≤ 1% rate was numerically higher in the 40 mg BID group (range: 61.2% to 64.7%) than the 80 mg QD group (range: 53.6% to 64.3%) at each timepoint except Week 36.

<div style=\"page-break-after: always\"></div>

Figure 9: BCR::ABL1 (% IS) plot over time (Full analysis set) - Study A2302

<!-- image -->

Source: Study A2302 W48 CSR - Figure 14.2-1.4

## Secondary pharmacology

## Treatment-emergent secondary BCR::ABL1 gene mutations

In 1L study J12301 at baseline, the majority of patients in both treatment arms had no mutations in the BCR::ABL1 gene (97.0% in the asciminib arm vs. 96.6% of participants in the IS-TKI arm). Four patients in total had single mutations observed at baseline. No new post-baseline mutations were detected (until the Week 96 data cut off) in these 4 patients.

At Week 96 DCO, there were 10 (5.0%) patients in the asciminib arm with postbaseline treatmentemergent BCR::ABL1 gene mutations, typically appearing at Weeks 24 - 36. ( Table 7 ). Of these 10 patients, 9 discontinued treatment and 1 had treatment ongoing. The reasons for treatment discontinuation included treatment failure per ELN criteria 2020 in 6 participants; and unsatisfactory therapeutic effect, progressive disease, and confirmed loss of MMR in 1 participant each.

The mutations observed in the asciminib arm were distinct and non-overlapping with the IS-TKI arm. All post-baseline mutations in the asciminib arm were in the myristoyl pocket or functionally adjacent area of the KD domain, while a majority of postbaseline mutations in the IS-TKI arm were in the Ploop, adjacent to the ATP binding site. Valine and threonine exchanges at A337 were the most frequently observed mutations in asciminib arm (7 out of 10 patients with treatment-emergent mutations in the asciminib arm).

Table 7:

Post-baseline treatment-emergent BCR::ABL1 gene mutations (FAS)

<div style=\"page-break-after: always\"></div>

|                             | Asciminib                    | Asciminib                  | Asciminib                 | InvestigatorSelectedTKI      | InvestigatorSelectedTKI    | InvestigatorSelectedTKI     |
|-----------------------------|------------------------------|----------------------------|---------------------------|------------------------------|----------------------------|-----------------------------|
| Post-baseline mutations     | Imatinib Stratum N=101 n (%) | 2G TKI Stratum N=100 n (%) | AlI Asciminib N=201 n (%) | Imatinib Stratum N=102 n (%) | 2G TKI Stratum N=102 n (%) | AII Comparators N=204 n (%) |
| A337T1/A344P1/1502N1/P465Q1 | 0                            | 1 (1.0)                    | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337T1/F497L1               | 1 (1.0)                      | 0                          | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337T1/L340Q1               | 0                            | 1 (1.0)                    | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337T1/V506M1               | 1 (1.0)                      | 0                          | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337T1                      | 1(1.0)                       | 0                          | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337V1                      | 0                            | 1 (1.0)                    | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A337V1/V506M1               | 1 (1.0)                      | 0                          | 1 (0.5)                   | 0                            | 0                          | 0                           |
| A433D1                      | 1(1.0)                       | 1 (1.0)                    | 2 (1.0)                   | 0                            | 0                          | 0                           |
| E255V2/G250E2/L248V2        | 0                            | 0                          | 0                         | 1 (1.0)                      | 0                          | 1 (0.5)                     |
| E450G/L248V2                | 0                            | 0                          | 0                         | 1 (1.0)                      | 0                          | 1 (0.5)                     |
| E459K2                      | 0                            | 0                          | 0                         | 1 (1.0)                      | 0                          | 1 (0.5)                     |
| F317L2                      | 0                            | 0                          | 0                         | 1 (1.0)                      | 0                          | 1 (0.5)                     |
| L340Q1                      | 0                            | 1 (1.0)                    | 1 (0.5)                   | 0                            | 0                          | 0                           |
| Y253H2                      | 0                            | 0                          | 0                         | 0                            | 3 (2.9)                    | 3 (1.5)                     |
| Total                       | 5 (5.0)                      | 5 (5.0)                    | 10 (5.0)                  | 4 (3.9)                      | 3 (2.9)                    | 7 (3.4)                     |

Table 11-18 CSR J12301 week 96

In 3L+ study A2302 at baseline, 25 (14.8%) participants had at least one BCR::ABL1 gene mutation of which 2 (1.2%) participants had more than one mutation. Post-baseline, 90 participants were assessed for mutations at any timepoint post-baseline, and the mutations are presented in Table 8 .

<div style=\"page-break-after: always\"></div>

Table 8: Post-baseline BCR::ABL1 gene mutations by central lab (Full analysis set) - Study A2302

|                                                                             | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg QD N=84 n (%)   | All participants N=169 n (%)   |
|-----------------------------------------------------------------------------|-------------------------------------|---------------------------------|--------------------------------|
| Total participants assessed for mutation at any timepoint post baseline (m) | 44                                  | 46                              | 90                             |
| Mutation                                                                    |                                     |                                 |                                |
| p.Met244Val(244M>V)                                                         | 4 ( 9.09)                           | 2 ( 4.35)                       | 6 ( 6.67)                      |
| p.Thr315Ile(315T>I)                                                         | 0                                   | 3 ( 6.52)                       | 3 ( 3.33)                      |
| p.Phe317Leu(317F>L)                                                         | 1 ( 2.27)                           | 1 ( 2.17)                       | 2 ( 2.22)                      |
| p.Phe359Val(359F>V)                                                         | 0                                   | 2 ( 4.35)                       | 2 ( 2.22)                      |
| p.Ala433Thr(433A>T)                                                         | 0                                   | 1 ( 2.17)                       | 1 ( 1.11)                      |
| p.Ala68Pro(68A>P)                                                           | 0                                   | 1 ( 2.17)                       | 1 ( 1.11)                      |
| p.Gln252His(252Q>H)                                                         | 0                                   | 1 ( 2.17)                       | 1 ( 1.11)                      |
| p.Glu453Lys(453E>K)                                                         | 0                                   | 1 ( 2.17)                       | 1 ( 1.11)                      |
| p.Glu459Lys(459E>K)                                                         | 1 ( 2.27)                           | 0                               | 1 ( 1.11)                      |
| p.Gly250Glu(250G>E)                                                         | 1 ( 2.27)                           | 0                               | 1 ( 1.11)                      |
| p.Phe359Ile(359F>I)                                                         | 1 ( 2.27)                           | 0                               | 1 ( 1.11)                      |
| p.Pro465Ala(465P>A)                                                         | 1 ( 2.27)                           | 0                               | 1 ( 1.11)                      |

Not all randomised participants were analysed for post baseline mutation. Percentages calculated taking Total participants assessed for mutation at any timepoint post baseline (m) as denominator.

Table 9: Newly emergent or persistent mutations in the asciminib treatment arm in Study J12301 and Study A2302(Week 48 cut-off)

| Study J12301 (1L)   | Study A2302 (3L+)   |
|---------------------|---------------------|
| New:                | New:                |
| A337T               | A68P                |
| A337V               | P465A               |
| A344P               | A433T               |
| A433D               | F359V               |
| F497L               | M244V               |
| I502N               | Q252H               |
| L340Q               | Persisted:          |
| P465Q               | E453K               |
| V506M               | F317L               |
| Persisted:          | G250E               |

M244V

## 2.3.6. PK/PD modelling / exposure-response relationships

The PK-PD dataset included in total 430 patients with CML-CP from study J12301 (data cut- off date of 28-Nov-2023), A2301 (data cut-off date of 22-Mar-2023), and X2101 (data cut-off date of 14-Mar2023). Patients with the T315I mutation were excluded. At baseline, 327 of the 430 patients (76%) had BCR::ABL1 IS levels &gt;10%. The ERR analysis for efficacy was a retrospective modelling that utilized data from clinical trials of which none were designed to investigating relationships between PK metrics and clinical outcomes.

<div style=\"page-break-after: always\"></div>

## Exposure - Efficacy

## First line (1L) CML-CP

The result of the logistic regression showed positive relationship between exposure metrics (average daily AUC0-24 and Cmin) and the probability of MMR at Week 48 for asciminib 80 mg QD regimen based on the Binary MMR analysis set of Study J12301.

Clopper-Pearsons confidence intervals showed lower MMR rates (~45%) for the first quartile (Q1) of exposure metrics and no correlation for quartiles Q2-Q4 of AUC0-24 and Cmin. The response was constant between 70% to 80% from Q2-Q4, suggesting the response has reached plateau by Q2. Relatively more patients in Q1 exposure had a relative dose intensity (RDI) ≤75% as represented by red dots, contributing to the lower MMR rate. (Figure 10)

The mean (CV%) predicted steady-state AUC0-24 and Cmin from the PopPK model would be close to Q3 average daily AUC and Cmin in Figure 3, respectively. Overall, the dose of 80 mg QD provided sufficient exposure for showing robust and sustained efficacy in patients with newly diagnosed Ph+ CML-CP without T315I mutation.

Figure 10: Exposure-efficacy relationship between the probability of achieving MMR at Week 48 and daily average AUC0-24 (left) and Cmin (right) from prior 48 weeks (top); distribution of quartiles (middle); spread between responders and non-responders (bottom) - 1L Study J12301

<!-- image -->

<!-- image -->

DailyaverageAuC(ng.h/mL)

Source ERR model report Figures 5-1 and 5-2

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 3L+ CML-CP

For 3L+ CML, the ERR model-predicted MMR rates for asciminib 80 mg QD and 40 mg BID at Week 24 and Week 48, assuming maintenance of uninterrupted dosing, were as follows (Table 10):

Table 10: ERR model-predicted MMR rates for asciminib 80 mg QD and 40 mg BID at Week 24 and Week 48 in 3L+

| Dosing regimen   | Time of readout   | PredictedMMR rates mean [95%CI]   | ObservedMMRrates Estimate [95%Cl]   | Reference                    |
|------------------|-------------------|-----------------------------------|-------------------------------------|------------------------------|
| 40 mg b.i.d.     |                   |                                   |                                     |                              |
|                  | Week 24           | 36.1% [33.0, 39.6]                | 35.3% [25.2, 46.4]                  | A2302 (n=85) ASCEMBL (n=157) |
|                  |                   |                                   | 25.5% [18.9, 33.0]                  |                              |
|                  | Week 48           | 42.6% [38.4, 46.0]                | 42.4% [31.7,53.6]                   | A2302 (n=85)                 |
|                  |                   |                                   | 29.3% [22.3, 37.1]                  | ASCEMBL (n=157)              |
| 80 mg q.d.       |                   |                                   |                                     |                              |
|                  | Week 24           | 32.8% [29.2, 36.0]                | 29.8% [20.3, 40.7]                  | A2302 (n=84)                 |
|                  | Week48            | 39.6%[35.4,43.0]                  | 34.5% [24.5, 45.7]                  | A2302 (n=84)                 |

Note:ObservedMMRratesinA2302andASCEMBLtrialsareinthirdlinesetting.ASCEMBLtrialonlyevaluated 40 mq b.i.d.

## 2L CML-CP

As asciminib 2L data were not available, extrapolation into the 2L setting assumed that nilotinib and asciminib had similar differences in model parameters between 1L and 2L settings and the longitudinal BCR::ABL1 in the 2L for asciminib was simulated using the same difference in model parameters as that for nilotinib (model also submitted). For the extrapolation into 2L, the predicted MMR rate, assuming a total daily dose of 80 mg without dose interruption, ranged from 54 to 63% ± 2% at Week 48 and 66 to 74% ± 2% at Week 96, respectively.

## Line-independent 80 mg total-daily dose regimen

Assuming a total daily dose of 80 mg (80 mg QD or 40 mg BID) without interruption, time courses of BCR::ABL1 rates in the 1L to 3L+ setting were simulated with the EER model, including the extrapolation into 2L setting (Figure 10a).

Figure 10a: EER model-predicted time-course of BCR::ABL1 in 1L, 2L, and 3L settings after a total daily dose of 80 mg asciminib

<!-- image -->

<div style=\"page-break-after: always\"></div>

This plot presents the simulation based on Scenario 2 with parameters listed in [Exposure-efficacy Report-Table 4-2]. Blue line represents median; Purple shaded area represents 25th and 75th prediction percentiles; Pink shaded area represents 15th and 85th prediction percentiles; Yellow shaded area represents 5th and 95th prediction percentiles. Source: Exposure-efficacy Report-Figure 5-10

## Safety

According to the A2302 CSR the number of patients with 80 mg QD with TEAEs to those with 40 mg BID (88.1 vs. 90.5%) of which fatigue was increased &gt;3-fold (14.3 vs 3.6%). No difference was observed in AEs leading to discontinuation or dose reduction.

In the safety ERR model safety events from 1L and 3L+ studies over the full administered dose levels were evaluated. The PK-Safety Set included 550 participants (40.0% female and 60.0% male); 353 were pretreated and 197 newly diagnosed participants. The probability of occurrence of all safety events was lower for newly diagnosed than for pretreated participants with Ph+ CML. The higher event probability in pretreated participants was as expected. Comparable exposure was reached with the 40 mg BID and 80 mg QD asciminib doses, and no association was observed between exposure and most safety events, indicating the interchangeability of these two dosing regimens with respect to their safety profile.

## 2.3.7. Discussion on clinical pharmacology

This group of variations concerned an extension of indication to newly diagnosed (1L) CML-CP patients with 80 mg QD or 40 mg BID with PK data from study J12301 as well as the addition of the 80 mg QD dose regimen as alternative to the approved 40 mg BID for the 3L+ CML-CP population with PK data from study A2302. In addition, new modelling for popPK and exposure-response was included to also support an intrapolation to a 2L indication without clinical PK data and for an overall line independent dosing with either 40 mg BID or 80 mg QD, i.e. a total-daily-80 mg-dose regimen.

## Pharmacokinetics

Primary PK parameter for the 1L population with 80 mg QD in study J12301 were in the same ranges as known from the approved populations in later treatment lines. The steady-state (geo-mean) Cmax was 1470 ng/mL (geo-mean CV% 38.2%), AUClast (i.e. AUC0-12) was 8590 ng*hr/mL (CV% 42.2%), Cmin ranged between 161 -192 ng/ml and Tmax was at 2.0 hours. The PK parameters derived from NCA and popPK model (with the updated model) could be regarded similar, i.e. within the observed inter-individual variability for asciminib.

From popPK modelling and on basis of a 'daily dose of 80 mg' as underlying regimen, estimated clearance was 6.89 l/h and did not differ relevantly between 0 - 7 lines of TKI-pre-treatments. However, it is highlighted that in response to a respective question during initial MAA for comparison between the regimens 80 mg QD and 40 mg BID, the MAH had updated the popPK model to include regimen (QD/BID) as covariate instead of total daily dose. In the current updated model, again total daily dose was chosen as a covariate on clearance. With the updated model, including regimen as covariate, no statistically significant differences between the two regimens (40mg BID and 80mg QD) were detected. The comparison of PK metrics between regimens showed comparable AUC, i.e. within the observed inter-individual variability for asciminib, but lower Cmin and higher Cmax for 80 mg QD compared to 40 mg BID, as expected.

Modelling of special populations estimated no clinically relevant differences for gender, body weight, race, and elderly warranting dose adjustments in the PK of asciminib, in line with previous

<div style=\"page-break-after: always\"></div>

conclusions. For renal impairment, lower clearance was estimated with increasing severity of impairment, i.e. reducing GFR. However, for severe renal impairment the dataset is very limited. Therefore, no additional conclusions could be drawn and the relevant recommendations in the SmPC should remain unchanged.

For hepatic impairment, the popPK dataset comprised both the dedicated HI study and patient studies. As classifications by reduced liver function based on liver function tests and by NCI-ODWG criteria do not correlate, no additional definite conclusions can be drawn with regard to Child-Pughcategorised hepatic impairment outside from studied parameters. Therefore, the relevant recommendations in the SmPC should remainunchanged.

Asciminib is mainly (~60%) metabolised via UGT enzymes which show genetic polymorphism. The analysis of Ctrough levels for different phenotypes in study J12301 did not result in statistically significant differences between intermediate to ultrarapid metabolisers for UGT2B7 and between intermediate to poor metabolisers for UGT2B17.

## Pharmacodynamics

Asciminib is a potent inhibitor of BCR::ABL1 tyrosine kinase targeting the allosteric myristoyl binding pocket on the SH1 domain of ABL1, restoring the inactive kinase conformation. Thus, BCR::ABL IS (%) ratio is used as biomarker/measure for pharmacodynamics and efficacy in CML-CP.

When taking the NCA-derived Cmin range (161-192 ng/ml) from the 1L study J12301 as basis, which is lower than the current popPK-model derived measure, the unbound concentration (fu 2.7%) is ~4.7 ng/ml which is not relevantly higher than the IC50 of 0.6 nM (inhibition of proliferation in cell assay). In other assays the IC50 had even been higher.

In 1L study J12301 at 80 mg QD, no correlation of Ctrough levels at week 48 to BCR::ABL IS (%) change from baseline could be observed. Only a very slight Ctrough exposure-response correlation to achieving MMR (i.e. 0.1% IS ratio) at week 48 was detectable, however it could be derived that for deeper molecular responses higher average trough concentrations seem more advantageous.

Corresponding ERR analyses for 1L study J12301 revealed that at the levels of steady-state Cmin a 7080% probability of MMR at week 48 could be obtained. However, dose reductions to ≤75% RDI with resulting lower Cmin correlated with a lower probability of achieving MMR, or even nonresponse.

The MAH proposes the 40 mg BID or the 80 mg QD regimen independently of treatment line, i.e. an 80 mg daily-dose regimen, and has correspondingly revised the dosing recommendations in section 4.2 of the SmPC to state: ' The recommended total daily dose of Scemblix is 80 mg. Scemblix can be taken orally either as 80 mg once daily at approximately the same time each day, or as 40 mg twice daily at approximately 12-hour intervals .' Considering that the ERR demonstrated that with higher average Cmin, which would usually be observed with a 40 mg BID regimen rather than with an 80 mg QD regimen of 80 mg total daily dose, a higher probability of MMR would be achievable, this proposal could be supported for the 1L population.

However, on the other hand, the evaluation of BCR::ABL1 (% IS) rate over time in the 3L+ population in study A2302 revealed that the BCR::ABL1 ≤ 1% rate was numerically higher in the 40 mg BID group (range: 61.2% to 64.7%) than the 80 mg QD group (range: 53.6% to 64.3%) at each timepoint except Week 36. Also, the achievement of a comparable response was slower for the 80 mg QD regimen in the 3L+ population.

<div style=\"page-break-after: always\"></div>

The observed MMR rate in 3L+ study A2302 at week 48 was nearly 8% higher in the 40 mg BID vs. the 80 mg QD group, supporting the need of continued sufficiently high exposure at the target structures for adequate inhibition and response, which can usually be better achieved with a BID regimen. Safety ERR data show no obvious association between exposure and most safety events based on the comparable average exposure with the 40 mg BID and 80 mg QD asciminib dose regimens.  So, with respect to safety ERR modelling the interchangeability of these two dosing regimens in the 3L+ population could be supported. When considering molecular response, however, a nearly 8% lower rate of MMR in 3L+ CML treatment could become clinically relevant. So, it might be individually necessary and appropriate to switch the approved BID dosing to a QD dosing regimen in the 3L+ population, as the twice daily fasted intake of asciminib may be difficult for satisfactory compliance in all patients. On the other hand, dose reductions for adverse events could result also in reduced exposure and response rates, as observed in the 1L study, which could impact efficacy. In addition, the MAH provided model estimates of MMR rate intrapolated to a potential 2L CML-CP population, which can be followed and are acceptable with the proposed 80 mg daily-dose regimen. Both studies in 1L and 3L+ CML-CP also evaluated treatment-emergent secondary BCR::ABL1 gene mutations. As could be expected for a newly diagnosed untreated population 97% of the patients in study J12301 had no BCR::ABL1 gene mutations at baseline. During treatment new mutations were found in 5% of patients, most of them discontinued treatment for treatment failure/progress. The BCR::ABL1 gene mutations under asciminib treatment were all located in or near the asciminib binding myristoyl pocket. In contrast, the new mutations in the comparator-TKI treatment arm were near the ATP binding site, meaning that treatment-emergent secondary mutations were not overlapping between arms. In the 3L+ pre-treated patient group in study A2302 15% of patients had mutations of BCR::ABL1 at baseline and the MAH provided summary tabulations of mutations at baseline and newly emergent under treatment for both studies. The post-baseline mutations that occurred during asciminib treatment in the pre-treated CML population were different to those detected in the 1L population. Here, under asciminib treatment new mutations occurred both near the asciminib binding site and near the ATP binding site. In 3 patients new occurrence of T315I was observed under 80 mg QD, but not in the 40 mg BID arm. Most of these detected new mutations are already known e.g. from imatinib-resistant patients (Soverini, 2011). A337T/V was detected after 1L treatment with asciminib only and is described as an asciminib-specific mutation completely inhibiting BCR::ABL1 (Leyte-Vidal, 2024; Manley, 2020). Other mutations, such as M244V were observed both after 1L and 3L treatment or persisted it. This mutation was also recently published as a further novel resistance mechanism to class IV TKIs such as asciminib. The mutations are all in line with those described as specifically conferring resistance to asciminib in the 2025 ELN recommendations for management of CML (Apperley, 2025). As discussed in the referenced publications, for most asciminib treatment-emergent mutations other TKIs are available which target and can rescue these mutations. to asciminib and insofar, it is endorsed that the 1L study J12301 clinical study protocol was amended

These exploratory small datasets can only support to broaden the picture of resistance mechanisms to collect mutational data during survival follow-up, which will be included in the final CSR (see Annex II).

<div style=\"page-break-after: always\"></div>

The above assessment supports dose recommendations under section 4.2 of the on the option to take asciminib either as 80 mg once daily at approximately the same time each day, or as 40 mg twice daily at approximately 12-hour and on the possibilities to switch between the two as necessary for the benefit of the patient.

## 2.3.8. Conclusions on clinical pharmacology

The clinical pharmacology dataset of asciminib submitted in the current group of variations for supporting the 1L CML-CP treatment with 40 mg BID or 80 mg QD (i.e. an 80 mg total daily dose regimen), the inclusion of the 80 mg QD regimen as alternative for the previously approved 3L+ CMLCP population and the intrapolation of asciminib treatment to the adult 2L CML population, is considered appropriate. The PK data are considered consistent with previous PK data from the patient population in the currently approved setting.

The clinical pharmacology data supporting this group of variations is sufficient to support the posology recommendations.

Study J12301 clinical study protocol was amended to collect mutational data during survival follow-up, and this will be reported in the final CSR (see Annex II).

## 2.4. Clinical efficacy

## 2.4.1. Main study

Phase III study CABL001J12301: Open label, multi-centre, randomised study  of  oral  asciminib  vs.  Investigator  selected  TKI  to  determine efficacy, safety, PK, and tolerability of asciminib 80 mg QD  in participants with newly diagnosed Ph+ CML-CP (ASC4FIRST, NCT 04971226)

## Methods

## Study design

The pivotal study for the extension of indication to CP-CML-CP 1st line treatment is an ongoing phase III, randomised (1:1)-controlled, open-label, multicentre, superiority trial, J12301 (ASC4FIRST), comparing asciminib 80 mg QD monotherapy with investigator's selected TKI (imatinib 400 mg QD, nilotinib 300 mg BID dasatinib 100 mg QD or bosutinib 400 mg QD) in estimated 402 patients with CML-CP.

<div style=\"page-break-after: always\"></div>

<!-- image -->

imatinib,ornilotinib,ordasatiniborbosutinibfor≤2weeksisallowed.NoothertreatmentwithTKls(tyrosinekinase inhibitors)priortorandomizationispermitted.2G:2ndgeneration;CML-CP:ChronicMyelogenousLeukemiaChronicPhase;ELTS:EUTOSLongTermSurvival;IMA:imatinib;R:randomized;TKl:tyrosinekinaseinhibitor. The analysisDCO datesfor theplanned analyseswere:Week48primary analysis,Week96 analysis, and final analysis.

Figure 11:

Design study J12301 (ASC4FIRST)

Table 11 Overview of Phase III registration study - Study J12301

| Key features             | CABL001J12301                                                                                                                                                                                                                                                                                     |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase                    | III                                                                                                                                                                                                                                                                                               |
| Study design             | Open label, multi-centre, randomised study of oral asciminib vs. Investigator selected TKI to determine efficacy, safety, PK, and tolerability of asciminib 80 mg QD in participants with newly diagnosed Ph+ CML-CP QD in participants with newly diagnosed Ph+ CML-CP.                          |
| No. participants (total) | 405                                                                                                                                                                                                                                                                                               |
| Population               | Adult, treatment-naive participants with newly diagnosed Ph+ CML-CP (within 3 months of diagnosis)                                                                                                                                                                                                |
| Treatment duration       | Participants in the study will continue to receive the assigned treatment until the End of Study (5 years from last participant first treatment), or until premature discontinuation due to treatment failure, disease progression or intolerance or due to Investigator or participant decision. |
| Treatment(s)             | asciminib 80 mg QD imatinib 400 mg QD nilotinib 300 mg BID dasatinib 100mg QD bosutinib 400mgQD                                                                                                                                                                                                   |
| Completed/Ongoing        | Ongoing FPFV: 06-Oct-2021 Data cut-off date for the Week 48 primary analysis: 28-Nov-2023 Data cut-off date for the Week 96 key secondary analysis: 22-Oct-2024                                                                                                                                   |

## Justification for the selected dose

The asciminib dose of 80 mg QD  for participants with newly diagnosed Ph+ CML-CP was selected based on the clinical experience in participants with Ph+ CML-CP in Studies X2101 (multiple doses

#:either

<div style=\"page-break-after: always\"></div>

including 80 mg QD ) and A2301 (40 mg BID, equivalent to a total daily dose of 80 mg) and the PK/PD modelling-based exposure -response and exposure-safety analyses.

## Study participants

The population consisted of adult participants with newly diagnosed Ph+ CML-CP (diagnosed within 3 months prior to enrolment). The definition of Ph+ CML-CP was according to the ELN 2020 criteria.

Key inclusion criteria:

- Male or female participants ≥ 18 years of age
- Signed informed consent must be obtained prior to any study related screening procedures being performed.
- Participants with CML-CP within 3 months of diagnosis.
- Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of the Philadelphia chromosome
- o &lt; 15% blasts in peripheral blood and bone marrow
- o &lt; 30% blasts plus promyelocytes in peripheral blood and bone marrow
- o &lt; 20% basophils in the peripheral blood
- o Platelets count ≥ 100,000/mm3
- o No evidence of extramedullary leukemic involvement, except for hepatosplenomegaly
- Evidence of typical BCR::ABL1 transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized RQ-PCR quantification.
- ECOG performance status of 0, or 1.
- Adequate end organ function as defined by 1) Total bilirubin (TBL) &lt; 3 × ULN; participants with Gilbert's syndrome may only be included if TBL ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN 2) CrCl ≥ 30 mL/min as calculated using Cockcroft -Gault formula 3) Se rum lipase ≤ 1.5 × ULN. For serum lipase &gt; ULN ≤ 1.5 × ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis
- Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization: 1) Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/mi n) 2) Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min) 3) Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with CrCl ≥ 90 mL/mi n) 4) For participants with mild to moderate renal impairment (CrCl* ≥ 30 mL/min and &lt; 90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be ≥ LLN or corrected to within normal limits with supplements prior to randomisation.

## Key exclusion criteria

- Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide. Treatment with either imatinib, or nilotinib, or dasatinib or bosut inib for ≤ 2 weeks

<div style=\"page-break-after: always\"></div>

is allowed. No treatment with other tyrosine kinase inhibitors prior to randomization is permitted.

- Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)
- Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:
- o History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG).
- o Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II- and third-degree AV block).
- o QTc ≥ 450 ms (male participants), ≥ 460 ms (female participants) on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF ≥ 450 ms and electrolytes are not within normal ranges, electrolytes should be corrected and then the participant re-screened for QTc.
- Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
- o Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
- o Concomitant medication(s) with a 'Known risk of Torsades de Pointes' per //.crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
- o Inability to determine the QTcF interval.
- Severe and/or uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g., uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia).
- History of significant congenital or acquired bleeding disorder unrelated to cancer.
- Major surgery within 4 weeks prior to study entry or who have not recovered from prior surgery.
- History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively.
- History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.
- History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.

<div style=\"page-break-after: always\"></div>

## Treatments

The treatments administered in this study included: Arm 1: Asciminib 80 mg QD under fasting conditions For participants randomised to the asciminib treatment arm, dose escalation beyond 80 mg QD for asciminib was not permitted. Arm 2: IS-TKI that included one of the below treatments as per the PRS-TKI (imatinib or the 2G TKI nilotinib or dasatinib or bosutinib). · Imatinib 400 mg QD administered with food · Nilotinib 300 mg BID (total daily dose of 600 mg) administered under fasting conditions · Dasatinib 100 mg QD administered with or without food

- Bosutinib 400 mg QD administered with food

<div style=\"page-break-after: always\"></div>

## Objectives

Table 12 Objectives and related endpoints for efficacy

| Primary objectives                                                                                                                                                                                                                                                                                                                                                    | Endpointsforprimary objectives                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The study has 2primary objectives: To compare the efficacy of asciminib vs. IS-TKl, With respect to the proportion of participants that are in MMR at Week 48 Within the stratum of participants with imatinib as their PRS-TKl, with respect to the proportion of participants that are in MMR at Week 48 Thestudywasdeclaredpositiveandmetboththeprimary objectives | MMR at Week 48 (Yes/No)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Secondary objective(s)                                                                                                                                                                                                                                                                                                                                                | Endpoint(s)for secondary objective(s)                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Thestudyhas2keysecondaryobjectives: These objectives are the same as the 2 primary objectives except that they are analyzed at the Week 96 time point                                                                                                                                                                                                                 | MMR at Week 96 (Yes/No)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Othersecondary objectives forefficacy: To estimate the efficacy of asciminib vs. IS-TKl, within the stratum of participants with a 2G TKl as their PRS- TKl, with respect to the proportion of participants that are in: + MMR at Week 48 中 MMR at Week 96 To compare the efficacy of asciminib vs.IS-TKl, with respect to additional parameters of efficacy          | MMR at Week 48/Week 96 (Yes /No)                                                                                                                                                                                                                                                                                                                                                                                                                          |
| To compare the efficacy of asciminib vs. IS-TKl, within the stratum of participants with imatinib as their PRS-TKl, with respect to additional parametersofefficacy To estimate the efficacy of asciminib vs. IS-TKl, within the stratum of participants with a 2G TKl as their PRS-TKl, with respect to additional parametersofefficacy                              | MMR atall scheduled data collection time points (except at Week 48 and at Week 96) MMR by all scheduled data collection time points MR4.0 and MR4.5, at and by all scheduled data collection time points CHR,at and by all scheduled data collection time points BCR.:ABL1 (IS) ≤ 1% at and by all scheduled data collection time points CCyR by Week 48 and by Week 96 Duration of MMR, MR4.0, MR4.5 Time to first MMR, first MR4.0, first MR4.5 TTF FFS |

<div style=\"page-break-after: always\"></div>

| Exploratoryobjective(s)                                                                                                                                                                   | PFS OS Endpoint(s)forexploratoryobjective(s)                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| ExploratoryobjectivesforBiomarkersa: To characterizemutations in theBCR.ABL1gene andothermyeloidassociatedgenesatbaselineand during therapy and their association with molecular response | Proportionofpatientswhodevelop any BCR.ABL1 mutations and myeloid associatedmutationsatbaseline,uponloss ofresponseand atendof treatment（EOT) |
| Source:1LSCE-Table1-2                                                                                                                                                                     | Source:1LSCE-Table1-2                                                                                                                         |

## Outcomes/endpoints

Table 13 Criteria for response and relapse

| Response/Relapse         | Definition                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytogenetic response     | CCyR: No Ph-positive metaphases (corresponding to MR2.0)                                                                                                                                                                                                                                                                                                             |
| Hematologic response for | CHR: Defined as all of the following present ≥ 4 weeks: • Complete normalization of peripheral blood counts with leukocyte count <10 x 10 9 /L • Platelet count <450 x 10 9 /L • Basophils <5% • No blasts and promyelocytes in peripheral blood • Myelocytes + metamyelocytes <5% in peripheral blood • No evidence of extramedullary disease, including spleen and |

liver

Source: Clinical overview, page 44, tab. 4-2

## Estimand

Table 14 Estimand table for primary objectives

<div style=\"page-break-after: always\"></div>

| Population                                                      | Newly diagnosed adult Ph+ CML-CP patients                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition                                             | Treatment with asciminib vs. the (1) IS-TKI and (2) imatinib as IS-TKI regardless of dose modifications, dosing errors, deviation in any intake of concomitant medications, intake of prohibited medication, and taking or not taking a TKI different from their PRS-TKI in the comparator arm. |
| Endpoint (variable)                                             | composite endpoint of MMRat Week 48, without meeting any treatment failure criteria prior to Week 48 and without discontinuation due to any reasons prior to Week 48                                                                                                                            |
| Population-level summary                                        | stratum adjusted difference in the proportion of participants that were in MMRat Week 48 and corresponding 95% CI                                                                                                                                                                               |
| Intercurrent events and strategy to handle them                 | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                 |
| Treatment discontinuation or treatment failure prior to week 48 | Composite (counted as failure)                                                                                                                                                                                                                                                                  |
| Taking a TKI different from their PRS-TKI                       | Treatment policy                                                                                                                                                                                                                                                                                |
| dose reduction, interruption, allowed dose escalations          | Treatment policy                                                                                                                                                                                                                                                                                |
| Dosing errors                                                   | Treatment policy                                                                                                                                                                                                                                                                                |
| Deviation in any intake of concomitant medications              | Treatment policy                                                                                                                                                                                                                                                                                |
| Prohibited medication                                           | Treatment policy                                                                                                                                                                                                                                                                                |

Similar estimands are defined for the key secondary efficacy endpoints targeting MMR at week 96.

## Sample size

The proportions of participants expected to achieve the primary endpoint of being in MMR at Week 48 were assumed to be 0.525 for asciminib, 0.28 for imatinib, and 0.45 for any 2G TKI. The proportions of participants expected to achieve the secondary endpoint of MMR at Week 96 were assumed to be 0.635 for asciminib, 0.43 for imatinib, and 0.56 for any 2G TKI. The study design planned for a 50% versus 50% enrolment of imatinib versus 2G TKIs into the control arm. Therefore, the proportion of participants expected to achieve the primary endpoint of MMR at Week 48 was assumed to be 0.365 for the IS-TKI arm. Similarly, the proportion of participants expected to achieve the primary endpoint of MMR at Week 96 was assumed to be 0.495 for the IS-TKI arm.

Based on a 1-sided 2.5% level of significance, with 402 participants and 1:1 randomization ratio between arms (i.e. 201 participants in the asciminib arm and 201 participants in the IS-TKI arm) the study had 94.6% power to reject at least one of the null hypotheses (H1 or H2). At this sample size, the local power to reject the null hypothesis for H1 is 88.5% and local power to reject the null hypothesis for H2 is 92.7%.

## Randomisation

Randomisation was planned in a 1:1 ratio to Arm 1 (asciminib 80 mg QD) or Arm 2 (IS-TKI). No crossover across arms and no change of study treatment within the Arm 2 was allowed. Stratification was applied according to:

- ELTS score (low vs. intermediate vs. high)

<div style=\"page-break-after: always\"></div>

- PRS-TKI (imatinib vs. 2G TKI): prior to randomisation a selection of imatinib or 2G TKI was made by the investigator

## Blinding (masking)

This study was a randomised open label study. Treatment was open to participants, investigator staff, persons performing the assessments, and the Novartis Clinical Trial Team (CTT). Except review of unblinded safety data by a DMC, no aggregate statistical analyses by treatment arm were performed prior to the database lock. The enrolment into the strata of imatinib versus 2G TKIs based on the PRSTKIs was managed by IRT to be approximately 50% versus 50%.

## Statistical methods

The statistical analysis plan was finalized prior to the conduct of the primary analysis (week 48) and unblinding of the database. The primary analysis at week 48 was based on all data collected in the database up to the DCO date of 28-Nov-2023 with database lock on 19-Dec-2023 (all participants had been on study treatment for at least 48 weeks or discontinued earlier). The week 96 analysis was done when all participants had been on study treatment for at least 96 weeks or discontinued earlier (DCO 22-Oct-2024).

## Analyses sets

The Full Analysis Set (FAS) comprised of all participants to whom study treatment has been assigned by randomization.

The IMA Full Analysis Set (FASIMA) comprised of all participants from the FAS, whose PRS-TKI is imatinib.

The 2GTKI Full Analysis Set (FAS2GTKI) comprised of all participants from the FAS, whose PRS-TKI is a 2G TKI.

The Safety Set comprised of all participants who received at least one dose of any study treatment. Participants were analyzed according to the actual study treatment received, where actual treatment received was defined as the randomised treatment if the participant took at least one dose of that treatment, or the first treatment received if the randomised treatment was never received.

In line with the ITT principle and the targeted estimand, the FAS sets will be used for efficacy evaluations unless specified otherwise.

## Analyses of primary and key secondary MMR endpoints

Participants discontinuing the randomised treatment due to any reason prior to Week 48 and/or 96, or participants meeting any treatment failure criteria (as per European Leukemia Network (ELN) 2020 criteria, (ELN 2020)) prior to Week 48 and/or 96, were counted as not being in MMR at Week 48 and/or 96, respectively. When a participant had a missing Week 48 RQ-PCR evaluation but was in MMR both at Week 36 and Week 60, then the participant was imputed as in MMR at Week 48; similarly, when a participant had a missing Week 96 RQ-PCR evaluation but was in MMR both at Week 84 and Week 108, then the participant was imputed as in MMR at Week 96. If any evaluations were performed at unscheduled visits closer to the Week 48 and/or 96 visit (before or after), respectively, these were taken into account for the imputation. Within the overall population (FAS) and within the stratum of participants that have imatinib as their PRS-TKI (FASIMA), comparison of treatment groups for primary/key secondary MMR endpoints was performed with a one-sided stratified Cochran-MantelHaenszel (CMH) test. For the overall population both randomization stratification factors (ELTS risk

<div style=\"page-break-after: always\"></div>

group and PRS-TKI [imatinib vs. 2G TKI]) were taken into account while for the other only the ELTS risk group was used. Estimates of the common risk difference were provided.

A sensitivity analysis of the primary and key secondary endpoints was also conducted at Week 48 and Week 96. The CMH Chi-square test of MMR rate was repeated without the imputation rule used in the main primary and key secondary analyses for participants who had missing RTPCR evaluations at Week 48 and/or 96. In such cases these participants were considered non-responders for MMR at Week 48 and/or at Week 96.

Supplementary analyses of the primary and key secondary endpoints were also conducted at Week 48 and Week 96:

- In the first supplementary analysis, participants were analysed using the PRS-TKI as recorded in the baseline eCRF.
- In the second supplementary analysis, the one-sided stratified CMH test based on the ELTS and PRS-TKI strata in the IRT system was repeated (as for the primary estimand) after excluding participants who (1) had been a screen failure but randomised by mistake, (2) had atypical transcript at baseline [Study J12301 W48 CSR].
- Supplemental estimands for the endpoint of MMR at Week 48 and 96 based on the treatment policy, composite and hypothetical strategies have been produced.

Subgroup analyses for the primary and key secondary endpoints were conducted to assess the homogeneity of the treatment effect across subgroups (e.g., based on demographic and baseline disease characteristics, ELTS prognostic categories, geographic regions etc.)

## Analysis of the key secondary safety endpoint

The analysis of TTDAE was performed using the Safety Set. The comparison is between all participants receiving asciminib as their actual treatment and all participants receiving the 2G TKIs as their actual treatment. The formal comparison of the cause-specific hazard for the event of interest was implemented via the log-rank test. The cumulative incidence curve for the event of interest was to be plotted. The estimated cumulative incidence rates and 95% CI at specified scheduled visits was presented for each treatment group (asciminib and the 2G TKI).

As supplementary analysis, competing risk analysis via the sub-distribution hazard approach was performed. These supplementary analyses were to be provided for information purpose only for participants receiving asciminib vs those receiving 2G-TKI. In this analysis, discontinuation due to AE (including death due to AE) is the event of interests, and discontinuation due to other reasons is the competing risks. Patients who were still ongoing at the time of the analysis are considered censored.

In addition, the following analyses based on the Safety Set were to be conducted:

- The cause-specific hazard and the cumulative incidence function to be estimated for the time to discontinuation of study treatment due to AE for participants receiving asciminib vs those receiving all comparator treatments.
- The cause-specific hazard and the cumulative incidence function to be estimated for the time to discontinuation of study treatment due to AE for participants receiving asciminib vs those receiving imatinib.

## Multiplicity control

<div style=\"page-break-after: always\"></div>

The family wise error rate for the tests was controlled at 2.5% level via the graphical gatekeeping procedure ().

Figure 12: Testing hierarchy (graphical gatekeeping procedure)

<!-- image -->

H1 and H2 refer to the hypotheses for the primary endpoint (MMR at week 48) in the overall population and in the stratum of participants that have imatinib as their pre-randomization selection of TKI, respectively. Correspondingly H3 and H4 refer to the hypotheses for the key secondary endpoints MMR at week 96. H 5 corresponds to the hypothesis for the secondary safety endpoint (TTDAE).

The three families of hypotheses were to be tested in the following manner. The null hypotheses in family F1 (H1 and H2) will be examined first and tested using the weighted parametric tests (Bretz et al 2011); the hypotheses in family F2 (H3 and H4) will be tested using the fixed-sequence testing approach; followed by the hypothesis in family F3 (H5) will be tested using the fixed-sequence testing approach. The null hypotheses in key secondary end-point family F2 can be tested if the null hypothesis for H2 (or for both H1 and H2) in the primary end-point family F1 is rejected. The null hypotheses in secondary safety end-point family F3 can be tested if the null hypothesis for both H4 and H3 in the key secondary end-point family F2 are rejected.

Adjusted p-values in line with the above approach are provided.

## Results

## Participant flow

Overall, 475 participants with newly diagnosed CML-CP were screened in this study from 116 centres in 29 countries worldwide (Figure 13).

<div style=\"page-break-after: always\"></div>

Figure 13: Study J12301 Participant flow

<!-- image -->

## Recruitment

First patient first visit was on 6 October 2021 and last patient first visit on 5 December 2022. The randomisation period took 13.5 months. The analysis cut-off date was 28 November 2023. In the IS TKI arm, 99 patients received imatinib, 49 patients received nilotinib,42 dasatinib and 11 bosutinib.

## Conduct of the study

There were two protocol amendments for study J12301. There were no changes in study conduct and no changes in the planned analysis.

Table 15 Protocol amendments

Version and date

Summary of key changes

<div style=\"page-break-after: always\"></div>

| Amendment 01 09-May-2022   | The main purpose of this protocol amendment was to further clarify requirements for eligibility, dose administration and pregnancy testing in view of the comparator arm being approved TKIs selected by Investigators. In addition, BCR-ABL ≤ 1% was added as a secondary endpoint. Also added details on remote procedures that could be implemented in case of a Public Health emergency that limited or prevented on-site study visits.   |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 02               | The main purpose of this protocol amendment was to clarify dose modification guidelines                                                                                                                                                                                                                                                                                                                                                       |
|                            | for hepatotoxicity for asciminib and dose discontinuation rule as applicable to both                                                                                                                                                                                                                                                                                                                                                          |
| 15-May-2023                | treatment arms.                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Baseline data

Demographics and patient-baseline characteristics are presented in Table 16 . These were generally balanced between the all- asciminib arm and the all-comparators arm .

<div style=\"page-break-after: always\"></div>

Table 16 Demographics and baseline characteristics (FAS)

|                                               | Asciminib              | Asciminib            | Asciminib           | ISTKI                  | ISTKI                | ISTKI                 |
|-----------------------------------------------|------------------------|----------------------|---------------------|------------------------|----------------------|-----------------------|
| Baseline Characteristic Categories/Statistics | Imatinib Stratum N=101 | 2G TKI Stratum N=100 | All Asciminib N=201 | Imatinib Stratum N=102 | 2G TKI Stratum N=102 | All Comparators N=204 |
| Age (years)                                   |                        |                      |                     |                        |                      |                       |
| n                                             | 101                    | 100                  | 201                 | 102                    | 102                  | 204                   |
| Mean (SD)                                     | 55.8 (13.70)           | 45.7 (15.37)         | 50.8 (15.38)        | 55.1 (15.04)           | 46.3 (16.18)         | 50.7 (16.20)          |
| Median                                        | 56.0                   | 43.0                 | 52.0                | 54.5                   | 43.0                 | 50.5                  |
| Q1-Q3                                         | 49.0-66.0              | 35.0-59.5            | 39.0-63.0           | 46.0-66.0              | 33.0-56.0            | 39.0-64.0             |
| Min-Max                                       | 21.0-79.0              | 18.0-76.0            | 18.0-79.0           | 20.0-86.0              | 19.0-83.0            | 19.0-86.0             |
| Age group1 -n (%)                             |                        |                      |                     |                        |                      |                       |
| 18-<65 years                                  | 69 (68.3)              | 86 (86.0)            | 155 (77.1)          | 70 (68.6)              | 85 (83.3)            | 155 (76.0)            |
| 65-<75years                                   | 24 (23.8)              | 12 (12.0)            | 36 (17.9)           | 22 (21.6)              | 12 (11.8)            | 34 (16.7)             |
| ≥75 years                                     | 8 (7.9)                | 2 (2.0)              | 10 (5.0)            | 10 (9.8)               | 5 (4.9)              | 15 (7.4)              |
| Age group2 -n (%)                             |                        |                      |                     |                        |                      |                       |
| <65 years                                     | 69 (68.3)              | 86 (86.0)            | 155 (77.1)          | 70 (68.6)              | 85 (83.3)            | 155 (76.0)            |
| ≥65 years                                     | 32 (31.7)              | 14 (14.0)            | 46 (22.9)           | 32 (31.4)              | 17 (16.7)            | 49 (24.0)             |
| (%) u- xaS                                    |                        |                      |                     |                        |                      |                       |
| Male                                          | 62 (61.4)              | 69 (69.0)            | 131 (65.2)          | 65 (63.7)              | 60 (58.8)            | 125 (61.3)            |
| Female                                        | 39 (38.6)              | 31 (31.0)            | 70 (34.8)           | 37 (36.3)              | 42 (41.2)            | 79 (38.7)             |
| Race -n (%)                                   |                        |                      |                     |                        |                      |                       |
| White                                         | 63 (62.4)              | 45 (45.0)            | 108 (53.7)          | 66 (64.7)              | 44 (43.1)            | 110 (53.9)            |
| Black or African American                     | 1 (1.0)                | 1 (1.0)              | 2 (1.0)             | 1 (1.0)                | 1 (1.0)              | 2 (1.0)               |
| Asian                                         | 37 (36.6)              | 53 (53.0)            | 90 (44.8)           | 34 (33.3)              | 56 (54.9)            | 90 (44.1)             |
| Unknown                                       | 0                      | 1 (1.0)              | 1 (0.5)             | 1 (1.0)                | 1 (1.0)              | 2 (1.0)               |
| Ethnicity -n (%)                              |                        |                      |                     |                        |                      |                       |
| Hispanic/Latino                               | 1 (1.0)                | 3 (3.0)              | 4 (2.0)             | 2 (2.0)                | 5 (4.9)              | 7 (3.4)               |
| Not Hispanic/Latino                           | 95 (94.1)              | 90 (90.0)            | 185 (92.0)          | 86 (84.3)              | 92 (90.2)            | 178 (87.3)            |
| Unknown                                       | 1 (1.0)                | 1 (1.0)              | 2 (1.0)             | 0                      | 3 (2.9)              | 3 (1.5)               |

|                                                         | Asciminib              | Asciminib            | Asciminib           | ISTKI                  | ISTKI                | ISTKI                 |
|---------------------------------------------------------|------------------------|----------------------|---------------------|------------------------|----------------------|-----------------------|
| BaselineCharacteristic Categories/Statistics            | Imatinib Stratum N=101 | 2G TKI Stratum N=100 | All Asciminib N=201 | Imatinib Stratum N=102 | 2G TKI Stratum N=102 | All Comparators N=204 |
| Not Reported                                            | 4 (4.0)                | 6 (6.0)              | 10 (5.0)            | 14 (13.7)              | 2 (2.0)              | 16 (7.8)              |
| Framingham estimated 10-year CVD risk categories -n (%) |                        |                      |                     |                        |                      |                       |
| Low (estimated risk ≤10%)                               | 41 (40.6)              | 68 (68.0)            | 109 (54.2)          | 40 (39.2)              | 72 (70.6)            | 112 (54.9)            |
| Intermediate (estimated risk between 10% and 20%)       | 21 (20.8)              | 11 (11.0)            | 32 (15.9)           | 29 (28.4)              | 15 (14.7)            | 44 (21.6)             |
| High (estimated risk >=20%)                             | 39 (38.6)              | 21 (21.0)            | 60 (29.9)           | 33 (32.4)              | 15 (14.7)            | 48 (23.5)             |
| Charlson Comorbidity Index(CCl)(%)                      |                        |                      |                     |                        |                      |                       |
| 2                                                       | 22 (21.8)              | 56 (56.0)            | 78 (38.8)           | 30 (29.4)              | 58 (56.9)            | 88 (43.1)             |
| 3                                                       | 21 (20.8)              | 15 (15.0)            | 36 (17.9)           | 21 (20.6)              | 17 (16.7)            | 38 (18.6)             |
| 4                                                       | 26 (25.7)              | 16 (16.0)            | 42 (20.9)           | 17 (16.7)              | 14 (13.7)            | 31 (15.2)             |
| 5                                                       | 16 (15.8)              | 5 (5.0)              | 21 (10.4)           | 15 (14.7)              | 2 (2.0)              | 17 (8.3)              |
| 6                                                       | 7 (6.9)                | 7 (7.0)              | 14 (7.0)            | 9 (8.8)                | 7 (6.9)              | 16 (7.8)              |
| 7                                                       | 5 (5.0)                | 0                    | 5 (2.5)             | 5 (4.9)                | 3 (2.9)              | 8 (3.9)               |
| 8                                                       | 1 (1.0)                | 1 (1.0)              | 2 (1.0)             | 2 (2.0)                | 1 (1.0)              | 3 (1.5)               |
| 9                                                       | 2 (2.0)                | 0                    | 2 (1.0)             | 0                      | 0                    | 0                     |
| Missing                                                 | 1 (1.0)                | 0                    | 1 (0.5)             | 3 (2.9)                | 0                    | 3 (1.5)               |
| CCl estimated 10-year probability of survival (%)       |                        |                      |                     |                        |                      |                       |
| n                                                       | 100                    | 100                  | 200                 | 99                     | 102                  | 201                   |
| Mean (SD)                                               | 53.6 (31.69)           | 71.9 (27.80)         | 62.7 (31.12)        | 56.4 (33.61)           | 72.1 (28.90)         | 64.3 (32.21)          |
| Median                                                  | 53.4                   | 90.1                 | 77.5                | 77.5                   | 90.1                 | 77.5                  |
| Q1-Q3                                                   | 21.4-77.5              | 53.4-90.1            | 53.4-90.1           | 21.4-90.1              | 53.4-90.1            | 53.4-90.1             |
| Min-Max                                                 | 0.0-90.1               | 0.0-90.1             | 0.0-90.1            | 0.0-90.1               | 0.0-90.1             | 0.0-90.1              |
| ELTS Score (IRT)                                        |                        |                      |                     |                        |                      |                       |
| Low                                                     | 62 (61.4)              | 60 (60.0)            | 122 (60.7)          | 64 (62.7)              | 61 (59.8)            | 125 (61.3)            |
| Intermediate                                            | 30 (29.7)              | 26 (26.0)            | 56 (27.9)           | 30 (29.4)              | 27 (26.5)            | 57 (27.9)             |
| High                                                    | 9 (8.9)                | 14 (14.0)            | 23 (11.4)           | 8 (7.8)                | 14 (13.7)            | 22 (10.8)             |
| Pre-randomization selection TKI (IRT)                   |                        |                      |                     |                        |                      |                       |
| Imatinib stratum                                        | 101(100)               | 0                    | 101 (50.2)          | 102(100)               | 0                    | 102 (50.0)            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                               | Asciminib              | Asciminib            | Asciminib           | ISTKI                  | ISTKI                | ISTKI                |
|-----------------------------------------------|------------------------|----------------------|---------------------|------------------------|----------------------|----------------------|
| Baseline Characteristic Categories/Statistics | Imatinib Stratum N=101 | 2G TKI Stratum N=100 | All Asciminib N=201 | Imatinib Stratum N=102 | 2G TKI Stratum N=102 | AllComparators N=204 |
| 2G TKI stratum                                | 0                      | 100 (100)            | 100 (49.8)          | 0                      | 102 (100)            | 102 (50.0)           |
| Pre-randomization selection TKI(eCRF)         |                        |                      |                     |                        |                      |                      |
| Imatinib stratum                              | 101 (100)              | 0                    | 101 (50.2)          | 100 (98.0)             | 0                    | 100 (49.0)           |
| 2G TKI stratum                                | 0                      | 100 (100)            | 100 (49.8)          | 1 (1.0)                | 102 (100)            | 103 (50.5)           |
| Missing                                       | 0                      | 0                    | 0                   | 1 (1.0)                | 0                    | 1 (0.5)              |
| ReasonforTKlselection                         |                        |                      |                     |                        |                      |                      |
| Age                                           | 13 (12.9)              | 16 (16.0)            | 29 (14.4)           | 16 (15.7)              | 15 (14.7)            | 31 (15.2)            |
| Co-morbidities                                | 9 (8.9)                | 1 (1.0)              | 10 (5.0)            | 6 (5.9)                | 6 (5.9)              | 12 (5.9)             |
| Local practice/guidelines clinical experience | 33 (32.7)              | 42 (42.0)            | 75 (37.3)           | 29 (28.4)              | 46 (45.1)            | 75 (36.8)            |
| Other                                         | 14 (13.9)              | 13 (13.0)            | 27 (13.4)           | 20 (19.6)              | 11 (10.8)            | 31 (15.2)            |
| Risk category                                 | 23 (22.8)              | 13 (13.0)            | 36 (17.9)           | 24 (23.5)              | 18 (17.6)            | 42 (20.6)            |
| Treatment objective                           | 9 (8.9)                | 15 (15.0)            | 24 (11.9)           | 6 (5.9)                | 6 (5.9)              | 12 (5.9)             |
| Missing                                       | 0                      | 0                    | 0                   | 1 (1.0)                | 0                    | 1 (0.5)              |
| Source: Study J12301 W48 CSR-Table 14.1-4.1   |                        |                      |                     |                        |                      |                      |

An overview of disease history is provided in Table 17 . Baseline characteristics were generally balanced between the all- asciminib arm and the all-comparators arm. Three patients in the asciminib arm and one patient in the IS-TKI arm  had BCR::ABL1 gene mutations.

Table 17 Disease history (FAS)

|                                                                               | Asciminib                                                                     | Asciminib                                                                     | Asciminib                                                                     | IS-TKI                                                                        | IS-TKI                                                                        | IS-TKI                                                                        |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Disease history                                                               | Imatinib Stratum N=101                                                        | 2G TKI Stratum N=100                                                          | All Asciminib N=201                                                           | Imatinib Stratum N=102                                                        | 2G TKI Stratum N=102                                                          | All Comparators N=204                                                         |
| Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  | Time since initial diagnosis of CML to randomization (Weeks)                  |
| n                                                                             | 101                                                                           | 100                                                                           | 201                                                                           | 101                                                                           | 102                                                                           | 203                                                                           |
| Mean (SD)                                                                     | 5.38 (2.388)                                                                  | 5.38 (2.567)                                                                  | 5.38 (2.472)                                                                  | 5.56 (2.710)                                                                  | 5.15 (2.847)                                                                  | 5.35 (2.780)                                                                  |
| Median                                                                        | 5.00                                                                          | 5.07                                                                          | 5.00                                                                          | 5.00                                                                          | 4.57                                                                          | 4.71                                                                          |
| Q1-Q3                                                                         | 3.57-6.43                                                                     | 3.43-6.79                                                                     | 3.43-6.71                                                                     | 3.57-7.00                                                                     | 3.00-6.14                                                                     | 3.29-6.86                                                                     |
| Min-Max                                                                       | 1.9-12.3                                                                      | 1.9-16.1                                                                      | 1.9-16.1                                                                      | 1.4-14.9                                                                      | 1.3-12.3                                                                      | 1.3-14.9                                                                      |
| Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) | Time since initial diagnosis of CML to first hydroxyurea / anagrelide (Weeks) |
| n                                                                             | 66                                                                            | 76                                                                            | 142                                                                           | 57                                                                            | 77                                                                            | 134                                                                           |
| Mean (SD)                                                                     | 0.93 (1.694)                                                                  | 0.86 (1.908)                                                                  | 0.89 (1.806)                                                                  | 0.77 (1.286)                                                                  | 0.73 (1.443)                                                                  | 0.74 (1.374)                                                                  |
| Median                                                                        | 0.14                                                                          | 0.14                                                                          | 0.14                                                                          | 0.14                                                                          | 0.14                                                                          | 0.14                                                                          |
| Q1-Q3                                                                         | 0.14-0.71                                                                     | 0.14-1.00                                                                     | 0.14-0.86                                                                     | 0.14-1.00                                                                     | 0.14-0.57                                                                     | 0.14-0.71                                                                     |
| Min-Max                                                                       | 0.1-8.9                                                                       | 0.1-14.3                                                                      | 0.1-14.3                                                                      | 0.1-7.1                                                                       | 0.1-9.1                                                                       | 0.1-9.1                                                                       |
| Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        | Time since initial diagnosis of CML to any TKI (Weeks)                        |
| n                                                                             | 101                                                                           | 100                                                                           | 201                                                                           | 100                                                                           | 101                                                                           | 201                                                                           |
| Mean (SD)                                                                     | 5.02 (2.488)                                                                  | 5.19 (2.694)                                                                  | 5.10 (2.587)                                                                  | 5.60 (2.747)                                                                  | 5.07 (2.835)                                                                  | 5.33 (2.797)                                                                  |
| Median                                                                        | 4.86                                                                          | 4.86                                                                          | 4.86                                                                          | 5.00                                                                          | 4.29                                                                          | 4.71                                                                          |
| Q1-Q3                                                                         | 3.14-6.14                                                                     | 3.22-6.43                                                                     | 3.14-6.14                                                                     | 3.57-7.07                                                                     | 3.00-6.14                                                                     | 3.29-6.86                                                                     |
| Min-Max                                                                       | 0.3-12.3                                                                      | 0.1-16.1                                                                      | 0.1-16.1                                                                      | 1.4-14.9                                                                      | 0.7-12.4                                                                      | 0.7-14.9                                                                      |
| Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  | Prior use of TKI before randomization -n (%)                                  |
| No                                                                            | 85 (84.2)                                                                     | 92 (92.0)                                                                     | 177 (88.1)                                                                    | 99 (97.1)                                                                     | 95 (93.1)                                                                     | 194 (95.1)                                                                    |
| Yes                                                                           | 16 (15.8)                                                                     | 8 (8.0)                                                                       | 24 (11.9)                                                                     | 3 (2.9)                                                                       | 7 (6.9)                                                                       | 10 (4.9)                                                                      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                                | Asciminib                                                      | Asciminib                                                      | Asciminib                                                      | IS-TKI                                                         | IS-TKI                                                         | IS-TKI                                                         |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Disease history                                                | Imatinib Stratum N=101                                         | 2G TKI Stratum N=100                                           | AIl Asciminib N=201                                            | Imatinib Stratum N=102                                         | 2G TKI Stratum N=102                                           | All Comparators N=204                                          |
| Length of exposure (Weeks)  Mean (SD)                          | 1.94 (0.654)                                                   | 1.64 (0.388)                                                   | 1.84 (0.587)                                                   | 1.71 (0.497)                                                   | 1.94 (1.302)                                                   | 1.87 (1.094)                                                   |
| Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) | Prior use of antineoplastic therapy before randomization-n (%) |
| No                                                             | 27 (26.7)                                                      | 24 (24.0)                                                      | 51 (25.4)                                                      | 44 (43.1)                                                      | 22 (21.6)                                                      | 66 (32.4)                                                      |
| Yes                                                            | 74 (73.3)                                                      | 76 (76.0)                                                      | 150 (74.6)                                                     | 58 (56.9)                                                      | 80 (78.4)                                                      | 138 (67.6)                                                     |
| Length of exposure (Weeks) -Mean (SD)                          | 5.48 (9.899)                                                   | 5.29 (3.200)                                                   | 5.39 (7.292)                                                   | 5.08 (4.237)                                                   | 4.68 (2.788)                                                   | 4.84 (3.463)                                                   |
| Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          | Any extramedullary involvement- n (%)                          |
| No                                                             | 95 (94.1)                                                      | 93 (93.0)                                                      | 188 (93.5)                                                     | 96 (94.1)                                                      | 93 (91.2)                                                      | 189 (92.6)                                                     |
| Yes                                                            | 6 (5.9)                                                        | 7 (7.0)                                                        | 13 (6.5)                                                       | 4 (3.9)                                                        | 9 (8.8)                                                        | 13 (6.4)                                                       |
| Unknown                                                        | 0                                                              | 0                                                              | 0                                                              | 2 (2.0)                                                        | 0                                                              | 2 (1.0)                                                        |
| Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 | Location of extramedullary involvement - n (%)                 |
| Spleen                                                         | 6 (5.9)                                                        | 7 (7.0)                                                        | 13 (6.5)                                                       | 4 (3.9)                                                        | 9 (8.8)                                                        | 13 (6.4)                                                       |

Prior use of anti-neoplastic therapy and TKls before randomization refers to treatment with hydroxyurea and/or anagrelide and either imatinib, or nilotinib, or dasatinib or bosutinib for ≤ 2 weeks allowed per protocol.

Source: Study J12301 W48 CSR-Table 14.1-4.5

## Numbers analysed

The numbers of participants in each analysis set for study J12301 are summarised in Table 18 .

Table 18 Analysis Sets (FAS)

|                                      | Asciminib              | Asciminib            | Asciminib           | Investigator Selected TKl   | Investigator Selected TKl   | Investigator Selected TKl   |
|--------------------------------------|------------------------|----------------------|---------------------|-----------------------------|-----------------------------|-----------------------------|
| Analysis Set                         | Imatinib Stratum n (%) | 2G TKI Stratum n (%) | AlI Asciminib n (%) | Imatinib Stratum n (%)      | 2G TKI Stratum n (%)        | AII Comparators n (%)       |
| Safety Set*                          | 100                    | 100                  | 200                 | 99                          | 102                         | 201                         |
| Full Analysis Set                    | 101                    | 100                  | 201                 | 102                         | 102                         | 204                         |
| Imatinib Full Analysis Set (FASimA)  | 101                    | 0                    | 101                 | 102                         | 0                           | 102                         |
| 2G TKI Full Analysis Set (FAS2G TKi) | 0                      | 100                  | 100                 | 0                           | 102                         | 102                         |
| MMR Responder Set                    | 77                     | 80                   | 157                 | 52                          | 67                          | 119                         |
| MR4.0 Responder Set                  | 53                     | 44                   | 97                  | 18                          | 37                          | 55                          |
| MR4.5 ResponderSet                   | 31                     | 25                   | 56                  | 8                           | 23                          | 31                          |
| Phammacokinetic AnalysisSet          | 95                     | 99                   | 194                 | 0                           | 0                           | 0                           |

Percentages are computed using the number of &lt;ANALYSIS SET&gt; in each treatment group as the denominator. * Number of participants reported in Safety set is based on the actual received treatment

## Outcomes and estimation

## Primary endpoints and key secondary endpoints

## Co primary endpoints

Study J12301 had two primary endpoints. The primary endpoint 1, MMR at week 48 in the overall population (FAS) for asciminib vs. IS-TKI was positive: the MMR rate at Week 48 was higher in the asciminib arm with 67.7% compared to 49.0% in the IS-TKI arm. The common treatment difference

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

between the arms of the overall population was 18.88% (95% CI: 9.59, 28.17; one sided p-value: &lt;0.001; Table 19, Figure 14).

The primary endpoint 2, MMR rate at Week 48 in the imatinib stratum was 69.3% for asciminib IMA , compared to 40.2% in the IS-TKI IMA  (imatinib). The common treatment difference in the MMR rate in the imatinib stratum was 29.55% (95% CI: 16.91, 42.18; one-sided adjusted p-value: &lt; 0.001, Figure 15).

## Key secondary endpoints

The key secondary endpoint 1, MMR rate at Week 96 in the overall population (FAS) remained higher in the asciminib arm with 74.1% compared to 52.0% in the  IS- TKI arm (difference between arms 22.42%; 95% CI: 13.55, 31.29; p-value: &lt; 0.001; Table 19)

The key secondary endpoint 2, MMR rate after week 96 in the imatinib stratum (FASIMA) was positive with 76.2% vs. 47.1% patients achieving MMR in with asciminib vs. imatinib-treatment, respectively. The common treatment difference was 29.7% (95% CI, 17.6-41.8; p&lt;0.001).

In the following, results are presented according to the respective population (overall population (FAS) or imatinib stratum (FASIMA).

Table 19 Primary endpoint 1 MMR rate at Week 48 and key secondary endpoint 1 MMR rate at Week 96 (overall population, FAS)

|                                                                | Week 48                       | Week 48                      | Week 96                       | Week 96                      |
|----------------------------------------------------------------|-------------------------------|------------------------------|-------------------------------|------------------------------|
|                                                                | Asciminib All Asciminib N=201 | IS-TKI All Comparators N=204 | Asciminib All Asciminib N=201 | IS-TKI All Comparators N=204 |
| Response - n (%)                                               | 136 (67.66)                   | 100 (49.02)                  | 149 (74.13)                   | 106 (51.96)                  |
| 95% CI for response a                                          | (60.72, 74.07)                | (41.97, 56.10)               | (67.50, 80.03)                | (44.87, 58.99)               |
| Unstratified difference in response rates (vs. comparator) (%) | 18.64                         | -                            | 22.17                         | -                            |
| 95% CI for unstratified difference in response rates b         | (9.21, 28.07)                 | -                            | (13.02, 31.31)                | -                            |
| Common treatment difference (%) c                              | 18.88                         | -                            | 22.42                         | -                            |
| 95% CI for common treatment difference c                       | (9.59, 28.17)                 | -                            | (13.55, 31.29)                | -                            |
| CMH 1-sided test p-value d                                     | <.001                         | -                            | <.001                         | -                            |
| CMH 1-sided test adjusted p-value e                            | <.001                         | -                            | <.001                         | -                            |

Participants without PCR assessment at Week 48 are considered non-responders unless they are in MMR at both Week 36 and Week 60. One and 2 participants in the asciminib arm and in IS-TKI arm, respectively, are imputed as responders. Subjects without PCR assessment at Week 96 are considered non-responders unless they are in MMR at both Week 84 and Week 108. Zero and 0 subjects in Asciminib arm and in IS TKI arm, respectively, are imputed as responders. a Clopper-Pearson 95% CI;  b Wald 95% CI  c  Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (a) pre-randomization selected TKI, and (b) baseline ELTS risk groups (both IRT data).

d CMH 1-sided test stratified by the same stratification factors. e Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The null hypothesis is rejected if the adjusted p-value is less than or equal to 2.5%.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 14: MMR rate at Week 48 (primary endpoint 1) and Week 96 (key secondary endpoint 1) in the overall population (FAS) Error bars represent 95% CIs. The common treatment difference and its 95% CI were estimated using the Mantel- Haenszel method after stratifying for a pre-randomization-selected TKI and baseline ELTS risk groups (both IRT data). b Adjusted 1-sided P value was calculated based on the graphical gatekeeping procedure. The null hypothesis is rejected if the adjusted P value is ≤ .025. Source: SoE, p 34

<!-- image -->

## Subgroup analyses for the co- primary endpoint 1

Subgroup analysis for relevant patient-/ and disease characteristics are provided in Table 20 for the coprimary endpoint 1 and in Table 21 for the key secondary endpoint 1. In general, a concordant effect can be observed among important subgroups.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 20 Forest plot of risk difference with 95% confidence interval for MMR at Week 48 from subgroup analysis (FAS)

| Subgroup                     | AllAsciminib n/N(%)   | INVTKI All Comparators n/N(%)   | FavorsINVTKI   | FavorsAsciminib Risk difference(95%CI)   |
|------------------------------|-----------------------|---------------------------------|----------------|------------------------------------------|
| All subjects                 | 136/201 (67.7)        | 100/204 (49.0)                  |                | 18.6 (9.2, 28.1)                         |
| ELTSbasedonrandomizationdata |                       |                                 |                |                                          |
| Low                          | 88/122 (72.1)         | 72/125 (57.6)                   |                | 14.5 (2.8, 26.3)                         |
| Intermediate                 | 36/56 (64.3)          | 21/57 (36.8)                    |                | 27.4 (9.7, 45.2)                         |
| High                         | 12/23 (52.2)          | 7/22 (31.8)                     |                | 20.4 (-7.9, 48.6)                        |
| ELTS based on CRF data       |                       |                                 |                |                                          |
| Low                          | 90/122(73.8)          | 73/125 (58.4)                   |                | 15.4 (3.7, 27.0)                         |
| Intermediate                 | 35/57 (61.4)          | 21/58 (36.2)                    |                | 25.2 (7.5, 42.9)                         |
| High                         | 11/22 (50.0)          | 6/21 (28.6)                     |                | 21.4 (-7.0, 49.9)                        |
| Sex                          |                       |                                 |                |                                          |
| Female                       | 45/70 (64.3)          | 43/79 (54.4)                    |                | 9.9 (-5.8, 25.6)                         |
| Male                         | 91/131 (69.5)         | 57/125(45.6)                    |                | 23.9 (12.1, 35.6)                        |
| Race                         |                       |                                 |                |                                          |
| Asian                        | 58/90 (64.4)          | 41/90 (45.6)                    |                | 18.9 (4.6, 33.2)                         |
| White                        | 75/108 (69.4)         | 56/110 (50.9)                   |                | 18.5 (5.8,31.3)                          |
| Others                       | 3/3(100)              | 3/4 (75.0)                      |                | 25.0 (-17.4, 67.4)                       |
| Age category                 |                       |                                 |                |                                          |
| 18-65years                   | 100/155 (64.5)        | 75/155 (48.4)                   |                | 16.1 (5.2, 27.0)                         |
| 65-75 years                  | 27/36 (75.0)          | 19/34 (55.9)                    |                | 19.1 (-2.8, 41.0)                        |
| ≥75years                     | 9/10(90.0)            | 6/15 (40.0)                     |                | 50.0 (19.0, 81.0)                        |

n: The number of subjects who responded. N: The total number of subjects in the subgroup and treatment group. INVTKI = Investigator Selected TKI (IS-TKI). Source: [Study J12301 W48 CSR-Figure 14.2-1.7.1]

Table 21 Forest plot of risk difference with 95% confidence interval for MMR at Week 96 from subgroup analysis (FAS)

| Subgroup                         | Asciminib All Asciminib n/N (%)   | INVTKI All Comparators n/N (%)   | FavorsINVTKI   | Favors Asciminib Risk difference (95% CI)   |
|----------------------------------|-----------------------------------|----------------------------------|----------------|---------------------------------------------|
| All subjects                     | 149/201 (74.1)                    | 106/204 (52.0)                   |                | 22.2 (13.0, 31.3)                           |
| ELTS based on randomization data |                                   |                                  |                |                                             |
| Low                              | 98/122 (80.3)                     | 81/125 (64.8)                    |                | 15.5 (4.6, 26.5)                            |
| Intermediate                     | 37/56 (66.1)                      | 20/57 (35.1)                     |                | 31.0 (13.5, 48.5)                           |
| High                             | 14/23 (60.9)                      | 5/22 (22.7)                      |                | 38.1 (11.6, 64.7)                           |
| ELTSbasedonCRFdata               |                                   |                                  |                |                                             |
| Low                              | 100/122 (82.0)                    | 82/125 (65.6)                    |                | 16.4 (5.6, 27.1)                            |
| Intermediate                     | 36/57 (63.2)                      | 20/58 (34.5)                     |                | 28.7 (11.2, 46.2)                           |
| High                             | 13/22 (59.1)                      | 4/21 (19.1)                      |                | 40.0 (13.5, 66.6)                           |
| Sex                              |                                   |                                  |                |                                             |
| Female                           | 54/70 (77.1)                      | 42/79 (53.2)                     |                | 24.0 (9.2, 38.7)                            |
| Male                             | 95/131 (72.5)                     | 64/125 (51.2)                    |                | 21.3 (9.7, 32.9)                            |
| Race                             |                                   |                                  |                |                                             |
| Asian                            | 66/90 (73.3)                      | 51/90 (56.7)                     |                | 16.7 (2.9, 30.4)                            |
| White                            | 81/108 (75.0)                     | 53/110 (48.2)                    |                | 26.8 (14.4, 39.2)                           |
| Others                           | 2/3 (66.7)                        | 2/4 (50.0)                       |                | 16.7 (-55.8, 89.1)                          |
| Age category                     |                                   |                                  |                |                                             |
| 18-65 years                      | 113/155 (72.9)                    | 81/155 (52.3)                    |                | 20.6 (10.1, 31.2)                           |
| 65-75 years                      | 28/36 (77.8)                      | 21/34 (61.8)                     |                | 16.0 (-5.2, 37.3)                           |
| ≥75 years                        | 8/10 (80.0)                       | 4/15 (26.7)                      |                | 53.3 (19.9, 86.7)                           |

n: The number of subjects who responded. N: The total number of subjects in the subgroup and treatment group. 95% Wald CI for Risk Difference. Risk Difference is Asciminib vs INVTKI. INVTKI = Investigator Selected TKI (IS-TKI). Source: [Study J12301 W96 CSR-Figure 14.2-1.7.1a]

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 15: MMR rate at Week 48 (primary endpoint 2) and Week 96 (key secondary endpoint 2) in the imatinib stratum (FASIMA)

<!-- image -->

Error bars represent 95% CIs. The common treatment difference and its 95% CI were estimated using the Mantel- Haenszel method after stratifying for a pre-randomization-selected TKI and baseline ELTS risk groups (both IRT data). b Adjusted 1-sided P value was calculated based on the graphical gatekeeping procedure. The null hypothesis is rejected if the adjusted P value is ≤.025.  Source: SoE, p39

## Analyses for the primary endpoint 2 and key secondary endpoint 2

Subgroup analysis for relevant patient-/ and disease characteristics are provided for the FASIMA population regarding the primary endpoint 2 and key secondary endpoint 2.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 16: Forest plot of risk difference with 95% confidence interval for MMR at Week 48 from subgroup analysis (FASIMA)

<!-- image -->

| Subgroup                         | Asciminib ImatinibStratumImatinibStratum n/N (%)   | INVTKI n/N (%)   | FavorsINVTKI   | FavorsAsciminib Risk difference(95% CI)   |
|----------------------------------|----------------------------------------------------|------------------|----------------|-------------------------------------------|
| All subjects                     | 70/101 (69.3)                                      | 41/102 (40.2)    |                | 29.1 (16.0, 42.2)                         |
| ELTS based on randomization data |                                                    |                  |                |                                           |
| Low                              | 48/62 (77.4)                                       | 32/64 (50.0)     |                | 27.4 (11.3, 43.5)                         |
| Intermediate                     | 18/30 (60.0)                                       | 8/30 (26.7)      |                | 33.3 (9.7, 56.9)                          |
| High                             | 4/9 (44.4)                                         | 1/8 (12.5)       |                | 31.9 (-7.8, 71.7)                         |
| ELTSbased on CRFdata             |                                                    |                  |                |                                           |
| Low                              | 49/63 (77.8)                                       | 32/63 (50.8)     |                | 27.0 (10.9, 43.0)                         |
| Intermediate                     | 17/29 (58.6)                                       | 8/31 (25.8)      |                | 32.8 (9.2, 56.4)                          |
| High                             | 4/9 (44.4)                                         | 1/8 (12.5)       |                | 31.9 (-7.8, 71.7)                         |
| Sex                              |                                                    |                  |                |                                           |
| Female                           | 24/39 (61.5)                                       | 19/37 (51.4)     |                | 10.2 (-12.0, 32.4)                        |
| Male                             | 46/62 (74.2)                                       | 22/65 (33.9)     |                | 40.3 (24.5, 56.2)                         |
| Race                             |                                                    |                  |                |                                           |
| Asian                            | 25/37 (67.6)                                       | 10/34 (29.4)     |                | 38.2 (16.7, 59.7)                         |
| White                            | 44/63 (69.8)                                       | 30/66 (45.5)     |                | 24.4 (7.9, 40.9)                          |
| Others                           | 1/1 (100)                                          | 1/2 (50.0)       |                | 50.0 (-19.3, 100.0)                       |
| Age category                     |                                                    |                  |                |                                           |
| 18-65 years                      | 46/69 (66.7)                                       | 27/70 (38.6)     |                | 28.1 (12.2, 44.0)                         |
| 65-75 years                      | 17/24 (70.8)                                       | 10/22 (45.5)     |                | 25.4 (-2.3, 53.0)                         |
| ≥75 years                        | 7/8 (87.5)                                         | 4/10 (40.0)      |                | 47.5 (9.5, 85.5)                          |

Figure 17: Forest plot of risk difference with 95% confidence interval for MMR at Week 96 from subgroup analysis

|                              | Asciminib ImatinibStratumImatinibStratum n/N (%)   | INVTKI n/N (%)           | FavorsINVTKI   | FavorsAsciminibRiskdifference(95%CI)   |
|------------------------------|----------------------------------------------------|--------------------------|----------------|----------------------------------------|
| Allsubjects                  | 77/101 (76.2)                                      | 48/102 (47.1)            |                | 29.2 (16.4, 41.9)                      |
| ELTSbasedonrandomizationdata |                                                    |                          |                |                                        |
| Low                          | 52/62 (83.9) 20/30 (66.7)                          | 40/64 (62.5) 7/30 (23.3) |                | 21.4 (6.4, 36.4) 43.3 (20.7, 66.0)     |
| Intermediate                 |                                                    |                          |                |                                        |
| High                         | 5/9 (55.6)                                         | 1/8 (12.5)               |                | 43.1 (3.3, 82.8)                       |
| ELTSbased on CRFdata         |                                                    |                          |                |                                        |
| Low                          | 53/63 (84.1)                                       | 40/63 (63.5)             |                | 20.6 (5.7, 35.6)                       |
| Intermediate                 | 19/29 (65.5)                                       | 7/31 (22.6)              |                | 42.9 (20.2, 65.6)                      |
| High                         | 5/9 (55.6)                                         | 1/8 (12.5)               |                | 43.1 (3.3, 82.8)                       |
| Sex                          |                                                    |                          |                |                                        |
| Female                       | 29/39 (74.4)                                       | 19/37 (51.4)             |                | 23.0 (1.9, 44.2)                       |
| Male                         | 48/62 (77.4)                                       | 29/65 (44.6)             |                | 32.8 (16.9, 48.8)                      |
| Race                         |                                                    |                          |                |                                        |
| Asian                        | 27/37 (73.0)                                       | 15/34 (44.1)             |                | 28.9 (6.9, 50.8)                       |
| White                        | 49/63 (77.8)                                       | 32/66 (48.5)             |                | 29.3 (13.5, 45.1)                      |
| Others                       | 1/1 (100)                                          | 1/2 (50.0)               |                | 50.0 (-19.3, 100.0)                    |
| Age category                 |                                                    |                          |                |                                        |
| 18-65 years                  | 51/69 (73.9)                                       | 34/70 (48.6)             |                | 25.3 (9.7, 41.0)                       |
| 65-75 years                  | 20/24 (83.3)                                       | 11/22 (50.0)             |                | 33.3 (7.7, 59.0)                       |
| ≥75 years                    | 6/8 (75.0)                                         | 3/10 (30.0)              |                | 45.0 (3.7, 86.3)                       |

-20

20

40

60

80

100

n: The number of subjects who responded. N: The total number of subjects in the subgroup and treatment group. 95% Wald CI for Risk Difference. Risk Difference is Asciminib vs INVTKI. INVTKI = Investigator Selected TKI (IS-TKI). Source: [Study J12301 W96 CSR-Figure 14.2-1.7.2a]

## Sensitivity analysis of MMR rate at week 48 in the overall population without imutation

The imputation rule in case of missing reports of BCR::ABL1 transcript levels at Week 48 was used for primary analysis in one participant in the asciminib arm and two participants in the IS-TKI arm. The MMR rate at Week 48 (without imputation) in the overall population (FAS) was 67.2% in the asciminib arm and was 48.0% in the IS-TKI arm with the common treatment difference in the MMR rate of 19.37% (95% CI: 10.09, 28.64.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

There were no participants with missing reports of BCR::ABL1 transcript levels at Week 96, consequently no sensitivity analysis concerning the imputation rule was performed for week 96.

## Time to first MMR for the primary endpoints and key secondary endpoints

MMR was achieved earlier in the asciminib arm compared to the IS-TKI arm (KM estimated median time to first MMR: 24.3 weeks vs. 36.4 weeks, Figure 18 ) and earlier in comparison to imatinib (24.1 weeks vs. 48.6 weeks, Figure 19 ).

<!-- image -->

Figure 18: Cumulative incidence function of time to first MMR (FAS) a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MMR was considered a competing event. Source: SoE, figure 3-11 Censoreda OCompetingeventb

<!-- image -->

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Figure 19: Cumulative incidence function of time to first MMR (FASIMA)

a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MMR was considered a competing event. Source: SoE, figure 3-12

## Duration of MMR

Ninety-seven percent in the asciminib arm and 97.7% in the IS-TKI arm of participants who achieved MMR continued to remain in MMR at Week 96.

## Asciminib vs. IS-TKI

By the Week 96 data cut-off, 166 participants in the asciminib arm and 131 in the IS-TKI arm achieved MMR at least once, and 5/166 (3.0%) participants in the asciminib arm and 3/131 (2.3%) in the ISTKI arm lost MMR. Three of 82 (3.7%) participants in ASC IMA  and two of 59 (3.4%) participants in ISTKI IMA  lost MMR. Two of 84 (2.4%) participants in ASC 2G  and one in 72 (1.4%) participants in IS-TKI 2G lost MMR.

Among the 5 participants who lost response in the asciminib arm:

- 4 (2 each from the imatinib and the 2G TKI strata) had confirmed loss of MMR and subsequently discontinued treatment.
- 1 (from the imatinib stratum) discontinued treatment due to a protocol deviation before the loss of MMR could be confirmed.

Among the 3 participants who lost response in the IS-TKI arm:

- 2 (1 each from the imatinib and the 2G TKI strata) had confirmed loss of MMR and subsequently discontinued treatment.
- 1 (from the imatinib stratum) discontinued treatment due to an AE before the loss of MMR could be confirmed.

## Ancillary analyses

## Other secondary efficacy results

## MMR Rate at Week 48 and at week 96 for ASC 2G  vs. IS-TKI 2G

Within the 2G TKI stratum, the MMR rate at Week 48 was higher in ASC 2G  (66.0%) compared to ISTKI 2G  (57.8%). The common treatment difference in the MMR rate was 8.17% (95% CI: -5.14, 21.47; per the CMH one-sided test, stratified by baseline ELTS risk groups). MMR rate at Week 96 increased further and was higher in ASC 2G  (72.0%) while it remained similar in IS-TKI 2G  (56.9%). The treatment difference was 15.14% at Week 96 (95% CI: 2.32, 27.95; per the CMH one-sided test, stratified by baseline ELTS risk groups).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 20: MMR rate at Week 48 and Week 96 (FAS2GTKI) Error bars represent 95% CIs. The common treatment difference and its 95% CI were estimated using the Mantel- Haenszel method after stratifying for a baseline ELTS risk group (IRT data). Source: Source: Study J12301 W48 CSR-Table 14.2-1.1.1.3 and Study J12301 W96 CSR-Table 14.2-1.1.1.3a

<!-- image -->

Within the 2G TKI stratum MMR was reached numerically faster (KM estimated median time to first MMR: 24.3 weeks vs. 36.1 weeks):

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Time since randomization, weeks

Figure 21: Cumulative incidence function of time to first MMR (FAS2GTKI) a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MMR was considered a competing event. Source: SoE, figure 3-13 Censoreda Competing eventb

A higher MMR rate was achieved through Week 96 in the asciminib arm compared to the IS-TKI arm at or by each scheduled timepoints assessed (overall and within each stratum, Table 22)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 22 MMR rate at and by scheduled time points (FAS)

| MMR rate at scheduled time points (FAS)   | MMR rate at scheduled time points (FAS)   | MMR rate at scheduled time points (FAS)   | MMR rate at scheduled time points (FAS)   | MMR rate at scheduled time points (FAS)   | MMRrate by scheduled time points (FAS)   | MMRrate by scheduled time points (FAS)   | MMRrate by scheduled time points (FAS)   | MMRrate by scheduled time points (FAS)   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                           | Asciminib All Asciminib N=201             | IS-TKI All Comparator N=204               | Between treatments b                      | Between treatments b                      | Asciminib All Asciminib N=201            | IS-TKI All Comparators N=204             | Between treatments b                     | Between treatments b                     |
| MMR a                                     | n (%)                                     | n (%)                                     | Common treatment difference (%)           | 95% CI                                    | n (%)                                    | n (%)                                    | Common treatment difference (%)          | 95% CI                                   |
| Week 12                                   | 60 (29.85)                                | 15 (7.35)                                 | 22.55                                     | (15.32, 29.79)                            | 60 (29.85)                               | 15 (7.35)                                | 22.55                                    | (15.32, 29.79)                           |
| Week 24                                   | 116 (57.71)                               | 69 (33.82)                                | 24.12                                     | (14.95, 33.29)                            | 118 (58.71)                              | 69 (33.82)                               | 25.12                                    | (16.01, 34.22)                           |
| Week 36                                   | 125 (62.19)                               | 91 (44.61)                                | 17.83                                     | (8.42, 27.24)                             | 128 (63.68)                              | 92 (45.10)                               | 18.83                                    | (9.50, 28.16)                            |
| Week 48                                   | 136 (67.66)                               | 100 (49.02)                               | 18.88                                     | (9.59, 28.17)                             | 140 (69.65)                              | 104 (50.98)                              | 18.92                                    | (9.78, 28.07)                            |
| Week 60                                   | 144 (71.64)                               | 109 (53.43)                               | 18.46                                     | (9.44, 27.47)                             | 151 (75.12)                              | 117 (57.35)                              | 18.05                                    | (9.30, 26.80)                            |
| Week 72                                   | 145 (72.14)                               | 112 (54.90)                               | 17.53                                     | (8.52, 26.53)                             | 158 (78.61)                              | 123 (60.29)                              | 18.61                                    | (10.16, 27.06)                           |
| Week 84                                   | 148 (73.63)                               | 105 (51.47)                               | 22.40                                     | (13.42, 31.38)                            | 161 (80.10)                              | 124 (60.78)                              | 19.61                                    | (11.30, 27.93)                           |
| Week 96                                   | 149 (74.13)                               | 106 (51.96)                               | 22.42                                     | (13.55, 31.29)                            | 163 (81.09)                              | 125 (61.27)                              | 20.13                                    | (11.93, 28.32)                           |

An exploratory multivariate analysis of treatment effect after adjusting for baseline stratification and other important variables between treatment arms was assessed by logistic regression ( Table 23 ).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 23  Odds ratio of MMR rate at Week 48 adjusted for the stratification factors and other important variables (FAS)

| Adjusted for stratification factors (PRS-TKl and ELTS risk group)                               | Adjusted for stratification factors (PRS-TKl and ELTS risk group)                               | Adjusted for stratification factors (PRS-TKl and ELTS risk group)                               |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                                                                                 | Odds ratio                                                                                      | 95% CI                                                                                          |
| Treatment                                                                                       |                                                                                                 |                                                                                                 |
| Asciminib vs Investigator Selected TKI                                                          | 2.26                                                                                            | (1.50, 3.42)                                                                                    |
| Adjusted for stratification factors (PRS-TKl and ELTS risk group) and other important variables | Adjusted for stratification factors (PRS-TKl and ELTS risk group) and other important variables | Adjusted for stratification factors (PRS-TKl and ELTS risk group) and other important variables |
|                                                                                                 | Odds ratio                                                                                      | 95% CI                                                                                          |
| Treatment                                                                                       |                                                                                                 |                                                                                                 |
| Asciminib vs Investigator Selected TKI                                                          | 2.26                                                                                            | (1.48, 3.47)                                                                                    |
| Pre-Randomization selection TKl (IRT)                                                           |                                                                                                 |                                                                                                 |
| 2G TKl vs Imatinib                                                                              | 1.78                                                                                            | (1.13, 2.81)                                                                                    |
| ELTS Score (IRT)                                                                                |                                                                                                 |                                                                                                 |
| Intermediate vs Low                                                                             | 0.43                                                                                            | (0.25, 0.71)                                                                                    |
| High vs Low                                                                                     | 0.26                                                                                            | (0.13, 0.53)                                                                                    |
| Sex                                                                                             |                                                                                                 |                                                                                                 |
| Female vs Male                                                                                  | 1.19                                                                                            | (0.73, 1.94)                                                                                    |
| Race                                                                                            |                                                                                                 |                                                                                                 |
| Asian vs White                                                                                  | 0.83                                                                                            | (0.53, 1.31)                                                                                    |
| Other vs White                                                                                  | 4.47                                                                                            | (0.51, 38.93)                                                                                   |
| Age Group                                                                                       |                                                                                                 |                                                                                                 |
| 65 - < 75 years vs 18 -< 65 years                                                               | 1.67                                                                                            | (0.84, 3.32)                                                                                    |
| ≥75 years vs 18 - < 65 years                                                                    | 1.94                                                                                            | (0.70, 5.39)                                                                                    |
| Framingham estimated 10-year CDV risk category                                                  |                                                                                                 |                                                                                                 |
| Intermediate (estimated risk between 10% and 20%) vs Low (estimated risk < 10%)                 | 0.78                                                                                            | (0.43, 1.41)                                                                                    |
| High (estimated risk ≥ 20%) vs Low (estimated risk < 10%)                                       | 1.78                                                                                            | (0.90, 3.51)                                                                                    |

Including imputed MMR responders at Week 48.

Source: Table 14.2-1.7.1, Table 14.2-1.8.1

## Early molecular response (EMR) at Week 12

In Study J12301, 89.6% of participants in the asciminib arm achieved the treatment milestone EMR compared to 70.1% of participants in the IS-TKI arm overall (89.6% vs. 70.1%), including effects within the imatinib stratum (88.1% vs. 59.8%), and within the 2G TKI stratum (91.0% vs. 80.4%; Table 24 ).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 24 BCR::ABL1 ratio (% IS) at Week 12

一

|                                                            | FASX                                   | FASX                                | FASIMAO                                     | FASIMAO                       | FAS2GTKIo                              | FAS2GTKIo                            |
|------------------------------------------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|-------------------------------|----------------------------------------|--------------------------------------|
|                                                            | Asciminibao AI Asciminibo N=201 n·(%)μ | IS-TKIn All-Comparators N=204 (%)·u | Asciminibu Imatinibl Stratum# N=101# n·(%)μ | IS-TKIn Stratumu N=102 n-(%)μ | Asciminib→ 2G·TKI Stratumo N=100 n(%)μ | IS-TKI 2G-TKI Stratuma N=1020 n-(%)μ |
| Individual·category                                        | Individual·category                    |                                     | T                                           |                               |                                        |                                      |
| <=0.0032%x                                                 | 2·(1.0)α                               | 1-(0.5)x                            | 2-(2.0)x                                    | Qo                            | Qo:                                    | 1-(1.0)αx                            |
| >0.0032% <=0.01%                                           | 4-(2.0)αx                              | 2-(1.0)ox                           | 1-(1.0)α                                    | Oα                            | 3·(3.0)o                               | 2-(2.0)αx                            |
| >0.01% - <=0.1%                                            | 54-(26.9)o                             | 12-(5.9)                            | 29-(28.7)α                                  | 2-(2.0)αx                     | 25-(25.0)                              | 10·(9.8)x                            |
| >0.1%--<=1%x                                               | 92-(45.8)αx                            | 56-(27.5)α                          | 43-(42.6)α                                  | 22-(21.6)α                    | 49-(49.0)x                             | 34-(33.3)                            |
| >1%--<=10%α                                                | 28 -(13.9)                             | 72-(35.3)α                          | 14-(13.9)α                                  | 37-(36.3)α                    | 14-(14.0)α                             | 35-(34.3)x                           |
| >10%x                                                      | 13·(6.5)x                              | 47-(23.0)α                          | 6-(5.9)x                                    | 34-(33.3)α                    | 7·(7.0)α                               | 13-(12.7)x                           |
| Missingx                                                   | 8-(4.0)α                               | 14-(6.9)                            | 6-(5.9)x                                    | 7·(6.9)α                      | 2·(2.0)α                               | 7-(6.9)α                             |
| Assessment- not-evaluable-(1)                              | Qrx                                    | Qxot T T                            | Ox:                                         | Orx                           |                                        |                                      |
| Discontinued- due-to- unsatisfactory. therapeutic-effect/- | 1-(0.5)α                               | L T 3·(1.5)α                        | 1-(1.0)α                                    | 2-(2.0)αx                     | 1 QIx                                  | 1·(1.0)x                             |
| PD/death-(2)I Discontinued- due-to-other- reasons2).       | 3·(1.5)α                               | T 6·(2.9)αx                         | 3-(3.0)x                                    | 3·(2.9)α                      | T                                      | 3·(2.9)x                             |
| Missing assessment                                         | 4-(2.0)α                               | 5-(2.5)α                            | 2-(2.0)α                                    | 2·(2.0)α                      | 2·(2.0)o                               | 3-(2.9)α                             |
| Cumulative-over-categoriesx                                | Cumulative-over-categoriesx            |                                     |                                             |                               |                                        |                                      |
| <=0.0032%x                                                 | 2-(1.0)α                               | 1-(0.5)α                            | 2-(2.0)αx                                   | Ox                            |                                        | 1-(1.0)α                             |
| <=0.01%x                                                   | 6-(3.0)x                               | 3-(1.5)α                            | 3-(3.0)α                                    | x0                            | 3·(3.0)α                               | 3-(2.9)αx                            |
| <=0.1%x                                                    | 60-(29.9)x                             | 15-(7.4)α                           | 32-(31.7)                                   | 2·(2.0)α                      | 28 (28.0)α                             | 13-(12.7)α                           |
| <=1%x                                                      | 152-(75.6)α                            | 71-(34.8)o                          | 75-(74.3)ox                                 | 24-(23.5)αx                   | 77·(77.0)α                             | 47-(46.1)α                           |
| <=10%                                                      | 180-(89.6)                             | 143-(70.1)                          | 89-(88.1)                                   | 61·(59.8)                     | 91-(91.0)                              | 82-(80.4)                            |

Source: SoE, table 3-15

## MR2.0 at and by all scheduled data collection time points

Achievement of BCR::ABL1 ≤1% (MR 2.0, corresponding to CCyR) at 12 months was achieved by 87.06% in the asciminib arm and 68.14% in the IS-TKI arm (difference 14.78%; 95% CI 7.44; 22.12). The effect was observed at and by all assessed timepoints from week 8 to week 96 (

Table 25 ). Regarding the FASIMA population, the MR2.0 rate by Week 48 in ASCI MA  subgroup was 91.1% vs. 69.6% in IS-TKI IMA  subgroup (treatment difference of 22.00%, 95% CI: 11.95, 32.06). For FAS2GTKI

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

MR2.0 rate by Week 48 in ASC 2G  of 94.0% vs. 84.3% in IS-TKI 2G  (treatment difference: 9.67%, 95% CI: 1.45, 17.89).

Table 25 MR2.0 (BCR::ABL1 &lt;=1%) rate at and by scheduled time points (FAS)

| MR2.0(BCR::ABL1<=1%)rateatscheduled timepoints(FAS)   | MR2.0(BCR::ABL1<=1%)rateatscheduled timepoints(FAS)   | MR2.0(BCR::ABL1<=1%)rateatscheduled timepoints(FAS)   | MR2.0(BCR::ABL1<=1%)rateatscheduled timepoints(FAS)   | MR2.0(BCR::ABL1<=1%)rateatscheduled timepoints(FAS)   | MR2.0 (BCR::ABL1<=1%)rateby scheduled time points(FAS)   | MR2.0 (BCR::ABL1<=1%)rateby scheduled time points(FAS)   | MR2.0 (BCR::ABL1<=1%)rateby scheduled time points(FAS)   | MR2.0 (BCR::ABL1<=1%)rateby scheduled time points(FAS)   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                       | Asciminib AllAsciminib N=201                          | IS-TKI All Comparators N=204                          | Betweentreatmentsb                                    | Betweentreatmentsb                                    | Asciminib All Asciminib N=201                            | IS-TKI All Comparators N=204                             | Betweentreatmentsb                                       | Betweentreatmentsb                                       |
| MR2.0*                                                | n (%)                                                 | n (%)                                                 | Commontreatment difference(%)                         | 95% CI                                                | n (%)                                                    | (%) u                                                    | Commontreatment difference (%)                           | 95% CI                                                   |
| Week 8                                                | 31 (15.42)                                            | 6 (2.94)                                              | 12.52                                                 | (7.02, 18.03)                                         | 31 (15.42)                                               | 6 (2.94)                                                 | 12.52                                                    | (7.02, 18.03)                                            |
| Week 12                                               | 152 (75.62)                                           | 71 (34.80)                                            | 41.06                                                 | (32.69, 49.44)                                        | 152 (75.62)                                              | 72 (35.29)                                               | 40.58                                                    | (32.18, 48.98)                                           |
| Week 24                                               | 178 (88.56)                                           | 130 (63.73)                                           | 25.11                                                 | (17.40, 32.81)                                        | 182 (90.55)                                              | 132 (64.71)                                              | 26.13                                                    | (18.72, 33.54)                                           |
| Week36                                                | 176 (87.56)                                           | 139 (68.14)                                           | 19.68                                                 | (12.08, 27.28)                                        | 184 (91.54)                                              | 143 (70.10)                                              | 21.70                                                    | (14.55, 28.84)                                           |
| Week 48                                               | 175 (87.06)                                           | 148 (72.55)                                           | 14.78                                                 | (7.44, 22.12)                                         | 186 (92.54)                                              | 157 (76.96)                                              | 15.85                                                    | (9.30, 22.40)                                            |
| Week60                                                | 175 (87.06)                                           | 146 (71.57)                                           | 15.75                                                 | (8.30, 23.20)                                         | 186 (92.54)                                              | 157 (76.96)                                              | 15.85                                                    | (9.30, 22.40)                                            |
| Week 72                                               | 172 (85.57)                                           | 139 (68.14)                                           | 17.70                                                 | (9.92, 25.48)                                         | 186 (92.54)                                              | 157 (76.96)                                              | 15.85                                                    | (9.30, 22.40)                                            |
| Week 84                                               | 170 (84.58)                                           | 130 (63.73)                                           | 21.09                                                 | (13.05, 29.13)                                        | 186 (92.54)                                              | 157 (76.96)                                              | 15.85                                                    | (9.30, 22.40)                                            |
| Week96                                                | 167 (83.08)                                           | 126 (61.76)                                           | 21.55                                                 | (13.31, 29.80)                                        | 186 (92.54)                                              | 157 (76.96)                                              | 15.85                                                    | (9.30, 22.40)                                            |

Source: SoE, p 55

## MR4.0 at and by all scheduled data collection time points

The MR4.0 rate at and by each scheduled time point was higher for the asciminib arm compared to the IS-TKI arm. Differences were observed in week 24 (23.4% in the asciminib arm compared to 9.8% in the ISTKI arm, common treatment difference (Δ) of 13.66%, 95% CI: 6.63, 20.68) week 48 (40.8% in the asciminib arm vs. 22.1% in the IS-TKI arm; Δ: 18.91%, 95% CI: 10.30, 27.52) and week 96 (52.7% in the asciminib arm vs. 34.3% in the ISTKI arm; Δ: 18.62%, 95% CI: 9.34, 27.91, Table 26 ). Regarding MR4.0 rate, the numerical difference between arms by week 48 was 30.22% (95% CI: 18.61, 41.83; 56.4% vs. 28.4%) for the FASIMA and 7.54% (95% CI; -4.77, 19.86; 36.0% vs. 28.4%) for the FAS2G in favour of asciminib.

Table 26 MR4.0 rate at and by scheduled time points (FAS)

| MR4.0 rate at scheduled time points (FAS)   | MR4.0 rate at scheduled time points (FAS)   | MR4.0 rate at scheduled time points (FAS)   | MR4.0 rate at scheduled time points (FAS)   | MR4.0 rate at scheduled time points (FAS)   | MR4.0 rate by scheduled time points (FAS)   | MR4.0 rate by scheduled time points (FAS)   | MR4.0 rate by scheduled time points (FAS)   | MR4.0 rate by scheduled time points (FAS)   |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                             | Asciminib All Asciminib N=201               | IS-TKI All Comparators N=204                | Betweentreatmentsb                          | Betweentreatmentsb                          | Asciminib All Asciminib N=201               | IS-TKI AllComparators N=204                 | Betweentreatmentsb                          | Betweentreatmentsb                          |
| MR4.0a                                      | n (%)                                       | n (%)                                       | Common treatment difference (%)             | 95% CI                                      | n (%)                                       | n (%)                                       | Common treatment difference (%)             | 95% CI                                      |
| Week 12                                     | 6 (2.99)                                    | 3 (1.47)                                    | 1.49                                        | (-1.35, 4.34)                               | 6 (2.99)                                    | 3 (1.47)                                    | 1.49                                        | (-1.35, 4.34)                               |
| Week 24                                     | 47 (23.38)                                  | 20 (9.80)                                   | 13.66                                       | (6.63, 20.68)                               | 47 (23.38)                                  | 20 (9.80)                                   | 13.66                                       | (6.63, 20.68)                               |
| Week36                                      | 63 (31.34)                                  | 30 (14.71)                                  | 16.77                                       | (8.85, 24.69)                               | 66 (32.84)                                  | 31 (15.20)                                  | 17.78                                       | (9.74, 25.81)                               |
| Week 48                                     | 78 (38.81)                                  | 42 (20.59)                                  | 18.38                                       | (9.96, 26.79)                               | 82 (40.80)                                  | 45 (22.06)                                  | 18.91                                       | (10.30, 27.52)                              |
| Week60                                      | 82 (40.80)                                  | 51 (25.00)                                  | 15.94                                       | (7.13, 24.75)                               | 92 (45.77)                                  | 56 (27.45)                                  | 18.48                                       | (9.50, 27.46)                               |
| Week 72                                     | 85 (42.29)                                  | 53 (25.98)                                  | 16.46                                       | (7.58, 25.34)                               | 96 (47.76)                                  | 61 (29.90)                                  | 18.04                                       | (8.96, 27.13)                               |
| Week 84                                     | 91 (45.27)                                  | 55 (26.96)                                  | 18.47                                       | (9.47, 27.47)                               | 101 (50.25)                                 | 67 (32.84)                                  | 17.60                                       | (8.43, 26.77)                               |
| Week96                                      | 98 (48.76)                                  | 56 (27.45)                                  | 21.48                                       | (12.40, 30.56)                              | 106 (52.74)                                 | 70 (34.31)                                  | 18.62                                       | (9.34, 27.91)                               |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The cumulative incidence function for time to first MR4.0 was separately observed in the FASIMA population and to a lower extent in the FAS2GTKI population ( Figure 22 , Figure 23 , Figure 24 ). At Week 96, the majority of participants (97.4% in the asciminib arm and 97.4% in the IS-TKI arm) who achieved MR4.0 continued to remain in MR4.0.

<!-- image -->

## Time sincerandomization,weeks

Figure 22: Cumulative incidence function of time to first MR4.0 (FAS) a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MR4.5 is considered a competing event for cumulative incidence of Censoreda OCompetingeventb

MR4.5. Source: SoE, p 60

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Time since randomization,weeks

- Censoreda OCompeting eventb

Figure 23:

## Cumulative incidence function of time to first MR4.0 (FAS2GTKI)

a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MR4.0 is considered a competing event for cumulative incidence of MR4.0. Source: SoE, p 61

<!-- image -->

## Time since randomization, weeks

- Censoreda OCompeting eventb

Figure 24: Cumulative incidence function of time to first MR4.0 (FASIMA) a Nonresponders were censored at their last molecular assessment date. b Discontinuation from treatment for any reason without prior achievement of MR4.0 is considered a competing event for cumulative incidence of MR4.0. Source: SoE; p 59

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## MR4.5 at and by all scheduled data collection time points

MR4.5 rates at and by different time points were higher in the asciminib arm compared to IS-TKI and are presented in Table 27 .

For the FASIMA population, MR4.5 rate was 14.9% vs. 2.9% after 24 weeks, 21.8% vs. 5.9% after 48 weeks and 40.6% vs. 15.7% after 96 weeks for ASC IMA  and   IS-TKI IMA , respectively.

For the FAS2GTKI population, MR4.5 rate was 14.0% vs. 7.8% after 24 weeks, 18.0% vs. 17.7% after 48 weeks and 32.0% vs. 27.5% after 96 weeks for ASC IMA  and   IS-TKI IMA , respectively.

At Week 96, the majority of participants (98.9% in the asciminib arm vs. 98.1% in the IS-TKI arm) who achieved MR4.5 continued to remain in MR4.5.

Table 27 MR4.5 rate at and by scheduled time points (FAS)

| MR4.5rateatscheduledtimepoints(FAs)   | MR4.5rateatscheduledtimepoints(FAs)   | MR4.5rateatscheduledtimepoints(FAs)   | MR4.5rateatscheduledtimepoints(FAs)   | MR4.5rateatscheduledtimepoints(FAs)   | MR4.5ratebyscheduledtimepoints(FAs)   | MR4.5ratebyscheduledtimepoints(FAs)   | MR4.5ratebyscheduledtimepoints(FAs)   | MR4.5ratebyscheduledtimepoints(FAs)   |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                       | Asciminib All Asciminib N=201         | IS-TKI All Comparators N=204          | Betweentreatmentsb                    | Betweentreatmentsb                    | Asciminib All Asciminib N=201         | IS-TKI AlIl Comparators N=204         | Betweentreatmentsb                    | Betweentreatmentsb                    |
| MR4.5a                                | n (%)                                 | n (%)                                 | Commontreatment difference (%)        | 95% CI                                | n (%)                                 | n (%)                                 | Commontreatment difference (%)        | 95% CI                                |
| Week12                                | 2 (1.00)                              | 1 (0.49)                              | 0.51                                  | (-1.17, 2.20)                         | 2 (1.00)                              | 1 (0.49)                              | 0.51                                  | (-1.17, 2.20)                         |
| Week24                                | 29 (14.43)                            | 11 (5.39)                             | 9.11                                  | (3.43, 14.80)                         | 29 (14.43)                            | 11 (5.39)                             | 9.11                                  | (3.43, 14.80)                         |
| Week36                                | 32 (15.92)                            | 19 (9.31)                             | 6.71                                  | (0.34, 13.07)                         | 34 (16.92)                            | 21 (10.29)                            | 6.73                                  | (0.17, 13.28)                         |
| Week48                                | 34 (16.92)                            | 18 (8.82)                             | 8.20                                  | (1.78, 14.62)                         | 40 (19.90)                            | 24 (11.76)                            | 8.26                                  | (1.26, 15.25)                         |
| Week60                                | 44 (21.89)                            | 24 (11.76)                            | 10.20                                 | (3.09, 17.32)                         | 48 (23.88)                            | 29 (14.22)                            | 9.77                                  | (2.26, 17.28)                         |
| Week72                                | 51 (25.37)                            | 31 (15.20)                            | 10.30                                 | (2.65, 17.95)                         | 60 (29.85)                            | 37 (18.14)                            | 11.86                                 | (3.78, 19.94)                         |
| Week84                                | 57 (28.36)                            | 31 (15.20)                            | 13.27                                 | (5.50, 21.04)                         | 64 (31.84)                            | 40 (19.61)                            | 12.36                                 | (4.10, 20.62)                         |
| Week96                                | 62 (30.85)                            | 36 (17.65)                            | 13.26                                 | (5.07, 21.46)                         | 73 (36.32)                            | 44 (21.57)                            | 14.86                                 | (6.29, 23.43)                         |

MR4.5 was achieved earlier in the asciminib arm compared to the IS-TKI arm overall (KM estimated median time to first MR4.5: 120.3 weeks vs. 131.9 weeks), within the imatinib stratum (108.1 weeks vs. NE), and within the 2G TKI stratum (122.1 weeks vs. 131.9 weeks).

## Overview of BCR::ABL1 ratio (%IS) kinetics

BCR::ABL1 levels comparing asciminib vs. IS-TKIs are demonstrated in Figure 25 , Figure 26 and Figure 27.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

N:numberofparticipantswithavailableassessments. Values after treatment failure or end of treatment visit are not displayed. Squaresandtrianglesdenoteoutliers

BCR::ABL1 ratio (% IS) summary plot over time (FAS)

Figure 25: Source: SoE, figure 3-20

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

N: number of participantswith available assessments. Values after treatment failure or end of treatment visit are not displayed. Squaresandtrianglesdenoteoutliers

Figure 26: BCR::ABL1 ratio (% IS) summary plot over time (FASIMA)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

N: number of participantswith available assessments

Values after treatment failure or end of treatment visit are not displayed.

Squares and triangles denoteoutliers

Source:[StudyJ12301W96CSR-Figure14.2-2.2.3]

Figure 27:

BCR::ABL1 ratio (% IS) summary plot over time (FAS2GTKI)

## Complete haematological response

By Week 48, as expected, CHR was achieved in 94.5% of participants in the asciminib arm and 94.1% in the IS-TKI arm.

## Cytogenetic response

Due to current medical practice, bone marrow examination for cytogenetic assessment during the course of the study was not mandatory and only performed if clinically indicated. As a result, very few participants (n = 2) had the cytogenetic assessment performed by Week 96.

## Other time to event-endpoints

## Time to treatment failure:

The KM probability of treatment failure was lower in the asciminib arm compared to the IS-TKI arm (HR=0.37; 95% CI: 0.25, 0.55). By 1 year since randomisation, the KM estimated probability (%) of being treatment failure-free higher in the asciminib arm (88.0%, 95% CI: 82.6, 91.8) compared to the IS-TKI arm (74.1%, 95% CI: 67.5, 79.6). By 2 years since randomisation, the KM estimated probability (%) of being treatment failure-free was higher in the asciminib arm (82.9%, 95% CI: 76.9, 87.5) compared to the IS- TKI arm (61.5%, 95% CI: 54.4, 67.9). The median time to treatment failure was not estimable for either arm.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

For the FASIMA population, (ASCIMA vs. IS-TKIIMA), The KM probability of treatment failure was lower in ASCIMA compared to IS-TKIIMA (HR=0.27; 95% CI: 0.15, 0.47). By 1 year since randomization, the KM estimated probability (%) of being treatment failure-free was higher in ASCIMA (86.0%, 95% CI: 77.5 - 91.5) compared to IS-TKIIMA (63.0%, 95% CI: 52.8, 71.6). By 2 years since randomization, the KM estimated probability (%) of being treatment failure-free was higher in ASCIMA (83.0%, 95% CI: 74.1, 89.1) compared to IS-TKIIMA (52.8%, 95% CI: 42.5, 62.0). The median time to treatment failure was not estimable for either arm.

For the FAS2GTKI population, (ASC 2G  vs. IS-TKI 2G ), the KM probability of treatment failure was lower in ASC2G compared to IS-TKI2G (HR=0.54; 95% CI: 0.30, 0.95). By 1 year since randomization, the KM estimated probability (%) of being treatment failure-free was higher in ASC2G (90.0%, 95% CI: 82.2, 94.5) compared to IS-TKI2G (85.1%, 95% CI: 76.6, 90.8). By 2 years since randomization, the KM estimated probability (%) of being treatment failure-free was higher in ASC2G (83.0%, 95% CI: 74.1, 89.1) compared to IS-TKI2G (70.3%, 95% CI: 60.3, 78.2). The median time to treatment failure was not estimable for either arm.

## Event free survival (EFS):

The probability of EFS (including 1) treatment failure as defined in ELN criteria 2) confirmed loss of MMR at any time while the study 3) discontinuation from study treatment due to AE 4) progression to AP / BP 5) death due to any cause) remained higher in the asciminib arm compared to the IS-TKI arm through Week 96. At the Week 96 data cut-off, the number of participants with a relevant EFS event was half in the asciminib arm (29/201 participants, 14.4%) arm compared to the IS-TKI arm (60/204 participants, 29.4%, KM plot Figure 28). The number of participants with a competing risk for the EFS endpoint was lower in the asciminib (7/201 participants, 3.5%) compared to the IS-TKI arm (20/204 participants, 9.8%). By 48 weeks since randomization, the estimated probability of EFS was higher in the asciminib arm (91.0%, 95% CI: 86.5, 94.5) compared to the IS-TKI arm (83.6%, 95% CI: 78.1, 88.3). By 96 weeks since randomization, the estimated probability of EFS was higher in the asciminib arm (86.5%, 95% CI: 81.4, 90.8) compared to the IS-TKI arm (71.1%, 95% CI: 64.8, 77.3).

For the FASIMA population, the probability of EFS remained higher in ASCIMA compared to IS-TKIIMA through Week 96. At the Week 96 data cut-off, the number of participants with a relevant EFS event was half in ASCIMA (17/101 participants, 16.8%) compared to IS-TKIIMA (36/102 participants, 35.3%) [Study J12301 W96 CSR. No participant in ASCIMA and 12/102 (11.8%) participants in ISTKIIMA had a competing risk for the EFS endpoint. By 48 weeks since randomization, the estimated probability of EFS was higher in ASCIMA (88.0%, 95% CI: 80.8, 93.5) as compared to IS-TKIIMA (78.0%, 95% CI: 69.4, 85.6) [Study J12301 W96 CSR]. By 96 weeks since randomization, the estimated probability of EFS was higher in ASCIMA ( Figure 29 )

For the FAS2GTKI population, the probability of EFS remained generally higher in ASC2G compared to IS-TKI2G. At the Week 96 data cut-off, the number of participants with a relevant EFS event was half in ASC2G (12/100 participants, 12.0%) arm compared to IS-TKI2G (24/102 participants, 23.5%) [Study J12301 W96 CSR]. The number of participants with a competing risk for the EFS endpoint was similar in ASC2G (7/100 participants, 7.0%) and IS-TKI2G (8/102 participants, 7.8%). By 48 weeks since randomization, the estimated probability of EFS was higher in ASC2G (94.0%, 95% CI: 88.1, 97.6) as compared to IS-TKI2G (89.1%, 95% CI: 82.1, 94.2) [Study J12301 W96 CSR]. By 96 weeks since randomization, the estimated probability of EFS was higher in ASC2G (90.0%, 95% CI: 83.2, 94.9) compared to IS-TKI2G (77.2%, 95% CI: 68.6, 84.9).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 28 Kaplan-Meier survival plot of event free survival (Full Analysis Set)

<!-- image -->

## Figure 2-6 Kaplan-Meier survival plot of event free survival (lmatinib Full Analysis Set)

Figure 29 Kaplan-Meier survival plot of event free survival (Imatinib)

<!-- image -->

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 30 Kaplan-Meier survival plot of event free survival (2G TKI)

<!-- image -->

## Progression free survival (PFS)

A total of 5/201 (2.5%) participants in the asciminib arm and 8/204 participants (3.9%) in the IS-TKI arm had PFS events.

## Overall survival (OS)

There were no on-treatment deaths (up to 30 days after end of treatment) in either of the treatment arms. A total of 2/201 (1.0%) participants in the asciminib arm and 4/204 (2.0%) in the IS-TKI arm died during the study.

## Other exploratory variables

Details of participants with baseline BCR::ABL1 mutations are shown in Table 28 .

Table 28 Details of participants with baseline BCR::ABL1 gene mutations identified

| Treatment   | Ongoing or treatment discontinuation (a)   | Reason of treatment discontinuation (a)   | Best molecular response (b)   | Molecular Response at/ immediately prior to EOT (b)   |
|-------------|--------------------------------------------|-------------------------------------------|-------------------------------|-------------------------------------------------------|
| Asciminib   | Ongoing                                    | /                                         | W72: MR2.0 (0.24%)            | /                                                     |
| Asciminib   | Ongoing                                    | /                                         | W72: MR4.0 (0.01%)            | /                                                     |
| Asciminib   | Discontinued treatment Within W1           | Adverse event                             | W2: 16.01%                    | W2: 16.01%                                            |
| Bosutinib   | Ongoing                                    | /                                         | W60: MMR (0.03%)              | /                                                     |

Source: SoE study 12301, page 80

Post-baseline treatment-emergent BCR::ABL1 gene mutations were detected 5% of the patients in the asciminib arm and 3.4% of the patients of the IS-TKI arm, see Table 8 (Secondary pharmacology). Mutations in the asciminib arm were in the myristoyl pocket or in the functionally adjacent area of the

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

kinase domain, while the majority of mutations in the IS-TKI arm were in the P-loop adjacent to the ATP binding site.

Among the 10 participants in the asciminib arm with post-baseline BCR::ABL1 gene mutations identified, 1 is still receiving treatment, 5 achieved MR2.0 during study treatment with subsequent elevation in BCR::ABL1 at the time of treatment discontinuation. Overall, 8 discontinued due to unsatisfactory therapeutic effect (6 due to treatment failure per ELN, 1 due to confirmed loss of MMR, and 1 due to other reason (per Investigator's assessment)) and 1 discontinued due to disease progression.

Among the 7 participants in the IS-TKI arm with post-baseline BCR::ABL1 gene mutations identified, 1 is still receiving treatment and achieved MMR, 1 achieved MMR and 2 achieved MR2.0 during the study treatment. Overall, 6 discontinued due to unsatisfactory therapeutic effect (5 due to treatment failure per ELN, and 1 due to confirmed loss of MMR).

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 29 Summary of Efficacy for trial CABL001J12301/ ASC4FIRST

| Title: A phase III, multi-center, open-label, randomised study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase   | Title: A phase III, multi-center, open-label, randomised study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase                                                                                                                                                                                                                                                     | Title: A phase III, multi-center, open-label, randomised study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                    | CABL001J12301, EU CT 2023-508838-33-00, NCT04971226, ASC4FIRST                                                                                                                                                                                                                                                                                                                                                                                                                        | CABL001J12301, EU CT 2023-508838-33-00, NCT04971226, ASC4FIRST                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                              | Randomised, open-label, active-controlled, multi-centre Phase III study Randomization 1:1 to asciminib or Investigator selected TKI (IS-TKI; imatinib or nilotinib or dasatinib or bosutinib) Prior to randomization, the Investigator selected the TKI to be used in the event of randomization to the comparator arm. Stratification based on: 1) ELTS score (low versus intermediate versus high) 2) Pre-randomization selected TKI (PRS-TKI; imatinib versus 2G TKI (nilotinib or | Randomised, open-label, active-controlled, multi-centre Phase III study Randomization 1:1 to asciminib or Investigator selected TKI (IS-TKI; imatinib or nilotinib or dasatinib or bosutinib) Prior to randomization, the Investigator selected the TKI to be used in the event of randomization to the comparator arm. Stratification based on: 1) ELTS score (low versus intermediate versus high) 2) Pre-randomization selected TKI (PRS-TKI; imatinib versus 2G TKI (nilotinib or |
|                                                                                                                                                                                                                                     | d b b b)) Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                              | 5 years from last participant first treatment (LPFT) not applicable not applicable                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                   | Asciminib                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Treatment: Asciminib 80 mg QD under fasting conditions Duration: until End of Study (5 y from LPFT) or until premature discontinuation                                                                                                                                                                                                                                                                                                                                                |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                               | Investigator selected TKI (IS-TKI)                                       | Investigator selected TKI (IS-TKI)                                       | Treatment: one of the below IS-TKI • Imatinib 400 mg QD administered with food                                                 |
|---------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
|                                                               |                                                                          |                                                                          | • Nilotinib 300 mg BID (total daily dose of 600 mg) under fasting conditions                                                   |
|                                                               |                                                                          |                                                                          | • Dasatinib 100 mg QD administered with or without a meal                                                                      |
|                                                               |                                                                          |                                                                          | • Bosutinib 400 mg QD administered with food                                                                                   |
|                                                               |                                                                          |                                                                          | Duration: until End of Study (5 y from LPFT) or until premature                                                                |
| Treatment groups considering stratification based on PRS-TKI: | Treatment groups considering stratification based on PRS-TKI:            | Treatment groups considering stratification based on PRS-TKI:            | Treatment groups considering stratification based on PRS-TKI:                                                                  |
|                                                               | ASC IMA                                                                  | ASC IMA                                                                  | Participants randomised to asciminib, within the stratum of participants with imatinib as PRS-TKI N=101                        |
|                                                               | IS-TKI IMA                                                               | IS-TKI IMA                                                               | Participants randomised to IS-TKI, within the stratum of participants with imatinib as PRS-TKI N=102                           |
|                                                               | ASC 2G                                                                   | ASC 2G                                                                   | Participants randomised to asciminib, within the stratum of participants with 2G TKI as PRS-TKI N=100                          |
|                                                               | IS-TKI 2G                                                                | IS-TKI 2G                                                                | Participants randomised to IS-TKI, within the stratum of participants with 2G TKI as PRS-TKI N=102                             |
| Endpoints and definitions                                     | Primary endpoint                                                         | MMR rate at Week 48                                                      | Major Molecular Response (MMR) rate at Week 48 (asciminib vs. IS-TKI overall and within the imatinib stratum; formally tested) |
|                                                               | Key secondary endpoint                                                   | MMR rate at Week 96                                                      | Major Molecular Response (MMR) rate at Week 96 (asciminib vs. IS-TKI overall and within the imatinib stratum; formally tested) |
|                                                               | Other secondary endpoints                                                | MMR rate at Week 48 / 96                                                 | Major Molecular Response (MMR) rate at Week 48 / Week 96 (asciminib vs. IS-TKI within the 2G TKI stratum; not formally tested) |
|                                                               |                                                                          | MMR rate by Week 48 / 96                                                 | Major Molecular Response (MMR) rate by Week 48 / Week 96                                                                       |
|                                                               |                                                                          | EMR                                                                      | Early Molecular Response (EMR), BCR::ABL1 Ratio (% IS) <=10% at Week 12                                                        |
|                                                               |                                                                          | MR2.0 rate at / by Week 48 /96                                           | Molecular response 2.0 (MR2.0) (BCR::ABL1 ≤1%) rate at Week 48 / Week 96 and by Week 48 / Week 96                              |
|                                                               |                                                                          | MR4.0 rate at / by Week 48 /96                                           | Molecular response 4.0 (MR4.0) rate at Week 48 / Week 96 and by Week 48 / Week 96                                              |
|                                                               |                                                                          | MR4.5 rate at / by Week 48 /96                                           | Molecular response 4.5 (MR4.5) rate at Week 48 / Week 96 and by Week 48 / Week 96                                              |
| Database lock                                                 | Data cut-off dates: 28-Nov-2023 (Week 48 analysis), 22-Oct-2024 (Week 96 | Data cut-off dates: 28-Nov-2023 (Week 48 analysis), 22-Oct-2024 (Week 96 | Data cut-off dates: 28-Nov-2023 (Week 48 analysis), 22-Oct-2024 (Week 96                                                       |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Results and Analysis

Analysis description

Primary (Week 48) and Key Secondary (Week 96) Analysis

Analysis population and

time point description

Intent to treat; participants were analysed according to the treatment and stratum assigned to at randomization

Time points: Week 48, Week 96

| Descriptive statistics and                 | Treatment group                            | Asciminib                | IS-TKI                   | ASC IMA                  | IS-TKI IMA               | ASC 2G                     | IS-TKI 2G                  |
|--------------------------------------------|--------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| estimate variability / Effect estimate per | Number of subjects                         | N=201                    | N=204                    | N=101                    | N=102                    | N=100                      | N=102                      |
| estimate variability / Effect estimate per | MMR rate at Week 48                        | Primary objectives       | Primary objectives       | Primary objectives       | Primary objectives       | Other secondary objectives | Other secondary objectives |
| comparison                                 | n (%)                                      | 136 (67.66)              | 100 (49.02)              | 70 (69.31)               | 41 (40.20)               | 66 (66.00)                 | 59 (57.84)                 |
|                                            | Common treatment difference (%) (95% CI) a | 18.88 (9.59, 28.17)      | 18.88 (9.59, 28.17)      | 29.55 (16.91, 42.18)     | 29.55 (16.91, 42.18)     | 8.17 (-5.14, 21.47)        | 8.17 (-5.14, 21.47)        |
| CMH 1-sided adjusted p-value               | test b                                     | <0.001                   | <0.001                   | <0.001                   | <0.001                   | NA                         | NA                         |
| MMR rate at Week 96                        |                                            | Key secondary objectives | Key secondary objectives | Key secondary objectives | Key secondary objectives |                            |                            |
| n                                          | (%)                                        | 149 (74.13)              | 106 (51.96)              | 77 (76.24)               | 48 (47.06)               | 72 (72.00)                 | 58 (56.86)                 |
| Common treatment difference (%) (95% CI) a |                                            | 22.42 (13.55, 31.29)     | 22.42 (13.55, 31.29)     | 29.68 (17.57, 41.79)     | 29.68 (17.57, 41.79)     | 15.14 (2.32, 27.95)        | 15.14 (2.32, 27.95)        |
| CMH 1-sided adjusted p-value               | test b                                     | <0.001                   | <0.001                   | <0.001                   | <0.001                   | 0.011                      | 0.011                      |
| MMR rate by Week 48                        |                                            |                          |                          |                          |                          |                            |                            |
| n (%)                                      | 140                                        | (69.65)                  | 104 (50.98)              | 71 (70.30)               | 45 (44.12)               | 69 (69.00)                 | 59 (57.84)                 |
| Common treatment difference (%) (95% CI) a | 18.92                                      | (9.78, 28.07)            | (9.78, 28.07)            | 26.65 (14.06, 39.25)     | 26.65 (14.06, 39.25)     | 11.16 (-1.92, 24.25)       | 11.16 (-1.92, 24.25)       |
| MMR rate by Week 96                        |                                            |                          |                          |                          |                          |                            |                            |
| n (%)                                      | 163 (81.09)                                |                          | 125 (61.27)              | 81 (80.20)               | 57 (55.88)               | 82 (82.00)                 | 68 (66.67)                 |
| Common treatment difference (%) (95% CI) a | 20.13 (11.93,                              | 28.32)                   | 28.32)                   | 24.90 (13.38, 36.42)     | 24.90 (13.38, 36.42)     | 15.33 (3.75, 26.90)        | 15.33 (3.75, 26.90)        |
| EMR                                        |                                            |                          |                          |                          |                          |                            |                            |
| n (%) (cumulative categories)              | 180 (89.6)                                 |                          | 143 (70.1)               | 89 (88.1)                | 61 (59.8)                | 91 (91.0)                  | 82 (80.4)                  |
| MR2.0 rate at Week 48                      |                                            |                          |                          |                          |                          |                            |                            |
| n (%)                                      | 175 (87.06)                                |                          | 148 (72.55)              | 85 (84.16)               | 63 (61.76)               | 90 (90.00)                 | 85 (83.33)                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Common treatment difference (%) (95% CI) a   | 14.78 (7.44, 22.12)   | 14.78 (7.44, 22.12)   | 22.86 (11.52, 34.20)   | 22.86 (11.52, 34.20)   | 6.66 (-2.36, 15.68)   | 6.66 (-2.36, 15.68)   |
|----------------------------------------------|-----------------------|-----------------------|------------------------|------------------------|-----------------------|-----------------------|
| MR2.0 rate by Week 48                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 186 (92.54)           | 157 (76.96)           | 92 (91.09)             | 71 (69.61)             | 94 (94.00)            | 86 (84.31)            |
| Common treatment difference (%) (95% CI) a   | 15.85 (9.30, 22.40)   | 15.85 (9.30, 22.40)   | 22.00 (11.95, 32.06)   | 22.00 (11.95, 32.06)   | 9.67 (1.45, 17.89)    | 9.67 (1.45, 17.89)    |
| MR2.0 rate at Week 96                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 167 (83.08)           | 126 (61.76)           | 83 (82.18)             | 54 (52.94)             | 84 (84.00)            | 72 (70.59)            |
| Common treatment difference (%) (95% CI) a   | 21.55 (13.31, 29.80)  | 21.55 (13.31, 29.80)  | 29.64 (17.78, 41.50)   | 29.64 (17.78, 41.50)   | 13.43 (2.20, 24.66)   | 13.43 (2.20, 24.66)   |
| MR2.0 rate by Week 96                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 186 (92.54) 15.85     | 157 (76.96)           | 92 (91.09)             | 71 (69.61)             | 94 (94.00)            | 86 (84.31)            |
| Common treatment difference (%) (95% CI) a   | (9.30, 22.40)         | (9.30, 22.40)         | 22.00 (11.95, 32.06)   | 22.00 (11.95, 32.06)   | 9.67 (1.45, 17.89)    | 9.67 (1.45, 17.89)    |
| MR4.0 rate at Week 48                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 78 (38.81)            | 42 (20.59)            | 43 (42.57)             | 15 (14.71)             | 35 (35.00)            | 27 (26.47)            |
| Common treatment difference (%) (95% CI) a   | 18.38 (9.96, 26.79)   | 18.38 (9.96, 26.79)   | 28.22 (16.81, 39.63)   | 28.22 (16.81, 39.63)   | 8.49 (-3.58, 20.56)   | 8.49 (-3.58, 20.56)   |
| MR4.0 rate by Week 48                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 82 (40.80)            | 45 (22.06)            | 46 (45.54)             | 16 (15.69)             | 36 (36.00)            | 29 (28.43)            |
| Common treatment difference (%) (95% CI) a   | 18.91 (10.30, 27.52)  | 18.91 (10.30, 27.52)  | 30.22 (18.61, 41.83)   | 30.22 (18.61, 41.83)   | 7.54 (-4.77, 19.86)   | 7.54 (-4.77, 19.86)   |
| MR4.0 rate at Week 96                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 98 (48.76)            | 56 (27.45)            | 53 (52.48)             | 24 (23.53)             | 45 (45.00)            | 32 (31.37)            |
| Common treatment difference (%) (95% CI) a   | 21.48 (12.40, 30.56)  | 21.48 (12.40, 30.56)  | 29.30 (16.88, 41.73)   | 29.30 (16.88, 41.73)   | 13.62 (0.57, 26.68)   | 13.62 (0.57, 26.68)   |
| MR4.0 rate by Week 96                        |                       |                       |                        |                        |                       |                       |
| n (%)                                        | 106 (52.74)           | 70 (34.31)            | 57 (56.44)             | 29 (28.43)             | 49 (49.00)            | 41 (40.20)            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Common treatment difference (%) (95% CI) a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18.62 (9.34, 27.91)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18.62 (9.34, 27.91)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28.41 (15.74, 41.08)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28.41 (15.74, 41.08)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 8.79 (-4.51, 22.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.79 (-4.51, 22.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.79 (-4.51, 22.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.79 (-4.51, 22.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.79 (-4.51, 22.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MR4.5 rate at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 34 (16.92)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 (8.82)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18 (17.82)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 5 (4.90)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16 (16.00)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13 (12.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13 (12.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13 (12.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13 (12.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Common treatment difference (%) (95% CI) a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 8.20 (1.78, 14.62)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 8.20 (1.78, 14.62)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13.13 (4.69, 21.56)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13.13 (4.69, 21.56)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.24 (-6.34, 12.83)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.24 (-6.34, 12.83)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.24 (-6.34, 12.83)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.24 (-6.34, 12.83)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.24 (-6.34, 12.83)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| MR4.5 rate by Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (19.90)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 24 (11.76)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22 (21.78)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 6 (5.88)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18 (18.00)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 (17.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 (17.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 (17.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 (17.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| CI) a MR4.5 rate at                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.26 (1.26,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15.25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (7.01, 25.29)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.33 (-10.03, 10.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.33 (-10.03, 10.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.33 (-10.03, 10.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.33 (-10.03, 10.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.33 (-10.03, 10.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Week 96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 62 (30.85)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 36 (17.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 36 (35.64)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12 (11.76)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26 (26.00)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24 (23.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24 (23.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24 (23.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24 (23.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Common treatment difference (%) (95% CI) a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13.26 (5.07, 21.46)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13.26 (5.07, 21.46)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24.03 (12.89, 35.17)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24.03 (12.89, 35.17)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2.45 (-9.20, 14.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.45 (-9.20, 14.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.45 (-9.20, 14.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.45 (-9.20, 14.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.45 (-9.20, 14.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| MR4.5 rate by Week 96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Common treatment difference (%) (95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (36.32) (21.57)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (36.32) (21.57)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (13.44,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (13.44,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 4.53 (-7.67, 16.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 4.53 (-7.67, 16.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 4.53 (-7.67, 16.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 4.53 (-7.67, 16.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 4.53 (-7.67, 16.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| CI) a Participants without 48 unless they are in Participants without 96 unless they are in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14.86 (6.29,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23.43)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25.14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 36.84)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The | PCR assessment at Week 48 are considered non-responders at Week MMR at both Week 36 and Week 60. PCR assessment at Week 96 are considered non-responders at Week MMR at both Week 84 and Week 108. a Common treatment difference and common risk difference are synonymous. The common treatment difference and its 95% CI estimated using the Mantel-Haenszel method after stratifying for (1) pre-randomization selected TKI, and/or (2) baseline ELTS risk groups (both IRT data). b Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. The |
| hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | hypothesis is rejected if the adjusted p-value is less than or equal to 2.5% Source: eCTD,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Mod.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.3.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Supportive studies

CABL001AUS08 / ASC2ESCALATE: Phase II, single-arm, dose-escalation study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Methods

CABL001AUS08 is an ongoing, uncontrolled, open-label, single-arm, dose escalation multicentre phase II study in participants with CML-CP receiving asciminib 80 mg QD monotherapy as second-line or first-line treatment. Both cohorts have completed enrolment, with 101 participants in 2 nd  line (2L) treatment by 17-Sep-2024 and 95 participants in 1 st  line (1L) treatment by 25-Jul-2024. Endpoints were BCR::ABL =10%, MR2 rate, MMR rate, MR4 and MR4.5 rates at six months in patient with adequate follow up.

The results of the interim analysis 4 ( DCO 15 November 2024) for the 2 nd  line cohort are described below.

## Study participants

No detailed information given about eligibility criteria.

## Results

## Analysis sets

Information about analysis sets is given in Table 30 .

Table 30 Analysis sets for 2L cohort (FAS)

|                                    | 2L Cohort N=101   |
|------------------------------------|-------------------|
| Analysis set                       | n (%)             |
| Safety set                         | 101 (100)         |
| Full analysis set                  | 101 (100)         |
| Efficacy evaluable set at 6 months | 63 (62.4)         |

## Baseline characteristics

Overall, 101 patients in the 2L CML-CP were enrolled. However, efficacy and safety data is available for 63 patients, and the magnitude of the characteristics are generally comparable. Baseline characteristics of those patients with available efficacy is presented below in Table 31 .

In the uncontrolled SAT, mean age of the patients was 49.5 years, weight was 89.3 kg, 54% of participants were male. Pretreatment was with all four approved TKI, with the majority treated by dasatinib (47.6%) and imatinib (36.5%). In 96.8% of patients, no resistance mutations were detected. Mean time from diagnosis was 118.8 days (SD 107.83).

Table 31 Demographics, baseline and disease characteristics for 2L Cohort (Efficacy evaluable set at 6 month)

| Characteristic Categories/Statistics   | 2L Cohort N=63   |
|----------------------------------------|------------------|
| Age group -n (%)                       |                  |
| < 65 years                             | 46 (73.0)        |
| >= 65 years                            | 17 (27.0)        |
| Age (years)                            |                  |
| Mean (SD)                              | 49.5 (17.37)     |

<div style=\"page-break-after: always\"></div>

| Median                                   | 48.0           |
|------------------------------------------|----------------|
| Q1-Q3                                    | 35.0-67.0      |
| Min-Max                                  | 19 - 79        |
| Sex -n (%)                               |                |
| Male                                     | 34 (54.0)      |
| Female                                   | 29 (46.0)      |
| Race -n (%)                              |                |
| White                                    | 56 (88.9)      |
| Black or African American                | 2 (3.2)        |
| Asian                                    | 1 (1.6)        |
| Unknown                                  | 4 (6.3)        |
| Ethnicity -n (%)                         |                |
| Hispanic or Latino                       | 8 (12.7)       |
| Not Hispanic or Latino                   | 54 (85.7)      |
| Unknown                                  | 1 (1.6)        |
| Weight (kg)                              |                |
| n                                        | 63             |
| Mean (SD)                                | 89.3 (23.84)   |
| Median                                   | 88.0           |
| Q1-Q3                                    | 71.7-106.9     |
| Min-Max                                  | 44 - 137       |
| Height (cm)                              |                |
| n                                        | 55             |
| Mean (SD)                                | 171.3 (9.85)   |
| Median                                   | 170.2          |
| Q1-Q3                                    | 165.1-180.3    |
| Min-Max                                  | 153 - 191      |
| BMI (kg per m2)                          |                |
| n                                        | 55             |
| Mean (SD)                                | 30.5 (7.72)    |
| Median                                   | 28.5           |
| Q1-Q3                                    | 25.0-35.0      |
| Min-Max                                  | 18 - 55        |
| ECOG Performance Status -n (%)           |                |
| 0                                        | 46 (73.0)      |
| 1                                        | 16 (25.4)      |
| 2                                        | 1 (1.6)        |
| Timesince initial diagnosis ofCML(weeks) |                |
| Mean (SD)                                | 118.8 (107.83) |
| Median                                   | 76.4           |
| Q1-Q3                                    | 48.9-166.7     |
| Min-Max                                  | 8 - 450        |
| Baseline Mutations -n (%)                |                |
| E459G                                    | 1 (1.6)        |
| V299L                                    | 1 (1.6)        |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| No Mutation Detected                             | 61 (96.8)   |
|--------------------------------------------------|-------------|
| Total                                            | 63 (100)    |
| Evidence of extramedullary Involvement -n (%)    |             |
| Yes                                              | 1 (1.6)     |
|                                                  | 62 (98.4)   |
| No Location of extramedullary Involvement -n (%) |             |
| SPLEEN                                           | 1 (1.6)     |
| Prior TKI received                               |             |
| Yes                                              | 63 (100)    |
| Medication: #                                    |             |
| Bosutinib                                        | 2 (3.2)     |
| Dasatinib                                        | 30 (47.6)   |
| Imatinib                                         | 23 (36.5)   |
| Nilotinib                                        | 9 (14.3)    |
| Duration of prior TKI                            |             |
| <6mo                                             | 9 (14.3)    |
| >=6mo and < 12 mo                                | 11 (17.5)   |
| >=12mo                                           | 43 (68.3)   |
| Reason to discontinue last TKI                   |             |
| Lack of efficacy                                 | 37 (58.7)   |
| Lack of tolerability                             | 26 (41.3)   |

# Subject 1077001 has received two prior TKIs (DASATINIB for 41 months, IMATINIB for 1 month). The use of more than 1 prior TKI was identified by the sponsor after the patients were enrolled in the trial and have been documented as protocol deviations. The Baseline Mutations were analyzed by Sanger sequencing. Total shows the number of subjects who have been assessed for gene mutations. Source: Key outputs report, CABL001AUS08 study, tables 4.4a and 4.5 a

## Exposure

For 63 patients with evaluable efficacy at six months, duration of exposure is provided in Table 32.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 32 Duration of exposure to study drug for 2L Cohort (Efficacy evaluable set at 6 month)

|                                                                                                                                                                                                                                                                 | 2L Cohort N=63                                                                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Duration of exposure (weeks)                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                 |
| Mean (SD)                                                                                                                                                                                                                                                       | 40.1 (17.22)                                                                                                                                                                                                                                                    |
| Median                                                                                                                                                                                                                                                          | 40.4                                                                                                                                                                                                                                                            |
| Q1-Q3                                                                                                                                                                                                                                                           | 27.4-49.6                                                                                                                                                                                                                                                       |
| Min-Max                                                                                                                                                                                                                                                         | 6 -100                                                                                                                                                                                                                                                          |
| Duration of exposure categories - n(%)                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                 |
| Less than 24weeks                                                                                                                                                                                                                                               | 6 (9.5)                                                                                                                                                                                                                                                         |
| At least 24 weeks                                                                                                                                                                                                                                               | 57 (90.5)                                                                                                                                                                                                                                                       |
| At least 48 weeks                                                                                                                                                                                                                                               | 17 (27.0)                                                                                                                                                                                                                                                       |
| At least 96 weeks                                                                                                                                                                                                                                               | 1 (1.6)                                                                                                                                                                                                                                                         |
| Duration of exposure (patient-years)                                                                                                                                                                                                                            | 48.44                                                                                                                                                                                                                                                           |
| Duration of exposure to study treatment (weeks) = [(date of last administration of study medication) - (date of first administration of study medication) + 1]/ 7 Duration of exposure (patient-years) is the sum of each subject's treatment exposure in year. | Duration of exposure to study treatment (weeks) = [(date of last administration of study medication) - (date of first administration of study medication) + 1]/ 7 Duration of exposure (patient-years) is the sum of each subject's treatment exposure in year. |

Source: key output summary study AUS08

In an update at IA5, median duration of exposure to study treatment was 51.3 weeks in the secondline cohort, 54.5% (55 patients) had a duration of exposure &gt; 48 weeks.

## Outcomes and endpoints

At six months for the 63 evaluable patients, at the time of DCO in the ongoing uncontrolled trial and in order of the depths of remission, BCR::ABL1&lt;=10% rate was 90.5% (95%CI: 80.4%, 96.4%) was MR2 rate 82.5% (95%CI: 70.9%, 91.0%), MMR rate 44.4% (95%CI: 31.9%, 57.5%),  the rates of MR4.0 was 25.4% (95%CI: 15.3%, 37.9%) and MR4.5 rate was 9.5% (95% CI: 3.6%, 19.6%), see Table 33 , Table 36 , Table 37 .

Subgroup analyses are provided for patients who either dscontinued previous (1L) treatment due to lack of efficacy or lack of tolerability.

Table 33 Major molecular response (MMR) rate at scheduled visits with adequate follow-up for 2L Cohort (Full Analysis Set)

|            | 2L Cohort    | 2L Cohort   | 2L Cohort    |
|------------|--------------|-------------|--------------|
| Visit      | n/M (%)      | N=101       | 95% CI       |
| at 1 month | 1/94 (1.1)   |             | (0.0, 5.8)   |
| at 3 month | 34/86 (39.5) |             | (29.2, 50.7) |
| at 6 month | 28/63 (44.4) |             | (31.9, 57.5) |
| at 9 month | 22/42 (52.4) |             | (36.4, 68.0) |

n=Number of subjects who achieved MMR at scheduled visits; M=Number of subjects with adequate follow-up (subjects who have assessments within corresponding analysis time interval or subjects who discontinued earlier).

Exact 95% CI is calculated using Pearson-Clopper 2-sided method. Source: table 5-1.1, Key outputs Satudy AUS08

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

<!-- image -->

n=Number of subjects who achie/ed M M R at scheduled visits; M =Number of subjects with adlequatefollow-up (subjects who have assessments within correspondinganaly sis timeinterval or subjects who disoontinued earlier). Exact95%Cl is calculated usingPearson-Clopper 2-sided method.

Figure 31: Bar chart with 95% confidence intervals for MMR at visit with adequate follow-up for 2L Cohort (Full Analysis Set)

## Subgroup analysis for patients who discontinued last TKI for lack of efficacy

Table 34 MMR rate-Reason to discontinue last TKI: Lack of efficacy (FAS)

|            | 2L Cohort N=101   | 2L Cohort N=101   |
|------------|-------------------|-------------------|
| Visit      | n/M (%)           | 95% CI            |
| at 1 month | 1/52 (1.9)        | (0.1, 10.3)       |
| at 3 month | 18/48 (3.75)      | (24.0, 52.7)      |
| at 6 month | 13/37 (35.1)      | (20.2, 52.5)      |
| at 9 month | 14/27 (51.9)      | (32.0, 71.3)      |

## Subgroup analysis for patients who discontinued last TKI for lack of tolerability

Table 35 MRR rate -Reason to discontinue last TKI: Lack of tolerability (FAS)

|            | 2LCohort N=101   | 2LCohort N=101   |
|------------|------------------|------------------|
| Visit      | n/M (%)          | 95% CI           |
| at 1 month | 0/42             | (0.0, 8.4)       |
| at 3 month | 16/38 (42.1)     | (26.3, 59.2)     |
| at 6 month | 15/26 (57.7)     | (36.9, 76.7)     |
| at 9 month | 8/15 (53.3)      | (26.6, 78.7)     |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## MR2 rate at scheduled visits

Table 36 MR2 rate at scheduled visits with adequate follow-up for 2L Cohort (Full Analysis Set)

| Visit      | n/M (%)      | 2L Cohort N=101   | 95% CI       |
|------------|--------------|-------------------|--------------|
| at 1 month | 44/94 (46.8) |                   | (36.4, 57.4) |
| at 3 month | 73/86 (84.9) |                   | (75.5, 91.7) |
| at 6 month | 52/63 (82.5) |                   | (70.9, 91.0) |
| at 9 month | 34/42 (81.0) |                   | (65.9, 91.4) |

## MR4 rate at scheduled visits

Table 37 MR4 rate at scheduled visits with adequate follow-up for 2L Cohort (Full Analysis Set)

|            | 2L Cohort N=101   | 95% CI       |
|------------|-------------------|--------------|
| Visit      | n/M (%)           |              |
| at 1 month | 0/94              | (0.0, 3.9)   |
| at 3 month | 10/86 (11.6)      | (5.7, 20.4)  |
| at 6 month | 16/63 (25.4)      | (15.3, 37.9) |
| at 9 month | 10/42 (23.8)      | (12.1, 39.5) |

Plotted BCR: ABL ratio over time is shown in Figure 32 .

<!-- image -->

M=Number of subjects with PCR assessment at visit

Figure 32: BCR::ABL1 ratio (% IS) plot over time (Full Analysis Set)

At IA5, MMR rate at week 48 in patients with adequate follow-up was 55.6% (40/72; 95% CI: 43.4; 67.3%). Supportive results come from MR2 rate at 48 weeks with 77.8% (56/72; 95% CI: 66.4; 86.7%) and DMR at 48 weeks with 25% (18/72; 95%CI: 15.5%, 36.6%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

CABL001A2302: Phase III study non-comparative, open-label, multicenter, treatment optimisation study (1:1 randomised to 40 mg BID or 80 mg QD) in CML-CP patients after two or more lines of therapy (ASC4OPT)

This study was presented in support of the new posology of 80 mg QD in the 3rd line and beyond.

## Methods

Study A2302 is a non-comparative, open-label, multi-center, treatment optimisation study (1:1 randomised to 40 mg BID or 80 mg QD) in CML-CP patients after two or more lines of therapy see Figure 33.

As the study was not designed to assess the comparability between the two dosing regimens, propensity score weighting analysis was conducted to assess differences in MMR rates between the doses in study A2302 and in comparison, to study A 2301 (CABL001A2301, ASCEMBL, pivotal study for use in 3 rd  line+).

## Study design

Figure 33: Design of phase IIIb study A2302 ASC4OPT

<!-- image -->

## Study population

Participants with chronic myeloid leukemia in chronic phase (CML-CP) who had prior treatment with at least two ATP competitive TKIs and who were either in warning, resistant (ELN 2020 recommendations) or intolerant to the last TKI treatment. Participants who had T315I mutations at any time prior to study entry were excluded.

## Treatment

Asciminib administered orally 40 mg BID. or 80 mg QD as 20 mg and 40 mg tablets. The maximum treatment duration for each individual participant is 144 weeks.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Randomisation and stratification

Patients were randomised 1:1 to receive either asciminib 40 mg BID or asciminib 80 mg QD. No stratification was applied.

## Outcomes and endpoints

The primary endpoint of the study was major molecular response (MMR) rate at Week 48 for participants without MMR at baseline. Secondary efficacy endpoints are MMR rate for participants without MMR at baseline at all scheduled time-points including weeks 12, 24, 36, 72, 96 and 144 (except week 48), time to MMR, duration of MMR, BCR-ABL1 ratio (% IS) categories at and by scheduled time points, rate of complete cytogenetic response (CCyR) (complete, partial, major, minor, minimal, no response) at weeks 48 and EOT, time to treatment failure, progression free survival and overall survival.

Molecular response (MR) was assessed based on levels of BCR::ABL1 transcripts that were determined by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood and analysed at a central testing laboratory. Log reduction in BCR::ABL1 transcripts levels from the standardized baseline value, or the percent ratio of BCR::ABL1 transcripts versus control gene (ABL1) transcripts converted to a reference standard, international scale (IS), were calculated for each sample. Cytogenetic response (CyR) was assessed locally as the percentage of Ph+ metaphases in bone marrow analyses based on at least 20 metaphases examined.

## Statistical methodology

The primary efficacy endpoint of the study was the MMR rate at Week 48 evaluated in the overall population (combined 40mg BID and 80 mg QD). A participant was considered to be in MMR at Week 48 if he/she met the MMR criterion (BCR::ABL1 ≤ 0.1% IS) at Week 48 while on study treatment. The primary estimand (the same as discussed for study J12301) was analyzed based on the data from FAS and according to the Intention to Treat (ITT) principle. Exact test for single proportion was used at the one- sided 2.5% level of significance. MMR rate and its 95% confidence interval were based on the Clopper-Pearson method. The null hypothesis was that the MMR rate at Week 48 is equal to 0.23, which is the upper limit of 95% exact binomial CI of the MMR rate at Week 48 in the bosutinib arm (11.1%, 95% CI: 4.2-22.6) from Study A2301. The alternative hypothesis is that the rate is greater than 0.23. The null hypothesis was to be rejected when the lower bound of the two-sided 95% CI is above 23%. Handling of missing data for the primary endpoint was done as for study J12301. In addition to the primary efficacy analysis, various subgroup and sensitivity analyses were performed to assess the homogeneity of the treatment effect across demographic and baseline disease characteristics.

## Propensity score weighting (post hoc)

As Study A2302 was not designed to compare the 2 dose groups and no baseline characteristics were stratified,  propensity  score  weighting  methodology  was  used  to  assess  differences  in  MMR  rates between the two dosing regimens, to correct potential imbalances and lack of stratification in baseline characteristics.  The  propensity  score  weighting  method  is  a  statistical  technique  that  mitigates confounding by balancing dose groups and facilitates indirect comparisons when direct head-to-head comparisons are not possible.

Logistic regression accounting for gender, age (&lt;65, &gt;=65), reason for discontinuation of last prior TKI, number of prior TKI therapies, MR2 status at baseline and mutation type was used to assign

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

weights to patients which are then used to compare the 40mg BID and 80 mg QD  within study A2302 as well as the 40mg BID arm from study A2302 with the 40mg BID arm from study A2301.

## Analysis sets

FAS: includes participants resistant or intolerant to 2 or more prior TKI treatments without MMR at baseline to whom study treatment had been assigned by randomization.

## Results

## Conduct of the study

The study was initiated on 13 October 2021 and had a data cut-off for the week 48 analysis on 12 March 2024. The study enrolled 169 without MMR at baseline with 85 in asciminib 40 mg BID arm and 84 in asciminib 80 mg QD arm.

## Protocol deviations

An overview about protocol deviations is given in Table 38 .

Table 38 Protocol deviations (FAS)

| Category                                                                                                                                    | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | All subjects N=169   |
|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------------------------|----------------------|
| Protocol deviation                                                                                                                          | n (%)                         | n (%)                       | n (名)                |
| Any protocol deviation                                                                                                                      | 48 (56.5)                     | 49 (58.3)                   | 97 (57.4)            |
| Other deviation                                                                                                                             | 40 (47.1)                     | 46 (54.8)                   | 86 (50.9)            |
| KEY PROCEDURES TO ASSESS ELIGIBILITY，RANDOMIZE,REPORT SAFETYEVENTS ANDASSESSTHEPRIMARYOR KEYSECONDARY OUTCOME，NOT PERFORMED AS PER PROTOCOL | 28 (32.9)                     | 31 (36.9)                   | 59 (34.9)            |
| STUDYPROCEDURESNOT PERFORMED AS PER PROTOCOL                                                                                                | 11 (12.9)                     | 17 (20.2)                   | 28 (16.6)            |
| WEEK48ASSESSMENTS/VISITOUTOFWINDOW                                                                                                          | 5 (5.9)                       | 3 (3.6)                     | 8 (4.7)              |
| MISSING ECG AT DOSE ESCALATION (PRE AND POST DOSE)                                                                                          | 2 (2.4)                       | 5 (6.0)                     | 7 (4.1)              |
| RANDOMIZATION GROUP IN IRT (BID/QD REGIMEN)DIFFERS FROM GROUP REPORTED BY INVESTIGATOR ON CRF                                               | 1 (1.2)                       | 0                           | 1 (0.6)              |
| SAENOT REPORTEDTONOVARTIS WITHIN24 HOURS OFLEARNING ABOUT THE EVENT                                                                         | 1 (1.2)                       | 3 (3.6)                     | 4 (2.4)              |
| DOSE ESCALATIONNOT PER PROTOCOL                                                                                                             | 0                             | 2 (2.4)                     | 2 (1.2)              |
| Study treatment deviation                                                                                                                   | 13 (15.3)                     | 11 (13.1)                   | 24 (14.2)            |
| STUDY TREATMENTNOT REDUCED/INTERRUPTED/RESUMEDATLOWER DOSE LEVELAS REQUESTED PER PROTOCOL                                                   | 6 (10.6)                      | 7 (8.3)                     | 16 (9.5)             |
| MORE THAN 7 DAYS OF CONSECUTIVE INSUFFICIENT TREATMENT OR CUMULATEDINSUFFICIENT TREATMENT OVER APERIODOF 24 WEEKS IS OBSERVED.              | 3 (3.5)                       | 3 (3.6)                     | 6 (3.6)              |
| DRUG SUPPLY METHOD CHANGED                                                                                                                  | 2 (2.4)                       | 0                           | 2 (1.2)              |
| PATIENT DIDNOT RECEIVE STUDY TREATMENT                                                                                                      | 0                             | 1 (1.2)                     | 1 (0.6)              |
| Exclusion criteria not met                                                                                                                  | (8.2)                         | 4 (4.8)                     | 11 (6.5)             |

## Patient disposition

An overview about patient disposition is given in Table 39 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 39 Patient disposition (FAS) study A2302

|                                       | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg q.d. N=84 n (%)   | All participants N=169 n (%)   |
|---------------------------------------|-------------------------------------|-----------------------------------|--------------------------------|
| Participants randomized               |                                     |                                   |                                |
| Treated                               | 84 ( 98.8)                          | 84 ( 100)                         | 168 ( 99.4)                    |
| Not treated                           | 1 ( 1.2)                            | 0                                 | 1 ( 0.6)                       |
| Reason for not being treated          |                                     |                                   |                                |
| Participant Decision                  | 1 ( 1.2)                            | 0                                 | 1 ( 0.6)                       |
| Treatment ongoing *                   | 68 ( 80.0)                          | 68 ( 81.0)                        | 136 ( 80.5)                    |
| Discontinued from treatment           | 16 ( 18.8)                          | 16 ( 19.0)                        | 32 ( 18.9)                     |
| <Week 24                              | 10 ( 11.8)                          | 7 ( 8.3)                          | 17 ( 10.1)                     |
| ≥ Week 24 and < Week 48               | 4 ( 4.7)                            | 3 ( 3.6)                          | 7 ( 4.1)                       |
| ≥ Week 48 and < Week 96               | 2 ( 2.4)                            | 6 ( 7.1)                          | 8 ( 4.7)                       |
| Reason for discontinuation            |                                     |                                   |                                |
| Adverse Event                         | 6 ( 7.1)                            | 4 ( 4.8)                          | 10 ( 5.9)                      |
| Unsatisfactory Therapeutic Effect     | 4 ( 4.7)                            | 3 ( 3.6)                          | 7 ( 4.1)                       |
| Progressive Disease                   | 1 ( 1.2)                            | 5 ( 6.0)                          | 6 ( 3.6)                       |
| Physician Decision                    | 2 ( 2.4)                            | 2 ( 2.4)                          | 4 ( 2.4)                       |
| Failure To Meet Continuation Criteria | 2 ( 2.4)                            | 1 ( 1.2)                          | 3 ( 1.8)                       |
| Participant Decision                  | 1 ( 1.2)                            |                                   | 1 ( 0.6)                       |
| Protocol Deviation                    | 0                                   | 1 ( 1.2)                          | 1 ( 0.6)                       |
| Week 24                               |                                     |                                   |                                |
| Adverse Event                         | 4 ( 4.7)                            | 3 ( 3.6)                          | 7 ( 4.1)                       |
| Failure To Meet Continuation Criteria | 2 ( 2.4)                            | 0                                 | 2 ( 1.2)                       |
| Unsatisfactory Therapeutic Effect     | 2 ( 2.4)                            | 0                                 | 2 ( 1.2)                       |
| Physician Decision                    | 1 ( 1.2)                            | 0                                 | 1 ( 0.6)                       |
| Participant Decision                  | 1 ( 1.2)                            | 0                                 | 1 ( 0.6)                       |
| Progressive Disease                   | 0                                   | 3 ( 3.6)                          | 3 ( 1.8)                       |
| Protocol Deviation                    | 0                                   | 1 ( 1.2)                          | 1 ( 0.6)                       |
| 2 Week 24 and <Week 48                |                                     |                                   |                                |
| Adverse Event                         | 2 ( 2.4)                            | 1 ( 1.2)                          | 3 ( 1.8)                       |
| Physician Decision                    | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |
| Progressive Disease                   | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| ≥Week 48 and <Week 96                                            |           |            |            |
|------------------------------------------------------------------|-----------|------------|------------|
| Unsatisfactory Therapeutic Effect                                | 2 ( 2.4)  | 3 ( 3.6)   | 5 ( 3.0)   |
| Failure To Meet Continuation Criteria                            | 0         | 1 ( 1.2)   | 1 ( 0.6)   |
| Physician Decision                                               | 0         | 1 ( 1.2)   | 1 ( 0.6)   |
| Progressive Disease                                              | 0         | 1 ( 1.2)   | 1 ( 0.6)   |
| Post-Treatment safety follow-up for participant who Discontinued |           |            |            |
| Did not enter post-treatment safety follow-up                    | 1 ( 1.2)  | 0          | 1 ( 0.6)   |
| Completed post-treatment safety follow- up                       | 9 ( 10.6) | 11 ( 13.1) | 20 ( 11.8) |
| Entered post-treatment safety follow-up, discontinued            | 6 ( 7.1)  | 5 ( 6.0)   | 11 ( 6.5)  |
| Reason for Discontinuation                                       |           |            |            |
| Adverse Event                                                    | 4 ( 4.7)  | 0          | 4 ( 2.4)   |
| Physician Decision                                               | 1 ( 1.2)  | 1 ( 1.2)   | 2 ( 1.2)   |
| Participant Decision                                             | 1 ( 1.2)  | 1 ( 1.2)   | 2 ( 1.2)   |
| Death                                                            | 0         | 1 ( 1.2)   | 1 ( 0.6)   |
| Failure To Meet Continuation Criteria                            | 0         | 1 ( 1.2)   | 1 ( 0.6)   |
| Unsatisfactory Therapeutic Effect                                | 0         | 1 ( 1.2)   | 1 ( 0.6)   |

## Patient exposure

Table 40 Duration of exposure to study drug (Safety set) - Study A2302

|                                       | Asciminib 40 mg b.i.d. N=84   | Asciminib 80 mg QD N=84   | All participants N=168   |
|---------------------------------------|-------------------------------|---------------------------|--------------------------|
| Duration of exposure (week)           |                               |                           |                          |
| Mean (SD)                             | 68.0 (30.93)                  | 68.7 (27.38)              | 68.3 (29.12)             |
| Median                                | 67.3                          | 68.6                      | 67.8                     |
| Q1-Q3                                 | 51.7-92.4                     | 53.1-90.4                 | 52.2-91.5                |
| Min-Max                               | 2.6-116.1                     | 1.3-118.7                 | 1.3-118.7                |
| Duration of exposure categories-n (%) |                               |                           |                          |
| Less than 24 weeks                    | 10 (11.9)                     | 8 (9.5)                   | 18 (10.7)                |
| At least 24 weeks                     | 74 (88.1)                     | 76 (90.5)                 | 150 (89.3)               |
| At least 48 weeks                     | 70 (83.3)                     | 73 (86.9)                 | 143 (85.1)               |
| At least 96 weeks                     | 18 (21.4)                     | 16 (19.0)                 | 34 (20.2)                |
| At least 144 weeks                    | 0                             | 0                         | 0                        |
| Participant treatment time (year)     | 109.4                         | 110.5                     | 219.9                    |

Participant treatment time is the sum of each participant's treatment exposure in year.

Information about patient exposure is provided in Table 40 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Baseline characteristics

Important baseline characteristics are provided in Table 41 .

Table 41 Important patient-/ and disease baseline characteristics (Study A2302)

| Demographic Variable                         | Study A2302 40 mg b.i.d. N=85 n (%)   | Study A2302 80 mg QD N=84 n (%)   |
|----------------------------------------------|---------------------------------------|-----------------------------------|
| Age Group                                    |                                       |                                   |
| < 65 years                                   | 64 (75.3)                             | 59 (70.2)                         |
| ≥ 65 years                                   | 21 (24.7)                             | 25 (29.8)                         |
| Sex                                          |                                       |                                   |
| Female                                       | 37 (43.5)                             | 27 (32.1)                         |
| Male                                         | 48 (56.5)                             | 57 (67.9)                         |
| Number of prior TKI therapies                |                                       |                                   |
| 2                                            | 47 (55.3)                             | 42 (50.0)                         |
| ≥3                                           | 38 (44.7)                             | 42 (50.0)                         |
| Reason for discontinuation of last prior TKI |                                       |                                   |
| Failure                                      | 43 (50.6)                             | 46 (54.8)                         |
| Intolerance                                  | 19 (22.4)                             | 20 (23.8)                         |
| Unknown/Other                                | 23 (27.1)                             | 18 (21.4)                         |
| MR2 status at baseline                       |                                       |                                   |
| 0                                            | 55 (64.7)                             | 58 (69.0)                         |
| 1                                            | 30 (35.3)                             | 26 (31.0)                         |
| Mutational status                            |                                       |                                   |
| Mutation                                     | 5 (5.9)                               | 11 (13.1)                         |
| Wild Type                                    | 68 (80)                               | 63 (75.0)                         |
| Unknown                                      | 12 (14.1)                             | 10 (11.9)                         |

## Outcomes and estimation

## Primary endpoint:

The study met its primary endpoint. For participants without MMR at baseline, the overall rate of MMR at Week 48 in FAS was 38.5% (95% CI: 31.09, 46.24).

## Objective of the post- hoc comparison

The rate of MMR at Week 48 for patients without MRR at baseline was 42.4% (95% CI: 31.70, 53.55) in the asciminib 40 mg BID group and was 34.5% (95% CI: 24.48, 45.69) in the asciminib 80 mg QD group. The numerical difference in MMR rate between 40 mg BID and 80 mg QD is 7.9%.

Mean exposure was comparable between the arms (68.0 vs. 68.7 weeks)

Baseline characteristics show marginal differences in age groups ( ≥ 65 years 24.7% vs. 29.8% in 40 mg BID vs 80 mg QD), sex (female 43.5 vs. 32.1), patients with previous treatment failure (50.6% vs. 54.8%) or mutations (5.9% vs. 13.1%). However, the study was 1:1 randomised, and residual imbalances do not justify post-hoc rebalancing for the primary endpoint.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The primary endpoint  was met, due to the limitations in study design no comparison between 40 mg BID and 80 mg QD was predefined. The rate of MMR at Week 48 for patients without MRR at baseline was 42.4% (95% CI: 31.70, 53.55) in the asciminib 40 mg BID group and was 34.5% (95% CI: 24.48, 45.69) in the asciminib 80 mg QD group. The numerical difference in MMR rate between 40 mg BID and 80 mg QD is 7.9%, translating into a 23% higher change of achieving MMR at 48 weeks with 40 mg BID than with 80 mg QD without a predefined acceptable margin to claim equivalence.

The performed post-hoc propensity score weighting, which is not adequately justified and reliable, led to a reduced difference of 2.43 (95% CI: -12.71, 17.56).

## Propensity score weighting

Some differences in distribution among some baseline demographic and disease characteristics ( Table 41 ) were observed between the two dosing regimens. Baseline covariate differences were adjusted using propensity scores, and propensity score weighting was employed to compare the MMR rates at Week 48.

After propensity score weighting by the applicant, the difference in the MMR rates at Week 48 between the 40 mg BID and 80 mg QD dosing regimens was reduced. (MMR of 36.95% vs 34.52%, post- hoc p=0.753). The adjusted MMR rate at Week 48 in the 40 mg BID was 36.95% and the difference in MMR rate between the 40 mg BID and the 80 mg QD  dose groups after post-hoc adjustment was 2.43 (95% CI: -12.71, 17.56, Table 42 ).

Table 42 MMR rates at Week 48 for asciminib 80 mg QD  vs. unadjusted/adjusted 40 mg BID dosing regimens - Study A2302

| Study                   | N   |   MMR Week48 (%) | Difference   | 95% CI          | p-value   |
|-------------------------|-----|------------------|--------------|-----------------|-----------|
| 80 mg q.d.              | 84  |            34.52 | 2.43         |                 |           |
| 40 mg b.i.d. adjusted   | 71a |            36.95 |              | (-12.71, 17.56) | 0.753b    |
| 40 mg b.i.d. unadjusted | 85  |            42.35 |              |                 |           |

Cumulative MMR rate at scheduled timepoints is presented in Table 43 and the cumulative incidence visualised in Figure 34 . Risk difference at scheduled timepoints is 5.4% at week 12, 6.8% at week 24, 7.8% at week 36 and 5.4% at week 48 in favour of 40mg BID in comparison to 80 mg QD.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 43 MMR rate at scheduled timepoints (Full analysis set) - Study A2302

Table 3-11 MMR rate by scheduled timepoints (Full analysis set) - Study A2302

|            | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=169   | All participants N=169   |
|------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
|            | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                    | 95% CI                   |
| MMR (1)    |                               |                               |                             |                             |                          |                          |
| by Overall | 37 (43.5)                     | (32.80, 54.72)                | 32 (38.1)                   | (27.71, 49.34)              | 69 (40.8)                | (33.34, 48.64)           |
| by Week 12 | 26 (30.6)                     | (21.05, 41.53)                | 20 (23.8)                   | (15.19, 34.35)              | 46 (27.2)                | (20.67, 34.59)           |
| by Week 24 | 31 (36.5)                     | (26.29, 47.62)                | 26 (31.0)                   | (21.31, 41.98)              | 57 (33.7)                | (26.65, 41.39)           |
| by Week 36 | 37 (43.5)                     | (32.80, 54.72)                | 30 (35.7)                   | (25.55, 46.92)              | 67 (39.6)                | (32.22, 47.44)           |
| by Week 48 | 37 (43.5)                     | (32.80, 54.72)                | 32 (38.1)                   | (27.71, 49.34)              | 69 (40.8)                | (33.34, 48.64)           |

Figure 34: Cumulative incidence of MMR (Full analysis set) - Study A2302

<!-- image -->

The cumulative response plot of time to first MMR is shown below. The median time to response was 59.3 weeks (95% CI: 24.1, NE) vs 72.1 weeks (95% CI: 48.1, NE) for patients treated with 40 mg BID or 80 mg QD, respectively.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 44 Kaplan-Meier estimates of time to first MMR (Full analysis set) - Study A2302

|                                                                                                                                                                                                             | Asciminib 40 mg b.i.d. N=85                                                                                                                                                                                 | Asciminib 80 mg q.d. N=84                                                                                                                                                                                   | All participants N=169                                                                                                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of response (n)                                                                                                                                                                                      | 40                                                                                                                                                                                                          | 39                                                                                                                                                                                                          | 79                                                                                                                                                                                                          |
| Percentage of response (n/N) (%)                                                                                                                                                                            | 47.1                                                                                                                                                                                                        | 46.4                                                                                                                                                                                                        | 46.7                                                                                                                                                                                                        |
| Time to response (week) K-M percentiles (95% Cl)                                                                                                                                                            |                                                                                                                                                                                                             |                                                                                                                                                                                                             |                                                                                                                                                                                                             |
| 25th                                                                                                                                                                                                        | 12.4 (12.1, 22.7)                                                                                                                                                                                           | 23.7 (12.1, 36.0)                                                                                                                                                                                           | 12.4 (12.3, 23.7)                                                                                                                                                                                           |
| 50th                                                                                                                                                                                                        | 59.3 (24.1, NE)                                                                                                                                                                                             | 72.1 (48.1, NE)                                                                                                                                                                                             | 72.1 (36.9, NE)                                                                                                                                                                                             |
| 75th                                                                                                                                                                                                        | NE (NE, NE)                                                                                                                                                                                                 | NE (NE, NE)                                                                                                                                                                                                 | NE (NE, NE)                                                                                                                                                                                                 |
| K-M % in response (95% Cl)                                                                                                                                                                                  |                                                                                                                                                                                                             |                                                                                                                                                                                                             |                                                                                                                                                                                                             |
| 24 weeks                                                                                                                                                                                                    | 62.7 (50.9, 72.4)                                                                                                                                                                                           | 70.3 (59.0, 79.0)                                                                                                                                                                                           | 66.6 (58.6, 73.3)                                                                                                                                                                                           |
| 48 weeks                                                                                                                                                                                                    | 51.5 (39.7, 62.1)                                                                                                                                                                                           | 62.6 (51.1, 72.2)                                                                                                                                                                                           | 57.2 (49.1, 64.6)                                                                                                                                                                                           |
| 72 weeks                                                                                                                                                                                                    | 46.5 (34.0, 58.1)                                                                                                                                                                                           | 54.9 (42.4, 65.8)                                                                                                                                                                                           | 50.8 (42.0, 58.9)                                                                                                                                                                                           |
| 96 weeks                                                                                                                                                                                                    | 40.7 (25.7, 55.2)                                                                                                                                                                                           | 39.5 (25.2, 53.4)                                                                                                                                                                                           | 40.6 (30.4, 50.5)                                                                                                                                                                                           |
|                                                                                                                                                                                                             | Asciminib 40 mg b.i.d. N=85                                                                                                                                                                                 | Asciminib 80 mg q.d. N=84                                                                                                                                                                                   | All participants N=169                                                                                                                                                                                      |
| 144 weeks                                                                                                                                                                                                   | NE (NE, NE)                                                                                                                                                                                                 | NE (NE, NE)                                                                                                                                                                                                 | NE (NE, NE)                                                                                                                                                                                                 |
| Cls for K-M percentiles are based on Brookmeyer and Crowley (1982). Cls for K-M estimates of % in response are based on Greenwood formula. NE: Not estimable. Source: Study A2302 W48 CSR - Table 14.2-1.18 | Cls for K-M percentiles are based on Brookmeyer and Crowley (1982). Cls for K-M estimates of % in response are based on Greenwood formula. NE: Not estimable. Source: Study A2302 W48 CSR - Table 14.2-1.18 | Cls for K-M percentiles are based on Brookmeyer and Crowley (1982). Cls for K-M estimates of % in response are based on Greenwood formula. NE: Not estimable. Source: Study A2302 W48 CSR - Table 14.2-1.18 | Cls for K-M percentiles are based on Brookmeyer and Crowley (1982). Cls for K-M estimates of % in response are based on Greenwood formula. NE: Not estimable. Source: Study A2302 W48 CSR - Table 14.2-1.18 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 35 Cumulative response plot of time to first MMR (Full analysis set) - Study A2302

<!-- image -->

## Secondary endpoints: other depth of response levels

BCR::ABL1 ≤ 10% rate

The BCR::ABL1 ≤ 10% rate for all participants at 12 weeks was 75.1%, at 24 weeks was 74.6%, at 36 weeks was 76.9% and at 48 weeks was 75.1%. The BCR::ABL1 ≤ 10% rate by scheduled timepoints showed overall (by 48 weeks) was 82.2%.

The comparison of responses between 40 mg BID and 80 mg QD doses is provided in Table 45 and Table 46 .

Table 45 BCR::ABL1 ≤ 10% rate at scheduled timepoints (Full analysis set) -Study A2302

|                     | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=169   | All participants N=169   | All participants N=169   |                     |                     |
|---------------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|---------------------|---------------------|
|                     | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                    | 95% CI                   | 95% CI                   |                     |                     |
| BCR::ABL1 ≤ 10% (1) | BCR::ABL1 ≤ 10% (1)           | BCR::ABL1 ≤ 10% (1)           | BCR::ABL1 ≤ 10% (1)         | BCR::ABL1 ≤ 10% (1)         | BCR::ABL1 ≤ 10% (1)      | BCR::ABL1 ≤ 10% (1)      | BCR::ABL1 ≤ 10% (1)      | BCR::ABL1 ≤ 10% (1) | BCR::ABL1 ≤ 10% (1) |
| at Week 12          | 59 (69.4)(58.47,78.95)        |                               | 68 ( 81.0)                  | (70.92,88.70)               | 127 ( 75.1)              | (67.93,81.46)            |                          |                     |                     |
| at Week 24          | 62 (72.9)(62.21,82.01)        |                               | 64 ( 76.2)                  | (65.65,84.81)               | 126 ( 74.6)              | (67.30,80.93)            |                          |                     |                     |
| at Week 36          | 61(71.8)(60.96,81.00)         |                               | 69 ( 82.1)                  | (72.26,89.65)               | 130 ( 76.9)              | (69.83,83.05)            |                          |                     |                     |
| at Week 48          | 61(71.8)(60.96,81.00)         |                               | 66 ( 78.6)                  | (68.26,86.78)               | 127 ( 75.1)              | (67.93,81.46)            |                          |                     |                     |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 46 BCR::ABL1 ≤ 10% rate by scheduled timepoints (Full analysis set) - Study A2302

|                                                                                                    | Asciminib 40 mg b.i.d. N=85                                                                        | Asciminib 40 mg b.i.d. N=85                                                                        | Asciminib 80 mg q.d. N=84                                                                          | Asciminib 80 mg q.d. N=84                                                                          | All participants N=169                                                                             | All participants N=169                                                                             | All participants N=169                                                                             |                                                                                                    |                                                                                                    |
|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                                                                    | h (%)                                                                                              | 95% CI                                                                                             | n (%)                                                                                              | 95% CI                                                                                             | n (%)                                                                                              | 95% CI                                                                                             | 95% CI                                                                                             |                                                                                                    |                                                                                                    |
| BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 | BCR:ABL1 ≤ 10% (1)                                                                                 |
| by overall                                                                                         | 65 ( 76.5)                                                                                         | (66.03,85.00)                                                                                      | 74 ( 88.1)                                                                                         | (79.19,94.14)                                                                                      | 139 (82.2)                                                                                         | (75.64,87.69)                                                                                      |                                                                                                    |                                                                                                    |                                                                                                    |
| by Week 12                                                                                         | 59 ( 69.4)                                                                                         | (58.47.78.95)                                                                                      | 68 ( 81.0)                                                                                         | (70.92, 88.70)                                                                                     | 127 ( 75.1)                                                                                        | (67.93,81.46)                                                                                      |                                                                                                    |                                                                                                    |                                                                                                    |
| by Week 24                                                                                         | 63 ( 74.1)                                                                                         | (63.48,83.01)                                                                                      | 72 ( 85.7)                                                                                         | (76.38,92.39)                                                                                      | 135 (79.9)                                                                                         | (73.04,85.65)                                                                                      |                                                                                                    |                                                                                                    |                                                                                                    |
|                                                                                                    | Asciminib 40 mg b.i.d. N=85                                                                        | Asciminib 40 mg b.i.d. N=85                                                                        | Asciminib 80 mg q.d. N=84                                                                          | Asciminib 80 mg q.d. N=84                                                                          | All participants N=169                                                                             | All participants N=169                                                                             | All participants N=169                                                                             |                                                                                                    |                                                                                                    |
|                                                                                                    | n (%)                                                                                              | 95% CI                                                                                             | n (%)                                                                                              | 95% CI                                                                                             | n (%)                                                                                              | 95% CI                                                                                             | 95% CI                                                                                             |                                                                                                    |                                                                                                    |
| by Week 36                                                                                         | 65 ( 76.5)                                                                                         | (66.03,85.00)                                                                                      | 74 ( 88.1)                                                                                         | ( 79.19, 94.14)                                                                                    | 139 ( 82.2)                                                                                        | (75.64, 87.69)                                                                                     |                                                                                                    |                                                                                                    |                                                                                                    |
| by Week 48                                                                                         | 65 ( 76.5)                                                                                         | (66.03,85.00)                                                                                      | 74 ( 88.1)                                                                                         | (79.19, 94.14)                                                                                     | 139 ( 82.2)                                                                                        | (75.64,87.69)                                                                                      |                                                                                                    |                                                                                                    |                                                                                                    |
| (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 | (1) Pearson-Clopper 95% 2-sided Cl for response rate. Source: Study A2302 W48 CSR - Table 14.2-1.8 |

BCR::ABL1 ≤ 1% level (MR2.0)

The comparison of responses between 40 mg BID and 80 mg QD doses is provided in Table 47 and Table 48 .

Table 47 BCR::ABL1 ≤ 1% rate at scheduled timepoints (Full analysis set) -Study A2302

|                | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=169   | All participants N=169   | All participants N=169   |                |                |
|----------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|----------------|----------------|
|                | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                    | 95% CI                   | 95% CI                   |                |                |
| BCRABL1≤1% (1) | BCRABL1≤1% (1)                | BCRABL1≤1% (1)                | BCRABL1≤1% (1)              | BCRABL1≤1% (1)              | BCRABL1≤1% (1)           | BCRABL1≤1% (1)           | BCRABL1≤1% (1)           | BCRABL1≤1% (1) | BCRABL1≤1% (1) |
| at Week 12     | 52 ( 61.2)                    | (49.99,71.56)                 | 45 ( 53.6)                  | (42.35,64.53)               | 97 ( 57.4)               | (49.57,64.96)            |                          |                |                |
| at Week 24     | 55 ( 64.7)                    | (53.59, 74.77)                | 49 ( 58.3)                  | (47.06,69.00)               | 104 ( 61.5)              | (53.76,68.91)            |                          |                |                |
| at Week36      | 54 ( 63.5)                    | (52.38,73.71)                 | 54 ( 64.3)                  | (53.08,74.45)               | 108 ( 63.9)              | (56.17, 71.14)           |                          |                |                |
| at Week 48     | 55 ( 64.7)                    | (53.59,74.77)                 | 50 (59.5)                   | (48.25,70.10)               | 105 ( 62.1)              | (54.36,69.47)            |                          |                |                |

Source: Study A2302 W48 CSR - Table 14.2-1.9

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 48 BCR::ABL1 ≤ 1% rate by scheduled timepoints (Full analysis set) Study A2302

|                    | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. 8=N   | Asciminib 80 mg q.d. 8=N   | All participants N=169   | All participants N=169   | All participants N=169   |                    |
|--------------------|-------------------------------|-------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|--------------------------|--------------------|
|                    | n (%)                         | 95% CI                        | n (%)                      | 95% CI                     | n (%)                    | 95% CI                   | 95% CI                   |                    |
| BCR::ABL1 ≤ 1% (1) | BCR::ABL1 ≤ 1% (1)            | BCR::ABL1 ≤ 1% (1)            | BCR::ABL1 ≤ 1% (1)         | BCR::ABL1 ≤ 1% (1)         | BCR::ABL1 ≤ 1% (1)       | BCR::ABL1 ≤ 1% (1)       | BCR::ABL1 ≤ 1% (1)       | BCR::ABL1 ≤ 1% (1) |
| by overall         | 58 ( 68.2)                    | ( 57.24, 77.92)               | 56 ( 66.7)                 | (55.54,76.58)              | 114 ( 67.5)              | (59.83,74.45)            |                          |                    |
| by Week 12         | 52 ( 61.2)                    | (49.99, 71.56)                | 45 ( 53.6)                 | ( 42.35,64.53)             | 97 ( 57.4)               | (49.57,64.96)            |                          |                    |
| by Week 24         | 56 ( 65.9)                    | (54.80,75.82)                 | 51 ( 60.7)                 | (49.45, 71.20)             | 107 ( 63.3)              | (55.57,70.58)            |                          |                    |
| by Week 36         | 57 ( 67.1)                    | (56.02, 76.87)                | 56 ( 66.7)                 | (55.54,76.58)              | 113 ( 66.9)              | (59.22,73.90)            |                          |                    |
| by Week 48         | 58 (68.2)                     | ( 57.24, 77.92)               | 56 ( 66.7)                 | (55.54,76.58)              | 114 ( 67.5)              | (59.83,74.45)            |                          |                    |

Source: Study A2302 W48 CSR - Table 14.2-1.10

At the the BCR:: ABL1 ≤ 1% level, at week 48, 64.7% vs. 59.5% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm, respectively. The numerical trend is supported by assessments at different timepoints (week 12, 24) and an assessment by scheduled timepoints (week 12, 24, 36, 48).

## BCR::ABL1 ≤ 0.1% level (MR3.0)

Responses at the MR3.0 level (MMR) were the primary objective of the study A2302 and described there.

## Rate of MR4.0 and MR 4.5 (DMR)

At the MR4.0 level, at week 48, 20.0% vs. 13.0% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm, respectively. The numerical trend is supported by assessments at different timepoints (week 12, 24, 36) and an assessment by scheduled timepoints (week 12, 24, 36, 48).

At the MR4.5 level, at week 48, 11.8% vs. 8.3% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm, respectively. The numerical trend is supported by assessments at different timepoints (week 12, 24, 36) and an assessment by scheduled timepoints (week 24, 36, 48).

Table 49 MR4 rate at scheduled time points (Full analysis set) - Study A2302

|            | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | Allparticipants N=169   | Allparticipants N=169   |
|------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|-------------------------|-------------------------|
|            | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                   | 95% CI                  |
| MR4 (1)    |                               |                               |                             |                             |                         |                         |
| at Week 12 | 8 ( 9.4)                      | (4.15, 17.71)                 | 3 ( 3.6)                    | (0.74, 10.08)               | 11 ( 6.5)               | (3.29, 11.35)           |
| at Week 24 | 19 (22.4)                     | (14.03, 32.69)                | 9 (10.7)                    | (5.02, 19.37)               | 28 (16.6)               | (11.30, 23.05)          |
| at Week 36 | 17 (20.0)                     | (12.10, 30.08)                | 10 (11.9)                   | (5.86, 20.81)               | 27 (16.0)               | (10.80, 22.39)          |
| at Week 48 | 17 (20.0)                     | (12.10,30.08)                 | 11 (13.1)                   | ( 6.72, 22.22)              | 28 (16.6)               | (11.30.23.05)           |

Participants without PCR assessment at a time point are considered as non-responders at that time point.

Source: Study A2302 W48 CSR -Table 14.2-1.3

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 50 MR4 rate by scheduled time points (Full analysis set) - Study A2302

|            | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=169   | All participants N=169   |
|------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
|            | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                    | 95% CI                   |
| MR4 (1)    |                               |                               |                             |                             |                          |                          |
| by Overall | 19 (22.4)                     | (14.03,32.69)                 | 12 (14.3)                   | (7.61, 23.62)               | 31 (18.3)                | (12.82, 25.01)           |
| by Week 12 | 8 (9.4)                       | (4.15, 17.71)                 | 3 ( 3.6)                    | (0.74,10.08)                | 11 ( 6.5)                | (3.29, 11.35)            |
| by Week 24 | 19 (22.4)                     | (14.03,32.69)                 | 9 (10.7)                    | (5.02, 19.37)               | 28 (16.6)                | (11.30, 23.05)           |
| by Week 36 | 19 (22.4)                     | (14.03, 32.69)                | 11 (13.1)                   | ( 6.72, 22.22)              | 30 (17.8)                | (12.31, 24.36)           |
| by Week 48 | 19 (22.4)                     | (14.03, 32.69)                | 12 (14.3)                   | (7.61, 23.62)               | 31 (18.3)                | (12.82, 25.01)           |

Table 51 MR4.5 rate at scheduled time point (Full analysis set) - Study A2302

|            | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | Allparticipants N=169   | Allparticipants N=169   |
|------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|-------------------------|-------------------------|
|            | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                   | 95% CI                  |
| MR4.5 (1)  |                               |                               |                             |                             |                         |                         |
| at Week 12 | 1 ( 1.2)                      | (0.03, 6.38)                  | 1 ( 1.2)                    | (0.03, 6.46)                | 2 ( 1.2)                | ( 0.14, 4.21)           |
| at Week 24 | 10 (11.8)                     | (5.79, 20.57)                 | 4 ( 4.8)                    | (1.31, 11.75)               | 14 ( 8.3)               | (4.60, 13.51)           |
| at Week 36 | 12 (14.1)                     | (7.51, 23.36)                 | 6 ( 7.1)                    | (2.67,14.90)                | 18 (10.7)               | (6.44, 16.31)           |
| at Week 48 | 10 (11.8)                     | (5.79,20.57)                  | 7 ( 8.3)                    | (3.42, 16.42)               | 17 (10.1)               | (5.97, 15.62)           |

Participants without PCR assessment at a time point are considered as non-responders at that time point.

Source:StudyA2302W48CSR-Table14.2-1.5

Table 52 MR4.5 rate by scheduled time point (Full analysis set) - Study A2302

|            | Asciminib 40 mg b.i.d. N=85   | Asciminib 40 mg b.i.d. N=85   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=169   | All participants N=169   |
|------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
|            | n (%)                         | 95% CI                        | n (%)                       | 95% CI                      | n (%)                    | 95% CI                   |
| MR4.5 (1)  |                               |                               |                             |                             |                          |                          |
| by Overall | 15 (17.6)                     | (10.23, 27.43)                | 7 ( 8.3)                    | (3.42, 16.42)               | 22 (13.0)                | (8.34, 19.04)            |
| by Week 12 | 1 ( 1.2)                      | (0.03, 6.38)                  | 1 ( 1.2)                    | (0.03, 6.46)                | 2 ( 1.2)                 | ( 0.14, 4.21)            |
| by Week 24 | 10 (11.8)                     | (5.79, 20.57)                 | 4 ( 4.8)                    | (1.31, 11.75)               | 14 ( 8.3)                | (4.60, 13.51)            |
| by Week 36 | 14 (16.5)                     | (9.31, 26.09)                 | 6 ( 7.1)                    | (2.67, 14.90)               | 20 (11.8)                | (7.38, 17.68)            |
| by Week 48 | 15 (17.6)                     | (10.23, 27.43)                | 7 (8.3)                     | (3.42, 16.42)               | 22 (13.0)                | (8.34,19.04)             |

## Duration of MMR (MR3.0) and MR4.0

The majority of participants who achieved MMR continued to have MMR; subsequent loss of response was reported in 3 participants (3.8%) at or before 72 weeks. One participant (80 mg QD ) had loss of response by 24 weeks, one participant (40 mg b.i.d.) had loss of response by 48 weeks, and one participant (40 mg b.i.d.) had loss of response by 72 weeks.

MMR was lost in only 5% (2/40 patients, 40 mg BID) and 2.5% (1/39 patients, 80 mg QD) before week 72. MR4.0 was lost by 14.3% of patients in each arm (3/21 patients in 40 mg BID and 2/14 in 80 mg QD) before week 72.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Time to treatment failure

Treatment failure prior to 48 weeks was defined as participants who discontinued study treatment. Starting at 48 weeks, treatment failure included participants with BCR::ABL1 &gt; 1%. For participants without MMR at baseline, the Kaplan-Meier plot of time to treatment failure is presented in Figure 36 . After a median follow-up time of 1.0 year, 23.5% vs. 36.9% of patients had treatment failure in the 40 mg BID and 80 mg QD arm, respectively.

Table 53 Kaplan-Meier estimates of time to treatment failure (Full analysis set) - Study A2302

|                                                  | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg q.d. 8=N n (%)   | All participants N=169 n (%)   |
|--------------------------------------------------|-------------------------------------|----------------------------------|--------------------------------|
| Number of participants with event (n)            | 20                                  | 31                               | 51                             |
| Percentage of participants with events (n/N) (%) | 23.5                                | 36.9                             | 30.2                           |
| Maximum follow-up (year)                         | 2.1                                 | 2.1                              | 2.1                            |
| Median follow-up (year)                          | 1.0                                 | 1.0                              | 1.0                            |
| Time to event (year)                             |                                     |                                  |                                |
| K-M percentiles (95% Cl)                         |                                     |                                  |                                |
| 25th                                             | 0.9 (0.9, NE)                       | 0.9 (0.9, 0.9)                   | 0.9 (0.9, 0.9)                 |
| 50th                                             | NE (NE, NE)                         | NE (0.9, NE)                     | NE (NE, NE)                    |
| 75th                                             | NE (NE, NE)                         | NE (NE, NE)                      | NE (NE, NE)                    |
| K-M % event free (95% Cl)                        |                                     |                                  |                                |
| 1 Year                                           | 70.7 (58.1, 80.1)                   | 58.9 (46.9, 69.1)                | 64.6 (56.1, 71.9)              |
| 2 Years                                          | 70.7 (58.1, 80.1)                   | 58.9 (46.9, 69.1)                | 64.6 (56.1, 71.9)              |

|        | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg q.d. N=84 n (%)   | All participants N=169 n (%)   |
|--------|-------------------------------------|-----------------------------------|--------------------------------|
| 3Years | NE (NE, NE)                         | NE (NE, NE)                       | NE (NE, NE)                    |

% Event free probability estimate is the estimated probability that a participant will not have an event prior to the specified time point. % Event free probability estimates are obtained from the Kaplan-Meier survival estimates for all treatment groups. Here event is defined by treatment failure.

Cls for K-M estimates of % event free are based on Greenwood formula

Cls for K-M percentiles are based on Brookmeyer and Crowley (1982).

NE: Not estimable.

Source:Study A2302W48 CSR -Table 14.2-3.1

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 36:

<!-- image -->

Kaplan-Meier plot of time to treatment failure (Full analysis set) - Study A2302

## Progression-free survival

PFS data were immature at the time of DCO with 3.5% (3/85 patients) of participants and 4.8% (4/84) of participants with PFS events in the 40 mg BID and 80 mg QD groups respectively.

## Overall survival

Overall survival data were immature at time of the Week 48 analysis. One participant (1.2%) in the 80 mg QD group died due to cerebrovascular accident. The cause of death was not suspected to be related to the study drug.

## Supportive comparison of MMR rates in Study A2302 and Study A2301 at Week 48

Study A2301 was the pivotal phase 3 study confirming the efficacy and safety of asciminib in patients with CML-CP previously treated with at least 2 TKIs. The study met its primary objective, with superiority demonstrated for asciminib 40 mg BID (MRR rate at week 24: 25.5%) relative to bosutinib 500 mg (13.2%) QD for the primary endpoint of MMR at 24 weeks with a treatment difference of 12.2% % (95% CI: 2.19, 22.30, two-sided p-value: 0.029).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 54 Comparison of baseline characteristics between Study A2301 and Study A2302 that were adjusted using propensity scores

| Demographic Variable                         | StudyA2301* 40 mg b.i.d. N=157 n (%)   | StudyA2302 40 mg b.i.d. N=85 n (%)   | StudyA2302 80 mg q.d. N=84 n (%)   |
|----------------------------------------------|----------------------------------------|--------------------------------------|------------------------------------|
| Age Group                                    |                                        |                                      |                                    |
| <65 years                                    | 128 (81.5)                             | 64 (75.3)                            | 59 (70.2)                          |
| ≥ 65 years                                   | 29 (18.5)                              | 21 (24.7)                            | 25 (29.8)                          |
| Sex                                          |                                        |                                      |                                    |
| Female                                       | 75 (47.8)                              | 37 (43.5)                            | 27 (32.1)                          |
| Male                                         | 82 (52.2)                              | 48 (56.5)                            | 57 (67.9)                          |
| Number ofpriorTKl therapies                  |                                        |                                      |                                    |
| 2                                            | 89 (56.7)                              | 47 (55.3)                            | 42 (50.0)                          |
| ≥3                                           | 68 (43.3)                              | 38 (44.7)                            | 42 (50.0)                          |
| Reason for discontinuation of last prior TKl |                                        |                                      |                                    |
| Failure                                      | 95 (60.5)                              | 43 (50.6)                            | 46 (54.8)                          |
| Intolerance                                  | 59 (37.6)                              | 19 (22.4)                            | 20 (23.8)                          |
| Unknown/Other                                | 3 (1.9)                                | 23 (27.1)                            | 18 (21.4)                          |
| MR2statusatbaseline                          |                                        |                                      |                                    |
| 0                                            | 142 (90.4)                             | 55 (64.7)                            | 58 (69.0)                          |
| 1                                            | 15 (9.6)                               | 30 (35.3)                            | 26 (31.0)                          |
| Mutation                                     |                                        |                                      |                                    |
| Mutation                                     | 17 (10.8)                              | 5 (5.9)                              | 11 (13.1)                          |
| Wild Type                                    | 125 (79.6)                             | 68 (80)                              | 63 (75.0)                          |
| Unknown                                      | 15 (9.6)                               | 12 (14.1)                            | 10 (11.9)                          |

Source:SCEAppendix1-Table1

A post-hoc propensity score analysis to, following the applicant, considering differences in baseline characteristics ( Table 54 ), was performed to compare the following:

- MMR rate at Week 48 between Study A2302 40 mg BID vs. Study A2301 40 mg BID for asciminib
- MMR rate at Week 48 between Study A2302 80 mg QD vs. Study A2301 40 mg BID for Asciminib

The difference in MMR rate between Study A2301 40 mg BID and Study A2302 40 mg BID dose groups after adjustment for differences for baseline characteristics due to different study designs by the applicant is provided in Table 55 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 55 MMR at Week 48 for Study A2302 40 mg BID vs. unadjusted/adjusted Study A2301 40 mg BID

| Study                                                                                                                                                                                  | N                                                                                                                                                                                      | MMR Week 48 (%)                                                                                                                                                                        | Difference                                                                                                                                                                             | 95% CI                                                                                                                                                                                 | p-value                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study A230240 mg b.i.d.                                                                                                                                                                | 62a                                                                                                                                                                                    | 40.32                                                                                                                                                                                  | -2.45                                                                                                                                                                                  | (-18.96, 14.06)                                                                                                                                                                        | 0.771c                                                                                                                                                                                 |
| StudyA230140 mg b.i.d. adjusted                                                                                                                                                        | 73b                                                                                                                                                                                    | 37.88                                                                                                                                                                                  |                                                                                                                                                                                        |                                                                                                                                                                                        |                                                                                                                                                                                        |
| Study A2301 40 mg b.i.d. unadjusted                                                                                                                                                    | 154a                                                                                                                                                                                   | 29.87                                                                                                                                                                                  |                                                                                                                                                                                        |                                                                                                                                                                                        |                                                                                                                                                                                        |
| bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 | bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 | bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 | bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 | bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 | bEffective sample size = square of the summed weights/ sum of squared weights cNominal p-value computed only for post-hoc analysis for descriptive purposes Source:SCEAppendix1-Table2 |

The difference in MMR rate at Week 48 for Study A2301 40 mg BID vs. Study A2302 80 mg QD  dose groups after adjustment for differences for baseline characteristics due to different study designs by the applicant is provided in Table 56 .

Table 56 MMR rate at Week 48 for Study A2301 40 mg BID vs. Study A2302 80 mg QD

| Study                               | N    | MMR Week 48 (%)   | Difference   | 95% CI          | p-value   |
|-------------------------------------|------|-------------------|--------------|-----------------|-----------|
| Study A2302 80 mg q.d.              | 66a  | 33.33             | 0.74         | (-14.32, 15.79) | 0.923c    |
| Study A2301 40 mg b.i.d. adjusted   | 89b  | 34.07             |              |                 |           |
| Study                               | N    | MMRWeek48 (%)     | Difference   | 95% CI          | p-value   |
| Study A2301 40 mg b.i.d. unadjusted | 154a | 29.87             |              |                 |           |

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

## I. Extension of indication to patients with newly diagnosed CML-CP

The applicant conducted one pivotal study for the extension of indication to CP-CML-CP 1st line treatment. Ongoing phase III, randomised (1:1)-controlled, open-label, multicentre, superiority trial J12301 (ASC4FIRST) comparing asciminib 80 mg QD monotherapy with investigator's selected TKI

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

(imatinib 400 mg QD, nilotinib 300 mg BID dasatinib 100 mg QD or bosutinib 400 mg QD) in estimated 402 patients with CML-CP.

Diagnosis of CML-CP was made following ELN 2020 criteria, thereby excluding CML-AP and CML-BP. Only patients with ECOG PS 0 and 1 were eligible for enrolment.

Protocol assistance was obtained before study start in March 2021. Regarding the study design, activity as an estimate to measure positive effects was accepted but should ideally be supported by estimates that reflects changes in clinical management and a favourable safety profile.

The proposed primary endpoint 'MMR (MR3.0) at 48 weeks' for the overall population was considered difficult for interpretation, regarding the heterogeneity of the multi -comparator control arm and that the effect may mainly be driven by imatinib. Furthermore, activity after one year was seen rather short for a reliable comparison, as the current EMA guidance recommends assessment after 18 months in this setting.

The applicant chose 'MMR at week 48' for asciminib vs. IS-TKI (FAS) as 'primary endpoint 1' and MMR at week 48 for asciminib IMA  vs. IS-TKI IMA , in the imatinib-stratum, as 'primary endpoint 2', implying a positive study if either is positive. MMR at week 96 was planned as a key secondary endpoint in the corresponding populations.

The Applicant addressed the efficacy comparison between asciminib and 2G TKI by stratification and a secondary endpoint for MMR at weeks 48 and 96 for this subpopulation in the primary analysis. Further secondary objectives included different molecular levels and duration of the remission at different time points up to week 96 (CHR, MR2.0, MR3.0 (MMR), MR4.0 and MR4.5 by all scheduled data collection time points), time to treatment failure and event free survival.

The choice of primary endpoints can in principle be followed. Current (2020) ELN and NCCN (2025) guidelines highlight 'MMR at 48 weeks' as a so-called 'optimal' response to treatment. However, a grey zone exists (so called 'warning') of clinical decision making between MMR and MR2.0 after 48 weeks. Interpretability in terms of clinical meaningfulness of this landmark analysis for MMR is somewhat limited, as many of these patients may also deepen responses (potentially allowing for TFR) at a later time. Of note, not achieving MR2.0 is considered treatment failure with implication on survival rates, MR2.0 rate was implemented as a secondary endpoint. However, evidence of translation into clinically meaningful endpoints like number and duration of TFR and a more mature EFS analysis, a data update was requested, as PFS or even OS is unlikely to become mature. The MAH committed to provide an 8 year follow-up for study J12301 (Annex II condition).

The specified estimands combining treatment policy and composite strategy for relevant intercurrent events are overall agreed and considered relevant in this situation.

All four control arm TKIs were initially planned to be administered at the approved dosages.

Stratification was performed based on the ELTS risk score (low vs. intermediate vs. high) and the TKI selected prior to randomisation (imatinib vs. second-generation TKI). Unfortunately, geographic region was not included in the study design as a stratum. The effect of region on the outcome is at least partially addressed by the stratification due to respective TKI selection.

The open-label design was previously accepted in this setting because the use of different dosing regimens (QD, BID, food restrictions, etc.) and additional placebos would have made conducting the study extremely difficult.

Sample size (planned n=402) for the primary endpoints was calculated assuming MMR rates at week 48 to be 52.5% for asciminib, 28% for imatinib, and 45% for any 2G TKI. Based on a 1-sided 2.5%

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

level of significance, the study had 94.6% power to reject at least one of the null hypotheses (MRR at week 48 in the FAS and/or FAS IMA ).

The statistical analyses are overall considered appropriate and aligned to the targeted estimands. For multiplicity controlled primary and key secondary efficacy endpoints, sufficient sensitivity analyses evaluating alternative missing data handling were done and supportive estimands were addressed with results aligned to the primary evaluation.

While the SAP was only finalized after starting the study, which is less ideal for an open label study, this is not of further concern, as the protocol contained extensive and sufficient information on the statistical analyses in particular for the multiplicity-controlled endpoints.

The study was conducted between October 2021 and December 2022. The data cut-off for efficacy was on 28 November 2023. The  study is planned to be terminated after five years from last patient first treatment. Overall, 405 patients were randomised in 116 centres in 29 countries worldwide. An Interactive Response Technology safeguarded equal distribution of enrolment in the strata of imatinib vs. 2G TKI. At the time of data cut-off, treatment was ongoing for 86.1% of patients in the ASC arm and 68.6% in the 2G- TKI arm. More patients in the control arm had a treatment failure compared to asciminib (ASC 5%; IS-TKI 11.8% (including TKI IMA  15.7%/ TKI 2G  7.8%) until DCO. Confirmed loss of MRR (ASC 0.5%; IS-TKI 0%) or progressive disease (ASC 1%; IS-TKI 2%) were rare.

The two protocol amendments were minor without implications for the study interpretability.

Protocol deviations were generally seen in both arms (any deviation: ASC 54.2%; IS-TKI 51.5%) with a high rate of 'selection criteria not met' (ASC 14.4% vs. IS-TKI 12.3%) after randomisation.

Baseline characteristics were generally balanced between the ASC- and IS-TKI arm. This accounts especially for age, BMI and CVD risk categories. ELTS Risk Score was employed for stratification and balanced between ASC- and IS-TKI arm. As expected, patients in the imatinib - stratum had a higher age, and a higher CVD risk compared to patients from the 2G-TKi stratum. No difference in the ECOGPS (0 vs. 1) was observed.

## II. Extension of the indication to 2nd line CML-CP treatment

To close the gap between approved 3L or later line indication and the applied first line indication the applicant submitted data from 63 2L CML- CP patients treated with asciminib 80 mg QD monotherapy from an ongoing uncontrolled, single-arm, dose escalation, phase II trial CABL001AUS08. At the time of submission, the study had completed enrolment, with 101 participants in 2nd line treatment by 17Sep-2024. Endpoints were, among others, BCR::ABL =&lt; 10% rate, MR2-/ MMR-/ MR4- and MR4.5 rates.

Most evaluable patients were pretreated with dasatinib and imatinib, which is adequate. Mean time of exposure at DCO was 40.1 (SD 17.22) weeks. Overall, treatment discontinuation was reported for 8.9% of patients (4% due to AE).

## III. New posology of 80 mg QD for the 3 rd  or later line, 40 mg BID in earlier lines

Besides available data of the effectiveness in the 1 st  and 2 nd  line of the 80 mg QD posology for potential extrapolation to the 3 rd  and later line, the applicant provided data from supportive study A2302.

In the initial MAA for Scemblix, conclusions on comparative efficacy and safety could not be reliably drawn for the 80 mg QD dose regimen in 3 rd  or later line CML-CP patients in comparison to 40 mg BID due to only 17 preliminary investigated subjects (in phase I study X2101) on that respective dose. At the time of the positive CHMP opinion in June 2022, the clinical study A2302 for this question was already initiated as a PASS supportive for the benefit and risk for the 80 mg QD posology.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Ongoing non- comparative, multicentre, randomised (1:1) controlled, open-label, phase IIIb treatment optimisation study A2302 (ASC4OPT) in patients who had prior treatment with at least two TKIs and who were either in warning, resistant (ELN 2020 recommendations) or intolerant to the last TKI treatment. Randomisation was between asciminib monotherapy 40 mg BID and 80 mg QD with MMR rate at week 48 as the primary endpoint, aiming at a statistically significant difference to MMR rate at week 48 of 23% in the overall population. No stratification was applied. However, the actual comparison between the established dosing regimen and the proposed alternative regimen was not adequately addressed in the study design.  No direct comparison was planned or conducted between both groups and no margin for equivalence/non-inferiority was pre-specified. Extrapolation of efficacy of 40 mg BID dosing to earlier treatment lines can be accepted.

## Efficacy data and additional analyses

## I. Extension of indication to patients with newly diagnosed CML-CP

On 28 November 2023 DCO, the study was positive for the two primary endpoints and the two key secondary endpoints. The difference between MMR rates at week 48 was Δ 18.88% (95% CI: 9.59, 28.17; one sided p-value: &lt;0.001) comparing the overall ASC arm (67.7%) to the overall IS-TKI arm (49.0%). The effect was more pronounced in the imatinib stratum, primary endpoint 2 showed a difference in the MMR rate of 29.55% 95% CI: 16.91, 42.18; one-sided adjusted p-value: &lt; 0.001; ASC IMA  74.1% vs. IS-TKI IMA  52.0%). For the key secondary endpoints, the difference in MMR rate at week 96 increased in the overall population (FAS) to Δ 22.4% (ASC 74.1% and 52.0% IS -TKI) and to 29.7% in the FAS IMA  population (ASC IMA  76.2% IS-TKI IMA  47.1%). As a prespecified analysis in the 2G TKI stratum, MMR rate between ASC 2G  and IS-TKI 2G was numerically higher at 48 weeks (Δ 8.2%, 66.0 vs. 57.8%) and 96 weeks (Δ 15.1%, 72.0% vs. 56.9%).

Sensitivity analyses of MMR rate at week 48 without imputation and analyses for important subgroups (ELTS score, age) supported the result of the primary analysis.

Achieving MR2 (analogous to CCyR) within the 1 st  year of treatment has been considered to be prognostically relevant for long term survival in treatment guidelines for 1 st  and 2 nd  generation TKI. In the FAS IMA numerical difference between arms is Δ 22.0% (91.1% vs. 69.6%) and for the FAS 2G Δ 9.67% (94.0% vs. 84.3%). The difference is maintained in the 2-year assessment.

Achieving DMR (MR4 or better) offers, among other necessary factors, the possibility for treatment discontinuation. MR4 rates are numerically higher in the ASC arm compared to IS-TKI. The effect is present in the different strata and at different timepoints (FAS IMA  48 week: 37.0% vs. 10.0%; week 96: 56.0% vs. 27.2%; FAS 2G  48 week: 31.0% vs. 21.8%; week 96: 45.0% vs. 40.8%).

For MMR, a sustained effect was observed in the 1 st  two years of treatment, as 97% of patients who achieved MMR in both arms continued to remain in MMR at week 96.

Early molecular response (EMR; ≤ 10% BCR::ABL1 IS at 12 weeks) is, according to clinical guidelines (NCCN 2025), another response milestone predictive for long term PFS. Here asciminib treatment showed a numerical difference of Δ 28.3% (88.1% vs. 59.8%) and Δ 10.6% (91.0% vs. 80.4%) in the imatinib-/ and 2GTKI- stratum for asciminib vs. IS-TKI, respectively.

Rates of discontinuation due to treatment failure per ELN criteria was remarkably higher in patients receiving imatinib (18.6%) and 2G TKI (8.8%) than in patients receiving asciminib (5.0%). The probability of treatment failure was lower in the asciminib arm compared to IS TKI arm (HR=0.37; 95% CI: 0.25, 0.55). The effect was coherent in both strata (FAS IMA  and FAS2 GTKI ).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

EFS, including death, progression or treatment change at week 96 was numerically higher for the asciminib arm irrespective of the imatinib (16.8% vs. 35.3%) or 2G-TKI stratum (12.0% vs. 23.5%).

## II. Extension of the indication to 2nd line CML-CP treatment

At six months, 82.5% (95%CI: 70.9%, 91.0%) of evaluable 2L patients achieved MR2 and 44.4% (95%CI: 31.9%, 57.5%) achieved MMR in the single - arm trial. Observed MMR rate at week 36 is 52.4 % (36.4, 68.0). Due to the uncontrolled nature of the data, interpretability of data is hampered. The observed activity lays within MMR rates of asciminib after 6 months in 1L (57.71%, study J12301, see above) and &gt;=3L (25.5%, study A2301, initial MAA). The observed MR2.0 rate is promising in comparison to historical CCyR rates of TKI in the 2 nd  line (Jabbour et al.; 2024). In an update at IA5, median duration of exposure to study treatment was 51.3 weeks in the second-line cohort, 54.5% (55 patients) had a duration of exposure &gt; 48 weeks. At IA5, MMR rate at week 48 in patients with adequate follow-up was 55.6% (40/72; 95% CI: 43.4; 67.3%). Supportive results come from MR2 rate at 48 weeks with 77.8% (56/72; 95% CI: 66.4; 86.7%) and DMR at 48 weeks with 25% (18/72; 95%CI: 15.5%, 36.6%).

## III. New posology of 80 mg QD for the 3 rd  or later line and 40 mg BID to earlier lines

In study A2302, mean exposure was comparable between the arms (68.0 vs. 68.7 weeks). Baseline characteristics show marginal differences in age groups (≥ 65 years 24.7% vs. 29.8% in 40 mg BID vs 80 mg QD), sex (female 43.5 vs. 32.1), patients with previous treatment failure (50.6% vs. 54.8%) or mutations (5.9% vs. 13.1%).

The study met its primary endpoint, for participants without MMR at baseline, the overall rate of MMR at Week 48 in FAS was 38.5% (95% CI: 31.09, 46.24).

In a post- hoc comparison, the rate of MMR at Week 48 was 42.4% (95% CI: 31.70, 53.55) vs. 34.5% (95% CI: 24.48, 45.69) for the asciminib 40 mg BID group vs. asciminib 80 mg QD group, respectively. The numerical difference in MMR rate is 7.8% in favour of 40 mg BID.

Residual imbalances and lack of stratification do not justify post hoc rebalancing for the primary endpoint. The primary focus should be on the randomised comparison (even if not preplanned) considering that there are no extensive imbalances observed between randomised treatment arms.

The provided analyses are considered insufficient to alleviate the concern of a considerably higher MMR rate at week 48 for the 40mg BID group. Aside from this, selection of covariates included in the posthoc analysis and robustness of results with respect to the selection of included covariates is unclear. Furthermore, neither based on the randomised nor the post-hoc comparison a non-inferiority claim with a reasonable margin (5-10%) can be made.

The primary endpoint (rejecting an MMR rate at week 48 of 23% in the overall population) was met, due to the limitations in study design no comparison between 40 mg BID and 80 mg QD was predefined. The rate of MMR at Week 48 for patients without MRR at baseline was 42.4% (95% CI: 31.70, 53.55) in the asciminib 40 mg BID group and was 34.5% (95% CI: 24.48, 45.69) in the asciminib 80 mg QD group. The numerical difference in MMR rate between 40 mg BID and 80 mg QD is 7.8%, without a predefined acceptable margin to claim equivalence.

The performed post-hoc propensity score weighting, which is not justified, adequate or reliable, led to a reduced difference of 2.43 (95% CI: -12.71, 17.56).

At the BCR::ABL1 ≤ 10% level, at week 48, 71.8% vs. 78.6% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm. The numerical trend is supported by assessments at different timepoints (week 12, 24, 36) and an assessment by scheduled timepoints.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

At the MR4.0 level, at week 48, 20.0% vs. 13.0% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm, respectively. The numerical trend is supported by assessments at different timepoints (week 12, 24, 36) and an assessment by scheduled timepoints (week 12, 24, 36, 48).

At the MR4.5 level, at week 48, 11.8% vs. 8.3% of patients showed a response for the 40 mg BID arm vs 80 mg QD arm, respectively. The numerical trend is supported by assessments at different timepoints (week 12, 24, 36) and an assessment by scheduled timepoints (week 24, 36, 48).

The majority of response assessments at deeper response levels show numerical favourable effects of the 40 mg BID dose at scheduled timepoints from week 12 to week 36 with few exceptions.

After a median follow-up time of 1.0 year, 23.5% vs. 36.9% of patients had treatment failure in the 40 mg BID and 80 mg QD arm, respectively.

Further propensity score-weighted analyses were conducted to compare MMR rates at week 48 in the 40 mg BID and 80 mg QD arms with the responses of 40 mg BID patients in the pivotal phase III A2301 study for initial MAA. However, the post hoc analysis attempting to rebalance the 12.5% difference in MMR rates (42.4% vs. 29.9%) is problematic and not adequately justified, although the fact that to a certain extent, different populations were included in both studies (including patients with 'warning' according to ELN 2020 criteria only in study A2302) is acknowledged.

Of note, strong supportive evidence for efficacy of the 80 mg QD posology comes from the efficacy and activity data in the 1 st  and 2 nd  line of treatment, indicating a benefit for patients also in the 3 rd  line. Whether efficacy can be generally considered equipotent to the 40 mg BID posology or the once daily intake is only recommended to patients with problems following the twice daily intake in the fasting state, like some patients with diabetes mellitus, difficulties to swallow or low adherence, also depends on the outcome of the post-hoc comparison of the two study arms in study A2302.

In response to a request for additional information, the MAH confirmed the results of the post hoc comparison of the primary endpoint for the two dosing arms, showing a difference in MMR rate at week 48 of -7.8% (95% CI: -22.45, 6.79). This difference was clinically relevant in favour of the 40 mg BID dosing regimen, despite the confidence intervals overlapping. This potential for lower efficacy with the 80 mg QD regimen has been reflected in section 4.4 of the SmPC.

## 2.4.3. Conclusions on the clinical efficacy

## Extension of indication to patients with newly diagnosed CML-CP

The pivotal RCT J12301 comparing asciminib monotherapy to imatinib or 2G-TKI was positive, as the primary endpoint, the difference between MMR rates at week 48 was 18.88% (95% CI: 9.59, 28.17; one sided p-value: &lt;0.001) in the overall population. The effect was present in both, the imatinib stratum and the 2G- stratum, at different prescheduled timepoints (week 12-96), across different response levels (MR2.0, MMR/ MR3.0, DMR ink. MR4.0 and MR4.5) and for important subgroups (ELTS score, age). The effect is supported by numerically lower rates of discontinuation and higher EFS at week 96. Although no robust data on 'hard' clinical endpoints like mature EFS/ PFS data, OS- data, number and duration of TFR is available yet, efficacy in newly diagnosed CML-CP patients has been demonstrated.

The results of the long-term (&gt;96 weeks) outcomes of this potentially lifelong therapy are pending. The MAH should provide, via an Annex IID condition, long-term efficacy and safety data for the J12301 (ASC4FIRST) trial, including but not limited to treatment free intervals (TRI) and durations of TRI, OS, PFS, PFS2, resistance mechanisms, resistance mutations and response rates to subsequent TKIs for 8 years.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Extension of the indication to 2nd line CML-CP treatment

The provided uncontrolled response data in 101 2 nd  line CML-CP patients with an MMR rate at week 24 of 44.4% (95%CI: 31.9%, 57.5%), 52.4 % (36.4, 68.0) at week 36 and 55.6% (43.4; 67.3%) at week 48 are in between described responses in 1L treatment (Study J12301) and 3 rd  or later line treatment (study 2301). Despite the limitations of the data, evidence has been provided to support the claim of activity in 2L CML-CP.

## New posology of 80 mg QD for the 3rd or later line, 40 mg BID in earlier lines

Results of Phase III RCT Study A2302 do not provide evidence for similar efficacy of the 80 mg QD dosing in comparison to 40 mg BID dosing. Extrapolation of efficacy of 40 mg BID dosing to earlier treatment lines can be accepted.

The following measures are considered necessary to address issues related to efficacy:

In order to further evaluate the long-term efficacy and safety of asciminib in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP), the MAH should submit the final CSR of study CABL001J12301 (ASC4FIRST), by 30 September 2031.

## 2.5. Clinical safety

## Introduction

The safety results in this application were not pooled as a whole but presented individually within the framework of the respective studies presented in this application, which is accepted.

Therefore the safety data in this assessment is presented in 3 parts:  Extension of indication to patients with newly diagnosed CML-CP, Extension of the indication to 2nd line CML-CP treatment and New posology of 80 mg QD for the 3rd or later line.

## 2.5.1. Extension of indication to patients with newly diagnosed CML-CP

The evaluation for extension of indication to patients with newly diagnosed CML-CP is primary based on safety data from the Phase III registration Study CABL001J12301 (ASC4FIRST, hereafter referred to as Study J12301) up to the data cut-off date of 22-Oct-2024 at Week 96, with 201 patients exposed to a dose of 80 mg QD from studies and 204 patients exposed to IS-TKI (imatinib, dasatinib, bosutinib, nilotinib) along with supportive data from Study CABL001A2301 (hereafter referred to as Study A2301) and Study CABL001X2101 (hereafter referred to as Study X2101).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 57 Overview of clinical studies contributing to the All Asciminib Safety Pool

| Studies/Population/ Total no. of No. of participants included in the safety pool (n)                         | Study description                                                                                                                                                    | Dose schedule                                                                                                                                             | Data Cut-off dates                                                                              | Completion status   |
|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------|
| Registration study                                                                                           |                                                                                                                                                                      |                                                                                                                                                           |                                                                                                 |                     |
| Study J12301 / Adult patients with newly diagnosed Ph+ CML-CP N= 405/ n=200                                  | A Phase III, multi-center, open-label, randomised study of oral asciminib vs. Investigator selected TKI in patients with newly diagnosedPh+ CML-CP                   | 80 mg QD                                                                                                                                                  | 22-Oct-2024 (Week 96 - Secondary analysis CSR) And 28-Nov-2023 (Week 48 - Primary analysis CSR) | Ongoing             |
| Supportive studies                                                                                           |                                                                                                                                                                      |                                                                                                                                                           |                                                                                                 |                     |
| Study A2301 # / Adult patients with Ph+ CML- CP previously treated with ≥ 2 TKIs N=233/ n=156                | A Phase III, multi-center, open-label, randomised study of oral ABL001 (asciminib) vs. bosutinib in patients with Ph+ CML-CP, previously treated with 2 or more TKIs | 40 mg b.i.d.                                                                                                                                              | 22-Mar-2023 (End of Treatment CSR)                                                              | Ongoing             |
| Study X2101 / Adult patients with Ph+ CML or ALL, relapsed, refractory to or intolerant of TKIs N=326/ n=200 | A Phase I, multicenter, open-label study of oral ABL001 in patients with Ph+ CML or Ph+ALL                                                                           | 10, 20, 40, 80, 150, 160, 200, 280 mg b.i.d. and 40, 60 80, 120, 160 and 200mgQD as single agent* or in combination with imatinib, nilotinib or dasatinib | 14-Mar-2023 (Final CSR)                                                                         | Completed           |

Study J12301- No crossover of study treatment was allowed.

#Excludes switched participants from Study A2301

*Includes only asciminib monotherapy participants (Arm 1) from Study X2101

Source: [Study J12301 W96 CSR], [Study J12301 W48 CSR], [Study A2301 EOT CSR], [Study X2101 Final CSR] and [Tabular Listing of All Clinical Studies]

## Patient exposure

Study J12301: As of the Week 96 data cut-off, the median duration of exposure was marginally longer in the asciminib group (115.79 weeks) relative to the IS-TKI group (108.70 weeks). A higher proportion of participants had a duration of exposure of at least 96 weeks in the asciminib group (81.0%) compared to the IS-TKI group (61.2%). Total exposure in the asciminib group was 410.6 patient-treatment year (PTY) vs. 353.6 PTY in the IS-TKI group. Within the IS-TKI group, the median duration of exposure was 100.29 weeks for imatinib and 115.57 weeks for 2G TKI; and the total exposure was 151.1 PTY for imatinib and 202.5 PTY for 2G TKI, Table 1-4. The enrolment for 2G TKI group was completed on 22-Sep-2022, and between 22-Sep-2022 and 21-Dec-2022 and 48 participants were enrolled in imatinib group to complete enrolment of 405 participant in the study. The difference in the duration of exposure between imatinib and 2G TKI can be attributed in part to the

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

recruitment dynamics, the 2G TKI stratum was closed earlier by approximately 3 months than the imatinib stratum, as well as the higher proportion of treatment discontinuations in imatinib compared to the 2G TKI.

In the All Asciminib Safety Pool, the median (min-max) duration of exposure was 123.29 weeks (0.1 to 439.0 weeks) and the total exposure to asciminib was 1558.6 PTY.

Table 58 Duration of exposure to study drug - Safety set

|                               |                |               | Study J12301        | Study J12301              | Study J12301              | Study J12301              | SafetyPool          |
|-------------------------------|----------------|---------------|---------------------|---------------------------|---------------------------|---------------------------|---------------------|
|                               |                | Asciminib     |                     | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI |                     |
|                               | Imatinib N=100 | 2G TKI N=100  | AIl Asciminib N=200 | Imatinib N=99             | 2G TKI N=102              | AIl Comparators N=201     | All Asciminib N=556 |
| Duration of exposure-weeks    |                |               |                     |                           |                           |                           |                     |
| Mean (SD)                     | 100.6 (34.7)   | 113.6 (32.8)  | 107.1 (34.3)        | 79.7 (41.4)               | 103.6 (37.7)              | 91.8 (41.2)               | 146.3 (108.2)       |
| Median                        | 107.50         | 121.07        | 115.79              | 100.29                    | 115.57                    | 108.71                    | 123.29              |
| Q1-Q3                         | 99.86-121.29   | 111.07-133.00 | 102.57-129.43       | 42.57-111.29              | 86.00-128.29              | 59.71-122.14              | 64.43-195.64        |
| Min-Max                       | 0.7-154.7      | 5.9-152.1     | 0.7-154.7           | 2.7-146.0                 | 1.3-150.1                 | 1.3-150.1                 | 0.1-439.0           |
| Durationofexposure-categories |                |               |                     |                           |                           |                           |                     |
| <8weeks                       | 4 (4.0)        | 1 (1.0)       | 5 (2.5)             | 5 (5.1)                   | 3 (2.9)                   | 8 (4.0)                   | 29 (5.2)            |
| 8-<16 weeks                   | 2 (2.0)        | 1 (1.0)       | 3 (1.5)             | 1 (1.0)                   | 3 (2.9)                   | 4 (2.0)                   | 14 (2.5)            |
| 16-<24weeks                   | 2 (2.0)        | 3 (3.0)       | 5 (2.5)             | 8 (8.1)                   | 2 (2.0)                   | 10 (5.0)                  | 27 (4.9)            |
| 24 - < 48 weeks               | 4 (4.0)        | 3 (3.0)       | 7 (3.5)             | 13 (13.1)                 | 4 (3.9)                   | 17 (8.5)                  | 45 (8.1)            |
| 48 -<96 weeks                 | 5 (5.0)        | 8 (8.0)       | 13 (6.5)            | 17 (17.2)                 | 16 (15.7)                 | 33 (16.4)                 | 47 (8.5)            |
| 96 -< 144 weeks               | 82 (82.0)      | 80 (80.0)     | 162 (81.0)          | 54 (54.5)                 | 69 (67.6)                 | 123 (61.2)                | 183 (32.9)          |
| 144 - < 192 weeks             | 1 (1.0)        | 4 (4.0)       | 5 (2.5)             | 1 (1.0)                   | 5 (4.9)                   | 6 (3.0)                   | 69 (12.4)           |
| ≥192 weeks                    | 0              | 0             | 0                   | 0                         | 0                         | 0                         | 142 (25.5)          |
| Patient-Treatment-Year        | 192.9          | 217.8         | 410.6               | 151.1                     | 202.5                     | 353.6                     | 1558.6              |

PTY is the sum of each participant's treatment exposure in year. Source:1LSCSAppendix2-Table 1-2

## Relative dose intensity

In study J12301 the planned dose for asciminib group was 80 mg QD for the IS-TKI group, the planned doses were 400 mg QD for imatinib, 300 mg BID for nilotinib, 100 mg QD for dasatinib, and 400 mg QD for bosutinib. The median RDI was 100.0% (range: 49.9% - 100.4%) in the asciminib group and 99.3% (range: 24.3% - 100.1%) in the IS-TKI group. Overall, 87.0% of participants in the asciminib group had the RDI &gt; 90 to 110% compared to 74.1% in the IS- TKI group (ranging from 45.5% to 79.8%); a smaller proportion of participants received treatment with bosutinib (11 participants for bosutinib vs. 42 for dasatinib vs. 49 for nilotinib, and 99 for imatinib).

## Patient disposition

As of the Week 96 data cut-off (22-Oct-2024) in study J12301, a higher proportion of participants were still on treatment in the asciminib group (81.6%) compared to IS-TKI group (60.3%). The proportion of participants who discontinued study treatment was lower in the asciminib group compared to the IS-TKI group, overall (17.9% vs. 38.2%) as well as for individual reasons, including mainly unsatisfactory therapeutic effect (9.5% vs. 20.6%) and AEs (6.0% vs. 12.7%), other individual reasons for discontinuatio n were each reported in ≤ 2.0% of participants. Among the participants who discontinued treatment due to unsatisfactory therapeutic effect, the most frequent reasons were treatment failure per ELN criteria 2020 (5.0% vs 13.7%), followed by other (2.5% vs 5.4%) and confirmed loss of MMR (2.0% vs 1.5%).

Time to discontinuation of study treatment (TTDAE) due to AE was a secondary objective in study J12301 assessed by cause-specific hazard analysis. The risk of study treatment discontinuation due to AEs at week 96 was d statistically significantly lower in the asciminib group compared to 2G TKI

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

(TTDAE, HR = 0.463; 95% CI: 0.215, 0.997; adjusted one sided p-value: 0.0246) and numerically lower compared to the imatinib group (HR = 0.381; 95% CI: 0.178, 0.818).

## Adverse events

Overall, the incidence of AEs was comparable between the asciminib and IS-TKI groups (95.5% vs. 98.0%). Grade ≥ 3 AEs occurred at a lower frequency in the asciminib group compared to the IS -TKI group (44.5% vs. 54.7%). SAEs and treatment-related AEs also occurred at a lower frequency in the asciminib group compared to the IS-TKI group, whereas and AEs requiring additional therapy occurred at a similar frequency in both groups ( Table 59 ).

The incidence of AEs leading to study treatment discontinuation (5.0% vs. 13.1%) and AEs leading to dose adjustment and/or interruption (33.0% vs. 41.4%) was lower in the asciminib-/ compared to the imatinib group and to the 2G TKI group (discontinuation: 5.0 % vs.  12.7%; adjustment/interruption: 33.0% vs. 57.8%).

Table 59 Overview of adverse events - Safety set

Table 2-1 Overviewofadverseevents-Safetyset

|                                          |                   |                | Study J12301      | Study J12301   | Study J12301     | Study J12301   | Study J12301     | Study J12301   | Study J12301                    | Study J12301                    | Study J12301          | Study J12301          | Safety Pool          | Safety Pool          |
|------------------------------------------|-------------------|----------------|-------------------|----------------|------------------|----------------|------------------|----------------|---------------------------------|---------------------------------|-----------------------|-----------------------|----------------------|----------------------|
|                                          |                   |                | Asciminib         | Asciminib      | All Asciminib    | All Asciminib  | Imatinib         | Imatinib       | InvestigatorSelected TKI 2G TKI | InvestigatorSelected TKI 2G TKI | All Comparators N=201 | All Comparators N=201 | AlIl Asciminib N=556 | AlIl Asciminib N=556 |
| Category                                 | AlIl grades n (%) | Grade ≥3 n (%) | AlIl grades n (%) | Grade ≥3 n (%) | AIl grades n (%) | Grade ≥3 n (%) | All grades n (%) | Grade ≥3 n (%) | All grades n (%)                | Grade ≥3 n (%)                  | AIl grades n (%)      | Grade ≥3 n (%)        | AlIl grades n (%)    | Grade ≥3 n (%)       |
| Adverseevents                            | 97 (97.0)         | 48 (48.0)      | 94 (94.0)         | 41 (41.0)      | 191 (95.5)       | 89 (44.5)      | 95 (96.0)        | 49 (49.5)      | 102 (100)                       | 61 (59.8)                       | 197 (98.0)            | 110 (54.7)            | 533 (95.9)           | 324 (58.3)           |
| Treatment-related                        | 77 (77.0)         | 29 (29.0)      | 79 (79.0)         | 27 (27.0)      | 156 (78.0)       | 56 (28.0)      | 84 (84.8)        | 35 (35.4)      | 98 (96.1)                       | 46 (45.1)                       | 182 (90.5)            | 81 (40.3)             | 440 (79.1)           | 207 (37.2)           |
| SAEs                                     | 18 (18.0)         | 14 (14.0)      | 11 (11.0)         | 9 (9.0)        | 29 (14.5)        | 23 (11.5)      | 16 (16.2)        | 14 (14.1)      | 25 (24.5)                       | 18 (17.6)                       | 41 (20.4)             | 32 (15.9)             | 159 (28.6)           | 125 (22.5)           |
| Treatment-related                        | 4 (4.0)           | 3 (3.0)        | 4 (4.0)           | 4 (4.0)        | 8 (4.0)          | 7 (3.5)        | 4 (4.0)          | 3 (3.0)        | 9 (8.8)                         | 7 (6.9)                         | 13 (6.5)              | 10 (5.0)              | 37 (6.7)             | 30 (5.4)             |
| Fatal SAEs                               | 0                 | 0              | 0                 | 0              | 0                | 0              | 0                | 0              | 0                               | 0                               | 0                     | 0                     | 11 (2.0)             | 11 (2.0)             |
| Treatment-related                        | 0                 | 0              | 0                 | 0              | 0                | 0              | 0                | 0              | 0                               | 0                               | 0                     | 0                     | 1 (0.2)              | 1 (0.2)              |
| AEs leading to discontinuation           | 6 (6.0)           | 3 (3.0)        | 4 (4.0)           | 3 (3.0)        | 10 (5.0)         | 6 (3.0)        | 13 (13.1)        | 7 (7.1)        | 13 (12.7)                       | 5 (4.9)                         | 26 (12.9)             | 12 (6.0)              | 48 (8.6)             | 38 (6.8)             |
| Treatment-related                        | 5 (5.0)           | 3 (3.0)        | 3 (3.0)           | 2 (2.0)        | 8 (4.0)          | 5 (2.5)        | 11 (11.1)        | 6 (6.1)        | 13 (12.7)                       | 5 (4.9)                         | 24 (11.9)             | 11 (5.5)              | 32 (5.8)             | 26 (4.7)             |
| AEsleadingtodose adjustment/interruption | 33 (33.0)         | 28 (28.0)      | 33 (33.0)         | 27 (27.0)      | 66 (33.0)        | 55 (27.5)      | 41 (41.4)        | 25 (25.3)      | 59 (57.8)                       | 39 (38.2)                       | 100 (49.8)            | 64 (31.8)             | 241 (43.3)           | 198 (35.6)           |
| AEsrequiring additional therapy          | 83 (83.0)         | 26 (26.0)      | 85 (85.0)         | 25 (25.0)      | 168 (84.0)       | 51 (25.5)      | 83 (83.8)        | 20 (20.2)      | 93 (91.2)                       | 33 (32.4)                       | 176 (87.6)            | 53 (26.4)             | 460 (82.7)           | 214 (38.5)           |

A participant with multiple severity grades for an AE is only counted under the maximum grade. MedDRA version 27.1, CTCAE version 5.0. Source:1LSCSAppendix2-Table2-1

## Exposure-adjusted incidence rate of AEs

The EAIR of AEs per 100 PTY in the asciminib treatment group was lower compared to the IS- TKI treatment group (484.6 vs.1106.6), including compared to imatinib (484.6 vs. 711.5) and compared to 2G TKI (484.6 vs. 2292.6).

## Adverse events by system organ class (SOC)

SOC where events were reported less frequently in the asciminib group (and with a ≥ 10% difference compared to IS-TKI group) included blood and lymphatic system disorders (31.5% vs. 42.8%). Vascular disorders AEs were reported more frequently in the asciminib group and with a ≥ 5% difference compared to the IS-TKI group (16.5% vs. 8.5%), and the difference was mainly due to hy pertension (21 participants, 10.5% vs. 10 participants, 5.0%). There was no SOC where grade ≥ 3 events were reported more frequently (with a ≥ 5% difference) in the asciminib group compared to the ISTKI group. The SOCs where grade ≥ 3 events were reported less frequently in the asciminib group

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

compared to the IS-TKI group included blood and lymphatic system disorders (10.5% vs. 18.4%). In comparison to the imatinib group, in the asciminib group, general disorders and administration site conditions (33.5% vs. 46.5%) and eye disorders (15.5% vs. 34.3%) were reported less frequently, while grade ≥ 3 events vascular disorders were reported more frequently (7.0% vs. 2.0%). In comparison to 2G-TKI, the SOC vascular disorders was reported more frequently in the asciminib group (16.5% vs. 7.8%), with the difference mainly due to hypertension (10.5% vs. 4.9%). SOC events less frequently reported included infections and infestations (54.0% vs. 64.7%), investigations (47.0% vs. 66.7%), gastrointestinal disorders' (45.5% vs. 60.8%), skin and subcutaneous tissue disorders (39.5% vs. 52.9%), blood and lymphatic system disorders (31.5% vs. 48.0%), respiratory, thoracic and mediastinal disorders (18.0% vs. 31.4%) and cardiac disorders (4.5% vs. 15.7%). The SOCs where grade ≥ 3 events were reported less frequently (with a ≥ 5%) in the asciminib group difference compared to the 2G TKI group included blood and lymphatic system disorders (10.5% vs. 22.5%) and investigations (19.5% vs. 27.5%).

## Table 60 Adverse events by system organ class- Safety set

|                                                 |            |           |                  |                  | Study J12301   | Study J12301   | Study J12301   | Study J12301   |              |              |                       |                       | Safety Pool         | Safety Pool         |
|-------------------------------------------------|------------|-----------|------------------|------------------|----------------|----------------|----------------|----------------|--------------|--------------|-----------------------|-----------------------|---------------------|---------------------|
|                                                 |            |           | Asciminib 2G TKI | Asciminib 2G TKI | All Asciminib  | All Asciminib  | Imatinib       | Imatinib       | 2G TKI N=102 | 2G TKI N=102 | All Comparators N=201 | All Comparators N=201 | AIl Asciminib N=556 | AIl Asciminib N=556 |
|                                                 | AIl grades | Grade ≥3  | AlI grades       | Grade ≥3         | All grades     | Grade ≥3       | AlI grades     | Grade ≥3       | All grades   | Grade ≥3     | All grades            | Grade ≥3              | AIl grades          | Grade ≥3            |
| Primary system organ                            | n (%)      |           |                  |                  |                |                |                |                |              |              |                       |                       |                     |                     |
| class                                           |            | n (%)     | n (%)            | n (%)            | n (%)          | n (%)          | n (%)          | n (%)          | n (%)        | n (%)        | n (%)                 | n (%)                 | n (%)               | n (%)               |
| At least one event                              | 97 (97.0)  | 48 (48.0) | 94 (94.0)        | 41 (41.0)        | 191 (95.5)     | 89 (44.5)      | 95 (96.0)      | 49 (49.5)      | 102 (100)    | 61 (59.8)    | 197 (98.0)            | 110 (54.7)            | 533 (95.9)          | 324 (58.3)          |
| Infections and infestations                     | 50 (50.0)  | 3 (3.0)   | 58 (58.0)        | 5 (5.0)          | 108 (54.0)     | 8 (4.0)        | 52 (52.5)      | 6 (6.1)        | 66 (64.7)    | 7 (6.9)      | 118 (58.7)            | 13 (6.5)              | 324 (58.3)          | 49 (8.8)            |
| Gastrointestinal disorders                      | 43 (43.0)  | 1 (1.0)   | 48 (48.0)        | 2 (2.0)          | 91 (45.5)      | 3 (1.5)        | 49 (49.5)      | 3 (3.0)        | 62 (60.8)    | 6 (5.9)      | 111 (55.2)            | 9 (4.5)               | 297 (53.4)          | 34 (6.1)            |
| Investigations                                  | 47 (47.0)  | 20 (20.0) | 47 (47.0)        | 19 (19.0)        | 94 (47.0)      | 39 (19.5)      | 45 (45.5)      | 19 (19.2)      | 68 (66.7)    | 28 (27.5)    | 113 (56.2)            | 47 (23.4)             | 284 (51.1)          | 131 (23.6)          |
| Musculoskeletal and connective tissue disorders | 42 (42.0)  | 7 (7.0)   | 34 (34.0)        | 3 (3.0)          | 76 (38.0)      | 10 (5.0)       | 46 (46.5)      | 3 (3.0)        | 45 (44.1)    | 1 (1.0)      | 91 (45.3)             | 4 (2.0)               | 266 (47.8)          | 35 (6.3)            |
| Skin and subcutaneous tissue disorders          | 40 (40.0)  | 0         | 39 (39.0)        | 0                | 79 (39.5)      | 0              | 31 (31.3)      | 2 (2.0)        | 54 (52.9)    | 2 (2.0)      | 85 (42.3)             | 4 (2.0)               | 251 (45.1)          | 3 (0.5)             |
| General disorders and administration site       | 30 (30.0)  | 1 (1.0)   | 37 (37.0)        | 1 (1.0)          | 67 (33.5)      | 2 (1.0)        | 46 (46.5)      | 3 (3.0)        | 41 (40.2)    | 1 (1.0)      | 87 (43.3)             | 4 (2.0)               | 235 (42.3)          | 25 (4.5)            |
| Nervous system disorders                        | 32 (32.0)  | 3 (3.0)   | 24 (24.0)        | 3 (3.0)          | 56 (28.0)      | 6 (3.0)        | 20 (20.2)      | 1 (1.0)        | 37 (36.3)    | 1 (1.0)      | 57 (28.4)             | 2 (1.0)               | 230 (41.4)          | 32 (5.8)            |
| Blood and lymphatic system disorders            | 30 (30.0)  | 13 (13.0) | 33 (33.0)        | 8 (8.0)          | 63 (31.5)      | 21 (10.5)      | 37 (37.4)      | 14 (14.1)      | 49 (48.0)    | 23 (22.5)    | 86 (42.8)             | 37 (18.4)             | 192 (34.5)          | 99 (17.8)           |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                 |                |                | Asciminib    |              | Study J12301        | Study J12301        | Study J12301   | Study J12301   |              |              |                       |                       | Safety Pool          | Safety Pool          |
|-------------------------------------------------|----------------|----------------|--------------|--------------|---------------------|---------------------|----------------|----------------|--------------|--------------|-----------------------|-----------------------|----------------------|----------------------|
|                                                 | Imatinib N=100 | Imatinib N=100 | 2G TKI N=100 | 2G TKI N=100 | AIl Asciminib N=200 | AIl Asciminib N=200 | Imatinib N=99  | Imatinib N=99  | 2G TKI N=102 | 2G TKI N=102 | All Comparators N=201 | All Comparators N=201 | AlII Asciminib N=556 | AlII Asciminib N=556 |
|                                                 | All grades     | Grade ≥3       | AIl grades   | Grade ≥3     | AIl grades          | Grade ≥3            | AlIl grades    | Grade ≥3       | AIl grades   | Grade ≥3     | AlIl grades           | Grade ≥3              | All grades           | Grade ≥3             |
| Primary system organ class                      | n (%)          | n (%)          | n (%)        | n (%)        | n (%)               | n (%)               | n (%)          | n (%)          | n (%)        | n (%)        | n (%)                 | n (%)                 | n (%)                | n (%)                |
| Respiratory, thoracic and mediastinal disorders | 17 (17.0)      | 1 (1.0)        | 19 (19.0)    | 0            | 36 (18.0)           | 1 (0.5)             | 15 (15.2)      | 1 (1.0)        | 32 (31.4)    | 3 (2.9)      | 47 (23.4)             | 4 (2.0)               | 177 (31.8)           | 17 (3.1)             |
| Metabolismandnutrition disorders                | 30 (30.0)      | 4 (4.0)        | 27 (27.0)    | 2 (2.0)      | 57 (28.5)           | 6 (3.0)             | 26 (26.3)      | 4 (4.0)        | 32 (31.4)    | 2 (2.0)      | 58 (28.9)             | 6 (3.0)               | 182 (32.7)           | 45 (8.1)             |
| Vascular disorders                              | 19 (19.0)      | 8 (8.0)        | 14 (14.0)    | 6 (6.0)      | 33 (16.5)           | 14 (7.0)            | 9 (9.1)        | 2 (2.0)        | 8 (7.8)      | 5 (4.9)      | 17 (8.5)              | 7 (3.5)               | 138 (24.8)           | 68 (12.2)            |
| Eye disorders                                   | 11 (11.0)      | 1 (1.0)        | 20 (20.0)    | 1 (1.0)      | 31 (15.5)           | 2 (1.0)             | 34 (34.3)      | 0              | 15 (14.7)    | 1 (1.0)      | 49 (24.4)             | 1 (0.5)               | 119 (21.4)           | 10 (1.8)             |
| Injury, poisoning and procedural complications  | 6 (6.0)        | 1 (1.0)        | 14 (14.0)    | 2 (2.0)      | 20 (10.0)           | 3 (1.5)             | 5 (5.1)        | 0              | 12 (11.8)    | 0            | 17 (8.5)              | 0                     | 108 (19.4)           | 17 (3.1)             |
| Psychiatric disorders                           | 11 (11.0)      | 1 (1.0)        | 11 (11.0)    | 0            | 22 (11.0)           | 1 (0.5)             | 7 (7.1)        | 0              | 11 (10.8)    | 0            | 18 (9.0)              | 0                     | 101 (18.2)           | 9 (1.6)              |
| Cardiac disorders                               | 6 (6.0)        | 0              | 3 (3.0)      | 0            | 9 (4.5)             | 0                   | 4 (4.0)        | 1 (1.0)        | 16 (15.7)    | 3 (2.9)      | 20 (10.0)             | 4 (2.0)               | 79 (14.2)            | 24 (4.3)             |
| Reproductive system and breast disorders        | 9 (9.0)        | 0              | 10 (10.0)    | 0            | 19 (9.5)            | 0                   | 4 (4.0)        | 0              | 12 (11.8)    | 2 (2.0)      | 16 (8.0)              | 2 (1.0)               | 59 (10.6)            | 0                    |
| Renal and urinary disorders                     | 5 (5.0)        | 0              | 2 (2.0)      | 0            | 7 (3.5)             | 0                   | 6 (6.1)        | 0              | 8 (7.8)      | 1 (1.0)      | 14 (7.0)              | 1 (0.5)               | 49 (8.8)             | 9 (1.6)              |
| Ear and labyrinth disorders                     | 4 (4.0)        | 0              | 1 (1.0)      | 0            | 5 (2.5)             | 0                   | 7 (7.1)        | 1 (1.0)        | 9 (8.8)      | 0            | 16 (8.0)              | 1 (0.5)               | 39 (7.0)             | 1 (0.2)              |

|                                                                     |            |          |             |           | Study J12301   | Study J12301   | Study J12301   | Study J12301   |                                           |                                           |                       |                       | Safety Pool         | Safety Pool         |
|---------------------------------------------------------------------|------------|----------|-------------|-----------|----------------|----------------|----------------|----------------|-------------------------------------------|-------------------------------------------|-----------------------|-----------------------|---------------------|---------------------|
|                                                                     |            |          | Asciminib   | Asciminib |                |                |                |                | Investigator Selected TKI Imatinib 2G TKI | Investigator Selected TKI Imatinib 2G TKI | All Comparators N=201 | All Comparators N=201 | AII Asciminib N=556 | AII Asciminib N=556 |
|                                                                     | All grades | Grade ≥3 | AlIl grades | Grade ≥3  | AlI grades     | Grade ≥3       | AIl grades     | Grade ≥3       | AIl grades                                | Grade ≥3                                  | AlIl grades           | Grade ≥3              | AlI grades          | Grade ≥3            |
| Primary system organ class                                          | n (%)      | n (%)    | n (%)       | n (%)     | n (%)          | n (%)          | n (%)          | n (%)          | n (%)                                     | n (%)                                     | n (%)                 | n (%)                 | n (%)               | n (%)               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 (2.0)    | 0        | 4 (4.0)     | 1 (1.0)   | 6 (3.0)        | 1 (0.5)        | 7 (7.1)        | 2 (2.0)        | 8 (7.8)                                   | 2 (2.0)                                   | 15 (7.5)              | 4 (2.0)               | 32 (5.8)            | 9 (1.6)             |
| Hepatobiliary disorders                                             | 8 (8.0)    | 2 (2.0)  | 7 (7.0)     | 1 (1.0)   | 15 (7.5)       | 3 (1.5)        | 3 (3.0)        | 1 (1.0)        | 5 (4.9)                                   | 1 (1.0)                                   | 8 (4.0)               | 2 (1.0)               | 34 (6.1)            | 8 (1.4)             |
| Endocrine disorders                                                 | 1 (1.0)    | 0        | 4 (4.0)     | 0         | 5 (2.5)        | 0              | 3 (3.0)        | 0              | 0                                         | 0                                         | 3 (1.5)               | 0                     | 13 (2.3)            | 0                   |
| Immune system disorders                                             | 0          | 0        | 0           | 0         | 0              | 0              | 2 (2.0)        | 0              | 2 (2.0)                                   | 0                                         | 4 (2.0)               | 0                     | 10 (1.8)            | 1 (0.2)             |
| Pregnancy, puerperium and perinatal conditions                      | 0          | 0        | 0           | 0         | 0              | 0              | 0              | 0              | 0                                         | 0                                         | 0                     | 0                     | 4 (0.7)             | 2 (0.4)             |
| Product issues                                                      | 1 (1.0)    | 1 (1.0)  | 0           | 0         | 1 (0.5)        | 1 (0.5)        | 0              | 0              | 0                                         | 0                                         | 0                     | 0                     | 4 (0.7)             | 2 (0.4)             |
| Congenital, familial and genetic disorders                          | 0          | 0        | 0           | 0         | 0              |                | 1 (1.0)        | 0              | 0                                         | 0                                         | 1 (0.5)               | 0                     | 1 (0.2)             | 0                   |

A participant with multiple severity grades for an AE is only counted under the maximum grade. MedDRA version 27.1, CTCAE version 5.0. Source:1LSCSAppendix2-Table2-2.1

## Adverse events by preferred term (PT)

AEs that were reported more frequently (with ≥ 5% difference) in the asciminib group compared to imatinib included abdominal pain (11.0% vs. 3.0%) headache (16.5% vs. 9.1%) constipation (10.0% vs. 4.0%) and hypertension (10.5% vs. 5.1%) pruritus (9.5% vs. 4.0%) and dry skin (6.0% vs. 1.0%). Less frequently reported in the asciminib arm compared to imatinib was diarrhea (17.5% vs. 28.3%), anemia (12.5% vs. 26.3%), WBC count decreased (11.0% vs. 17.2%), neutropenia (10.5% vs. 16.2%), nausea (9.5% vs. 21.2%), Blood ALP increased (6.0% vs. 13.1%), vomiting (7.0% vs. 13.1%), back pain (6.0% vs. 12.1%), lymphocyte count decreased (5.0% vs. 13.1%), muscle spasms (3.0% vs. 19.2%), edema peripheral (1.5% vs. 7.1%), periorbital edema (1.0% vs. 11.1%), hypokalemia (0.5% vs. 6.1%), hypophosphatemia (0.5% vs. 9.1%), eyelid edema (0% vs. 8.1%) and face edema (0% vs. 10.1%). There were no grade ≥ 3 AEs reported more frequently (with a ≥ 5%

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

difference) in the asciminib group compared to the imatinib. Grade ≥ 3 AEs reported less frequently in asciminib group compared to imatinib included neutropenia (4.5% vs. 11.1%).

In comparison to 2G-TKI, AEs that were reported more frequently in the asciminib group compared to 2G TKI (with ≥ 5% difference) included hypertension (10.5% vs. 4.9%). AEs that were reported less frequently (with ≥ 5% difference) in the asciminib group compared to 2G TKI includ ed diarrhoea (17.5% vs. 27.5%), neutrophil count decreased (15.0% vs. 20.6%), headache (16.5% vs. 23.5%), rash (14.5% vs. 23.5%), anaemia (12.5% vs. 25.5%), neutropenia (10.5% vs. 16.7%), nausea (9.5% vs. 18.6%), ALT increased (8.5% vs. 20.6%), AST increased (3.0% vs. 15.7%), blood bilirubin increased (4.0% vs. 10.8%), cough (6.0% vs. 12.7%), alopecia (2.5% vs. 8.8%), influenza like illness (2.5% vs. 9.8%), dyspnoea (1.0% vs. 6.9%) and pleural effusion (0% vs. 9.8%). There were no grade ≥ 3 AEs reported more frequently (with a ≥ 5% difference) in the asciminib group compared to the 2GTKI. Grade ≥ 3 AEs reported less frequently in the asciminib group compared to the 2G -TKI included neutropenia (4.5% vs. 9.8%) and ALT increased (2.0% vs. 7.8%, Table 61 ).

Table 61 AEs by preferred term (≥ 10% in Safety Pool All asciminib) - Safety set

|                    |                  |                | Asciminib         |                | Study J12301     | Study J12301   | Study J12301     | Study J12301   | Study J12301     | Study J12301   | Study J12301          | Study J12301          | SafetyPool          | SafetyPool          |
|--------------------|------------------|----------------|-------------------|----------------|------------------|----------------|------------------|----------------|------------------|----------------|-----------------------|-----------------------|---------------------|---------------------|
|                    | Imatinib         | Imatinib       | 2G TKI            | 2G TKI         | AIl Asciminib    | AIl Asciminib  | Imatinib         | Imatinib       | 2G TKI           | 2G TKI         | AIl Comparators N=201 | AIl Comparators N=201 | All Asciminib N=556 | All Asciminib N=556 |
| PreferredTerm      | AIl grades n (%) | Grade ≥3 n (%) | AlIl grades n (%) | Grade ≥3 n (%) | AIl grades n (%) | Grade ≥3 n (%) | AIl grades n (%) | Grade ≥3 n (%) | AIl grades n (%) | Grade ≥3 n (%) | AIl grades n (%)      | Grade 3 n (%)         | AIl grades n (%)    | Grade ≥3 n (%)      |
| At least one event | 97 (97.0)        | 48 (48.0)      | 94 (94.0)         | 41 (41.0)      | 191 (95.5)       | 89 (44.5)      | 95 (96.0)        | 49 (49.5)      | 102 (100)        | 61 (59.8)      | 197 (98.0)            | 110 (54.7)            | 533 (95.9)          | 324 (58.3)          |
| Headache           | 18 (18.0)        | 1 (1.0)        | 15 (15.0)         | 0              | 33 (16.5)        | 1 (0.5)        | 9 (9.1)          | 0              | 24 (23.5)        | 0              | 33 (16.4)             | 0                     | 127 (22.8)          | 8 (1.4)             |
| Fatigue            | 15 (15.0)        | 0              | 15 (15.0)         | 1 (1.0)        | 30 (15.0)        | 1 (0.5)        | 15 (15.2)        | 1 (1.0)        | 20 (19.6)        | 0              | 35 (17.4)             | 1 (0.5)               | 116 (20.9)          | 6 (1.1)             |
| Arthralgia         | 16 (16.0)        | 3 (3.0)        | 10 (10.0)         | 1 (1.0)        | 26 (13.0)        | 4 (2.0)        | 10 (10.1)        | 1 (1.0)        | 9 (8.8)          | 0              | 19 (9.5)              | 1 (0.5)               | 115 (20.7)          | 9 (1.6)             |
| Diawhaea           | 14 (14.0)        | 0              | 21 (21.0)         | 0              | 35 (17.5)        | 0              | 28 (28.3)        | 0              | 28 (27.5)        | 2 (2.0)        | 56 (27.9)             | 2 (1.0)               | 115 (20.7)          | 2 (0.4)             |
| Thrombocytopenia   | 15 (15.0)        | 9 (9.0)        | 12 (12.0)         | 7 (7.0)        | 27 (13.5)        | 16 (8.0)       | 14 (14.1)        | 4 (4.0)        | 17 (16.7)        | 7 (6.9)        | 31 (15.4)             | 11 (5.5)              | 109 (19.6)          | 70 (12.6)           |
| COVID-19           | 13 (13.0)        | 0              | 30 (30.0)         | 0              | 43 (21.5)        | 0              | 20 (20.2)        | 0              | 24 (23.5)        | 1 (1.0)        | 44 (21.9)             | 1 (0.5)               | 103 (18.5)          | 5 (0.9)             |
| Lipase increased   | 20 (20.0)        | 6 (6.0)        | 7 (7.0)           | 0              | 27 (13.5)        | 6 (3.0)        | 15 (15.2)        | 2 (2.0)        | 15 (14.7)        | 5 (4.9)        | 30 (14.9)             | 7 (3.5)               | 96 (17.3)           | 48 (8.6)            |
| Hypertension       | 14 (14.0)        | 8 (8.0)        | 7 (7.0)           | 3 (3.0)        | 21 (10.5)        | 11 (5.5)       | 5 (5.1)          | 2 (2.0)        | 5 (4.9)          | 5 (4.9)        | 10 (5.0)              | 7 (3.5)               | 94 (16.9)           | 51 (9.2)            |
| Nausea             | 8 (8.0)          | 0              | 11                | 0              | 19 (9.5)         | 0              | 21 (21.2)        | 0              | 19               | 0              | 40 (19.9)             | 0                     | 93 (16.7)           | 3 (0.5)             |

(11.0)

(18.6)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                   |                |                | Asciminib        |                | Study J12301        | Study J12301        | Study J12301      | Study J12301   |                  |               |                       |                       | Safety Pool         | Safety Pool         |
|-----------------------------------|----------------|----------------|------------------|----------------|---------------------|---------------------|-------------------|----------------|------------------|---------------|-----------------------|-----------------------|---------------------|---------------------|
|                                   | Imatinib N=100 | Imatinib N=100 | 2G TKI N=100     | 2G TKI N=100   | AlI Asciminib N=200 | AlI Asciminib N=200 | Imatinib N=99     | Imatinib N=99  | 2G TKI N=102     | 2G TKI N=102  | All Comparators N=201 | All Comparators N=201 | All Asciminib N=556 | All Asciminib N=556 |
|                                   | All grades     | Grade ≥3       | All grades n (%) | Grade ≥3 n (%) | All grades n (%)    | Grade ≥3 n (%)      | AlIl grades n (%) | Grade ≥3 n (%) | AlI grades n (%) | Grade 3 n (%) | AIl grades n (%)      | Grade ≥3 n (%)        | All grades n (%)    | Grade ≥3 n (%)      |
| PreferredTerm Rash                | n (%) 9 (9.0)  | n (%) 0        | 20 (20.0)        | 0              | 29 (14.5)           | 0                   | 11 (11.1)         | 2 (2.0)        | 24 (23.5)        | 1 (1.0)       | 35 (17.4)             | 3 (1.5)               | 88 (15.8)           | 0                   |
| Vomiting                          | 6 (6.0)        | 0              | 8 (8.0)          | 0              | 14 (7.0)            | 0                   | 13 (13.1)         | 0              | 7 (6.9)          | 0             | 20 (10.0)             | 0                     | 78 (14.0)           | 8 (1.4)             |
| Neutropenia                       | 12 (12.0)      | 5 (5.0)        | 9 (9.0)          | 4 (4.0)        | 21 (10.5)           | 9 (4.5)             | 16 (16.2)         | 11 (11.1)      | 17 (16.7)        | 10 (9.8)      | 33 (16.4)             | 21 (10.4)             | 77 (13.8)           | 51 (9.2)            |
| Abdominal pain                    | 11 (11.0)      | 0              | 11 (11.0)        | 1 (1.0)        | 22 (11.0)           | 1 (0.5)             | 3 (3.0)           | 0              | 11 (10.8)        | 1 (1.0)       | 14 (7.0)              | 1 (0.5)               | 76 (13.7)           | 6 (1.1)             |
| Myalgia                           | 15 (15.0)      | 0              | 16 (16.0)        | 1 (1.0)        | 31 (15.5)           | 1 (0.5)             | 18 (18.2)         | 0              | 17 (16.7)        | 0             | 35 (17.4)             | 0                     | 75 (13.5)           | 5 (0.9)             |
| Anaemia                           | 11 (11.0)      | 1 (1.0)        | 14 (14.0)        | 3 (3.0)        | 25 (12.5)           | 4 (2.0)             | 26 (26.3)         | 5 (5.1)        | 26 (25.5)        | 7 (6.9)       | 52 (25.9)             | 12 (6.0)              | 70 (12.6)           | 23 (4.1)            |
| Cough                             | 4 (4.0)        | 0              | 8 (8.0)          | 0              | 12 (6.0)            | 0                   | 7 (7.1)           | 0              | 13 (12.7)        | 0             | 20 (10.0)             | 0                     | 67 (12.1)           | 0                   |
| Upper respiratory tract infection | 9 (9.0)        | 0              | 8 (8.0)          | 0              | 17 (8.5)            | 0                   | 12 (12.1)         | 1 (1.0)        | 11 (10.8)        | 0             | 23 (11.4)             | 1 (0.5)               | 67 (12.1)           | 2 (0.4)             |
| Pruritus                          | 9 (9.0)        | 0              | 10 (10.0)        | 0              | 19 (9.5)            | 0                   | 4 (4.0)           | 0              | 5 (4.9)          | 0             | 9 (4.5)               | 0                     | 64 (11.5)           | 1 (0.2)             |
| Constipation                      | 9 (9.0)        | 0              | 11 (11.0)        | 0              | 20 (10.0)           | 0                   | 4 (4.0)           | 0              | 14 (13.7)        | 1 (1.0)       | 18 (9.0)              | 1 (0.5)               | 63 (11.3)           | 1 (0.2)             |
| Dizziness                         | 4 (4.0)        | 0              | 5 (5.0)          | 0              | 9 (4.5)             | 0                   | 2 (2.0)           | 0              | 7 (6.9)          | 0             | 9 (4.5)               | 0                     | 62 (11.2)           | 1 (0.2)             |
| Pain in extremity                 | 7 (7.0)        | 1 (1.0)        | 3 (3.0)          | 0              | 10 (5.0)            | 1 (0.5)             | 6 (6.1)           | 0              | 5 (4.9)          | 0             | 11 (5.5)              | 0                     | 61 (11.0)           | 3 (0.5)             |

|                                    |                           |                     |                  |                     | Study J12301           | Study J12301   | Study J12301     | Study J12301            |                         |                         |                         |                |                        | Safety Pool    |
|------------------------------------|---------------------------|---------------------|------------------|---------------------|------------------------|----------------|------------------|-------------------------|-------------------------|-------------------------|-------------------------|----------------|------------------------|----------------|
|                                    |                           |                     | Asciminib        | Asciminib           | All                    |                |                  | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI |                |                        |                |
| PreferredTerm                      | Imatinib AIl grades n (%) | N=100 Grade 3 n (%) | All grades n (%) | N=100 Grade 3 n (%) | N=200 All grades n (%) | Grade ≥3 n (%) | All grades n (%) | N=99 Grade 3 n (%)      | N=102 AIl grades n (%)  | Grade 23 n (%)          | N=201 All grades n (%)  | Grade ≥3 n (%) | N=556 All grades n (%) | Grade ≥3 n (%) |
| Back pain                          | 5 (5.0)                   | 0                   | 7 (7.0)          | 0                   | 12 (6.0)               | 0              | 12 (12.1)        | 1 (1.0)                 | 10 (9.8)                | 0                       | 22 (10.9)               | 1 (0.5)        | 58 (10.4)              | 5 (0.9)        |
| Nasopharyngitis                    | 11 (11.0)                 | 0                   | 4 (4.0)          | 0                   | 15 (7.5)               | 0              | 7 (7.1)          | 0                       | 8 (7.8)                 | 0                       | 15 (7.5)                | 0              | 58 (10.4)              | 0              |
| Alanine aminotransferase increased | 9 (9.0)                   | 3 (3.0)             | 8 (8.0)          | 1 (1.0)             | 17 (8.5)               | 4 (2.0)        | 7 (7.1)          | 2 (2.0)                 | 21 (20.6)               | 8 (7.8)                 | 28 (13.9)               | 10 (5.0)       | 57 (10.3)              | 14 (2.5)       |

A participant with multiple severity grades for an AE is only counted under the maximum grade.MedDRAversion 27.1,CTCAEversion 5.0 Source:[1LSCSAppendix2-Table2-2.2]

## Incidence of AE over time

The first occurrence of AEs was primarily observed within the first 3 months of therapy across treatment groups with few participants experiencing a new AE at later time points.

## Serious adverse events

## Deaths

As of the Week 96 data cut-off, no on-treatment death (up to 30 days after end of treatment) was reported. Overall, 2 (1.0%) participants from the asciminib group and 4 participants (2.0%; all were in the imatinib group) from the IS-TKI group died during the survival follow-up (more than 30 days after study treatment discontinuation). Reasons for death were complications due to HSCT after progression, after HSCT for unknown reason, after HSCT due to study indication, due to metastatic bronchial carcinoma or congestive heart failure.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Serious adverse events

Overall, the incidence of SAEs was lower in the asciminib group (14.5%) compared to the  IS-TKI group (20.4%) as well as to 2G TKI (24.5%) and was similar to imatinib (16.2%). The incidence of individual SAEs was low in both asciminib and IS-TKI groups. The SAEs that were reported in at least 2 participants included for the asciminib group: Cholecystitis acute, large intestine perforation, neuralgia, and osteoarthritis (2 participants each). For the IS-TKI group: pneumonia (6 participants overall; including 1 in imatinib group, and 5 in the 2G TKI group), pleural effusion (4 participants overall; all in 2G TKI group), COVID-19 (2 participants overall; both in 2G TKI group), colitis (2 participants overall; both in 2G TKI group), prostate cancer (2 participants overall; including 1 in imatinib group and 1 in 2G TKI group), URTI (2 participants overall; including 1 in imatinib group and 1 in 2G TKI group). All other SAEs were reported as single cases.

SAEs of grade ≥ 3 occurred in similar proportion of participants in the asciminib group compared to the ISTKI group (11.5% vs. 15.9%). Grade ≥ 3 SAEs that occurred in more than 1 participant in the asciminib group included cholecystitis acute, neuralgia, and osteoarthritis (in 2 participants each). Grade ≥ 3 SAEs that occurred in more than 1 participant in the IS -TKI group included: pneumonia (5 participants overall, including 1 in imatinib group and 4 in 2G TKI group); and pleural effusion (2 participants, both in 2G TKI group).

## Adverse events of special interest

The MedDRA grouping definitions used to define each AESI are presented in Table 62 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 62 Adverse events of special interest - MedDRA grouping definitions

| Topic                                                                                                                                                               | Definition                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Acute pancreatitis(including isolated pancreatic enzyme elevations)                                                                                                 | Pancreatitis(includinglaboratoryterms)(CMQ,Broad) Pancreatitis andPancreatitis acute                                                                                                                                                |
| Acutepancreatitis(clinicalevents)                                                                                                                                   | Acute pancreatitis(SMQ,Narrow)                                                                                                                                                                                                      |
| Arterialocclusiveevents(AOEs)                                                                                                                                       | Embolicand thromboticevents,arterial(SMQ) Ischaemic central nervous system vascular conditions (SMQ) Ischaemicheartdisease(SMQ,Narrow)                                                                                              |
| Cardiacfailure(clinicalevents)                                                                                                                                      | Cardiacfailure(SMQ,Narrow)                                                                                                                                                                                                          |
| Edema andfluidretention                                                                                                                                             | Haemodynamicoedema,effusionsandfluidoverload(SMQ)                                                                                                                                                                                   |
| Gl toxicity                                                                                                                                                         | Gastrointestinal nonspecific symptoms and therapeutic procedures (SMQ,Narrow)                                                                                                                                                       |
| Hemorrhage                                                                                                                                                          | Haemorrhages (SMQ, Narrow)                                                                                                                                                                                                          |
| HepatitisBvirusreactivation                                                                                                                                         | HepatitisBvirusreactivation(CMQ)                                                                                                                                                                                                    |
| Hepatotoxicity (including laboratory terms)                                                                                                                         | Cholestasis andjaundiceofhepaticorigin(SMQ,Broad) Liverrelatedinvestigations,signsandsymptoms(SMQ,Broad) Hepatitis,non-infectious (SMQ,Broad) Hepaticfailure,fibrosisandcirrhosisand otherliverdamage-related conditions(SMQ,Broad) |
| Hepatotoxicity (clinical events)                                                                                                                                    | Hepatitis, non-infectious (SMQ, Broad) Hepaticfailure,fibrosisandcirrhosisandotherliverdamage-related conditions(SMQ,Broad)                                                                                                         |
| Hypersensitivity                                                                                                                                                    | Hypersensitivity (SMQ,Narrow)                                                                                                                                                                                                       |
| Ischemicheartand CNSconditions                                                                                                                                      | Ischaemicheart disease(SMQ,Broad) Ischaemiccentralnervoussystemvascularconditions(SMQ)                                                                                                                                              |
| Myelosuppression                                                                                                                                                    | Haematopoietic cytopenias affectingmore than one type of blood cell (SMQ, Narrow) Haematopoieticerythropenial(SMQ,Broad) Haematopoietic leukopenia (SMQ,Narrow) Haematopoietic thrombocytopenia(SMQ,Narrow)                         |
| Phototoxicity                                                                                                                                                       | Photosensitivity reactions (NMQ)                                                                                                                                                                                                    |
| QTc prolongation                                                                                                                                                    | Torsade de pointes/QT prolongation (SMQ,Broad)                                                                                                                                                                                      |
| Reproductivetoxicity                                                                                                                                                | Pregnancy and neonatal topics (SMQ,Broad)                                                                                                                                                                                           |
| Note:the definitions ofArterial occlusive events (AOEs)and Ischemic heart and CNS conditions contain highly overlappingterms. Source: 1L SCS Appendix 2-Listing 6-1 | Note:the definitions ofArterial occlusive events (AOEs)and Ischemic heart and CNS conditions contain highly overlappingterms. Source: 1L SCS Appendix 2-Listing 6-1                                                                 |

AESI all grades that were less frequent in the asciminib treatment group compared to the IS-TKI treatment group. In comparison with imatinib, none of the AESI was more often reported in the asciminib group. Exposure-adjusted incidence rates of AESI were lower in the asciminib group compared to the IS-TKI group (129.4 vs. 387.3- imatinib: 280.1, 2G-TKI 574.7).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 63 Overview of adverse events of special interest - Safety set

|                                                                |                  |                |                        |                        | Study J12301        | Study J12301        | Study J12301     | Study J12301   |                                        |                                        |                       |                       | Safety Pool        | Safety Pool        |
|----------------------------------------------------------------|------------------|----------------|------------------------|------------------------|---------------------|---------------------|------------------|----------------|----------------------------------------|----------------------------------------|-----------------------|-----------------------|--------------------|--------------------|
|                                                                | Imatinib N=100   | Imatinib N=100 | Asciminib 2G TKI N=100 | Asciminib 2G TKI N=100 | All Asciminib N=200 | All Asciminib N=200 | Imatinib 66=N    | Imatinib 66=N  | Investigator Selected TKI 2G TKI N=102 | Investigator Selected TKI 2G TKI N=102 | All Comparators N=201 | All Comparators N=201 | AllAsciminib N=556 | AllAsciminib N=556 |
| Safety topic                                                   | All grades n (%) | Grade ≥3 n (%) | All grades n (%)       | Grade ≥3 n (%)         | All grades n (%)    | Grade ≥3 n (%)      | All grades n (%) | Grade ≥3 n (%) | All grades n (%)                       | Grade ≥3 n (%)                         | All grades n (%)      | Grade ≥3 n (%)        | AIl grades n (%)   | Grade ≥3 n (%)     |
| Gl toxicity                                                    | 34 (34.0)        | 0              | 44 (44.0)              | 1 (1.0)                | 78 (39.0)           | 1 (0.5)             | 43 (43.4)        | 0              | 53 (52.0)                              | 5 (4.9)                                | 96 (47.8)             | 5 (2.5)               | 259 (46.6)         | 19 (3.4)           |
| Myelosuppression* 41(41.0)                                     |                  | 19 (19.0)      | 46 (46.0)              | 21 (21.0)              | 87 (43.5)           | 40 (20.0)           | 51 (51.5)        | 24 (24.2)      | 65 (63.7)                              | 34 (33.3)                              | 116 (57.7)            | 58 (28.9)             | 220 (39.6)         | 127 (22.8)         |
| Myelosuppression 11 (11.0) (Erythropenia)                      |                  | 1 (1.0)        | 14 (14.0)              | 3 (3.0)                | 25 (12.5)           | 4 (2.0)             | 26 (26.3)        | 5 (5.1)        | 26 (25.5)                              | 7 (6.9)                                | 52 (25.9)             | 12 (6.0)              | 72 (12.9)          | 23 (4.1)           |
| Myelosuppression 31 (31.0) (Leukopenia)                        |                  | 11 (11.0)      | 32 (32.0)              | 15 (15.0)              | 63 (31.5)           | 26 (13.0)           | 38 (38.4)        | 23 (23.2)      | 42 (41.2)                              | 19 (18.6)                              | 80 (39.8)             | 42 (20.9)             | 136 (24.5)         | 84 (15.1)          |
| Myelosuppression 26 (26.0) (Thrombocytopenia)                  |                  | 12 (12.0)      | 30 (30.0)              | 14 (14.0)              | 56 (28.0)           | 26 (13.0)           | 28 (28.3)        | 6 (6.1)        | 35 (34.3)                              | 14 (13.7)                              | 63 (31.3)             | 20 (10.0)             | 156 (28.1)         | 92 (16.5)          |
| Myelosuppression 0 (cytopenias affecting more thanone lineage) |                  | 0              | 0                      | 0                      | 0                   | 0                   | 0                | 0              | 0                                      | 0                                      | 0                     | 0                     | 2 (0.4)            | 1 (0.2)            |
| Hypersensitivity                                               | 23 (23.0)        | 0              | 29 (29.0)              | ）1 (1.0)               | 52 (26.0)           | 1 (0.5)             | 43 (43.4)        | 3 (3.0)        | 46 (45.1)                              | 2 (2.0)                                | 89 (44.3)             | 5 (2.5)               | 173 (31.1)         | 8 (1.4)            |
| Hepatotoxicity (including laboratory terms)                    | 21 (21.0)        | 3 (3.0)        | 19 (19.0)              | 2 (2.0)                | 40 (20.0)           | 5 (2.5)             | 21 (21.2)        | 4 (4.0)        | 37 (36.3)                              | 8 (7.8)                                | 58 (28.9)             | 12 (6.0)              | 120 (21.6)         | 23 (4.1)           |
| Hepatotoxicity (clinical events)                               | 3 (3.0)          | 0              | 4 (4.0)                | 1 (1.0)                | 7 (3.5)             | 1 (0.5)             | 1 (1.0)          | 1 (1.0)        | 3 (2.9)                                | 0                                      | 4 (2.0)               | 1 (0.5)               | 12 (2.2)           | 2 (0.4)            |

|                                                                     | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | Study J12301 InvestigatorSelectedTKI   | SafetyPool          | SafetyPool          |
|---------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|---------------------|---------------------|
|                                                                     | Imatinib                               | Imatinib                               | Asciminib 2G TKI N=100                 | Asciminib 2G TKI N=100                 | All Asciminib N=200                    | All Asciminib N=200                    | Imatinib 66=N                          | Imatinib 66=N                          | 2G TKI N=102                           | 2G TKI N=102                           | All Comparators N=201                  | All Comparators N=201                  | All Asciminib N=556 | All Asciminib N=556 |
| Safetytopic                                                         | AIl grades n (%)                       | Grade ≥3 n (%)                         | AIl grades n (%)                       | Grade ≥3 n (%)                         | AIl grades n (%)                       | Grade ≥3 n (%)                         | All grades n (%)                       | Grade ≥3 n (%)                         | AIl grades n (%)                       | Grade ≥3 n (%)                         | AIl grades n (%)                       | Grade ≥3 n (%)                         | AIl grades n (%)    | Grade ≥3 n (%)      |
| Acute pancreatitis (including isolated pancreaticenzyme elevations) | 21 (21.0)                              | 6 (6.0)                                | 8 (8.0)                                | 1 (1.0)                                | 29 (14.5)                              | 7 (3.5)                                | 16 (16.2)                              | 3 (3.0)                                | 18 (17.6)                              | 6 (5.9)                                | 34 (16.9)                              | 9 (4.5)                                | 114 (20.5)          | 57 (10.3)           |
| Acute pancreatitis (clinicalevents)                                 | 1 (1.0)                                | 1 (1.0)                                | 1 (1.0)                                | 1 (1.0)                                | 2 (1.0)                                | 2 (1.0)                                | 2 (2.0)                                | 1 (1.0)                                | 0                                      | 0                                      | 2 (1.0)                                |                                        | 1 (0.5) 11 (2.0)    | 6 (1.1)             |
| Hemorrhage                                                          | 6 (6.0)                                | 0                                      | 7 (7.0)                                | 0                                      | 13 (6.5)                               | 0                                      | 10 (10.1)                              | 1 (1.0)                                | 12 (11.8)                              | 3 (2.9)                                | 22 (10.9)                              |                                        | 4 (2.0)76 (13.7)    | 10 (1.8)            |
| Edema and fluid retention                                           | 3 (3.0)                                | 0                                      | 6 (6.0)                                | 0                                      | 9 (4.5)                                | 0                                      | 15 (15.2)                              | 0                                      | 15 (14.7)                              | 5 (4.9)                                | 30 (14.9)                              |                                        | 5 (2.5)74 (13.3)    | 9 (1.6)             |
| Ischemic heart and CNS conditions                                   | 7 (7.0)                                | 2 (2.0)                                | 8 (8.0)                                | 4 (4.0)                                | 15 (7.5)                               | 6 (3.0)                                | 7 (7.1)                                | 0                                      | 11 (10.8)                              | 4 (3.9)                                | 18 (9.0)                               | 4 (2.0)                                | 58 (10.4)           | 26 (4.7)            |
| Ischemicheart conditions                                            | 6 (6.0)                                | 1 (1.0)                                | 8 (8.0)                                | 4 (4.0)                                | 14 (7.0)                               | 5 (2.5)                                | 7 (7.1)                                | 0                                      | 10 (9.8)                               | 4 (3.9)                                | 17 (8.5)                               | 4 (2.0)                                | 46 (8.3)            | 18 (3.2)            |
| Ischemic CNS conditions                                             | 1 (1.0)                                | 1 (1.0)                                | 0                                      | 0                                      | 1 (0.5)                                | 1 (0.5)                                | 0                                      | 0                                      | 2 (2.0)                                | 0                                      | 2 (1.0)                                | 0                                      | 16 (2.9)            | 9 (1.6)             |
| Arterial-occlusive events (AOEs)                                    | 2 (2.0)                                | 1 (1.0)                                | 2 (2.0)                                | 0                                      | 4 (2.0)                                | 1 (0.5)                                | 0                                      | 0                                      | 3 (2.9)                                | 1 (1.0)                                | 3 (1.5)                                | 1 (0.5)                                | 39 (7.0)            | 18 (3.2)            |
| QTc prolongation                                                    | 1 (1.0)                                | 1 (1.0)                                | 3 (3.0)                                | 2 (2.0)                                | 4 (2.0)                                | 3 (1.5)                                | 0                                      | 0                                      | 5 (4.9)                                | 1 (1.0)                                | 5 (2.5)                                | 1 (0.5)                                | 23 (4.1)            | 12 (2.2)            |
| Phototoxicity                                                       | 0                                      | 0                                      | 3 (3.0)                                | 0                                      | 3 (1.5)                                | 0                                      | 0                                      | 0                                      | 2 (2.0)                                | 0                                      | 2 (1.0)                                | 0                                      | 16 (2.9)            | 0                   |
| Cardiacfailure                                                      | 0                                      | 0                                      | 0                                      | 0                                      | 0                                      | 0                                      | 0                                      | 0                                      | 2 (2.0)                                | 2 (2.0)                                | 2 (1.0)                                | 2 (1.0)                                | 14 (2.5)            | 11 (2.0)            |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                              |                        |                |                  |                      | StudyJ12301      | StudyJ12301          | StudyJ12301      | StudyJ12301             |                         |                         |                         |                      |                  | SafetyPool           |
|------------------------------|------------------------|----------------|------------------|----------------------|------------------|----------------------|------------------|-------------------------|-------------------------|-------------------------|-------------------------|----------------------|------------------|----------------------|
|                              |                        |                | Asciminib        | Asciminib            |                  | AllAsciminib         |                  | InvestigatorSelectedTKl | InvestigatorSelectedTKl | InvestigatorSelectedTKl | InvestigatorSelectedTKl |                      |                  |                      |
| Safety topic                 | N=100 AlI grades n (%) | Grade ≥3 n (%) | AlI grades n (%) | N=100 Grade ≥3 n (%) | AlI grades n (%) | N=200 Grade ≥3 n (%) | AlI grades n (%) | N=99 Grade ≥3 n (%)     | AlI grades n (%)        | N=102 Grade ≥3 n (%)    | AIl grades n (%)        | N=201 Grade ≥3 n (%) | All grades n (%) | N=556 Grade ≥3 n (%) |
| Reproductive toxicity        | 1 (1.0)                | 0              | 2 (2.0)          | 1 (1.0)              | 3 (1.5)          | 1 (0.5)              | 1 (1.0)          | 0                       | 1 (1.0)                 | 0                       | 2 (1.0)                 | 0                    | 9 (1.6)          | 4 (0.7)              |
| HepatitisBvirus reactivation | 0                      | 0              | 0                | 0                    | 0                | 0                    | 1 (1.0)          | 0                       | 0                       | 0                       | 1 (0.5)                 | 0                    | 1 (0.2)          | 0                    |

*MyelosuppressionincludesErythropenia,Leukopenia,Neutropenia,Thrombocytopenia,cytopeniasaffecting morethanonelineage.

Source:1LSCSAppendix2-Table2-13

An overview about the risk difference for TKI - class effects is provided in Table 64 .

Table 64 Overview of AESI by risk difference between Asciminib and IS-TKI treatment groups - Safety Set

<!-- image -->

Source: SCS, figure 2-4

## Gastrointestinal toxicity

Overall, 39.0% of participants in the asciminib treatment group had GI toxicity AESI vs. 47.8% in ISTKI treatment group, including 43.4% in imatinib and 52.0% in 2G TKI. The effect was present according to diarrhoea, nausea and vomiting. Abdominal pain was reported more often in the asciminib arm (11%) in comparison to imatinib (3.0%), but not to 2G-TKI (10.8%), &gt;=G3 events were overall rave, with 0.5% in the asciminib group, no events in the imatinib group and 4.9% in the 2G-group. However, the AE had not recovered in 9.0 % vs. 14.0% vs. 20.6% of patients having such an AE.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 65 Clinical impact of AESI Gastrointestinal toxicity - Safety set

|                            | Study J12301      | Study J12301        | Study J12301        | Study J12301             | Study J12301             | Study J12301             | SafetyPool            |
|----------------------------|-------------------|---------------------|---------------------|--------------------------|--------------------------|--------------------------|-----------------------|
|                            |                   | Asciminib           |                     | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI |                       |
|                            | Imatinib N=100    | 2G TKI N=100        | All Asciminib N=200 | Imatinib 66=N            | 2G TKI N=102             | AlIl Comparators N=201   | All Asciminib N=556   |
|                            |                   |                     | n (%)               |                          |                          |                          |                       |
| Gastrointestinaltoxicity   |                   |                     |                     |                          |                          | n (%)                    |                       |
|                            | n (%)             | n (%)               |                     | n (%)                    | n (%)                    |                          | n (%)                 |
| Atleastoneevent            | 34 (34.0)         | 44 (44.0)           | 78 (39.0) 35 (17.5) | 43 (43.4)                | 53 (52.0)                | 96 (47.8) 56 (27.9)      | 259 (46.6) 115 (20.7) |
| Diarrhoea Nausea           | 14 (14.0) 8 (8.0) | 21 (21.0) 11 (11.0) | 19 (9.5)            | 28 (28.3) 21 (21.2)      | 28 (27.5) 19 (18.6)      | 40 (19.9)                | 93 (16.7)             |
| Vomiting                   | 6 (6.0)           | 8 (8.0)             | 14 (7.0)            | 13 (13.1)                | 7 (6.9)                  | 20 (10.0)                | 78 (14.0)             |
| Abdominal pain             | 11 (11.0)         | 11 (11.0)           | 22 (11.0)           | 3 (3.0)                  | 11 (10.8)                | 14 (7.0)                 | 76 (13.7)             |
| Constipation               | (0:6) 6           | 11 (11.0)           | 20 (10.0)           | 4 (4.0)                  | 14 (13.7)                | 18 (9.0)                 | 63 (11.3)             |
| Abdominal pain upper       | 1 (1.0)           | 8 (8.0)             | 9 (4.5)             | 4 (4.0)                  | 3 (2.9)                  | 7 (3.5)                  | 41 (7.4)              |
| Non-cardiac chest pain     | 1 (1.0)           | 4 (4.0)             | 5 (2.5)             | 0                        | 1 (1.0)                  | 1 (0.5)                  | 37 (6.7)              |
| Abdominal distension       | 0                 | 1 (1.0)             | 1 (0.5)             | 1 (1.0)                  | 5 (4.9)                  | 6 (3.0)                  | 11 (2.0)              |
| Abdominal discomfort       | 1 (1.0)           | 1 (1.0)             | 2 (1.0)             | 1 (1.0)                  | 3 (2.9)                  | 4 (2.0)                  | 10 (1.8)              |
| Flatulence                 | 1 (1.0)           | 2 (2.0)             | 3 (1.5)             | 0                        | 2 (2.0)                  | 2 (1.0)                  | 9 (1.6)               |
| Abdominalpain lower        | 0                 | 1 (1.0)             | 1 (0.5)             | 0                        | 0                        | 0                        | 6 (1.1)               |
| Gastrointestinal pain      | 1 (1.0)           | 0                   | 1 (0.5)             | 0                        | 0                        | 0                        | 3 (0.5)               |
| Eructation                 | 0                 | 1 (1.0)             | 1 (0.5)             | 0                        | 0                        | 0                        | 2 (0.4)               |
| Bowelmovement irregularity | 0                 | 0                   | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 0                     |
| Maximum grade              |                   |                     |                     |                          |                          |                          |                       |
| Grade3AEs                  | 0                 | 1 (1.0)             | 1 (0.5)             | 0                        | 5 (4.9)                  | 5 (2.5)                  | 19 (3.4)              |
| Treatment-related AEs      | 17 (17.0)         | 18 (18.0)           | 35 (17.5)           | 37 (37.4)                | 33 (32.4)                | 70 (34.8)                | 133 (23.9)            |
| SAEs                       | 0                 | 1 (1.0)             | 1 (0.5)             | 1 (1.0)                  | 2 (2.0)                  | 3 (1.5)                  | 14 (2.5)              |

|                             | Study J12301         | Study J12301       | Study J12301              | Study J12301            | Study J12301            | Study J12301                | Safety Pool               |
|-----------------------------|----------------------|--------------------|---------------------------|-------------------------|-------------------------|-----------------------------|---------------------------|
|                             |                      | Asciminib          |                           | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI     |                           |
| Gastrointestinaltoxicity    | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | AIl Asciminib N=200 n (%) | Imatinib 66=N n (%)     | 2G TKI N=102 n (%)      | All Comparators N=201 n (%) | All Asciminib N=556 n (%) |
| Action taken                |                      |                    |                           |                         |                         |                             |                           |
| Drug withdrawn              | 0                    | 0                  | 0                         | 3 (3.0)                 | 0                       | 3 (1.5)                     | 1 (0.2)                   |
| Dose adjusted               | 0                    | 0                  | 0                         | 4 (4.0)                 | 2 (2.0)                 | 6 (3.0)                     | 11 (2.0)                  |
| Drug interrupted            | 2 (2.0)              | 4 (4.0)            | 6 (3.0)                   | 4 (4.0)                 | 4 (3.9)                 | 8 (4.0)                     | 27 (4.9)                  |
| Dose not changed/NA/Unknown | 34 (34.0)            | 42 (42.0)          | 76 (38.0)                 | 40 (40.4)               | 51 (50.0)               | 91 (45.3)                   | 252 (45.3)                |
| AE outcome                  |                      |                    |                           |                         |                         |                             |                           |
| Recovered/resolved          | 32 (32.0)            | 42 (42.0)          | 74 (37.0)                 | 39 (39.4)               | 45 (44.1)               | 84 (41.8)                   | 234 (42.1)                |
| Recovering/resolving        | 3 (3.0)              | 3 (3.0)            | 6 (3.0)                   | 2 (2.0)                 | 8 (7.8)                 | 10 (5.0)                    | 22 (4.0)                  |
| Notrecovered/notresolved    | 8 (8.0)              | 10 (10.0)          | 18 (9.0)                  | 14 (14.1)               | 21 (20.6)               | 35 (17.4)                   | 87 (15.6)                 |

Participants/outcome with no events inStudyJ12301are omitted from thisin-text table.A participantmaybecounted inseveral rowsfor action taken andoutcome. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024.

Source:[1LSCSAppendix2-Table2-14.1]

## Myelosuppression

Myelosuppression events all grades occurred less frequently in the asciminib group (43.5%) compared to the IS-TKI group overall (57.7%) as well as imatinib (51.5%) and 2G TKI (63.7%). Grade 3 and Grade 4 events occurred in 14.0% and 6.0% of participants in the asciminib group compared to 21.4% and 7.5% in the IS-TKI group overall (17.2% and 7.1% in the imatinib group; 25.5% and 7.8% in the 2G TKI group). For more details, see Table 66 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 66 Clinical impact of AESI Myelosuppression - Safety set

|                              | Study J12301        | Study J12301        | Study J12301        | Study J12301            | Study J12301            | Study J12301            | Safety Pool           |
|------------------------------|---------------------|---------------------|---------------------|-------------------------|-------------------------|-------------------------|-----------------------|
|                              |                     | Asciminib           |                     | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI |                       |
|                              | Imatinib N=100      | 2G TKI N=100        | All Asciminib N=200 | Imatinib 66=N           | 2G TKI N=102            | All Comparators N=201   | All Asciminib N=556   |
|                              |                     |                     |                     |                         |                         |                         | n (%)                 |
|                              |                     |                     |                     |                         |                         | n (%)                   |                       |
| Myelosuppression*            | n (%)               | n (%)               | n (%)               | n (%)                   | n (%)                   |                         |                       |
| At least one event           | 41 (41.0) 15 (15.0) | 46 (46.0) 12 (12.0) | 87 (43.5) 27 (13.5) | 51 (51.5) 14 (14.1)     | 65 (63.7) 17 (16.7)     | 116 (57.7) 31 (15.4)    | 220 (39.6) 109 (19.6) |
| Thrombocytopenia Neutropenia | 12 (12.0)           | 9 (9.0)             | 21 (10.5)           | 16 (16.2)               | 17 (16.7)               | 33 (16.4)               | 77 (13.8)             |
| Anaemia                      | 11 (11.0)           | 14 (14.0)           | 25 (12.5)           | 26 (26.3)               | 26 (25.5)               | 52 (25.9)               | 70 (12.6)             |
| Plateletcountdecreased       | 11 (11.0)           | 18 (18.0)           | 29 (14.5)           | 14 (14.1)               | 19 (18.6)               | 33 (16.4)               | 52 (9.4)              |
| Neutrophilcount decreased    | 13 (13.0)           | 17 (17.0)           | 30 (15.0)           | 16 (16.2)               | 21 (20.6)               | 37 (18.4)               | 49 (8.8)              |
| Whitebloodcellcountdecreased | 10 (10.0)           | 12 (12.0)           | 22 (11.0)           | 17 (17.2)               | 13 (12.7)               | 30 (14.9)               | 34 (6.1)              |
| Leukopenia                   | 7 (7.0)             | 10 (10.0)           | 17 (8.5)            | 12 (12.1)               | 8 (7.8)                 | 20 (10.0)               | 24 (4.3)              |
| Lymphocyte count decreased   | 6 (6.0)             | 4 (4.0)             | 10 (5.0)            | 13 (13.1)               | 3 (2.9)                 | 16 (8.0)                | 10 (1.8)              |
| Lymphopenia                  | 3 (3.0)             | 0                   | 3 (1.5)             | 4 (4.0)                 | 4 (3.9)                 | 8 (4.0)                 | 7 (1.3)               |
| Monocytecountdecreased       | 2 (2.0)             | 3 (3.0)             | 5 (2.5)             | 3 (3.0)                 | 2 (2.0)                 | 5 (2.5)                 | 5 (0.9)               |
| Febrile neutropenia          | 0                   | 1 (1.0)             | 1 (0.5)             | 0                       | 0                       | 0                       | 4 (0.7)               |
| Redbloodcellcountdecreased   | 0                   | 1 (1.0)             | 1 (0.5)             | 0                       | 0                       | 0                       | 1 (0.2)               |
| Erythropenia                 | 0                   | 0                   | 0                   | 1 (1.0)                 | 0                       | 1 (0.5)                 | 0                     |
| Haematocrit decreased        | 0                   | 0                   | 0                   | 1 (1.0)                 | 0                       | 1 (0.5)                 | 0                     |
| Maximum grade                |                     |                     |                     |                         |                         |                         |                       |
| Grade3AEs                    | 16 (16.0)           | 12 (12.0)           | 28 (14.0)           | 17 (17.2)               | 26 (25.5)               | 43 (21.4)               | 60 (10.8)             |
| Grade 4 AEs                  | 3 (3.0)             | 9 (9.0)             | 12 (6.0)            | 7 (7.1)                 | 8 (7.8)                 | 15 (7.5)                | 67 (12.1)             |
| Treatment-related AEs        | 37 (37.0)           | 42 (42.0)           | 79 (39.5)           | 47 (47.5)               | 59 (57.8)               | 106 (52.7)              | 178 (32.0)            |

|                             | Study J12301   | Study J12301   | Study J12301   | Study J12301             | Study J12301             | Study J12301             | Safety Pool               |
|-----------------------------|----------------|----------------|----------------|--------------------------|--------------------------|--------------------------|---------------------------|
|                             |                | Asciminib      |                | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI |                           |
| Myelosuppression*           |                | 2G TKI         | AlI Asciminib  |                          | 2G TKI N=102             | AlIl Comparators N=201   | All Asciminib N=556 n (%) |
|                             | Imatinib N=100 |                |                | Imatinib                 |                          |                          |                           |
|                             |                | N=100          | N=200          | 66=N                     |                          |                          |                           |
|                             | n (%)          | n (%)          | n (%)          | n (%)                    | n (%)                    |                          |                           |
|                             |                |                |                |                          |                          | n (%)                    |                           |
| SAEs                        | 0              | 1 (1.0)        | 1 (0.5)        | 1 (1.0)                  | 2 (2.0)                  | 3 (1.5)                  | 7 (1.3)                   |
| Action taken                |                |                |                |                          |                          |                          |                           |
| Drug withdrawn              | 1 (1.0)        | 1 (1.0)        | 2 (1.0)        | 3 (3.0)                  | 1 (1.0)                  | 4 (2.0)                  | 12 (2.2)                  |
| Dose adjusted               | 5 (5.0)        | 2 (2.0)        | 7 (3.5)        | 6 (6.1)                  | 15 (14.7)                | 21 (10.4)                | 31 (5.6)                  |
| Drug interrupted            | 14 (14.0)      | 19 (19.0)      | 33 (16.5)      | 19 (19.2)                | 21 (20.6)                | 40 (19.9)                | 85 (15.3)                 |
| Dose not changed/NA/Unknown | 39 (39.0)      | 44 (44.0)      | 83 (41.5)      | 47 (47.5)                | 59 (57.8)                | 106 (52.7)               | 206 (37.1)                |
| AE outcome                  |                |                |                |                          |                          |                          |                           |
| Recovered/resolved          | 41 (41.0)      | 45 (45.0)      | 86 (43.0)      | 50 (50.5)                | 59 (57.8)                | 109 (54.2)               | 200 (36.0)                |
| Recovering/resolving        | 17 (17.0)      | 22 (22.0)      | 39 (19.5)      | 20 (20.2)                | 25 (24.5)                | 45 (22.4)                | 104 (18.7)                |
| Notrecovered/notresolved    | 14 (14.0)      | 17 (17.0)      | 31 (15.5)      | 26 (26.3)                | 36 (35.3)                | 62 (30.8)                | 114 (20.5)                |

A participant maybecounted inseveral rowsfor action taken and outcome.Participants/outcome with no events inStudyJ12301are omitted from this in-text table. MedDRAversion27.1,CTCAEversion5.0caseRetrievalStrategyversionreleased28-Nov-2024.

*Myelosuppression includes Erythropenia,Leukopenia,MeutropeniaThrombocytopenia Cytopenias affecting more than one lineage.

Source:[1LSCSADDendix2-Table2-14.11

## Hypersensivity

Hypersensitivity events (all grades) occurred markedly less frequently with asciminib as compared to IS-TKIs (26.0% vs. 44.3%) including as compared to imatinib (26.0% vs. 43.4%) and 2G TKI (26.0% vs. 45.1%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 67 Clinical impact of AESI Hypersensitivity - Safety set

|                             |                |              | StudyJ12301          | StudyJ12301              | StudyJ12301              | StudyJ12301              | Safety Pool        |
|-----------------------------|----------------|--------------|----------------------|--------------------------|--------------------------|--------------------------|--------------------|
|                             |                | Asciminib    |                      | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI |                    |
|                             | Imatinib N=100 | 2G TKI N=100 | AlIl Asciminib N=200 | Imatinib 66=N            | 2G TKI N=102             | All Comparators N=201    | AllAsciminib N=556 |
| Hypersensitivity            | n (%)          | n (%)        | n (%)                | n (%)                    | n (%)                    | n (%)                    | n (%)              |
| Atleastone event            | 23 (23.0)      | 29 (29.0)    | 52 (26.0)            | 43 (43.4)                | 46 (45.1)                | 89 (44.3)                | 173 (31.1)         |
| Rash                        | (0:6) 6        | 20 (20.0)    | 29 (14.5)            | 11 (11.1)                | 24 (23.5)                | 35 (17.4)                | 88 (15.8)          |
| Rash maculo-papular         | 1 (1.0)        | 2 (2.0)      | 3 (1.5)              | 0                        | 3 (2.9)                  | 3 (1.5)                  | 22 (4.0)           |
| Urticaria                   | 4 (4.0)        | 2 (2.0)      | 6 (3.0)              | 0                        | 5 (4.9)                  | 5 (2.5)                  | 19 (3.4)           |
| Dermatitis acneiform        | 2 (2.0)        | 1 (1.0)      | 3 (1.5)              | 1 (1.0)                  | 3 (2.9)                  | 4 (2.0)                  | 12 (2.2)           |
| Eczema                      | 2 (2.0)        | 2 (2.0)      | 4 (2.0)              | 3 (3.0)                  | 6 (5.9)                  | 9 (4.5)                  | 11 (2.0)           |
| Rhinitis allergic           | 1 (1.0)        | 1 (1.0)      | 2 (1.0)              | 0                        | 1 (1.0)                  | 1 (0.5)                  | 9 (1.6)            |
| Dermatitis allergic         | 2 (2.0)        | 1 (1.0)      | 3 (1.5)              | 0                        | 3 (2.9)                  | 3 (1.5)                  | 5 (0.9)            |
| Periorbital oedema          | 0              | 2 (2.0)      | 2 (1.0)              | 11 (11.1)                | 1 (1.0)                  | 12 (6.0)                 | (6:0) g            |
| Rash pruritic               | 1 (1.0)        | 0            | 1 (0.5)              | 2 (2.0)                  | 0                        | 2 (1.0)                  | (6:0) g            |
| Rash pustular               | 0              | 0            | 0                    | 0                        | 1 (1.0)                  | 1 (0.5)                  | 4 (0.7)            |
| Allergictransfusionreaction | 0              | 1 (1.0)      | 1 (0.5)              | 0                        | 0                        | 0                        | 2 (0.4)            |
| Eye swelling                | 0              | 2 (2.0)      | 2 (1.0)              | 2 (2.0)                  | 0                        | 2 (1.0)                  | 2 (0.4)            |
| Faceoedema                  | 0              | 0            |                      | 10 (10.1)                | 0                        | 10 (5.0)                 | 2 (0.4)            |
|                             |                |              | 0                    |                          |                          |                          | 1 (0.2)            |
| Contrast mediareaction      | 0              | 0            | 0                    | 1 (1.0)                  | 0                        | 1 (0.5)                  |                    |
| Infusionrelatedreaction     | 0              | 1 (1.0)      | 1 (0.5)              | 0                        | 0                        | 0                        | 1 (0.2)            |
| Periorbital swelling        | 0              | 1 (1.0)      | 1 (0.5)              | 1 (1.0)                  | 0                        | 1 (0.5)                  | 1 (0.2)            |

|                           |                | Study J12301   | Study J12301        | Study J12301             | Study J12301             | Study J12301             | Safety Pool        |
|---------------------------|----------------|----------------|---------------------|--------------------------|--------------------------|--------------------------|--------------------|
|                           |                | Asciminib      |                     | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI |                    |
|                           | Imatinib N=100 | 2G TKI         | All Asciminib N=200 | Imatinib 66=N            | 2G TKI N=102 n (%)       | All Comparators N=201    | AllAsciminib N=556 |
|                           |                | N=100          |                     |                          |                          |                          |                    |
| Hypersensitivity          | n (%)          | n (%)          | n (%)               | n (%)                    |                          | n (%)                    | n (%)              |
| Rashmacular               | 0              | 0              | 0                   | 1 (1.0)                  | 0                        | 1 (0.5)                  | 1 (0.2)            |
| Rash vesicular            | 1 (1.0)        | 0              | 1 (0.5)             | 0                        | 0                        | 0                        | 1 (0.2)            |
| Vulvaleczema              | 1 (1.0)        | 0              | 1 (0.5)             | 0                        | 0                        | 0                        | 1 (0.2)            |
| Dermatitisexfoliative     | 0              | 0              | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 0                  |
| Drug eruption             | 0              | 0              | 0                   | 1 (1.0)                  | 0                        | 1 (0.5)                  | 0                  |
| Eyelid oedema             | 0              | 0              | 0                   | 8 (8.1)                  | 0                        | 8 (4.0)                  | 0                  |
| Solar urticaria           | 0              | 0              | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 0                  |
| Swellingof eyelid         | 0              | 0              | 0                   | 3 (3.0)                  | 2 (2.0)                  | 5 (2.5)                  | 0                  |
| Maximum grade             |                |                |                     |                          |                          |                          |                    |
| Grade3AEs                 | 0              | 1 (1.0)        | 1 (0.5)             | 3 (3.0)                  | 2 (2.0)                  | 5 (2.5)                  | 7 (1.3)            |
| Treatment-related AEs     | 18 (18.0)      | 21 (21.0)      | 39 (19.5)           | 40 (40.4)                | 37 (36.3)                | 77 (38.3)                | 106 (19.1)         |
| Action taken              |                |                |                     |                          |                          |                          |                    |
| Drug withdrawn            | 0              | 0              | 0                   | 1 (1.0)                  | 3 (2.9)                  | 4 (2.0)                  | 2 (0.4)            |
| Dose adjusted             | 0              | 0              | 0                   | 4 (4.0)                  | 4 (3.9)                  | 8 (4.0)                  | 2 (0.4)            |
| Drug interrupted          | 1 (1.0)        | 1 (1.0)        | 2 (1.0)             | 3 (3.0)                  | 4 (3.9)                  | 7 (3.5)                  | 6 (1.1)            |
| Dosenotchanged/NA/Unknown | 22 (22.0)      | 29 (29.0)      | 51 (25.5)           | 38 (38.4)                | 44 (43.1)                | 82 (40.8)                | 170 (30.6)         |

|                          | Study J12301   | Study J12301   | Study J12301   | Study J12301              | Study J12301              | Study J12301              | Safety Pool   |
|--------------------------|----------------|----------------|----------------|---------------------------|---------------------------|---------------------------|---------------|
|                          |                | Asciminib      |                | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI |               |
|                          |                | 2G TKI         | All            |                           |                           | AlIl                      |               |
|                          | Imatinib       |                | Asciminib      | Imatinib                  | 2G TKI                    | Comparators               | All Asciminib |
|                          | N=100          | N=100          | N=200          | 66=N                      | N=102                     | N=201                     | N=556         |
| Hypersensitivity         | n (%)          | n (%)          | n (%)          | n (%)                     | n (%)                     | n (%)                     | n (%)         |
| AEoutcome                |                |                |                |                           |                           |                           |               |
| Recovered/resolved       | 16 (16.0)      | 21 (21.0)      | 37 (18.5)      | 31 (31.3)                 | 28 (27.5)                 | 59 (29.4)                 | 131 (23.6)    |
| Recovering/resolving     | 2 (2.0)        | 1 (1.0)        | 3 (1.5)        | 3 (3.0)                   | 5 (4.9)                   | 8 (4.0)                   | 9 (1.6)       |
| Notrecovered/notresolved | 8 (8.0)        | 11 (11.0)      | 19 (9.5)       | 21 (21.2)                 | 22 (21.6)                 | 43 (21.4)                 | 60 (10.8)     |

Participants/outcome with no events in Study J12301 are omitted from this in-text table.A participant may be counted inseveral rows for action taken and outcome.

Source:1LSCSAppendix2-Table2-14.1

## Hepatotoxicity

Detailed information about hepatotoxicity including laboratory terms is provided in Table 68. Following the applicant, no participant met Hy's law criteria after receiving the study treatment.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 68 Clinical impact of AESI Hepatotoxicity (including laboratory terms) - Safety set

|                                          | Study J12301         | Study J12301       | Study J12301              | Study J12301              | Study J12301              | Study J12301                | Safety Pool              |
|------------------------------------------|----------------------|--------------------|---------------------------|---------------------------|---------------------------|-----------------------------|--------------------------|
|                                          |                      | Asciminib          |                           | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI   |                          |
| Hepatotoxicity(includinglaboratoryterms) | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | AIl Asciminib N=200 n (%) | Imatinib 66=N n (%)       | 2G TKI N=102 n (%)        | All Comparators N=201 n (%) | AllAsciminib N=556 n (%) |
| At least one event                       | 21 (21.0)            | 19 (19.0)          | 40 (20.0)                 | 21 (21.2)                 | 37 (36.3)                 | 58 (28.9)                   | 120 (21.6)               |
| Alanineaminotransferaseincreased         | (0:6) 6              | 8 (8.0)            | 17 (8.5)                  | 7 (7.1)                   | 21 (20.6)                 | 28 (13.9)                   | 57 (10.3)                |
| Aspartateaminotransferaseincreased       | 2 (2.0)              | 4 (4.0)            | 6 (3.0)                   | 7 (7.1)                   | 16 (15.7)                 | 23 (11.4)                   | 42 (7.6)                 |
| Gamma-glutamyl transferaseincreased      | 7 (7.0))             | 7 (7.0)            | 14 (7.0)                  | 4 (4.0)                   | 9 (8.8)                   | 13 (6.5)                    | 36 (6.5)                 |
| Blood alkalinephosphataseincreased       | 10 (10.0)            | 2 (2.0)            | 12 (6.0)                  | 13 (13.1)                 | 6 (5.9)                   | 19 (9.5)                    | 24 (4.3)                 |
| Bloodbilirubin increased                 | 2 (2.0)              | 6 (6.0)            | 8 (4.0)                   | 2 (2.0)                   | 11 (10.8)                 | 13 (6.5)                    | 24 (4.3)                 |
| Hyper transaminasaemia                   | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 7 (1.3)                  |
| Bilirubin conjugated increased           | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 5 (0.9)                  |
| Hepatic steatosis                        | 3 (3.0)              | 0                  | 3 (1.5)                   | 0                         | 0                         | 0                           | 5 (0.9)                  |
| Liver disorder                           | 1 (1.0)              | 2 (2.0)            | 3 (1.5)                   | 0                         | 1 (1.0)                   | 1 (0.5)                     | 4 (0.7)                  |
| Blood bilirubin unconjugated increased   | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 0                         | 0                           | 3 (0.5)                  |
| Hyper bilirubinaemia                     | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 3 (0.5)                  |
| Hepatic function abnormal                | 1 (1.0)              | 0                  | 1 (0.5)                   | 2 (2.0)                   | 0                         | 2 (1.0)                     | 2 (0.4)                  |
| Hepatobiliary disease                    | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 1 (0.2)                  |
| Hepatotoxicity                           | 0                    | 1 (1.0)            | 1 (0.5)                   | 1 (1.0)                   | 0                         | 1 (0.5)                     | 1 (0.2)                  |
| Liver injury                             | 0                    | 1 (1.0)            | 1 (0.5)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 1 (0.2)                  |
| 5'nucleotidaseincreased                  | 0                    | 0                  | 0                         | 0                         | 1 (1.0)                   | 1 (0.5)                     | 0                        |
| Hepaticenzymeincreased                   | 0                    | 0                  | 0                         | 0                         | 2 (2.0)                   | 2 (1.0)                     | 0                        |

|                                          | Study J12301         | Study J12301       | Study J12301              | Study J12301            | Study J12301            | Study J12301                | Safety Pool              |
|------------------------------------------|----------------------|--------------------|---------------------------|-------------------------|-------------------------|-----------------------------|--------------------------|
|                                          |                      | Asciminib          |                           | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI     |                          |
| Hepatotoxicity(includinglaboratoryterms) | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | All Asciminib N=200 n (%) | Imatinib 66=N n (%)     | 2G TKI N=102 n (%)      | AII Comparators N=201 n (%) | AllAsciminib N=556 n (%) |
| Maximum grade                            |                      |                    |                           |                         |                         |                             |                          |
| Grade 3AEs                               | 3 (3.0)              | 0                  | 3 (1.5)                   | 3 (3.0)                 | 8 (7.8)                 | 11 (5.5)                    | 18 (3.2)                 |
| Grade 4AEs                               | 0                    | 2 (2.0)            | 2 (1.0)                   | 1(1.0)                  | 0                       | 1 (0.5)                     | 5 (0.9)                  |
| Treatment-related AEs                    | 14 (14.0)            | 14 (14.0)          | 28 (14.0)                 | 16 (16.2)               | 31 (30.4)               | 47 (23.4)                   | 65 (11.7)                |
| SAEs                                     | 0                    | 1 (1.0)            | 1 (0.5)                   | 0                       | 0                       | 0                           | 2 (0.4)                  |
| Action taken                             |                      |                    |                           |                         |                         |                             |                          |
| Drug withdrawn                           | 0                    | 1 (1.0)            | 1 (0.5)                   | 2 (2.0)                 | 0                       | 2 (1.0)                     | 1 (0.2)                  |
| Dose adjusted                            | 1 (1.0)              | 0                  | 1 (0.5)                   | 1 (1.0)                 | 3 (2.9)                 | 4 (2.0)                     | 4 (0.7)                  |
| Drug interrupted                         | 6 (6.0)              | 1 (1.0)            | 7 (3.5)                   | 3 (3.0)                 | 9 (8.8)                 | 12 (6.0)                    | 18 (3.2)                 |
| Dosenotchanged/NA/Unknown                | 20 (20.0)            | 18 (18.0)          | 38 (19.0)                 | 18 (18.2)               | 34 (33.3)               | 52 (25.9)                   | 114 (20.5)               |
| AE outcome                               |                      |                    |                           |                         |                         |                             |                          |
| Recovered/resolved                       | 18 (18.0)            | 16 (16.0)          | 34 (17.0)                 | 20 (20.2)               | 34 (33.3)               | 54 (26.9)                   | 107 (19.2)               |
| Recovering/resolving                     | 5 (5.0)              | 2 (2.0)            | 7 (3.5)                   | 5 (5.1)                 | 10 (9.8)                | 15 (7.5)                    | 26 (4.7)                 |
| Notrecovered/notresolved                 | 8 (8.0)              | 11 (11.0)          | 19 (9.5)                  | 5 (5.1)                 | 13 (12.7)               | 18 (9.0)                    | 52 (9.4)                 |

Participants/outcomewithnoeventsinStudyJ12301areomittedfromthisin-text table.Aparticipantmaybecountedinseveralrowsforactiontakenandoutcome. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024. Source:1LSCSAppendix2-Table2-14.1

## Acute pancreatitis

Overall, 14.5% of participants in the asciminib treatment group had acute pancreatitis (including isolated pancreatic enzyme elevations) AESI vs. 16.9% in IS-TKI treatment group, including 16.2% in imatinib and 17.6% in 2G TKI. The majority of patients were presenting with isolated laboratory abnormalities. Detailed information about acute pancreatitis including laboratory terms is provided in Table 69.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 69 Clinical impact of AESI Acute pancreatitis (including isolated pancreatic enzyme elevations) Safety set

|                                                                  | StudyJ12301          | StudyJ12301        | StudyJ12301               | StudyJ12301               | StudyJ12301               | StudyJ12301                | SafetyPool               |
|------------------------------------------------------------------|----------------------|--------------------|---------------------------|---------------------------|---------------------------|----------------------------|--------------------------|
|                                                                  |                      |                    | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI  |                          |
| Acutepancreatitis(includingisolatedpancreatic enzyme elevations) | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | AllAsciminib N=200 n (%)  | Imatinib 66=N n (%)       | 2G TKI N=102 n (%)        | AllComparators N=201 n (%) | AllAsciminib N=556 n (%) |
| Atleastoneevent                                                  | 21 (21.0)            | 8 (8.0)            | 29 (14.5)                 | 16 (16.2)                 | 18 (17.6)                 | 34 (16.9)                  | 114 (20.5)               |
| Lipase increased                                                 | 20 (20.0)            | 7 (7.0)            | 27 (13.5)                 | 15 (15.2)                 | 15 (14.7)                 | 30 (14.9)                  | 96 (17.3)                |
| Amylaseincreased                                                 | 9 (9.0)              | 2 (2.0)            | 11 (5.5)                  | 4 (4.0)                   | 6 (5.9)                   | 10 (5.0)                   | 53 (9.5)                 |
| Pancreatitis                                                     | 0                    | 1 (1.0)            | 1 (0.5)                   | 2 (2.0)                   | 0                         | 2 (1.0)                    | 9 (1.6)                  |
| Pancreatitis acute                                               | 1 (1.0)              | 0                  | 1 (0.5)                   | 1 (1.0)                   | 0                         | 1 (0.5)                    | 3 (0.5)                  |
| Pancreaticenzymesincreased                                       | 0                    | 0                  | 0                         | 0                         | 1 (1.0)                   | 1 (0.5)                    | 0                        |
| Maximum grade                                                    |                      |                    |                           |                           |                           |                            |                          |
| Grade3 AEs                                                       | 4 (4.0)              | 1 (1.0)            | 5 (2.5)                   | 3 (3.0)                   | 5 (4.9)                   | 8 (4.0)                    | 46 (8.3)                 |
| Grade 4AEs                                                       | 2 (2.0)              | 0                  | 2 (1.0)                   | 0                         | 1 (1.0)                   | 1 (0.5)                    | 11 (2.0)                 |
| Treatment-relatedAEs                                             | 16 (16.0)            | 7 (7.0)            | 23 (11.5)                 | 14 (14.1)                 | 14 (13.7)                 | 28 (13.9)                  | 89 (16.0)                |
| SAEs                                                             | 1 (1.0)              | 1 (1.0)            | 2 (1.0)                   | 1 (1.0)                   | 0                         | 1 (0.5)                    | 7 (1.3)                  |
| Action taken                                                     |                      |                    |                           |                           |                           |                            |                          |
| Drug withdrawn                                                   | 3 (3.0)              | 0                  | 3 (1.5)                   | 1 (1.0)                   | 0                         | 1 (0.5)                    | 13 (2.3)                 |
| Drug interrupted                                                 | 4 (4.0)              | 3 (3.0)            | 7 (3.5)                   | 2 (2.0)                   | 3 (2.9)                   | 5 (2.5)                    | 42 (7.6)                 |
| Dose not changed/NA/Unknown                                      | 20 (20.0)            | 7 (7.0)            | 27 (13.5)                 | 16 (16.2)                 | 16 (15.7)                 | 32 (15.9)                  | 103 (18.5)               |

|                                                                 | Study J12301         | Study J12301       | Study J12301             | Study J12301             | Study J12301                                  | Safety Pool              |
|-----------------------------------------------------------------|----------------------|--------------------|--------------------------|--------------------------|-----------------------------------------------|--------------------------|
|                                                                 |                      |                    |                          | InvestigatorSelected TKI | InvestigatorSelected TKI                      |                          |
| Acutepancreatitis(includingisolatedpancreatic enzymeelevations) | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | AllAsciminib N=200 n (%) | Imatinib 66=N n (%)      | 2G TKI AllComparators N=102 N=201 n (%) n (%) | AllAsciminib N=556 n (%) |
| AEoutcome                                                       |                      |                    |                          |                          |                                               |                          |
| Recovered/resolved                                              | 20 (20.0)            | 8 (8.0)            | 28 (14.0)                | 16 (16.2)                | 17 (16.7) 33 (16.4)                           | 111 (20.0)               |
| Recovering/resolving                                            | 4 (4.0)              | 0                  | 4 (2.0)                  | 4 (4.0)                  | 6 (5.9) 10 (5.0)                              | 22 (4.0)                 |
| Notrecovered/notresolved                                        | 5 (5.0)              | 2 (2.0)            | 7 (3.5)                  | 5 (5.1)                  | 5 (4.9) 10 (5.0)                              | 28 (5.0)                 |

A participant maybecounted in several rows foraction taken and outcome.Participants/outcome withno events in Study J12301are omitted from this in-text table. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024. Source:1LSCSAppendix2-Table2-14.1

## Haemorrhage

Overall, 6.5% of participants in the asciminib treatment group had Hemorrhage AESI vs. 10.9% in ISTKI treatment group, including 10.1% in imatinib and 11.8% in 2G TKI. All events were low grade (grade ≤ 2), except for one grade 3 in imatinib and three gra de 3 events in 2G TKI. There was no permanent treatment discontinuation attributed to haemorrhage. Detailed information is provided in Table 70.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 70 Clinical impact of AESI Hemorrhage - Safety set

|                          | Study J12301   | Study J12301   | Study J12301    | Study J12301            | Study J12301            | Study J12301            | Safety Pool        |
|--------------------------|----------------|----------------|-----------------|-------------------------|-------------------------|-------------------------|--------------------|
|                          |                | Asciminib      | All             | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI |                    |
|                          | Imatinib N=100 | 2G TKI N=100   | Asciminib N=200 | Imatinib 66=N           | 2G TKI N=102            | All Comparators N=201   | AllAsciminib N=556 |
|                          |                |                |                 |                         |                         |                         | n (%)              |
|                          | n (%)          |                | n (%)           | n (%)                   |                         |                         |                    |
|                          |                |                |                 |                         |                         | n (%)                   |                    |
| Hemorrhage               |                | n (%)          |                 |                         | n (%)                   |                         |                    |
| Atleastoneevent          | 6 (6.0)        | 7 (7.0)        | 13 (6.5)        | 10 (10.1)               | 12 (11.8)               | 22 (10.9)               | 76 (13.7)          |
| Contusion                | 2 (2.0)        | 2 (2.0)        | 4 (2.0)         | 0 1 (1.0)               | 3 (2.9) 1 (1.0)         | 3 (1.5) 2 (1.0)         | 18 (3.2) 10 (1.8)  |
| Epistaxis Haematoma      | 0 2 (2.0)      | 1 (1.0) 0      | 1 (0.5) 2 (1.0) | 1 (1.0)                 | 1 (1.0)                 | 2 (1.0)                 | 7 (1.3)            |
| Haematuria               | 0              | 0              | 0               | 0                       | 1 (1.0)                 | 1 (0.5)                 | 6 (1.1)            |
| Heavymenstrualbleeding   | 0              | 2 (2.0)        | 2 (1.0)         | 1 (1.0)                 | 2 (2.0)                 | 3 (1.5)                 | 6 (1.1)            |
| Haematochezia            | 1 (1.0)        | 0              | 1 (0.5)         | 1 (1.0)                 | 2 (2.0)                 | 3 (1.5)                 | 4 (0.7)            |
| Mouth haemorrhage        | 0              | 1 (1.0)        | 1 (0.5)         | 0                       | 0                       | 0                       | 4 (0.7)            |
| Vaginal haemorrhage      | 2 (2.0)        | 0              | 2 (1.0)         | 0                       | 0                       | 0                       | 4 (0.7)            |
| Conjunctival haemorrhage | 0              | 0              | 0               | 4 (4.0)                 | 0                       | 4 (2.0)                 | 3 (0.5)            |
| Bone contusion           | 0              | 0              | 0               | 0                       | 1 (1.0)                 | 1 (0.5)                 | 2 (0.4)            |
| Haemarthrosis            | 0              | 1 (1.0)        | 1 (0.5)         | 0                       | 0                       | 0                       | 1 (0.2)            |
| Haematospermia           | 0              | 1 (1.0)        | 1 (0.5)         | 0                       | 0                       | 0                       | 1 (0.2)            |
| Melaena                  | 0              | 0              | 0               | 1 (1.0)                 | 0                       | 1 (0.5)                 | 1 (0.2)            |
| Purpura                  | 0              | 0              | 0               | 1 (1.0)                 | 0                       | 1 (0.5)                 | 1 (0.2)            |
| Ecchymosis               | 0              | 0              | 0               | 1 (1.0)                 | 0                       | 1 (0.5)                 | 0                  |
| Haemorrhage subcutaneous | 0              | 0              | 0               | 0                       | 1 (1.0)                 | 1 (0.5)                 | 0                  |
| Haemorrhagicdiathesis    | 0              | 0              | 0               | 0                       | 1 (1.0)                 | 1 (0.5)                 | 0                  |
| Intestinal haemorrhage   | 0              | 0              | 0               | 0                       | 1 (1.0)                 | 1 (0.5)                 | 0                  |

|                           | Study J12301         | Study J12301       | Study J12301              | Study J12301            | Study J12301            | Study J12301                | Safety Pool              |
|---------------------------|----------------------|--------------------|---------------------------|-------------------------|-------------------------|-----------------------------|--------------------------|
|                           |                      | Asciminib          |                           | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI     |                          |
| Hemorrhage                | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | AIl Asciminib N=200 n (%) | Imatinib 66=N n (%)     | 2G TKI N=102 n (%)      | All Comparators N=201 n (%) | AllAsciminib N=556 n (%) |
| Maximum grade             |                      |                    |                           |                         |                         |                             |                          |
| Grade3 AEs                | 0                    | 0                  | 0                         | 1 (1.0)                 | 3 (2.9)                 | 4 (2.0)                     | (91)6                    |
| Treatment-related AEs     | 1 (1.0)              | 0                  | 1 (0.5)                   | 4 (4.0)                 | 3 (2.9)                 | 7 (3.5)                     | 17 (3.1)                 |
| SAEs                      | 0                    | 1 (1.0)            | 1 (0.5)                   | 1 (1.0)                 | 1 (1.0)                 | 2 (1.0)                     | 8 (1.4)                  |
| Action taken              |                      |                    |                           |                         |                         |                             |                          |
| Dose adjusted             | 0                    | 0                  | 0                         | 0                       | 1 (1.0)                 | 1 (0.5)                     | 0                        |
| Drug interrupted          | 0                    | 0                  | 0                         | 1 (1.0)                 | 1 (1.0)                 | 2 (1.0)                     | 7 (1.3)                  |
| Dosenotchanged/NA/Unknown | 6 (6.0)              | 7 (7.0)            | 13 (6.5)                  | 9 (9.1)                 | 10 (9.8)                | 19 (9.5)                    | 71 (12.8)                |
| AEoutcome                 |                      |                    |                           |                         |                         |                             |                          |
| Recovered/resolved        | 5 (5.0)              | 7 (7.0)            | 12 (6.0)                  | 8 (8.1)                 | 10 (9.8)                | 18 (9.0)                    | 71 (12.8)                |
| Notrecovered/notresolved  | 1 (1.0)              | 0                  | 1 (0.5)                   | 3 (3.0)                 | 2 (2.0)                 | 5 (2.5)                     | 10 (1.8)                 |

Aparticipant maybecounted inseveralrowsforactiontakenandoutcome.Participants/outcomewithnoeventsinStudyJ12301areomittedfromthisin-text table. Source: 1L SCS Appendix 2-Table 2-14.1

## Ischemic heart and CNS conditions related AESI

Overall incidence of ischemic heart and CNS conditions related AESI were comparable across all treatment groups: 7.5% in the asciminib group vs. 9.0% in IS-TKI group, including 7.1% in imatinib and 10.8% in 2G TKI, the effect was mostly driven by reported blood CK elevations (5.5% in asciminib group, 7.5% in IS-TKI group, 6.1% in imatinib and 8.8% in 2G TKI) with Grade 3 or 4 and SAEs were rare events across all treatment groups (reported in ≤ 3%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 71 Clinical impact of AESI Ischemic heart and CNS conditions - Safety set

|                                     | StudyJ12301          | StudyJ12301        | StudyJ12301               | StudyJ12301               | StudyJ12301               | StudyJ12301                 | SafetyPool                |
|-------------------------------------|----------------------|--------------------|---------------------------|---------------------------|---------------------------|-----------------------------|---------------------------|
|                                     |                      | Asciminib          |                           | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI   |                           |
| Ischemicheartand cNS conditions     | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | All Asciminib N=200 n (%) | Imatinib 66=N n (%)       | 2G TKI N=102 n (%)        | AIl Comparators N=201 n (%) | All Asciminib N=556 n (%) |
| Atleastone event                    | 7 (7.0)              | 8 (8.0)            | 15 (7.5)                  | 7 (7.1)                   | 11 (10.8)                 | 18 (9.0)                    | 58 (10.4)                 |
| Bloodcreatinephosphokinaseincreased | 5 (5.0)              | 6 (6.0)            | 11 (5.5)                  | 6 (6.1)                   | 9 (8.8)                   | 15 (7.5)                    | 24 (4.3)                  |
| Angina pectoris                     | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 10 (1.8)                  |
| Cerebrovascularaccident             | 1(1.0)               | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 6 (1.1)                   |
| Myocardial infarction               | 0                    | 0                  | 0                         | 0                         | 1 (1.0)                   | 1 (0.5)                     | 4 (0.7)                   |
| Myocardial ischaemia                | 0                    | 0                  | 0                         | 0                         | 1 (1.0)                   | 1 (0.5)                     | 4 (0.7)                   |
| Arteriosclerosiscoronaryartery      | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 0                         | 0                           | 2 (0.4)                   |
| Cerebralinfarction                  | 0                    | 0                  | 0                         | 0                         | 1 (1.0)                   | 1 (0.5)                     | 2 (0.4)                   |
| ElectrocardiogramTwaveabnormal      | 0                    | 1 (1.0)            | 1 (0.5)                   | 0                         | 0                         | 0                           | 2 (0.4)                   |
| ElectrocardiogramSTsegmentabnormal  | 0                    | 1 (1.0)            | 1 (0.5)                   | 1 (1.0)                   | 0                         | 1 (0.5)                     | 1 (0.2)                   |
| Maximumgrade                        |                      |                    |                           |                           |                           |                             |                           |
| Grade3 AEs                          | 0                    | 3 (3.0)            | 3 (1.5)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 16 (2.9)                  |
| Grade 4 AEs                         | 2 (2.0)              | 1 (1.0)            | 3 (1.5)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 8 (1.4)                   |
| Treatment-relatedAEs                | 2 (2.0)              | 4 (4.0)            | 6 (3.0)                   | 4 (4.0)                   | 7 (6.9)                   | 11 (5.5)                    | 20 (3.6)                  |
| SAEs                                | 2 (2.0)              | 0                  | 2 (1.0)                   | 0                         | 3 (2.9)                   | 3 (1.5)                     | 21 (3.8)                  |
| Action taken                        |                      |                    |                           |                           |                           |                             |                           |
| Drug withdrawn                      | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 3 (0.5)                   |
| Drug interrupted                    | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 3 (2.9)                   | 3 (1.5)                     | 14 (2.5)                  |
| Dose notchanged/NA/Unknown          | 6 (6.0)              | 7 (7.0)            | 13 (6.5)                  | 7 (7.1)                   | 9 (8.8)                   | 16 (8.0)                    | 50 (9.0)                  |

|                               | Study J12301   | Study J12301   | Study J12301   | Study J12301            | Study J12301            | Study J12301            | Safety Pool   |
|-------------------------------|----------------|----------------|----------------|-------------------------|-------------------------|-------------------------|---------------|
|                               |                | Asciminib      |                | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI |               |
|                               | Imatinib       | 2G TKI N=100   | AlI Asciminib  | Imatinib                | 2G TKI                  | AIl Comparators         | All Asciminib |
| IschemicheartandCNsconditions | N=100 n (%)    | n (%)          | N=200 n (%)    | 66=N n (%)              | N=102 n (%)             | N=201 n (%)             | N=556 n (%)   |
| AE outcome                    |                |                |                |                         |                         |                         |               |
| Recovered/resolved            | 6 (6.0)        | 6 (6.0)        | 12 (6.0)       | 4 (4.0)                 | 11 (10.8)               | 15 (7.5)                | 41 (7.4)      |
| Recovering/resolving          | 1 (1.0)        | 1 (1.0)        | 2 (1.0)        | 1 (1.0)                 | 0                       | 1 (0.5)                 | 7 (1.3)       |
| Notrecovered/notresolved      | 0              | 3 (3.0)        | 3 (1.5)        | 4 (4.0)                 | 2 (2.0)                 | 6 (3.0)                 | 19 (3.4)      |

A participant maybecounted inseveral rowsforaction taken andoutcome.Participants/outcome withno events inStudyJ12301are omitted from this in-text table. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024.

Source:1LSCSAppendix2-Table2-14.1

## Arterial occlusive events (AOE)

AOE were sporadic events in all treatment groups (2.0% in asciminib compared to 1.5% in IS TKI, including none in imatinib and 2.9% in 2G TKI). In the asciminib group, one patient had a grade 4 cerebrovascular accident, however, resolving the next day without residues on the brain CT scan. Two more patients had grade 1 coronary artery disease and grade 1 angina pectoris.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 72 Clinical impact of AESI Arterial-occlusive events - Safety set

|                                     |                      |                    |                           |                          |                          |                             | Safety Pool               |
|-------------------------------------|----------------------|--------------------|---------------------------|--------------------------|--------------------------|-----------------------------|---------------------------|
|                                     |                      | Asciminib          |                           | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI    |                           |
| AOEs                                | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | All Asciminib N=200 n (%) | Imatinib 66=N n (%)      | 2G TKI N=102 n (%)       | All Comparators N=201 n (%) | All Asciminib N=556 n (%) |
| Participantswithatleastoneevent     | 2 (2.0)              | 2 (2.0)            | 4 (2.0)                   | 0                        | 3 (2.9)                  | 3 (1.5)                     | 39 (7.0)                  |
| Angina pectoris                     | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                        | 0                        | 0                           | 10 (1.8)                  |
| Cerebrovascularaccident             | 1(1.0)               | 0                  | 1 (0.5)                   | 0                        | 0                        | 0                           | 6 (1.1)                   |
| Peripheralarterial occlusivedisease | 0                    | 1 (1.0)            | 1 (0.5)                   | 0                        | 0                        | 0                           | 5 (0.9)                   |
| Myocardialinfarction                | 0                    | 0                  | 0                         | 0                        | 1 (1.0)                  | 1 (0.5)                     | 4 (0.7)                   |
| Myocardialischaemia                 | 0                    | 0                  | 0                         | 0                        | 1 (1.0)                  | 1 (0.5)                     | 4 (0.7)                   |
| Arteriosclerosiscoronaryartery      | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                        | 0                        | 0                           | 2 (0.4)                   |
| Cerebral infarction                 | 0                    | 0                  | 0                         | 0                        | 1 (1.0)                  | 1 (0.5)                     | 2 (0.4)                   |
| Vertebralarteryarteriosclerosis     | 0                    | 0                  | 0                         | 0                        | 1 (1.0)                  | 1 (0.5)                     | 0                         |
| Maximum grade                       |                      |                    |                           |                          |                          |                             |                           |
| Grade 4 AEs                         | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                        | 1 (1.0)                  | 1 (0.5)                     | 3 (0.5)                   |
| Treatment-relatedAEs                | 1 (1.0)              | 2 (2.0)            | 3 (1.5)                   | 0                        | 2 (2.0)                  | 2 (1.0)                     | 14 (2.5)                  |
| SAEs                                | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                        | 2 (2.0)                  | 2 (1.0)                     | 20 (3.6)                  |
| Action taken                        |                      |                    |                           |                          |                          |                             |                           |
| Drug withdrawn                      | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                        | 0                        | 0                           | 3 (0.5)                   |
| Drug interrupted                    | 0                    | 0                  | 0                         | 0                        | 2 (2.0)                  | 2 (1.0)                     | 10 (1.8)                  |
| Dose not changed/NA/Unknown         | 1 (1.0)              | 2 (2.0)            | 3 (1.5)                   | 0                        | 2 (2.0)                  | 2 (1.0)                     | 32 (5.8)                  |

|                          | Study J12301         | Study J12301       | Study J12301              | Study J12301              | Study J12301              | Study J12301                | Safety Pool              |
|--------------------------|----------------------|--------------------|---------------------------|---------------------------|---------------------------|-----------------------------|--------------------------|
|                          |                      | Asciminib          |                           | Investigator Selected TKI | Investigator Selected TKI | Investigator Selected TKI   |                          |
| AOEs                     | Imatinib N=100 n (%) | 2G TKI N=100 n (%) | All Asciminib N=200 n (%) | Imatinib 66=N n (%)       | 2G TKI N=102 n (%)        | All Comparators N=201 n (%) | AllAsciminib N=556 n (%) |
| AE outcome               |                      |                    |                           |                           |                           |                             |                          |
| Recovered/resolved       | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 20 (3.6)                 |
| Recovering/resolving     | 1 (1.0)              | 0                  | 1 (0.5)                   | 0                         | 0                         | 0                           | 7 (1.3)                  |
| Notrecovered/notresolved | 0                    | 2 (2.0)            | 2 (1.0)                   | 0                         | 2 (2.0)                   | 2 (1.0)                     | 19 (3.4)                 |

A participant may be counted in several rows foraction taken and outcome.Participants/outcome with no events inStudyJ12301 are omitted from this in-text table. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024. Source:1LSCSAppendix2-Table2-14.1

## QTc prolongation

QTcF increase from baseline &gt;30 to ≤ 60 ms occurred in a lower proportion of participants treated with asciminib (2.5%) compared to IS-TKIs (4.5%), as well as imatinib (4.0%) and 2G TKIs (4.9%). QTc prolongation related AESI were low across all treatment groups: asciminib treatment group (2.0%), IS-TKI treatment group (2.5%), imatinib (0%) and 2G TKI (4.9%). From the four patients in the asciminib group with an AESI, only one had a nonserious grad 3 prolongation by Δ 36 ms and a subsequent dose reduction to 40 mg QD.

## Edema and fluid retention

AESI related to Edema and fluid retention occurred markedly less frequently with asciminib as compared to IS-TKIs (4.5% vs. 14.9%) including as compared to imatinib (4.5% vs. 15.2%) and to 2G TKI (4.5% vs. 14.7%), leading to no dose interruptions in the asciminib and imatinib group, but to 4.9% discontinuation, 1% dose reduction and 5.9% dose interruption of study treatment.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 73 Clinical impact of AESI QTc prolongation - Safety set

|                              |                |           |                     |                          |                          |                          | Safety Pool        |
|------------------------------|----------------|-----------|---------------------|--------------------------|--------------------------|--------------------------|--------------------|
|                              |                | Asciminib |                     | InvestigatorSelected TKI | InvestigatorSelected TKI | InvestigatorSelected TKI |                    |
|                              | Imatinib N=100 | 2G TKI    | All Asciminib N=200 | Imatinib 66=N            | 2G TKI N=102             | All Comparators N=201    | AllAsciminib N=556 |
| QTcprolongation              |                | N=100     |                     |                          |                          |                          |                    |
|                              | n (%)          |           | n (%)               |                          | n (%)                    |                          |                    |
|                              |                | n (%)     |                     | n (%)                    |                          | n (%)                    | n (%)              |
| Atleastoneevent              | 1 (1.0)        | 3 (3.0)   | 4 (2.0)             | 0                        | 5 (4.9)                  | 5 (2.5)                  | 23 (4.1)           |
| Syncope                      | 0              | 3 (3.0)   | 3 (1.5)             | 0                        | 2 (2.0)                  | 2 (1.0)                  | 11 (2.0)           |
| ElectrocardiogramQTprolonged | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 2 (2.0)                  | 2 (1.0)                  | 5 (0.9)            |
| Long QT syndrome             | 0              | 0         | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 0                  |
| Maximum grade                |                |           |                     |                          |                          |                          |                    |
| Grade3AEs                    | 1 (1.0)        | 2 (2.0)   | 3 (1.5)             | 0                        | 1 (1.0)                  | 1 (0.5)                  | 10 (1.8)           |
| Treatment-related AEs        | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 2 (2.0)                  | 2 (1.0)                  | 3 (0.5)            |
| SAEs                         | 0              | 0         | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 4 (0.7)            |
| Action taken                 |                |           |                     |                          |                          |                          |                    |
| Drug withdrawn               | 0              | 0         | 0                   | 0                        | 1 (1.0)                  | 1 (0.5)                  | 1 (0.2)            |
| Dose adjusted                | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 0                        | 0                        | 1 (0.2)            |
| Drug interrupted             | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 0                        | 0                        | 3 (0.5)            |
| Dosenotchanged/NA/Unknown    | 0              | 3 (3.0)   | 3 (1.5)             | 0                        | 5 (4.9)                  | 5 (2.5)                  | 21 (3.8)           |
| AE outcome                   |                |           |                     |                          |                          |                          |                    |
| Recovered/resolved           | 0              | 3 (3.0)   | 3 (1.5)             | 0                        | 5 (4.9)                  | 5 (2.5)                  | 20 (3.6)           |
| Recovering/resolving         | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 0                        | 0                        | 2 (0.4)            |
| Notrecovered/notresolved     | 1 (1.0)        | 0         | 1 (0.5)             | 0                        | 0                        | 0                        | 3 (0.5)            |

Aparticipantmaybecountedinseveralrowsforactiontakenandoutcome.Participants/outcomewithnoeventsinStudyJ12301areomittedfromthisin-texttable. MedDRAversion27.1,CTCAEversion5.0.CaseRetrievalStrategyversionreleased28-Nov-2024 Source:1LSCSAppendix2-Table2-14.1

## Cardiac failure

AEs pertaining to cardiac failures were reported not reported in the asciminib group in comparison to two participants 2G TKI group with grade 3 cardiac failure in a [18-86] year old participant on day 129 dasatinib treatment and a [18-86]-year-old participant with grade 3 pulmonary edema on day 161 under dasatinib treatment.

## Phototoxicity

AEs regarding phototoxicity were rare and all events were low grade with 3 (1.5%) participants in asciminib treatment group and 2 (1.0%) participants in IS-TKI treatment group.

## Hepatitis B virus infection reactivation

One participant was reported with an AE pertaining to Hepatitis B infection reactivation. This event was a grade 1 Hepatitis B reactivation (local laboratory test was positive for hepatitis B virus DNA) in imatinib-treated participant (IS-TKI treatment group). None was reported in an asciminib-treated participants.

## Laboratory findings

An overview of post baseline abnormalities for haematology and for biochemistry is provided in the tables below.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 74 Haematology worst post-baseline abnormality based on CTC grades - Safety Set

|                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                |                                                                | SafetyPool                                                     | SafetyPool                                                     |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                |                                                                |                                                                | Asciminib                                                      | Asciminib                                                      | AII                                                            | AII                                                            | Imatinib                                                       | Imatinib                                                       | InvestigatorSelectedTKI 2G TKI N=102                           | InvestigatorSelectedTKI 2G TKI N=102                           | AII Comparators N=201                                          | AII Comparators N=201                                          | AllAsciminib N=556                                             | AllAsciminib N=556                                             |
|                                                                | AlIl grades n (%)                                              | Imatinib N=100 Grade 3/4 n (%)                                 | AlIl grades n (%)                                              | 2G TKI N=100 Grade 3/4 n (%)                                   | All grades n (%)                                               | Asciminib N=200 Grade 3/4 n (%)                                | All grades n (%)                                               | 66=N Grade 3/4 n (%)                                           | AIl grades n (%)                                               | Grade 3/4 n (%)                                                | AlIl grades n (%)                                              | Grade 3/4 n (%)                                                | AIl grades n (%)                                               | Grade 3/4 n (%)                                                |
| Hemoglobin (g/L), Blood decrease                               | 69 (69.0)                                                      | 2 (2.0)                                                        | 78 (78.0)                                                      | 5 (5.0)                                                        | 147 (73.5)                                                     | 7 (3.5)                                                        | 85 (85.9)                                                      | 5 (5.1)                                                        | 93 (91.2)                                                      | 9 (8.8)                                                        | 178 (88.6)                                                     | 14 (7.0)                                                       | 384 (69.1)                                                     | 26 (4.7)                                                       |
| Leukocytes (10%/L), Blood decrease                             | 58 (58.0)                                                      | 4 (4.0)                                                        | 59 (59.0)                                                      | 6 (6.0)                                                        | 117 (58.5)                                                     | 10 (5.0)                                                       | 72 (72.7)                                                      | 15 (15.2)                                                      | 69 (67.6)                                                      | 12 (11.8)                                                      | 141 (70.1)                                                     | 27 (13.4)                                                      | 294 (52.9)                                                     | 46 (8.3)                                                       |
| Lymphocytes (10%/L), Blood decrease                            | 84 (84.0)                                                      | 3 (3.0)                                                        | 83 (83.0)                                                      | 4 (4.0)                                                        | 167 (83.5)                                                     | 7 (3.5)                                                        | 93 (93.9)                                                      | 16 (16.2)                                                      | 90 (88.2)                                                      | 7 (6.9)                                                        | 183 (91.0)                                                     | 23 (11.4)                                                      | 467 (84.0)                                                     | 42 (7.6)                                                       |
| Neutrophils (10%/L), Blooddecrease                             | 43 (43.0)                                                      | 11 (11.0)                                                      | 55 (55.0)                                                      | 14 (14.0)                                                      | 98 (49.0)                                                      | 25 (12.5)                                                      | 60 (60.6)                                                      | 21 (21.2)                                                      | 70 (68.6)                                                      | 20 (19.6)                                                      | 130 (64.7)                                                     | 41 (20.4)                                                      | 268 (48.2)                                                     | 98 (17.6)                                                      |
| Platelets (10%/L), Blood decrease                              | 46 (46.0)                                                      | 11 (11.0)                                                      | 53 (53.0)                                                      | 15 (15.0)                                                      | 66 (49.5)                                                      | 26 (13.0)                                                      | 47 (47.5)                                                      | 7 (7.1)                                                        | 68 (66.7)                                                      | 15 (14.7)                                                      | 115 (57.2)                                                     | 22 (10.9)                                                      | 295 (53.1)                                                     | 94 (16.9)                                                      |
| Prothrombin Intl. NormalizedRatio (RATIO),Plasma- increase     | 1 (1.0)                                                        | 0                                                              | 2 (2.0)                                                        | 0                                                              | 3 (1.5)                                                        | 0                                                              | 0                                                              | 0                                                              | 1 (1.0)                                                        | 0                                                              | 1 (0.5)                                                        | 0                                                              | 24 (4.3)                                                       | 3 (0.5)                                                        |
| GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 | GradesbasedonCTCAEversion5.0. Source:1LSCSAppendix2-Table3.3-3 |

Table 75 Biochemistry worst post-baseline abnormality based on CTC grades - Safety set

|                                                     | StudyJ12301      | StudyJ12301     | StudyJ12301      | StudyJ12301     | StudyJ12301      | StudyJ12301     | StudyJ12301      | StudyJ12301     | StudyJ12301      | StudyJ12301     | StudyJ12301           | StudyJ12301           | StudyJ12301         | StudyJ12301         |
|-----------------------------------------------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|------------------|-----------------|-----------------------|-----------------------|---------------------|---------------------|
|                                                     |                  |                 | Asciminib        | Asciminib       | AIl Asciminib    | AIl Asciminib   | Imatinib         | Imatinib        | 2G TKI           | 2G TKI          | AIl Comparators N=201 | AIl Comparators N=201 | All Asciminib N=556 | All Asciminib N=556 |
|                                                     | AIl grades (%) u | Grade 3/4 n (%) | AIl grades n (%) | Grade 3/4 n (%) | All grades n (%) | Grade 3/4 n (%) | All grades n (%) | Grade 3/4 n (%) | AlI grades n (%) | Grade 3/4 n (%) | All grades n (%)      | Grade 3/4 n (%)       | All grades n (%)    | Grade 3/4 n (%)     |
| Cholesterol (mmol/L), Serum- increase               | 63 (63.0)        | 0               | 52 (52.0)        | 0               | 115 (57.5)       | 0               | 34 (34.3)        | 0               | 69 (67.6)        | 0               | 103 (51.2)            | 0                     | 230 (41.4)          | 1 (0.2)             |
| Triglycerides (mmol/L),Plasma or Serum-increase     | 60 (60.0)        | 2 (2.0)         | 60 (60.0)        | 2 (2.0)         | 120 (60.0)       | 4 (2.0)         | 53 (53.5)        | 1 (1.0)         | 64 (62.7)        | 2 (2.0)         | 117 (58.2)            | 3 (1.5)               | 380 (68.3)          | 30 (5.4)            |
| Alanine Aminotransferase (U/L), Serum-increase      | 40 (40.0)        | 4 (4.0)         | 40 (40.0)        | 1 (1.0)         | 80 (40.0)        | 5 (2.5)         | 32 (32.3)        | 3 (3.0)         | 67 (65.7)        | 8 (7.8)         | 99 (49.3)             | 11 (5.5)              | 254 (45.7)          | 15 (2.7)            |
| Alkaline Phosphatase (U/L), Serum-increase          | 40 (40.0)        | 0               | 32 (32.0)        | 1 (1.0)         | 72 (36.0)        | 1 (0.5)         | 48 (48.5)        | 0               | 42 (41.2)        | 0               | 90 (44.8)             | 0                     | 156 (28.1)          | 1 (0.2)             |
| Aspartate Aminotransferase (U/L), Serum-increase    | 26 (26.0)        | 2 (2.0)         | 22 (22.0)        | 1 (1.0)         | 48 (24.0)        | 3 (1.5)         | 28 (28.3)        | 1 (1.0)         | 51 (50.0)        | 2 (2.0)         | 79 (39.3)             | 3 (1.5)               | 191 (34.4)          | 11 (2.0)            |
| Creatinine (μmol/L), Plasma or Serum-increase       | 26 (26.0)        | 0               | 20 (20.0)        | 0               | 46 (23.0)        | 0               | 44 (44.4)        | 0               | 30 (29.4)        | 0               | 74 (36.8)             | 0                     | 148 (26.6)          | 0                   |
| Lipase (U/L), Serum -increase                       | 48 (48.0)        | 13 (13.0)       | 34 (34.0)        | 10 (10.0)       | 82 (41.0)        | 23 (11.5)       | 54 (54.5)        | 9 (9.1)         | 52 (51.0)        | 16 (15.7)       | 106 (52.7)            | 25 (12.4)             | 213 (38.3)          | 75 (13.5)           |
| Amylase (U/L),Serum-increase                        | 32 (32.0)        | 2 (2.0)         | 18 (18.0)        | 0               | 50 (25.0)        | 2 (1.0)         | 25 (25.3)        | 2 (2.0)         | 38 (37.3)        | 5 (4.9)         | 63 (31.3)             | 7 (3.5)               | 146 (26.3)          | 20 (3.6)            |
| Bilirubin (μmol/L), Serum - increase                | 12 (12.0)        | 1 (1.0)         | 22 (22.0)        | 0               | 34 (17.0)        | 1 (0.5)         | 8 (8.1)          | 1 (1.0)         | 31 (30.4)        | 0               | 39 (19.4)             | 1 (0.5)               | 101 (18.2)          | 2 (0.4)             |
| Albumin(g/L),Serum-decrease                         | 2 (2.0)          | 0               | 3 (3.0)          | 0               | 5 (2.5)          | 0               | 4 (4.0)          | 0               | 3 (2.9)          | 0               | 7 (3.5)               | 0                     | 58 (10.4)           | 3 (0.5)             |
| Calcium Corrected (mmol/L), Plasma orSerum-decrease | 50 (50.0)        | 1 (1.0)         | 54 (54.0)        | 0               | 104 (52.0)       | 1 (0.5)         | 77 (77.8)        | 1 (1.0)         | 84 (82.4)        | 3 (2.9)         | 161 (80.1)            | 4 (2.0)               | 228 (41.0)          | 4 (0.7)             |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                                     | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | StudyJ12301                                                         | SafetyPool                                                          | SafetyPool                                                          |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
|                                                                     |                                                                     |                                                                     | Asciminib                                                           | Asciminib                                                           | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             | InvestigatorSelectedTKI                                             |                                                                     |                                                                     |
|                                                                     | Imatinib N=100                                                      | Imatinib N=100                                                      | 2G TKI N=100                                                        | 2G TKI N=100                                                        | All Asciminib N=200                                                 | All Asciminib N=200                                                 | Imatinib N=99                                                       | Imatinib N=99                                                       | 2G TKI N=102                                                        | 2G TKI N=102                                                        | All Comparators N=201                                               | All Comparators N=201                                               | All Asciminib N=556                                                 | All Asciminib N=556                                                 |
|                                                                     | AIl grades n (%)                                                    | Grade 3/4 n (%)                                                     | AIl grades n (%)                                                    | Grade 3/4 n (%)                                                     | AIl grades n (%)                                                    | Grade 3/4 n (%)                                                     | All grades n (%)                                                    | Grade 3/4 n (%)                                                     | All grades n (%)                                                    | Grade 3/4 n (%)                                                     | All grades n (%)                                                    | Grade 3/4 n (%)                                                     | All grades n (%)                                                    | Grade 3/4 n (%)                                                     |
| CalciumCorrected(mmol/L), Plasma or Serum-increase                  | 0                                                                   | 0                                                                   | 1 (1.0)                                                             | 0                                                                   | 1 (0.5)                                                             | 0                                                                   | 0                                                                   | 0                                                                   | 1 (1.0)                                                             | 0                                                                   | 1 (0.5)                                                             | 0                                                                   | 22 (4.0)                                                            | 1 (0.2)                                                             |
| Magnesium(mmol/L),Serum- decrease                                   | 5 (5.0)                                                             | 0                                                                   | 1 (1.0)                                                             | 0                                                                   | 6 (3.0)                                                             | 0                                                                   | 5 (5.1)                                                             | 0                                                                   | 1 (1.0)                                                             | 0                                                                   | 6 (3.0)                                                             | 0                                                                   | 62 (11.2)                                                           | 2 (0.4)                                                             |
| Magnesium(mmol/L),Serum- increase                                   | 2 (2.0)                                                             | 0                                                                   | 2 (2.0)                                                             | 1 (1.0)                                                             | 4 (2.0)                                                             | 1 (0.5)                                                             | 1 (1.0)                                                             | 0                                                                   | 4 (3.9)                                                             | 0                                                                   | 5 (2.5)                                                             | 0                                                                   | 81 (14.6)                                                           | 6 (1.1)                                                             |
| Potassium(mmol/L),Plasma or Serum-decrease                          | 2 (2.0)                                                             | 0                                                                   | 0                                                                   | 0                                                                   | 2 (1.0)                                                             | 0                                                                   | 9 (9.1)                                                             | 3 (3.0)                                                             | 5 (4.9)                                                             | 0                                                                   | 14 (7.0)                                                            | 3 (1.5)                                                             | 46 (8.3)                                                            | 5 (0.9)                                                             |
| Potassium(mmol/L),Plasma or Serum-increase                          | 16 (16.0)                                                           | 1 (1.0)                                                             | 9 (9.0)                                                             | 0                                                                   | 25 (12.5)                                                           | 1 (0.5)                                                             | 4 (4.0)                                                             | 0                                                                   | 8 (7.8)                                                             | 0                                                                   | 12 (6.0)                                                            | 0                                                                   | 128 (23.0)                                                          | 7 (1.3)                                                             |
| Sodium (mmol/L), Plasma or Serum-decrease                           | 9 (9.0)                                                             | 0                                                                   | 5 (5.0)                                                             | 0                                                                   | 14 (7.0)                                                            | 0                                                                   | 10 (10.1)                                                           | 0                                                                   | 14 (13.7)                                                           | 0                                                                   | 24 (11.9)                                                           | 0                                                                   | 75 (13.5)                                                           | 3 (0.5)                                                             |
| Sodium(mmol/L),Plasma or Serum-increase                             | 0                                                                   | 0                                                                   | 0                                                                   | 0                                                                   | 0                                                                   | 0                                                                   | 2 (2.0)                                                             | 0                                                                   | 1 (1.0)                                                             | 0                                                                   | 3 (1.5)                                                             | 0                                                                   | 39 (7.0)                                                            | 1 (0.2)                                                             |
| GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 | GradesbasedonCTCAEversion5.0. Source: 1L SCS Appendix 2-Table 3.4-3 |

## Safety by age category

The number of participants in the asciminib and IS-TKI treatment groups in each age category were: 154 and 153 participants 18 to &lt; 65 year; 46 and 48 participants ≥ 65 year; 10 and 14 participants ≥ 75 year. An overview for patients treated with asciminib according to age group irrespective of stratum is provided Table 76 ￼ .

Table 76 Overview of adverse events in asciminib-treated participants by age groups in study J12301

| Asciminib (N)                               | Age subgroup       | Age subgroup       | Age subgroup      | Age subgroup      | Age subgroup   | Age subgroup   |
|---------------------------------------------|--------------------|--------------------|-------------------|-------------------|----------------|----------------|
|                                             | 18 - <65 yrs N (%) | 18 - <65 yrs N (%) | ≥65 -74 yrs N (%) | ≥65 -74 yrs N (%) | ≥75 yrs N (%)  | ≥75 yrs N (%)  |
| J12301 (200) Grades                         | 154 All            | ≥G3                | 36 All            | ≥G3               | 10 All         | ≥G3            |
| AEs                                         | 146 (94.8)         | 62 (40.3)          | 36  (100)         | 23 (63.9)         | 9 (90.0)       | 4 (40.0)       |
| SAEs                                        | 16 (10.4)          | 11 ( (7.1)         | 10 (27.8)         | 9 (25.0)          | 3 (30.0)       | 3 (30.0)       |
| Fatal SAEs                                  | 0                  | 0                  | 0                 | 0                 | 0              | 0              |
| AEs leading to discontinuation              | 5 (3.2)            | 3 (1.9)            | 3 (8.3)           | 3 (8.3)           | 2 (20.0)       | 0              |
| AEs leading to dose adjustment interruption | 48 (31.2)          | 40 (26.0)          | 15 (41.7)         | 13 (36.1)         | 3 (30.0)       | 2 (20.0)       |
| AEs requiring additional therapy            | 128 (83.1)         | 33 (21.4)          | 31 (86.1)         | 15 (41.7)         | 9 (90.0)       | 3 (30.0)       |

Most frequent PTs by age group were presented in Table 77 , Table 78 , Table 79 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 77 Most frequent PTs by age group - Safety set subgroup 18-64 years of age (reported in at least 15% of patients in the safety pool)

|                  |                                                                                              |                                                                                              |                                                                                              |                                                                                              | Study J12301                                                                                 | Study J12301                                                                                 | Study J12301                                                                                 | Study J12301                                                                                 | InvestigatorSelectedTKl                                                                      |                                                                                              |                                                                                              |                                                                                              | SafetyPool                                                                                   |                                                                                              |
|------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
|                  | Imatinib N=100                                                                               | Imatinib N=100                                                                               | Asciminib 2G TKI N=100                                                                       | Asciminib 2G TKI N=100                                                                       | All Asciminib N=200                                                                          | All Asciminib N=200                                                                          | Imatinib N=99                                                                                | Imatinib N=99                                                                                | 2G TKI N=102                                                                                 | 2G TKI N=102                                                                                 | All Comparators N=201                                                                        | All Comparators N=201                                                                        | All Asciminib N=556                                                                          | All Asciminib N=556                                                                          |
|                  | AIl grades                                                                                   | Grade ≥3                                                                                     | AIl grades                                                                                   | Grade ≥3                                                                                     | All grades                                                                                   | Grade ≥3                                                                                     | All grades                                                                                   | Grade ≥3                                                                                     | AlIl grades                                                                                  | Grade ≥3                                                                                     | All grades                                                                                   | Grade ≥3                                                                                     | AIl grades                                                                                   | Grade ≥3                                                                                     |
| PreferredTerm    |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              |                                                                                              | n (%)                                                                                        |                                                                                              |                                                                                              |
|                  | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        |                                                                                              | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        | n (%)                                                                                        |                                                                                              | n (%)                                                                                        | n (%)                                                                                        |
|                  | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) | n (%) Subgroup: 18 -<65 year (reported in at least 15.0% of participants in the Safety pool) |
|                  | n=68                                                                                         | n=68                                                                                         | n=86                                                                                         | n=86                                                                                         | n=154                                                                                        | n=154                                                                                        | n=68                                                                                         | n=68                                                                                         | n=8                                                                                          | n=8                                                                                          | n=153                                                                                        | n=153                                                                                        | n=426                                                                                        | n=426                                                                                        |
| Atleastoneevent  | 66 (97.1)                                                                                    | 29 (42.6)                                                                                    | 80 (93.0)                                                                                    | 33 (38.4)                                                                                    | 146 (94.8)                                                                                   | 62 (40.3)                                                                                    | 65 (95.6)                                                                                    | 32 (47.1)                                                                                    | 85(100)48(56.5)                                                                              |                                                                                              | 150 (98.0)                                                                                   | 80 (52.3)                                                                                    | 405 (95.1)                                                                                   | 233 (54.7)                                                                                   |
| Headache         | 10 (14.7)                                                                                    | 1 (1.5)                                                                                      | 13 (15.1)                                                                                    | 0                                                                                            | 23 (14.9)                                                                                    | 1 (0.6)                                                                                      | 8 (11.8)                                                                                     | 0                                                                                            | 21 (24.7)                                                                                    | 0                                                                                            | 29 (19.0)                                                                                    | 0                                                                                            | 103 (24.2)                                                                                   | 8 (1.9)                                                                                      |
| Fatigue          | 11 (16.2)                                                                                    | 0                                                                                            | 14 (16.3)                                                                                    | 1 (1.2)                                                                                      | 25 (16.2)                                                                                    | 1 (0.6)                                                                                      | 10 (14.7)                                                                                    | 1 (1.5)                                                                                      | 16 (18.8)                                                                                    | 0                                                                                            | 26 (17.0)                                                                                    | 1 (0.7)                                                                                      | 92 (21.6)                                                                                    | 4 (0.9)                                                                                      |
| Diarrhoea        | 8 (11.8)                                                                                     | 0                                                                                            | 20 (23.3)                                                                                    | 0                                                                                            | 28 (18.2)                                                                                    | 0                                                                                            | 17 (25.0)                                                                                    | 0                                                                                            | 20 (23.5)                                                                                    | 1 (1.2)                                                                                      | 37 (24.2)                                                                                    | 1 (0.7)                                                                                      | 88 (20.7)                                                                                    | 2 (0.5)                                                                                      |
| Arthralgia       | 10 (14.7)                                                                                    | 1 (1.5)                                                                                      | 9 (10.5)                                                                                     | 1 (1.2)                                                                                      | 19 (12.3)                                                                                    | 2 (1.3)                                                                                      | 8 (11.8)                                                                                     | 0                                                                                            | 7 (8.2)                                                                                      | 0                                                                                            | 15 (9.8)                                                                                     | 0                                                                                            | 85 (20.0)                                                                                    | 5 (1.2)                                                                                      |
| COVID-19         | 9 (13.2)                                                                                     | 0                                                                                            | 24 (27.9)                                                                                    | 0                                                                                            | 33 (21.4)                                                                                    | 0                                                                                            | 17 (25.0)                                                                                    | 0                                                                                            | 19 (22.4)                                                                                    | 0                                                                                            | 36 (23.5)                                                                                    | 0                                                                                            | 84 (19.7)                                                                                    | 3 (0.7)                                                                                      |
| Rash             | 9 (13.2)                                                                                     | 0                                                                                            | 17 (19.8)                                                                                    | 0                                                                                            | 26 (16.9)                                                                                    | 0                                                                                            | 6 (8.8)                                                                                      | 1 (1.5)                                                                                      | 20 (23.5)                                                                                    | 1 (1.2)                                                                                      | 26 (17.0)                                                                                    | 2 (1.3)                                                                                      | 78 (18.3)                                                                                    | 0                                                                                            |
| Thrombocytopenia | 10 (14.7)                                                                                    | 6 (8.8)                                                                                      | 10 (11.6)                                                                                    | 5 (5.8)                                                                                      | 20 (13.0)                                                                                    | 11 (7.1)                                                                                     | 10 (14.7)                                                                                    | 3 (4.4)                                                                                      | 15 (17.6)                                                                                    | 7 (8.2)                                                                                      | 25 (16.3)                                                                                    | 10 (6.5)                                                                                     | 78 (18.3)                                                                                    | 51 (12.0)                                                                                    |
| Nausea           | 4 (5.9)                                                                                      | 0                                                                                            | 10 (11.6)                                                                                    | 0                                                                                            | 14 (9.1)                                                                                     | 0                                                                                            | 14 (20.6)                                                                                    | 0                                                                                            | 16 (18.8)                                                                                    | 0                                                                                            | 30 (19.6)                                                                                    | 0                                                                                            | 71 (16.7)                                                                                    | 2 (0.5)                                                                                      |
| StudyJ12301      | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | StudyJ12301                                                                                  | Safety Pool                                                                                  | Safety Pool                                                                                  |
|                  | Imatinib                                                                                     | Imatinib                                                                                     | Asciminib 2G TKI                                                                             | Asciminib 2G TKI                                                                             | AllAsciminib                                                                                 | AllAsciminib                                                                                 | Imatinib                                                                                     | Imatinib                                                                                     | InvestigatorSelectedTKI 2G TKI                                                               | InvestigatorSelectedTKI 2G TKI                                                               | All Comparators                                                                              | All Comparators                                                                              | All Asciminib                                                                                | All Asciminib                                                                                |
| Lipase increased | 12 (17.6)                                                                                    | 5 (7.4)                                                                                      | 7 (8.1)                                                                                      | 0                                                                                            | 19 (12.3)                                                                                    | 5 (3.2)                                                                                      | 9 (13.2)                                                                                     | 1 (1.5)                                                                                      | 11 (12.9)                                                                                    | 4 (4.7)                                                                                      | 20 (13.1)                                                                                    | 5 (3.3)                                                                                      | 68 (16.0)                                                                                    | 37 (8.7)                                                                                     |
| Myalgia          | 12 (17.6)                                                                                    | 0                                                                                            | 13 (15.1)                                                                                    | 1 (1.2)                                                                                      | 25 (16.2)                                                                                    | 1 (0.6)                                                                                      | 18 (26.5)                                                                                    | 0                                                                                            | 15 (17.6)                                                                                    | 0                                                                                            | 33 (21.6)                                                                                    | 0                                                                                            | 65 (15.3)                                                                                    | 5 (1.2)                                                                                      |
| Hypertension     | 9 (13.2)                                                                                     | 4 (5.9)                                                                                      | 5 (5.8)                                                                                      | 2 (2.3)                                                                                      | 14 (9.1)                                                                                     | 6 (3.9)                                                                                      | 3 (4.4)                                                                                      | 0                                                                                            | 4 (4.7)                                                                                      | 4 (4.7)                                                                                      | 7 (4.6)                                                                                      | 4 (2.6)                                                                                      | 64                                                                                           | 29 (6.8)                                                                                     |

Source: SOS, CML 1L,  Table 5-1

Table 78 Most frequent PTs by age group - Safety set subgroup &gt;=65 years of age

|                   |                                                                                    |                                                                                    |                                                                                    |                                                                                    | Study J12301                                                                       | Study J12301                                                                       | Study J12301                                                                       | Study J12301                                                                       |                                                                                    |                                                                                    |                                                                                    |                                                                                    | SafetyPool                                                                         | SafetyPool                                                                         |
|-------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
|                   | Imatinib N-100                                                                     | Imatinib N-100                                                                     | Asciminib 2G TKI N-100                                                             | Asciminib 2G TKI N-100                                                             | All Asciminib N-200                                                                | All Asciminib N-200                                                                | Imatinib 66=N                                                                      | Imatinib 66=N                                                                      | 2G TKI N=102                                                                       | 2G TKI N=102                                                                       | InvestigatorSelectedTKI All Comparators N=201                                      | InvestigatorSelectedTKI All Comparators N=201                                      | All Asciminib N=556                                                                | All Asciminib N=556                                                                |
|                   | AII grades                                                                         | Grade                                                                              | AIl grades                                                                         | Grade                                                                              | AIl grades                                                                         | Grade                                                                              | AII grades                                                                         | Grade                                                                              | AIl grades                                                                         | Grade                                                                              | All grades                                                                         | Grade                                                                              | AII grades                                                                         | Grade ≥3                                                                           |
| PreferredTerm     | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              | n (%)                                                                              |
|                   | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) | Subgroup: ≥65 year (reported in at least 15.0% of participants in the Safety pool) |
|                   | n=32                                                                               | n=32                                                                               | n=14                                                                               | n=14                                                                               | n=46                                                                               | n=46                                                                               | n=31                                                                               | n=31                                                                               | n=17                                                                               | n=17                                                                               | n=48                                                                               | n=48                                                                               | n=130                                                                              | n=130                                                                              |
| Atleastoneevent   | 31 (96.9)                                                                          | 19 (59.4)                                                                          | 14 (100)                                                                           | 8 (57.1)                                                                           | 45 (97.8)                                                                          | 27 (58.7)                                                                          | 30 (96.8)                                                                          | 17 (54.8)                                                                          | 17 (100)                                                                           | 13 (76.5)                                                                          | 47 (97.9)                                                                          | 30 (62.5)                                                                          | 128 (98.5)                                                                         | 91 (70.0)                                                                          |
| Thrombocytopenia  | 5 (15.6)                                                                           | 3 (9.4)                                                                            | 2 (14.3)                                                                           | 2 (14.3)                                                                           | 7 (15.2)                                                                           | 5 (10.9)                                                                           | 4 (12.9)                                                                           | 1 (3.2)                                                                            | 2 (11.8)                                                                           | 0                                                                                  | 6 (12.5)                                                                           | 1 (2.1)                                                                            | 31 (23.8)                                                                          | 19 (14.6)                                                                          |
| Arthralgia        | 6 (18.8)                                                                           | 2 (6.3)                                                                            | 1 (7.1)                                                                            | 0                                                                                  | 7 (15.2)                                                                           | 2 (4.3)                                                                            | 2 (6.5)                                                                            | 1 (3.2)                                                                            | 2 (11.8)                                                                           | 0                                                                                  | 4 (8.3)                                                                            | 1 (2.1)                                                                            | 30 (23.1)                                                                          | 4 (3.1)                                                                            |
| Hypertension      | 5 (15.6)                                                                           | 4 (12.5)                                                                           | 2 (14.3)                                                                           | 1 (7.1)                                                                            | 7 (15.2)                                                                           | 5 (10.9)                                                                           | 2 (6.5)                                                                            | 2 (6.5)                                                                            | 1 (5.9)                                                                            | 1 (5.9)                                                                            | 3 (6.3)                                                                            | 3 (6.3)                                                                            | 30 (23.1)                                                                          | 22 (16.9)                                                                          |
| Lipaseincreased   | 8 (25.0)                                                                           | 1 (3.1)                                                                            | 0                                                                                  | 0                                                                                  | 8 (17.4)                                                                           | 1 (2.2)                                                                            | 6 (19.4)                                                                           | 1 (3.2)                                                                            | 4 (23.5)                                                                           | 1 (5.9)                                                                            | 10 (20.8)                                                                          | 2 (4.2)                                                                            | 28 (21.5)                                                                          | 11 (8.5)                                                                           |
| Diarhoea          | 6 (18.8)                                                                           | 0                                                                                  | 1 (7.1)                                                                            | 0                                                                                  | 7 (15.2)                                                                           | 0                                                                                  | 11 (35.5)                                                                          | 0                                                                                  | 8 (47.1)                                                                           | 1 (5.9)                                                                            | 19 (39.6)                                                                          | 1 (2.1)                                                                            | 27 (20.8)                                                                          | 0                                                                                  |
| Fatigue           | 4 (12.5)                                                                           | 0                                                                                  | 1 (7.1)                                                                            | 0                                                                                  | 5 (10.9)                                                                           | 0                                                                                  | 5 (16.1)                                                                           | 0                                                                                  | 4 (23.5)                                                                           | 0                                                                                  | 9 (18.8)                                                                           | 0                                                                                  | 24 (18.5)                                                                          | 2 (1.5)                                                                            |
| Headache          | 8 (25.0)                                                                           | 0                                                                                  | 2 (14.3)                                                                           | 0                                                                                  | 10 (21.7)                                                                          | 0                                                                                  | 1 (3.2)                                                                            | 0                                                                                  | 3 (17.6)                                                                           | 0                                                                                  | 4 (8.3)                                                                            | 0                                                                                  | 24 (18.5)                                                                          | 0                                                                                  |
| Pain in extremity | 3 (9.4)                                                                            | 1 (3.1)                                                                            | 1 (7.1)                                                                            | 0                                                                                  | 4 (8.7)                                                                            | 1 (2.2)                                                                            | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 23                                                                                 | 2 (1.5)                                                                            |

(15.0)

(17.7)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Assessment report EMADOC-1700519818-2475374

<div style=\"page-break-after: always\"></div>

|              | StudyJ12301   | StudyJ12301   | StudyJ12301   | StudyJ12301   | StudyJ12301   | StudyJ12301   | StudyJ12301             | StudyJ12301             | StudyJ12301             | StudyJ12301             | StudyJ12301             | StudyJ12301             | SafetyPool   | SafetyPool   |
|--------------|---------------|---------------|---------------|---------------|---------------|---------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------|--------------|
|              |               |               | Asciminib     | Asciminib     |               |               | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI | InvestigatorSelectedTKI |              |              |
|              | Imatinib      | Imatinib      | 2G TKI        | 2G TKI        | AllAsciminib  | AllAsciminib  | Imatinib                | Imatinib                | 2G TKI                  | 2G TKI                  | AllComparators          | AllComparators          | AllAsciminib | AllAsciminib |
| Anaemia      | 4 (12.5)      | 0             | 1 (7.1)       | 1 (7.1)       | 5 (10.9)      | 1 (2.2)       | 9 (29.0)                | 0                       |                         | 7 (41.2)2 (11.8)        | 16 (33.3)               | 2 (4.2)                 | 22 (16.9)    | 9 (6.9)      |
| Nausea       | 4 (12.5)      | 0             | 1 (7.1)       | 0             | 5 (10.9)      | 0             | 7 (22.6)                | 0                       | 3 (17.6)                | 0                       | 10 (20.8)               | 0                       | 22 (16.9)    | 1 (0.8)      |
| Constipation | 5 (15.6)      | 0             | 4 (28.6)      | 0             | 9 (19.6)      | 0             | 0                       | 0                       | 5 (29.4)                | 1 (5.9)                 | 5 (10.4)                | 1 (2.1)                 | 20 (15.4)    | 0            |
| Neutropenia  | 3 (9.4)       | 1 (3.1)       | 1 (7.1)       | 1 (7.1)       | 4 (8.7)       | 2 (4.3)       |                         |                         | 8 (25.8)6(19.4)2(11.8)  | 1 (5.9)                 | 10 (20.8)               | 7 (14.6)                | 20 (15.4)    | 14 (10.8)    |

Table 79 Most frequent PTs by age group - Safety set subgroup &gt;=75 years of age

|                                                                                                                                               |                  |          |                                                                            |                                                                            | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | InvestigatorSelectedTKl                                                    |                                                                            |                                                                            |                                                                            | Safety Pool                                                                |                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------|----------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
|                                                                                                                                               | Imatinib         | Imatinib | Asciminib 2G TKI N-100                                                     | Asciminib 2G TKI N-100                                                     | AllAsciminib                                                               | AllAsciminib                                                               | Imatinib 66=N                                                              | Imatinib 66=N                                                              | 2G TKI N=102                                                               | 2G TKI N=102                                                               | All Comparators N-201                                                      | All Comparators N-201                                                      | All Asciminib N=556                                                        | All Asciminib N=556                                                        |
|                                                                                                                                               | N-100 AII grades | Grade    | AlI grades                                                                 | Grade ≥3                                                                   | AlIl grades                                                                | N200 Grade                                                                 | AlI grades                                                                 | Grade ≥3                                                                   | AIl grades                                                                 | Grade                                                                      | AlIl grades                                                                | Grade                                                                      | AIl grades                                                                 | Grade 23                                                                   |
| Preferred Term                                                                                                                                | n (%)            | n (%)    | n (%)                                                                      | n (%)                                                                      | n (%)                                                                      | n (%)                                                                      |                                                                            | n (%)                                                                      | n (%)                                                                      | n (%)                                                                      |                                                                            | n (%)                                                                      | n (%)                                                                      | n (%)                                                                      |
|                                                                                                                                               |                  |          |                                                                            |                                                                            |                                                                            |                                                                            | n (%)                                                                      |                                                                            |                                                                            |                                                                            | n (%)                                                                      |                                                                            |                                                                            |                                                                            |
|                                                                                                                                               |                  |          | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) | Subgroup:≥75year(reported in atleast 15.0%of participants intheSafetypool) |
|                                                                                                                                               | n=8              | n=8      | n=2                                                                        | n=2                                                                        | n=10                                                                       | n=10                                                                       | n=9                                                                        | n=9                                                                        | n=5                                                                        | n=5                                                                        | n=14                                                                       | n=14                                                                       | n=31                                                                       | n=31                                                                       |
| At least one event                                                                                                                            | 7 (87.5)         | 3 (37.5) | 2(100)                                                                     | 1 (50.0)                                                                   | 9 (90.0)                                                                   | 4 (40.0)                                                                   | 9 (100)                                                                    | 5 (55.6)                                                                   | 5 (100)                                                                    | 5 (100)                                                                    | 14 (100)                                                                   | 10 (71.4)                                                                  | 30 (96.8)                                                                  | 21 (67.7)                                                                  |
| Arthralgia                                                                                                                                    | 2 (25.0)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 1 (11.1)                                                                   | 1 (11.1)                                                                   | 1 (20.0)                                                                   | 0                                                                          | 2 (14.3)                                                                   | 1 (7.1)                                                                    | 13 (41.9)                                                                  | 1 (3.2)                                                                    |
| Nausea                                                                                                                                        | 2 (25.0)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 4 (44.4)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 4 (28.6)                                                                   | 0                                                                          | 11 (35.5)                                                                  | 0                                                                          |
| Hypertension                                                                                                                                  | 2 (25.0)         | 2 (25.0) | 0                                                                          | 0                                                                          | 2 (20.0)                                                                   | 2 (20.0)                                                                   | 0                                                                          | 0                                                                          | 1 (20.0)                                                                   | 1 (20.0)                                                                   | 1 (7.1)                                                                    | 1 (7.1)                                                                    | 9 (29.0)                                                                   | 8 (25.8)                                                                   |
| Pain in extremity                                                                                                                             | 2 (25.0)         | 1 (12.5) | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 1(10.0)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 9 (29.0)                                                                   | 1 (3.2)                                                                    |
| Constipation                                                                                                                                  | 2 (25.0)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 3 (60.0)                                                                   | 0                                                                          | 3 (21.4)                                                                   | 0                                                                          | 8 (25.8)                                                                   | 0                                                                          |
| Diarhoea                                                                                                                                      | 2 (25.0)         | 0        | 0                                                                          | 0                                                                          | 2 (20.0)                                                                   | 0                                                                          | 5 (55.6)                                                                   | 0                                                                          | 4 (80.0)                                                                   | 0                                                                          | 9 (64.3)                                                                   | 0                                                                          | 8 (25.8)                                                                   | 0                                                                          |
| Fatigue                                                                                                                                       | 1 (12.5)         | 0        | 0                                                                          | 0                                                                          | 1 (10.0)                                                                   | 0                                                                          | 2 (22.2)                                                                   | 0                                                                          | 3 (60.0)                                                                   | 0                                                                          | 5 (35.7)                                                                   | 0                                                                          | 8 (25.8)                                                                   | 1 (3.2)                                                                    |
| Headache                                                                                                                                      | 3 (37.5)         | 0        | 0                                                                          | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 8 (25.8)                                                                   | 0                                                                          |
| Pruritus                                                                                                                                      | 2 (25.0)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 8 (25.8)                                                                   | 0                                                                          |
| Back pain                                                                                                                                     | 1 (12.5)         | 0        | 0                                                                          | 0                                                                          | 1 (10.0)                                                                   | 0                                                                          | 2 (22.2)                                                                   | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 3 (21.4)                                                                   | 0                                                                          | 6 (19.4)                                                                   | 0                                                                          |
| COVID-19                                                                                                                                      | 2 (25.0)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 3 (30.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 1 (7.1)                                                                    | 0                                                                          | 6 (19.4)                                                                   | 0                                                                          |
|                                                                                                                                               |                  |          |                                                                            |                                                                            | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Study J12301                                                               | Safety Pool                                                                | Safety Pool                                                                |
|                                                                                                                                               |                  |          | Asciminib                                                                  | Asciminib                                                                  |                                                                            |                                                                            |                                                                            |                                                                            | InvestigatorSelectedTKl                                                    | InvestigatorSelectedTKl                                                    |                                                                            |                                                                            |                                                                            |                                                                            |
|                                                                                                                                               | Imatinib         | Imatinib |                                                                            |                                                                            |                                                                            |                                                                            | Imatinib                                                                   | Imatinib                                                                   | 2G TKI                                                                     | 2G TKI                                                                     |                                                                            |                                                                            |                                                                            |                                                                            |
|                                                                                                                                               |                  |          | 2G TKI                                                                     | 2G TKI                                                                     | All Asciminib                                                              | All Asciminib                                                              |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |
|                                                                                                                                               |                  |          |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            | All Comparators                                                            | All Comparators                                                            | All Asciminib                                                              | All Asciminib                                                              |
|                                                                                                                                               |                  | 0        | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 2 (22.2)                                                                   | 2 (22.2)                                                                   |                                                                            |                                                                            | 3 (21.4) 1 (7.1)                                                           | 3 (21.4) 1 (7.1)                                                           |                                                                            |                                                                            |
| Lipase increased                                                                                                                              | 0                |          |                                                                            |                                                                            | 0                                                                          |                                                                            |                                                                            | 1 (11.1)                                                                   | 1 (20.0)                                                                   | 0                                                                          |                                                                            |                                                                            | 6 (19.4)                                                                   | 2 (6.5)                                                                    |
| Platelet count decreased                                                                                                                      | 1 (12.5)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 2 (20.0)                                                                   | 0                                                                          | 1 (11.1)                                                                   | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 2 (14.3)                                                                   | 0                                                                          | 6 (19.4)                                                                   | 3 (9.7)                                                                    |
| Thrombocytopenia                                                                                                                              | 0                | 0        | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 1 (11.1)                                                                   | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 2 (14.3)                                                                   | 0                                                                          | 6 (19.4)                                                                   | 5 (16.1)                                                                   |
| Vomiting                                                                                                                                      | 1 (12.5)         | 0        | 0                                                                          | 0                                                                          | 1 (10.0)                                                                   | 0                                                                          | 3 (33.3)                                                                   | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 4 (28.6)                                                                   | 0                                                                          | 6 (19.4)                                                                   | 1 (3.2)                                                                    |
| Abdominal pain                                                                                                                                | 0                | 0        | 1 (50.0)                                                                   | 1 (50.0)                                                                   | 1 (10.0)                                                                   | 1 (10.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 5 (16.1)                                                                   | 2 (6.5)                                                                    |
| Amylaseincreased                                                                                                                              | 0                | 0        | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 1 (11.1)                                                                   | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 2 (14.3)                                                                   | 0                                                                          | 5 (16.1)                                                                   | 0                                                                          |
| Anaemia                                                                                                                                       | 1 (12.5)         | 0        |                                                                            |                                                                            | 2 (20.0)                                                                   |                                                                            | 4 (44.4)                                                                   |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            | 5 (16.1)                                                                   | 3 (9.7)                                                                    |
|                                                                                                                                               |                  |          | 1 (50.0)                                                                   | 1 (50.0)                                                                   |                                                                            | 1 (10.0)                                                                   |                                                                            | 0                                                                          | 4 (80.0)                                                                   | 1 (20.0)                                                                   | 8 (57.1)                                                                   | 1 (7.1)                                                                    |                                                                            |                                                                            |
| Insomnia                                                                                                                                      | 1 (12.5)         | 0        | 1 (50.0)                                                                   | 0                                                                          | 2 (20.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 5 (16.1)                                                                   | 0                                                                          |
| Myalgia A participant with multiple severity grades for lan AE is only counted under the maximum grade.MedDRA version 27.1,CTCAE version 5.0. | 2 (25.0)         | 0        | 2 (100)                                                                    | 0                                                                          | 4 (40.0)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          | 1 (20.0)                                                                   | 0                                                                          | 1 (7.1)                                                                    | 0                                                                          | 5 (16.1)                                                                   | 0                                                                          |

The secondary endpoint of TTDAE was numerically in favour of asciminib in different age groups.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 80 Cause specific hazard ratios of TTDAE by age subgroups (Safety Set)

| Age group            | All asciminib m/N (%)      | All controls m/N (%)   | Hazard ratio (95% CI) *   | Imatinib m/N (%)     | Hazardratio (95% CI) *   | 2G TKI m/N (%)       | Hazard ratio (95% CI) *   |
|----------------------|----------------------------|------------------------|---------------------------|----------------------|--------------------------|----------------------|---------------------------|
| All                  | 12/200 26/201 (6.0) (12.9) | 0.419 (0.216, 0.814)   | 13/99 (13.1)              | 0.381 (0.178, 0.818) | 13/102 (12.7)            | 0.463 (0.215, 0.997) |                           |
| 7/154 (18, 65] (4.5) | 16/153 (10.5)              |                        | 0.400 (0.170, 0.944)      | 8/68 (11.8)          | 0.356 (0.134, 0.940)     | 8/85 (9.4)           | 0.468 (0.174, 1.261)      |
| (65, 75]             | 3/36 (8.3)                 | 4/34 (11.8)            | 0.664 (0.150, 2.937)      | 2/22 (9.1)           | 0.824 (0.138,4.928)      | 2/12 (16.7)          | 0.484 (0.084,2.791)       |
| 75 or older          | 2/10 (20.0)                | 6/14 (42.9)            | 0.136 (0.022, 0.852)      | 3/9 (33.3)           | 0.189 (0.024, 1.466)     | 3/5 (60.0)           | 0.076 (0.011, 0.516)      |

m: number of participants experienced TTDAE in each subgroup.

N: number of participants in each subgroup

* Hazard ratios are “All asciminib\" vs “All controls\", \"Imatinib\", and “2G TKI

Sources:Week 96 CSR Tables 14.3.1-30.2.1,14.3.1-30.2.2,14.3.1-30.2.3,Appendix Tables 14.3.1-30.2.1a,

14.3.1-30.2.2a,14.3.1-30.2.3a

## Safety related to drug-drug interactions and other interactions

Asciminib is a substrate of CYP3A4, UGT2B7 and UGT2B17, contributing with 36.0%, 13.3% and 7.8% to its clearance, respectively. It is estimated that the efflux transporter BCRP contributes to total systemic clearance by 31.1%. New DDI information from Study A2111 and Study A2110 has been provided as part of an ongoing procedure to update the prescribing information. Study A2111 demonstrated a small, but not clinically relevant increase in exposure of atorvastatin when coadministered with asciminib and no changes in CP-1 concentrations in coadministration with asciminib. Study A2111 also provided evidence that OATP1B is not inhibited by asciminib at 80 mg once daily dose. In addition, Study A2110 demonstrated no change in CP-1 concentrations following a single dose of 200 mg asciminib, providing further evidence that there is no clinically relevant interaction between asciminib and OATP1B substrates at all recommended doses (80 mg total daily dose and 200 mg twice daily).

## Discontinuation, interruption and dose reduction due to adverse events

The cumulative incidences of AEs leading to treatment discontinuation were always lower at each time point (at Week 8, 24, 48, 96) in the asciminib treatment group compared to the IS- TKI treatment group, including compared to imatinib and 2G TKI ( Table 81 ). The overall incidence of treatmentrelated AEs leading to dose interruption were lower in the asciminib group (22.5%) compared to the IS-TKI group (37.8%), including compared to imatinib (31.3%) and to 2G TKI (32.4%). The overall incidence of treatment-related AEs leading to dose reduction all grades was lower in the asciminib group (6.0%) compared to the IS-TKI group (20.4%), including compared to imatinib (16.2%) and to 2G TKI (24.5%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 81 Cumulative incidences of AEs leading to study drug discontinuation - Safety set

|                    |                    |                    |                    |                    | StudyJ12301            | StudyJ12301        | StudyJ12301           | StudyJ12301        | StudyJ12301             | StudyJ12301             | StudyJ12301            | StudyJ12301        | SafetyPool             | SafetyPool         |
|--------------------|--------------------|--------------------|--------------------|--------------------|------------------------|--------------------|-----------------------|--------------------|-------------------------|-------------------------|------------------------|--------------------|------------------------|--------------------|
|                    |                    |                    | Asciminib          | Asciminib          | AlI                    | AlI                | Imatinib              | Imatinib           | InvestigatorSelectedTKl | InvestigatorSelectedTKl | AlI Comparators        | AlI Comparators    | AlI Asciminib          | AlI Asciminib      |
|                    | N=100 All grades   | Grade              | N=100 All grades   | Grade ≥3           | N=200 All grades n (%) | Grade ≥3           | N=99 All grades n (%) | Grade ≥3           | All grades n (%)        | N=102 Grade ≥3 n (%)    | N=201 All grades n (%) | Grade ≥3           | N=556 All grades n (%) | Grade ≥3           |
|                    | n (%)              | ≥3 n (%)           |                    |                    |                        | n (%)              |                       | n (%)              |                         |                         |                        | n (%)              |                        | (%) u              |
|                    | cum.IP             | cum.IP             | n (%) cum.IP       | n (%) cum.IP       | cum.IP                 | cum.IP             | cum.IP                | cum.IF             | cum.IP                  | cum.IP                  | cum.IP                 | cum.IP             | cum.IP                 | cum.IP             |
| Atleastoneeventat: | Atleastoneeventat: | Atleastoneeventat: | Atleastoneeventat: | Atleastoneeventat: | Atleastoneeventat:     | Atleastoneeventat: | Atleastoneeventat:    | Atleastoneeventat: | Atleastoneeventat:      | Atleastoneeventat:      | Atleastoneeventat:     | Atleastoneeventat: | Atleastoneeventat:     | Atleastoneeventat: |
| Week8 (Day 56)     | 3 (3.0)            | 2 (2.0)            | 0                  | 0                  | 3 (1.5)                | 2 (1.0)            | 4 (4.0)               | 2 (2.0)            | 3 (2.9)                 | 1 (1.0)                 | 7 (3.5)                | 3 (1.5)            | 16 (2.9)               | 14 (2.5)           |
| Week24 (Day 168)   | 5 (5.0)            | 3 (3.0)            | 1 (1.0)            | 1 (1.0)            | 6 (3.0)                | 4 (2.0)            | 6 (6.1)               | 3 (3.0)            | 4 (3.9)                 | 2 (2.0)                 | 10 (5.0)               | 5 (2.5)            | 27 (4.9)               | 23 (4.1)           |
| Week48 (Day 336)   | 5 (5.0)            | 3 (3.0)            | 2 (2.0)            | 2 (2.0)            | 7 (3.5)                | 5 (2.5)            | 12 (12.1)             | 6 (6.1)            | 5 (4.9)                 | 3 (2.9)                 | 17 (8.5)               | 9 (4.5)            | 30 (5.4)               | 25 (4.5)           |
| Week96 (Day 672)   | 6 (6.0)            | 3 (3.0)            | 3 (3.0)            | 3 (3.0)            | 9 (4.5)                | 6 (3.0)            | 13 (13.1)             | 7 (7.1)            | 13 (12.7)               | 5 (4.9)                 | 26 (12.9)              | 12 (6.0)           | 36 (6.5)               | 29 (5.2)           |

Cum IP= cumulative incidence proportion up toDay x,considering competing risks(death,discontinuation due to any reason).

MedDRA version 27.1,CTCAEversion 5.0.

Source:[1L SCS Appendix 2-Table 2.1-11]

## Post marketing experience

The post-marketing experience with asciminib has been reviewed on an ongoing basis since the first registration in the United States on 29-Oct-2021. The most recent PSUR submitted to the EMA, covering the interval 29-Oct-2023 to 28-Apr-2024, presented post-marketing analyses representing an estimated cumulative post-marketing exposure of 7,601 PTY.

## 2.5.2. Extension of the indication to 2nd line CML-CP treatment

Listings were provided for the assessment of safety in 101 patients from ongoing study ABL001AUS08 2 nd  line safety cohort (n=101 patients). The median duration of exposure to study treatment was 26.1 weeks, with 58 patients having an exposure of more than 24 weeks, data cut-off was 15 November 2024.

## Adverse events

An overview of adverse events is provided in Table 82 . The most common adverse events reported in participants in the 2L cohort were headache (22.8%), nausea (20.8%), cough (15.8%), diarrhoea (15.8%), fatigue (15.8%) and hypertension (15.8%). The most common Grade &gt;= 3 adverse event was hypertension, reported in 8.9% participants.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 82 Overview of adverse events for 2L Cohort (Safety Set)

|                                                                                                                                                  | 2L Cohort (N=101) n (%)                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Any AEs                                                                                                                                          | 98 (97.0%)                                                                                                                                       |
| Treatment-related                                                                                                                                | 75 (74.3%)                                                                                                                                       |
| Grade ≥3 AEs                                                                                                                                     | 36 (35.6%)                                                                                                                                       |
| Treatment-related                                                                                                                                | 15 (14.9%)                                                                                                                                       |
| Serious AEs                                                                                                                                      | 10 (9.9%)                                                                                                                                        |
| Treatment-related                                                                                                                                | 1 (1.0%)                                                                                                                                         |
| AEs leading to discontinuation                                                                                                                   | 7 (6.9%)                                                                                                                                         |
| Treatment-related                                                                                                                                | 7 (6.9%)                                                                                                                                         |
| AEs leading to dose reduction/ interruption                                                                                                      | 36 (35.6%)                                                                                                                                       |
| Numbers (n) represent counts of participants. AEs/SAEs occurring during treatment or within 30 days of the last study medication are summarized. | Numbers (n) represent counts of participants. AEs/SAEs occurring during treatment or within 30 days of the last study medication are summarized. |

Information about SAE is shown in Table 83 . No on-treatment deaths occurred in the 2 nd  line cohort. Narratives were provided for the three patients with SAE were provided. All patients restarted asciminib treatment after recovering.

Table 83 Serious adverse events, by system organ class and preferred term for 2L Cohort (IA 4, Safety Set)

| Primary system organ class Preferred term          | 2L Cohort N=101 All grades n (%)   | Grade >=3 n (%)   |
|----------------------------------------------------|------------------------------------|-------------------|
| Numberofsubjectswith atleastone event              | 3 (3.0)                            | 3 (3.0)           |
| Cardiac disorders                                  | 1 (1.0)                            | 1 (1.0)           |
| Aortic valve disease                               | 1 (1.0)                            | 1(1.0)            |
| Gastrointestinal disorders                         | 1 (1.0)                            | 1 (1.0)           |
| Nausea                                             | 1(1.0)                             | 1 (1.0)           |
| Vomiting                                           | 1 (1.0)                            | 1 (1.0)           |
| Generaldisordersand administration site conditions | 2 (2.0)                            | 2 (2.0)           |
| Catheter site pain                                 | 1 (1.0)                            | 1 (1.0)           |
| Chest pain                                         | 1 (1.0)                            | 1 (1.0)           |
| Non-cardiac chest pain                             | 1 (1.0)                            | 1 (1.0)           |

Source: 6-Month Efficacy Key Outputs for 2L Cohort study CABL001AUS08, table 6-2

## Adverse events of special interest

The most common adverse events of special interest for the 2L cohort were gastrointestinal toxicity (51.5%), hypersensitivity (21.8%) and acute pancreatitis (including isolated pancreatic enzyme

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

elevations) (16.8%). The most common Grade &gt;=3 adverse events of special interest were thrombocytopenia (6.9%) and leukopenia (5.9%). No arterial occlusive events (AOEs) were reported. Haemorrhage was reported in 7.95% (G3-5: 1%). GI toxicity is higher in the AUS08  2 nd  line cohort (51.5%; G3-G5: 3%) compared to the newly diagnosed population of J12301 (39.0%, G3-5 0.5%) and in 3 rd  or later line study A2301 (31.4%, G3-5: 1.9%).Myelosuppression was reported in 11.9% of patients, 43.5% in the 1 st  line 37.8 % in 3 rd  or later line study A2301 with limited comparability due to different exposure in the respective lines, with otherwise comparable safety profiles. No new safety signal was detected.

Table 84 Overview of adverse events of special interest for 2L Cohort (Safety Set)

|                                                                      | 2L Cohort N=101   | 2L Cohort N=101   |
|----------------------------------------------------------------------|-------------------|-------------------|
|                                                                      | All grades n (%)  | Grade >=3 n (%)   |
| Gastrointestinal toxicity                                            | 52 (51.5)         | 3 (3.0)           |
| Hypersensitivity                                                     | 22 (21.8)         | 0                 |
| Acute pancreatitis (including isolated pancreatic enzyme elevations) | 17 (16.8)         | 2 (2.0)           |

|                                             | 2L Cohort N=101   | 2L Cohort N=101   |
|---------------------------------------------|-------------------|-------------------|
|                                             | All grades n (%)  | Grade >=3 n (%)   |
| Acute pancreatitis (clinical events)        | 0                 | 0                 |
| Myelosuppression*                           | 12 (11.9)         | 8 (7.9)           |
| Myelosuppression (Thrombocytopenia)         | 8 (7.9)           | 7 (6.9)           |
| Myelosuppression (Leukopenia)               | 7 (6.9)           | 6 (5.9)           |
| Myelosuppression (Erythropenia)             | 6 (5.9)           | 1 (1.0)           |
| Myelosuppression (cytopenias affecting more | 1 (1.0)           | 1 (1.0)           |
| than one lineage)                           |                   |                   |
| Hepatotoxicity (including laboratory terms) | 9 (8.9)           | 1 (1.0)           |
| Hepatotoxicity (clinical events)            | 1 (1.0)           | 0                 |
| Hemorrhage                                  | 8 (7.9)           | 1 (1.0)           |
| Edema and fluid retention                   | 7 (6.9)           | 1 (1.0)           |
| Phototoxicity                               | 3 (3.0)           | 0                 |
| Ischemic heart and CNS conditions           | 1 (1.0)           | 0                 |
| Ischemic heart conditions                   | 1 (1.0)           | 0                 |
| Ischemic CNS conditions                     | 0                 | 0                 |
| Arterial-occlusive events (AoE)             | 0                 | 0                 |
| Cardiac failure                             | 0                 | 0                 |
| Hepatitis B virus infection reactivation    | 0                 | 0                 |
| QTc prolongation                            | 0                 | 0                 |
| Reproductive toxicity                       | 0                 | 0                 |

Numbers (n) represent counts of subjects.

A subject with multiple severity grades for an AE is only counted under the maximum grade.

lineage.

MedDRA version 27.1, CTCAE version 5.0, Case Retrieval Strategy version released 2025-01-14.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 2.5.3. New posology of 80 mg QD for the 3rd or later line

The safety data submitted for the new posology includes safety results from the primary analysis of Study CABL001A2302 (ASC4OPT, hereafter referred to as Study A2302), a Phase IIIb, multi-center, non-comparative, open-label, treatment optimization study of oral asciminib (40 mg BID or 80 mg QD) in patients with CML-CP previously treated with 2 or more TKIs, additionally to data from the pivotal phase III Study CABL001A2301 (hereafter referred to as Study A2301) (using asciminib at a dose of 40 mg b.i.d.), the supplemental phase I Study CABL001X2101 (hereafter referred to as Study X2101) (studying various BID and QD dose regimens of asciminib) and exposure-response modelling served as the basis for the original asciminib approval for Ph+ CML-CP in the third line and beyond (3L+).

Table 85 Overview of clinical safety study and source of data

| Key features                                                                         | StudyA2302                                                                                                                 |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Controlled study                                                                     | No                                                                                                                         |
| Phase                                                                                | Ib                                                                                                                         |
| Study design                                                                         | Non-comparative,treatmentoptimizationstudy                                                                                 |
| Population                                                                           | Adultparticipantspreviouslytreatedwith2ormoreTKis                                                                          |
| Treatmentduration                                                                    | 144 weeks                                                                                                                  |
| No.participants (total)                                                              | 1691.2 (participants without MMR at baseline)                                                                              |
| No.on Treatment(s)                                                                   |                                                                                                                            |
| Relevantentrycriteria                                                                |                                                                                                                            |
| Age                                                                                  | ≥18years                                                                                                                   |
| Diseaseseverity                                                                      |                                                                                                                            |
| Completed/Ongoing                                                                    | Ongoing(studywasinitiatedon13-Oct-2021andhad adatacut-offdatefor thelastparticipantvisitfortheWeek48analysison12-Mar-2024) |
| enrolled(N=30);results from thisexploratory cohort are not inscope of this document. | enrolled(N=30);results from thisexploratory cohort are not inscope of this document.                                       |

The safety analysis set (SAF) was defined as all participants who received at least one dose of study treatment except the additional participants who were intolerant to the last TKI and were in MMR at baseline. The SAF was used for baseline disease characteristics, exposure, and all safety analyses.

## Patient exposure

The median exposure to asciminib 40 mg BID and 80 mg QD were 67.3 and 68.6 weeks, respectively.

Table 86 Duration of exposure to study drug (SAF)

|                                    | Asciminib 40 mg b.i.d. N=84   | Asciminib 80 mg q.d. N=84   | Allparticipants N=168   |
|------------------------------------|-------------------------------|-----------------------------|-------------------------|
| Duration of exposure (week)        |                               |                             |                         |
| Mean (SD)                          | 68.0 (30.93)                  | 68.7 (27.38)                | 68.3 (29.12)            |
| Median                             | 67.3                          | 68.6                        | 67.8                    |
| Q1-Q3                              | 51.7-92.4                     | 53.1-90.4                   | 52.2-91.5               |
| Min-Max                            | 2.6-116.1                     | 1.3-118.7                   | 1.3-118.7               |
| Durationofexposurecategories-n (%) |                               |                             |                         |
| Less than 24 weeks                 | 10 (11.9)                     | 8 (9.5)                     | 18 (10.7)               |
| At least 24 weeks                  | 74 (88.1)                     | 76 (90.5)                   | 150 (89.3)              |
| At least 48 weeks                  | 70 (83.3)                     | 73 (86.9)                   | 143 (85.1)              |
| At least 96weeks                   | 18 (21.4)                     | 16 (19.0)                   | 34 (20.2)               |
| Atleast144weeks                    | 0                             | 0                           | 0                       |
| Participanttreatmenttime(year)     | 109.4                         | 110.5                       | 219.9                   |

The study is ongoing.

Source:StudyA2302W48CSR-Table14.3-1.1

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Patient disposition

Of the 169 participants, 84 participants were treated with asciminib 40 mg b.i.d., 84 participants were treated with 80 mg QD and 1 participant was randomised to the 40 mg BID group but was not treated. Information on patient disposition is provided.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 87 Patient disposition (FAS)

|                                   | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg q.d. N=84 n (%)   | All participants N=169 n (%)   |
|-----------------------------------|-------------------------------------|-----------------------------------|--------------------------------|
| Participants randomized           |                                     |                                   |                                |
| Treated                           | 84 (98.8)                           | 84 (100)                          | 168 ( 99.4)                    |
| Not treated                       | 1 ( 1.2)                            | 0                                 | 1 (0.6)                        |
| Reasonfornotbeing treated         |                                     |                                   |                                |
| Participant Decision              | 1 ( 1.2)                            | 0                                 | 1 (0.6)                        |
| Treatment ongoing*                | 68 ( 80.0)                          | 68 ( 81.0)                        | 136 (80.5)                     |
| Discontinued from treatment       | 16 (18.8)                           | 16 (19.0)                         | 32 ( 18.9)                     |
| <Week24                           | 10 ( 11.8)                          | 7 ( 8.3)                          | 17 ( 10.1)                     |
| ≥Week24and<Week48                 | 4 ( 4.7)                            | 3 (3.6)                           | 7 ( 4.1)                       |
| ≥Week48and<Week96                 | 2 ( 2.4)                            | 6 (7.1)                           | 8 ( 4.7)                       |
| Reasonfordiscontinuation          |                                     |                                   |                                |
| AdverseEvent                      | 6 (7.1)                             | 4 ( 4.8)                          | 10 (5.9)                       |
| UnsatisfactoryTherapeuticEffect   | 4 ( 4.7)                            | 3 (3.6)                           | 7 ( 4.1)                       |
| Progressive Disease               | 1 ( 1.2)                            | 5 (6.0)                           | 6 (3.6)                        |
| Physician Decision                | 2 ( 2.4)                            | 2 ( 2.4)                          | 4 ( 2.4)                       |
| FailureToMeetContinuationCriteria | 2 ( 2.4)                            | 1 ( 1.2)                          | 3 (1.8)                        |
| Participant Decision              | 1 ( 1.2)                            | 0                                 | 1 (0.6)                        |
| ProtocolDeviation                 | 0                                   | 1 ( 1.2)                          | 1(0.6)                         |
| <Week24                           |                                     |                                   |                                |
| AdverseEvent                      | 4 ( 4.7)                            | 3 (3.6)                           | 7 ( 4.1)                       |
| FailureToMeetContinuationCriteria | 2 ( 2.4)                            | 0                                 | 2 ( 1.2)                       |
| UnsatisfactoryTherapeuticEffect   | 2 ( 2.4)                            | 0                                 | 2 ( 1.2)                       |
| Physician Decision                | 1 ( 1.2)                            | 0                                 | 1(0.6)                         |
| ParticipantDecision               | 1 ( 1.2)                            | 0                                 | 1(0.6)                         |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

|                                                                | Asciminib 40 mg b.i.d. N=85 n (%)   | Asciminib 80 mg q.d. N=84 n (%)   | All participants N=169 n (%)   |
|----------------------------------------------------------------|-------------------------------------|-----------------------------------|--------------------------------|
| Progressive Disease                                            | 0                                   | 3(3.6)                            | 3 (1.8)                        |
| Protocol Deviation                                             | 0                                   | 1 ( 1.2)                          | 1 (0.6)                        |
| ≥Week24 and<Week 48                                            |                                     |                                   |                                |
| AdverseEvent                                                   | 2 ( 2.4)                            | 1 ( 1.2)                          | 3 (1.8)                        |
| Physician Decision                                             | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |
| ProgressiveDisease                                             | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |
| ≥Week48 and<Week96                                             |                                     |                                   |                                |
| UnsatisfactoryTherapeuticEffect                                | 2 ( 2.4)                            | 3(3.6)                            | 5 (3.0)                        |
| FailureToMeetContinuationCriteria                              | 0                                   | 1 ( 1.2)                          | 1 (0.6)                        |
| Physician Decision                                             | 0                                   | 1 ( 1.2)                          | 1 (0.6)                        |
| Progressive Disease                                            | 0                                   | 1 ( 1.2)                          | 1 (0.6)                        |
| Post-Treatment safety follow-up for participantwhoDiscontinued |                                     |                                   |                                |
| Did notenterpost-treatmentsafety follow-up                     | 1 ( 1.2)                            | 0                                 | 1 (0.6)                        |
| Completed post-treatment safety follow- 9(10.6) up             |                                     | 11 ( 13.1)                        | 20 ( 11.8)                     |
| Enteredpost-treatmentsafetyfollow- up, discontinued            | 6 (7.1)                             | 5 (6.0)                           | 11 (6.5)                       |
| Reason for Discontinuation                                     |                                     |                                   |                                |
| AdverseEvent                                                   | 4 ( 4.7)                            | 0                                 | 4 ( 2.4)                       |
| Physician Decision                                             | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |
| ParticipantDecision                                            | 1 ( 1.2)                            | 1 ( 1.2)                          | 2 ( 1.2)                       |
| Death                                                          | 0                                   | 1 ( 1.2)                          | 1(0.6)                         |
| FailureToMeetContinuationCriteria                              | 0                                   | 1 (1.2)                           | 1 (0.6)                        |
| UnsatisfactoryTherapeuticEffect                                | 0                                   | 1 ( 1.2)                          | 1(0.6)                         |

## Adverse events

A majority of participants treated in Study A2302 experienced at least 1 AE (76/84 (90.5%) participants in the asciminib 40 mg BID group and 74/84 (88.1%) participants in the asciminib 80 mg QD group). AEs considered to be treatment-related were reported in 46 (54.8%) participants in the asciminib 40 mg BID group and 53 (63.1%) participants in the asciminib 80 mg QD group. AEs ≥ grade 3 were reported in 21 (25.0%) participants in the asciminib 40 mg BID group and 29 (34.5%) participants in the asciminib 80 mg QD group.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 88 Overview of adverse events (SAF)

|                                             | Asciminib 40 mg b.i.d. N=84   | Asciminib 40 mg b.i.d. N=84   | Asciminib 80 mg QD N=84   | Asciminib 80 mg QD N=84   | All participants N=168   | All participants N=168   |
|---------------------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|--------------------------|--------------------------|
| Category                                    | All grades n (%)              | Grade ≥ 3 n (%)               | All grades n (%)          | Grade ≥ 3 n (%)           | All grades n (%)         | Grade ≥ 3 n (%)          |
| Adverse events                              | 76 (90.5)                     | 21 (25.0)                     | 74 (88.1)                 | 29 (34.5)                 | 150 (89.3)               | 50 (29.8)                |
| Treatment-related                           | 46 (54.8)                     | 13 (15.5)                     | 53 (63.1)                 | 16 (19.0)                 | 99 (58.9)                | 29 (17.3)                |
| SAEs                                        | 9 (10.7)                      | 6 (7.1)                       | 9 (10.7)                  | 8 (9.5)                   | 18 (10.7)                | 14 (8.3)                 |
| Treatment-related                           | 3 (3.6)                       | 2 (2.4)                       | 4 (4.8)                   | 4 (4.8)                   | 7 (4.2)                  | 6 (3.6)                  |
| Fatal SAEs                                  | 0                             | 0                             | 1 (1.2)                   | 1 (1.2)                   | 1 (0.6)                  | 1 (0.6)                  |
| Treatment-related                           | 0                             | 0                             | 0                         | 0                         | 0                        | 0                        |
| AEs leading to discontinuation              | 6 (7.1)                       | 3 (3.6)                       | 4 (4.8)                   | 3 (3.6)                   | 10 (6.0)                 | 6 (3.6)                  |
| Treatment-related                           | 4 (4.8)                       | 2 (2.4)                       | 3 (3.6)                   | 2 (2.4)                   | 7 (4.2)                  | 4 (2.4)                  |
| AEs leading to dose adjustment/interruption | 25 (29.8)                     | 17 (20.2)                     | 26 (31.0)                 | 21 (25.0)                 | 51 (30.4)                | 38 (22.6)                |
| AEs requiring additional therapy            | 53 (63.1)                     | 13 (15.5)                     | 52 (61.9)                 | 18 (21.4)                 | 105 (62.5)               | 31 (18.5)                |

grade. MedDRA version 26.1., CTCAE version 5.0

Source: [Study A2302 W48 CSR-Table 14.3.1-17]

## Adverse events by system organ class

AEs by SOCs occurred with ≥ 5% difference in 40 mg BID and 80 mg QD dose group included general disorders and administration site conditions (22.6% vs. 31.0%); injury, poisoning and procedural complications (8.3% vs. 2.4%) and psychiatric disorders (3.6% vs. 9.5%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 89 Adverse events by system organ class and severity (SAF)

|                                                                    | Asciminib 40 mg b.i.d. N=84 N=84   | Asciminib 40 mg b.i.d. N=84 N=84   | Asciminib 80 mg q.d.   | Asciminib 80 mg q.d.   | All participants       | All participants   |
|--------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------|------------------------|------------------------|--------------------|
| Primary system organ class                                         | All grades n (%)                   | Grade≥3 n (%)                      | All grades n (%)       | Grade≥3 n (%)          | N=168 All grades n (%) | Grade≥3 n (%)      |
| Numberofparticipantswith at leastoneevent                          | 76 (90.5)                          | 21 (25.0)                          | 74 (88.1)              | 29 (34.5)              | 150 (89.3)             | 50 (29.8)          |
| Blood and lymphatic system disorders                               | 15 (17.9)                          | 8 (9.5)                            | 17 (20.2)              | 12 (14.3)              | 32 (19.0)              | 20 (11.9)          |
| Cardiac disorders                                                  | 9 (10.7)                           | 1 (1.2)                            | 7 (8.3)                | 1 (1.2)                | 16 (9.5)               | 2 (1.2)            |
| Ear and labyrinth disorders                                        | 0                                  | 0                                  | 3 (3.6)                | 1 (1.2)                | 3 (1.8)                | 1 (0.6)            |
| Endocrine disorders                                                | 0                                  | 0                                  | 1 (1.2)                | 0                      | 1 (0.6)                | 0                  |
| Eye disorders                                                      | 5 (6.0)                            | 0                                  | 5 (6.0)                | 0                      | 10 (6.0)               | 0                  |
| Gastrointestinal disorders                                         | 24 (28.6)                          | 1 (1.2)                            | 27 (32.1)              | 2 (2.4)                | 51 (30.4)              | 3 (1.8)            |
| General disorders and administrationsiteconditions                 | 19 (22.6)                          | 0                                  | 26 (31.0)              | 1 (1.2)                | 45 (26.8)              | 1 (0.6)            |
| Hepatobiliary disorders                                            | 0                                  | 0                                  | 1 (1.2)                | 0                      | 1 (0.6)                | 0                  |
| Immune system disorders                                            | 1 (1.2)                            | 0                                  | 0                      | 0                      | 1 (0.6)                | 0                  |
| Infections and infestations                                        | 27 (32.1)                          | 1 (1.2)                            | 27 (32.1)              | 3 (3.6)                | 54 (32.1)              | 4 (2.4)            |
| Injury, poisoning and proceduralcomplications                      | 7 (8.3)                            | 1 (1.2)                            | 2 (2.4)                | 0                      | 9 (5.4)                | 1 (0.6)            |
| Investigations                                                     | 28 (33.3)                          | 7 (8.3)                            | 30 (35.7)              | 7 (8.3)                | 58 (34.5)              | 14 (8.3)           |
| Metabolism and nutrition disorders                                 | 10 (11.9)                          | 2 (2.4)                            | 9 (10.7)               | 3 (3.6)                | 19 (11.3)              | 5 (3.0)            |
| Musculoskeletal and connectivetissuedisorders                      | 25 (29.8)                          | 2 (2.4)                            | 25 (29.8)              | 1 (1.2)                | 50 (29.8)              | 3 (1.8)            |
| Neoplasms benign, malignant and unspecified (incl cystsand polyps) | 0                                  | 0                                  | 1 (1.2)                | 0                      | 1 (0.6)                | 0                  |
| Nervous system disorders                                           | 17 (20.2)                          | 3 (3.6)                            | 18 (21.4)              | 1 (1.2)                | 35 (20.8)              | 4 (2.4)            |
| Psychiatric disorders                                              | 3 (3.6)                            | 0                                  | 8 (9.5)                | 0                      | 11 (6.5)               | 0                  |
| Renal and urinary disorders                                        | 3 (3.6)                            | 0                                  | 5 (6.0)                | 2 (2.4)                | 8 (4.8)                | 2 (1.2)            |
| Reproductive system and breast disorders                           | 4 (4.8)                            | 0                                  | 5 (6.0)                | 0                      | 9 (5.4)                | 0                  |
| Respiratory,thoracic and mediastinal disorders                     | 8 (9.5)                            | 2 (2.4)                            | 10 (11.9)              | 1 (1.2)                | 18 (10.7)              | 3 (1.8)            |
| Skin and subcutaneous tissue disorders                             | 22 (26.2)                          | 0                                  | 22 (26.2)              | 1 (1.2)                | 44 (26.2)              | 1 (0.6)            |
| Vascular disorders                                                 | 9 (10.7)                           | 0                                  | 7 (8.3)                | 2 (2.4)                | 16 (9.5)               | 2 (1.2)            |

Numbers (n) represent counts of participants.

AEs occurring during treatment or within30days of last study medication are summarized.

A participant with multiple severity gradesfor an AE is only counted under themaximum grade.

MedDRAversion26.1,CTCAEversion5.0

Source:StudyA2302W48CSR-Table14.3.1-1

## Adverse events by preferred term

Adverse events by preferred term were presented. No major imbalance was observed between the arms.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 90 Adverse events by preferred term (&gt; 5% in all participants) (SAF)

|                                             | Asciminib 40 mg b.i.d. N=84   | Asciminib 40 mg b.i.d. N=84   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=168   | All participants N=168   |
|---------------------------------------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
| Preferred term                              | All grades n (%)              | Grade ≥3 n (%)                | All grades n (%)            | Grade≥3 n (%)               | All grades n (%)         | Grade≥3 n (%)            |
| Numberofparticipantswith at least one event | 76 (90.5)                     | 21 (25.0)                     | 74 (88.1)                   | 29 (34.5)                   | 150 (89.3)               | 50 (29.8)                |
| Arthralgia                                  | 10 (11.9)                     | 2 (2.4)                       | 13 (15.5)                   | 0                           | 23 (13.7)                | 2 (1.2)                  |
| COVID-19                                    | 11 (13.1)                     | 0                             | 9 (10.7)                    | 0                           | 20 (11.9)                | 0                        |
| Pruritus                                    | 12 (14.3)                     | 0                             | 5 (6.0)                     | 0                           | 17 (10.1)                | 0                        |
| Headache                                    | 8 (9.5)                       | 0                             | 8 (9.5)                     | 0                           | 16 (9.5)                 | 0                        |
| Thrombocytopenia                            | 7 (8.3)                       | 4 (4.8)                       | 9 (10.7)                    | 6 (7.1)                     | 16 (9.5)                 | 10 (6.0)                 |
| Fatigue                                     | 3 (3.6)                       | 0                             | 12 (14.3)                   | 1 (1.2)                     | 15 (8.9)                 | 1 (0.6)                  |
| Nausea                                      | 6 (7.1)                       | 0                             | 8 (9.5)                     | 0                           | 14 (8.3)                 | 0                        |
| Neutropenia                                 | 7 (8.3)                       | 6 (7.1)                       | 7 (8.3)                     | 5 (6.0)                     | 14 (8.3)                 | 11 (6.5)                 |
| Diarrhea                                    | 7 (8.3)                       | 0                             | 6 (7.1)                     | 0                           | 13 (7.7)                 | 0                        |
| Lipase increased                            | 6 (7.1)                       | 1 (1.2)                       | 7 (8.3)                     | 0                           | 13 (7.7)                 | 1 (0.6)                  |
| Alanineaminotransferase increased           | 9 (10.7)                      | 2 (2.4)                       | 2 (2.4)                     | 0                           | 11 (6.5)                 | 2 (1.2)                  |
| Back pain                                   | 4 (4.8)                       | 0                             | 7 (8.3)                     | 0                           | 11 (6.5)                 | 0                        |
| Hypertension                                | 6 (7.1)                       | 0                             | 5 (6.0)                     | 2 (2.4)                     | 11 (6.5)                 | 2 (1.2)                  |
| Plateletcountdecreased                      | 4 (4.8)                       | 3 (3.6)                       | 7 (8.3)                     | 4 (4.8)                     | 11 (6.5)                 | 7 (4.2)                  |
| Abdominal pain                              | 5 (6.0)                       | 0                             | 5 (6.0)                     | 1 (1.2)                     | 10 (6.0)                 | 1 (0.6)                  |
| Aspartateaminotransferase increased         | 8 (9.5)                       | 1 (1.2)                       | 2 (2.4)                     | 0                           | 10 (6.0)                 | 1 (0.6)                  |
| Dry skin                                    | 3 (3.6)                       | 0                             | 7 (8.3)                     | 1 (1.2)                     | 10 (6.0)                 | 1 (0.6)                  |
| Myalgia                                     | 5 (6.0)                       | 0                             | 4 (4.8)                     | 0                           | 9 (5.4)                  | 0                        |

Numbers (n)represent counts of participants

AEs occurring during treatment orwithin30daysof laststudy medication aresummarized.

MedDRAversion26.1,CTCAEversion5.0

Source:StudyA2302W48CSR-Table14.3.1-1b

## Serious adverse events

Overall, SAEs regardless of study treatment relationship were reported in 10.7% of patients. SAEs ≥ grade 3 were reported in 8.3% of patients. The incidence of individual SAEs was low. The most frequently reported SAEs, regardless of relationship to study drug were febrile neutropenia, neutropenia, atrial fibrillation, and hypertriglyceridemia (2 (1.2%) patients, each). The most frequently reported SAEs ≥ grade 3 were febrile neutropenia, neutropenia, and hypertriglyceridemia (2 (1.2%) patients, each).

The number of patients reporting AEs irrespective of grade is equal (88 vs. 90%), while for &gt;= G3 events, numerically more patients from the 80 mg QD arm report events (25.0 vs. 34.5%, Δ 8 patients).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 91 Serious adverse events by system organ class and preferred term in more than 1 participant (SAF)

| Primary system organ class                                                                                                                                                                                                                                                                                        | Asciminib 40 mg b.i.d. N=84                                                                                                                                                                                                                                                                                       | Asciminib 40 mg b.i.d. N=84                                                                                                                                                                                                                                                                                       | Asciminib 80 mg q.d. All participant N=84                                                                                                                                                                                                                                                                         | Asciminib 80 mg q.d. All participant N=84                                                                                                                                                                                                                                                                         | N=168                                                                                                                                                                                                                                                                                                             | N=168                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preferred term                                                                                                                                                                                                                                                                                                    | AlIl grades n (%)                                                                                                                                                                                                                                                                                                 | Grade≥ n (%)                                                                                                                                                                                                                                                                                                      | AlIl grades n (%)                                                                                                                                                                                                                                                                                                 | Grade ≥ n (%)                                                                                                                                                                                                                                                                                                     | All grades n (%)                                                                                                                                                                                                                                                                                                  | Grade ≥ 3 n (%)                                                                                                                                                                                                                                                                                                   |
| Number of participants with at least one event                                                                                                                                                                                                                                                                    | 9 (10.7)                                                                                                                                                                                                                                                                                                          | 6 (7.1)                                                                                                                                                                                                                                                                                                           | 9 (10.7)                                                                                                                                                                                                                                                                                                          | 8 (9.5)                                                                                                                                                                                                                                                                                                           | 18 (10.7)                                                                                                                                                                                                                                                                                                         | 14 (8.3)                                                                                                                                                                                                                                                                                                          |
| Blood and lymphatic system disorders                                                                                                                                                                                                                                                                              | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 4 (4.8)                                                                                                                                                                                                                                                                                                           | 4 (4.8)                                                                                                                                                                                                                                                                                                           | 6 (3.6)                                                                                                                                                                                                                                                                                                           | 6 (3.6)                                                                                                                                                                                                                                                                                                           |
| Febrile neutropenia                                                                                                                                                                                                                                                                                               | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           |
| Neutropenia                                                                                                                                                                                                                                                                                                       | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           |
| Cardiac disorders                                                                                                                                                                                                                                                                                                 | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 3 (3.6)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 5 (3.0)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           |
| Atrial fibrillation                                                                                                                                                                                                                                                                                               | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                                                                                 | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                                                                                 | 2 (1.2)                                                                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                                                                                 |
| Infections and infestations                                                                                                                                                                                                                                                                                       | 3 (3.6)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                                                                                 | 3 (1.8)                                                                                                                                                                                                                                                                                                           | 1 (0.6)                                                                                                                                                                                                                                                                                                           |
| Primary system organ class Preferred term                                                                                                                                                                                                                                                                         | Asciminib 40 mg b.i.d. n (%)                                                                                                                                                                                                                                                                                      | Asciminib 40 mg b.i.d. n (%)                                                                                                                                                                                                                                                                                      | Asciminib 80 mg q.d. All participant n (%)                                                                                                                                                                                                                                                                        | Asciminib 80 mg q.d. All participant n (%)                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                   | N=84 All grades                                                                                                                                                                                                                                                                                                   | Grade ≥ n (%)                                                                                                                                                                                                                                                                                                     | N=84 All grades                                                                                                                                                                                                                                                                                                   | Grade ≥ 3 n (%)                                                                                                                                                                                                                                                                                                   | N=168 All grades n (%)                                                                                                                                                                                                                                                                                            | Grade ≥ 3 n (%)                                                                                                                                                                                                                                                                                                   |
| Metabolism andnutrition disorders                                                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                   | 3 (3.6)                                                                                                                                                                                                                                                                                                           | 3 (3.6)                                                                                                                                                                                                                                                                                                           | 3 (1.8)                                                                                                                                                                                                                                                                                                           | 3 (1.8)                                                                                                                                                                                                                                                                                                           |
| Hypertriglyceridemia                                                                                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                                                                                 | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           | 2 (1.2)                                                                                                                                                                                                                                                                                                           |
| Nervous system disorders                                                                                                                                                                                                                                                                                          | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 2 (2.4)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 1 (1.2)                                                                                                                                                                                                                                                                                                           | 3 (1.8)                                                                                                                                                                                                                                                                                                           | 3 (1.8)                                                                                                                                                                                                                                                                                                           |
| Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 | Numbers (n) represent counts of participants A participant with multiple severity grades for an AE is only counted under the maximum grade. AEs occurring during treatment or within 30 days of last study medication are summarized. MedDRAversion26.1,CTCAEversion5.0 Source:Study A2302 W48 CSR-Table 14.3.1-6 |

## Adverse events leading to discontinuation, dose adjustment and/ or interruption

The occurrence of AEs leading to discontinuation of study treatment was low and comparable between participants receiving 40 mg BID and 80 mg QD dose regimens (6 (7.1%) participants and 4 (4.8%) participants) in terms of all grades and ≥ grade 3 events. The most frequently reported AE leading to dose adjustment and/or interruption were neutropenia (40 mg BID 8.3% vs. 80 mg QD 3.6%) and thrombocytopenia (4.8% vs. 7.1%).

## Deaths

No deaths were reported in asciminib 40 mg BID group; one death was reported in 80 mg QD group. One (0.6%) participant in the 80 mg QD group died on treatment. The primary reason of death was stroke (cerebrovascular accident). The participant had a history of stroke, treated with acetylsalicylic acid as prevention.

On Day 10, the participant had stroke (grade 4) with hemiparesis and coma. CT angiography revealed occlusion of the middle cerebral artery left and haemorrhage into the basal ganglia area right and increasing infarction demarcation. Participant received the last dose of the study drug on Day 9. On Day 11, CT revealed progressive cerebral edema, and, on the same day, the participant died. Autopsy was not performed. The event cerebrovascular accident was assessed as not suspected to be related with the study drug by the investigator.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest (AESI)

An overview of AESI is provided in Table 92.

## Table 92 Overview of AESI (SAF)

|                                     | Asciminib40 mg b.i.d. N=84   | Asciminib40 mg b.i.d. N=84   | Asciminib 80 mg q.d. N=84   | Asciminib 80 mg q.d. N=84   | All participants N=168   | All participants N=168   |
|-------------------------------------|------------------------------|------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
| Safety topic                        | All grades n (%)             | Grade≥3 n (%)                | All grades n (%)            | Grade≥3 n (%)               | All grades n (%)         | Grade≥3 n (%)            |
| Gl toxicity                         | 20 (23.8)                    | 0                            | 25 (29.8)                   | 1 (1.2)                     | 45 (26.8)                | 1 (0.6)                  |
| Myelosuppression*                   | 15 (17.9)                    | 11 (13.1)                    | 22 (26.2)                   | 15 (17.9)                   | 37 (22.0)                | 26 (15.5)                |
| Myelosuppression （Thrombocytopenia) | 11 (13.1)                    | 7 (8.3)                      | 15 (17.9)                   | 10 (11.9)                   | 26 (15.5)                | 17 (10.1)                |
| Myelosuppression (Leukopenia)       | 9 (10.7)                     | 7 (8.3)                      | 10 (11.9)                   | 6 (7.1)                     | 19 (11.3)                | 13 (7.7)                 |
| Myelosuppression (Erythropenia)     | 3 (3.6)                      | 1 (1.2)                      | 4 (4.8)                     | 3 (3.6)                     | 7 (4.2)                  | 4 (2.4)                  |

|                                                                    | Asciminib 40 mg b.i.d. N=84   | Asciminib 40 mg b.i.d. N=84   | Asciminib 80 mg_q.d. N=84   | Asciminib 80 mg_q.d. N=84   | All participants N=168   | All participants N=168   |
|--------------------------------------------------------------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
| Safety topic                                                       | Allgrades n (%)               | Grade≥3 n (%)                 | All grades n (%)            | Grade≥3 n (%)               | All grades n (%)         | Grade≥3 n (%)            |
| Hypersensitivity                                                   | 8 (9.5)                       | 0                             | 11 (13.1)                   | 0                           | 19 (11.3)                | 0                        |
| Acute pancreatitis (including isolatedpancreaticenzyme elevations) | 9 (10.7)                      | 2 (2.4)                       | 7 (8.3)                     | 0                           | 16 (9.5)                 | 2 (1.2)                  |
| Hepatotoxicity (including laboratoryterms)                         | 11 (13.1)                     | 2 (2.4)                       | 4 (4.8)                     | 0                           | 15 (8.9)                 | 2 (1.2)                  |
| Edema and fluid retention                                          | 8 (9.5)                       | 1 (1.2)                       | 6 (7.1)                     | 0                           | 14 (8.3)                 | 1 (0.6)                  |
| Ischemicheart and CNS conditions                                   | 3 (3.6)                       | 2 (2.4)                       | 8 (9.5)                     | 3 (3.6)                     | 11 (6.5)                 | 5 (3.0)                  |
| Ischemic heart conditions                                          | 2 (2.4)                       | 1 (1.2)                       | 8 (9.5)                     | 2 (2.4)                     | 10 (6.0)                 | 3 (1.8)                  |
| Ischemic CNS conditions                                            | 1 (1.2)                       | 1 (1.2)                       | 1 (1.2)                     | 1 (1.2)                     | 2 (1.2)                  | 2 (1.2)                  |
| Hemorrhage                                                         | 4 (4.8)                       | 0                             | 3 (3.6)                     | 0                           | 7 (4.2)                  | 0                        |
| Arterial-occlusiveevents(AOEs)                                     | 3 (3.6)                       | 2 (2.4)                       | 3 (3.6)                     | 1 (1.2)                     | 6 (3.6)                  | 3 (1.8)                  |
| Cardiacfailure(clinicalevents)                                     | 2 (2.4)                       | 0                             | 1 (1.2)                     | 0                           | 3 (1.8)                  | 0                        |
| Phototoxicity                                                      | 1 (1.2)                       | 0                             | 0                           | 0                           | 1 (0.6)                  | 0                        |
| QTc prolongation                                                   | 1 (1.2)                       | 1 (1.2)                       | 0                           | 0                           | 1 (0.6)                  | 1 (0.6)                  |

Numbers (n) represent counts of participants.

Aparticipant withmultipleseveritygradesfor anAEisonly countedunder themaximumgrade.

AESloccurring duringtreatmentorwithin30daysoflaststudymedication aresummarized.

MedDRAversion26.1.,CTCAEversion5.0,CaseRetrievalStrategyversionreleased 27-Feb-2024. Source:StudyA2302W48CSR-Table14.3.1-13

*Myelosuppressionincludes erythropenia,leucopenia,thrombocytopenia,cytopenias affecting more than one lineage.

Some AESI were numerically less often reported in 40-mg-BID than in 80-mg-QD patients: GI toxicity (23.8 vs. 29.8%); myelosuppression (13.1 vs. 17.9%) and hypersensivity (9.5 vs. 13.1%), ischaemic conditions (3.6 vs. 9.5%), other AESI were numerically more often observed as acute pancreatitis (including isolated enzyme elevations 10.7 vs. 8.3%) and haemorrhage (4.8 vs. 3.6%).

## Haematology

The haematological worst post-baseline value shifts to grade 3/4 events included haemoglobin decrease (grade 3: 0.6%), leukocytes decreased (grade 3: 3.0%), leukocytes increase (grade 3:1.8%), neutrophils decrease (grade 3: 4.2%; grade 4: 2.4%) and platelet decrease (grade 3: 3.6%; grade 4: 4.8%) without a clear trend between the arms.

## Clinical chemistry

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The biochemistry worst post-baseline value shifts to Grade 3/4 events were alanine aminotransferase increase (grade 3: 1.2%), amylase increase (grade 3: 1.8%), aspartate aminotransferase increase (grade 3: 0.6%), creatine kinase increase (grade 3: 3.0%), glucose decrease (grade 3: 0.6%, grade 4: 1.8%), magnesium increase (grade 3: 0.6%), potassium decrease (grade 3: 0.6%), triglycerides (fasting) increase (grade 3: 1.2%, grade 4: 0.6%), and triglycerides increase (grade 3: 2.4%, grade 4: 0.6%) without a clear trend between the arms.

## Electrocardiograms

Most common notable ECG findings were QT increase &gt; 30 ms to ≤ 60 ms (28.3%) and QTcF increase &gt; 30 ms to ≤ 60 ms (18.6%) without a clear trend between the arms.

## 2.5.1. Discussion on clinical safety

## Extension of indication to patients with newly diagnosed CML-CP

At data cut-off 22 October 2024, the median duration of exposure was marginally longer in the asciminib group (115.79 weeks) relative to the IS-TKI group (108.70 weeks, FASIMA 100.29; FAS2G 116 weeks). The safety pool hereby presented has a total exposure period of 1.557 patient-treatment years, pivotal study J12301 contributes with 411 years. A higher proportion of participants were still on treatment in the asciminib group (ASC 81.6% vs. IS-TKI 60.3%), as the predefined secondary endpoint TTDAE was positive in favour of asciminib.

The overall incidence of AEs was comparable (&gt;95% in both arms), however, adjusted for exposure, AEs per PTY were reported less frequently (485 vs. 1107). Furthermore, the incidence of Grade ≥ 3 AEs (44.5% vs. 54.7%), SAE (14.5% vs. 20.4%) AE leading to dose adjustment and/or interruption (33.0% vs. 41.4%) or treatment discontinuation (5.0% vs. 13.1%) was lower in the asciminib group. The effect was found in comparison to imatinib and to 2G TKI.

Concerning AE by organ class and preferred term, vascular disorders, including hypertension were reported more frequently in the asciminib group (16.5% vs. 8.5%). Systolic blood pressure increase was seen more often at all grades of hypertension (from ≥ 14 0 mmHg ASC 33.5% vs. IS-TKI 23.9% until ≥180 mmHg 2.0% vs. 0.5%) highlighting the importance for asciminib safety. An increase in body weight≥ 10%) was often and more frequently reported in the asciminib group (32.0% to 20.4%).

Regarding myelosuppression, the picture is inconsistent with remarkably less anaemia (all grades 12.5% vs. 25.9%) and neutropenia (10.5% vs. 16.4%) with asciminib treatment, but more thrombocytopenia (13.5 vs. 15.4% G3/4: 8.0 vs. 5.5%).

For other non-haematologic AE, diarrhoea (17.5% vs. 27.9%), nausea (9.5% vs. 19.9%), peripheral oedema (1.5% vs. 6.5%) or AST increased (3.0% vs. 11.4%) was reported less frequently in the asciminib group. SAE were rare events, with no apparent pattern in the asciminib group with mostly single cases. Until DCO, no on treatment death had occurred.

The cumulative incidences of AEs leading to treatment discontinuation were always lower at each time point (at Week 8, 24, 48, 96) in the asciminib treatment group (week 96: 4.5% vs. 12.9% - imatinib 13.1%; 2G TKI 12.7%), whereas 3 patients from the asciminib group were reported to have 'lipase increased' and two thrombocytopenia. In the IS-TKI group, pleural effusion, diarrhoea and asthenia led to discontinuation for at least two patients. This tendency is present in lower rates of treatment interruptions and dose reductions due to AE. This favourable effect of lower rates of dose reductions and interruptions is acknowledged. However, the applied (and approved) TKI doses in study J12301 are high, given the clinical knowledge of lower, equally effective dosages for 2G- TKI.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The high granularity of data workup for 14 predefined AESI by the Applicant is appreciated. AESI were less frequently found in the asciminib treatment group compared to the ISTKI treatment group (≥ 5.0% difference). In study J12301 asciminib showed lower rates for myelosuppression (43.5% vs. 51.5%), hypersensitivity (26.0% vs. 43.4%) and edema/fluid retention (4.5% vs. 15.2%) in comparison to imatinib and lower rates for myelosuppression (43.5% vs. 63.7%), GI toxicity (39.0% vs. 52.0%) hypersensitivity (26.0% vs. 45.1%) hepatotoxicity (20.0% vs. 36.3%), haemorrhage (potential sequala of thrombocytopenia, 6.5% vs. 11.8%) and edema/ fluid retention (4.5% vs. 14.7%) in comparison to 2G-TKI.

Across all age group categories, most of the AESI in the asciminib treatment group occurred at lower incidence relative to the IS-TKI treatment group. A higher incidence was observed for AE leading to discontinuation, dose adjustment and requiring additional therapy in some categories in the elderly age groups (≥ 65 and ≥ 75 year) compared to &lt; 65 year across all treatment groups. This aspect should be further addressed in comparison to IS-TKI in the follow-up with more data in older patients (long term safety data in the elderly population will be provided as part of the Annex II condition).

## Extension of indication to 2 nd  line CML-CP

In the 2nd line cohort of uncontrolled study CABL001AUS08, occurrence of AEs (95.0%, G3-5: 31.7%), SAEs (3.0%, G3-5: 3.0%) and the incidence of AE leading to dose adjustment (26.7%) is considered to be comparable to results from studies in other lines of therapy. No on-treatment death occurred.

The most common adverse events of special interest for the 2L cohort were gastrointestinal toxicity (51.5%), hypersensitivity (21.8%) and acute pancreatitis (including isolated pancreatic enzyme elevations) (16.8%). The most common Grade &gt;=3 adverse events of special interest were thrombocytopenia (6.9%) and leukopenia (5.9%). No arterial occlusive events (AOEs) were reported. Haemorrhage was reported in 7.95% (G3-5: 1%). GI toxicity is higher in the AUS08 2nd line cohort (51.5%; G3-G5: 3%) compared to the newly diagnosed population of J12301 (39.0%, G3-5 0.5%) and in 3rd or later line study A2301 (31.4%, G3-5: 1.9%). Myelosuppression was reported in 11.9% of patients, 43.5% in the 1st line 37.8 % in 3rd or later line study A2301 with limited comparability due to different exposure in the respective lines, with otherwise comparable safety profiles. No new safety signal was detected.

## New posology of 80 mg QD for the 3rd or later line

Study A2302 is a randomised open- label trial, including 84 patients with asciminib 40mg BID and 80mg QD each, data cut-off 12 March 2024 after a mean exposure of 68.3 weeks.

Patient exposure was comparable with median 67.3 (40 mg BID) vs. 68.6 (80 mg QD) weeks. The treatment was ongoing for 80 vs. 81% of patients. The number of patients reporting AEs irrespective of grade is equal (88 vs. 90%), while for &gt;= G3 events, numerically more patients from the 80 mg QD arm report events (25.0 vs. 34.5%, Δ 8 patients from various PT). The occurrence of AEs leading to discontinuation of study treatment was low and numerically higher in the 40 mg BID arm (7.1% vs. 4.8%) The most frequently reported AE leading to dose adjustment and/or interruption were neutropenia (8.3% vs. 3.6%) and thrombocytopenia (4.8% vs. 7.1%). One death occurred on treatment in the 80 mg QD arm by stroke in a patient who already had a history of stroke. The event was not suspected to be related to the study drug.

Some AESI were numerically less often reported in 40-mg-BID than in 80-mg-QD patients: GI toxicity (23.8 vs. 29.8%); myelosuppression (13.1 vs. 17.9%) and hypersensivity (9.5 vs. 13.1%), ischaemic conditions (3.6 vs. 9.5%), other AESI were numerically more often observed as acute pancreatitis (including isolated enzyme elevations 10.7 vs. 8.3%) and haemorrhage (4.8 vs. 3.6%). Further

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

comparison of haematology, clinical chemistry including liver enzymes and ECG leads for QTcF comparison did not show major imbalances comparing the two dosing regimens in study A2302.

The comparison of safety in 168 patients with either 40 mg BID or 80 mg QD did not show any further safety signal.

## 2.5.2. Conclusions on clinical safety

## Extension of indication to patients with newly diagnosed CML-CP

Regarding study J12301 for the use of asciminib in newly diagnosed CP-CML patients, no new safety concerns arose until DCO. The reported events suggest a manageable safety profile for CML-CP firstline treatment, consistent with previous descriptions. Thrombocytopenia was more common in patients treated with asciminib; however, this did not result in a higher bleeding rate. Instead, the haemorrhage rate was higher in the IS-TKI group. Hypertension and weight gain were observed more frequently with asciminib. Compared to imatinib, the safety profile shows more vascular events, including hypertension, as well as more constipation and abdominal pain. However, there are fewer cases of diarrhoea, anaemia, leukopenia, muscle spasms and oedema.  Compared to 2G-TKIs, asciminib shows more vascular events, including hypertension, but fewer events are reported for cardiac disorders, anaemia, neutropenia, oedema, pleural effusions and hepatic toxicity, as well as nausea and diarrhoea.

In conclusion, the safety profile in newly diagnosed patients was generally consistent with that previously described, with no new safety concerns identified.

Long-term safety data will be provided with the final CSR of study CABL001J12301 (ASC4FIRST) as committed by the MAH in an Annex II condition.

## Extension of indication to 2 nd  line CML-CP

Patients in study AUS08 demonstrated a safety that was generally comparable to the previously described safety profile of asciminib.

## New posology of 80 mg QD for the 3rd or later line

Numerically more patients from the 80 mg QD arm reported G3-5 events (25.0 vs. 34.5%). Discontinuation rate due to AE was higher in the 40 mg BID arm. One death occurred on treatment in the 80 mg QD arm by stroke who already had a history of stroke.

In conclusion, the safety of the two regimens is generally comparable.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.2 is acceptable.

The CHMP endorsed the Risk Management Plan version 4.2 with the following content:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Safety concerns

## Table Error! No text of specified style in document. -93  Part II SVIII.1: Summary of safety concerns

| Important identified risks   | • Acute pancreatitis (including isolated pancreatic enzyme elevations) • Myelosuppression • QTc prolongation   |
|------------------------------|----------------------------------------------------------------------------------------------------------------|
| Important potential risks    | • Hepatotoxicity • Hepatitis B virus infection reactivation • Reproductive toxicity                            |
| Missing information          | • Long-term safety • Use in patients with renal impairment • Use in patients with hepatic impairment           |

## Pharmacovigilance plan

## Routine pharmacovigilance activities

## Specific adverse reaction follow-up checklists:

Targeted follow-up checklist will be used to collect further data to help further characterize and/or closely monitor the safety concern specified below:

- Reproductive toxicity

Other forms of routine pharmacovigilance activities for risks

No other forms of routine PhV activities for important risks are proposed.

Other routine pharmacovigilance activities related to any safety topics for which a specific activity is required

The following safety topic will be closely monitored and reported in the Periodic Safety Update Reports:

- Arterial  occlusive  events  (including  ischemic  heart  and  CNS  conditions  plus  arterial  embolic  and thrombotic events).

## Additional pharmacovigilance activities

Table Error! No text of specified style in document. -94  Part III.1: Ongoing and planned additional pharmacovigilance activities

Study

Status

Summary

of

objectives

Safety

concerns

addressed

Milestones

Due dates

Category  1  -  Imposed  mandatory  additional  pharmacovigilance  activities  which  are  conditions  of  the  marketing authorization

None

Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances

None

Category 3 - Required additional pharmacovigilance activities

CABL001A2301

A Phase 3, multi- center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated

To compare the efficacy of asciminib with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of 2 prior ATP-binding site TKIs with BCR::ABL1 ratios ≥ 1% IS at screening

Long-term safety, acute pancreatitis (including isolated pancreatic enzyme elevations), myelosuppression, QTc prolongation, hepatotoxicity

Final report submission

31-Jul-2025

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

EMADOC-1700519818-2475374

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                 | Summary objectives                                                                                                                                                                                                                                                         | of                                                                                                                                                                        | Safety addressed                                                                                 | concerns Milestones           | Due dates   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------|-------------|
| Ongoing                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                            |                                                                                                                                                                           |                                                                                                  |                               |             |
| CABL001A2302 A Phase 3b, multi- center, open-label, treatment optimization study of oral asciminib in patients with chronic myelogenous leukemia in chronic phase (CMLCP) previously treated with 2 or more                                  | To optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).                                                                                        | Long-term pancreatitis isolated enzyme myelosuppression, prolongation, hepatotoxicity. virus infection reactivation, patients impairment, patients impairment.            | safety, acute (including pancreatic elevations), hepatitis use in with renal use in with hepatic | QTc B Final report submission | 11-Mar-2027 |
| Ongoing                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                            |                                                                                                                                                                           |                                                                                                  |                               |             |
| CABL001A2001B An open label, multi- center asciminib roll- over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment. | To assess long-term safety and provide continued treatment with asciminib for patients with CML-CP who have participated in a Novartis sponsored asciminib clinical study (parent study) and, in the opinion of the investigator, would benefit from continuing treatment. | Long-term safety, pancreatitis (including isolated pancreatic enzyme elevations), myelosuppression, prolongation, hepatotoxicity, hepatitis virus infection reactivation. | acute QTc                                                                                        | B Final report submission     | 31-Dec-2028 |

Ongoing

Table -95 Part IV.1: Planned and ongoing post-authorization efficacy studies that are conditions of the marketing authorization or that are specific obligations

| Study , Status                                                                                                                                                                                                                                    | Summary of Objectives                                                                                                                                                                                                                                                                                                                                        | Efficacy uncertainties addressed                                                                         | Safety concerns addressed                                                                                                                                                                                                                            | Milestones                                                           | Due Date                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Efficacy studies which are conditions of the marketing authorization                                                                                                                                                                              | Efficacy studies which are conditions of the marketing authorization                                                                                                                                                                                                                                                                                         | Efficacy studies which are conditions of the marketing authorization                                     | Efficacy studies which are conditions of the marketing authorization                                                                                                                                                                                 | Efficacy studies which are conditions of the marketing authorization | Efficacy studies which are conditions of the marketing authorization |
| CABL001J12301 A phase III, multi- center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase Ongoing | To compare the efficacy of asciminib versus Investigator selected TKI, with respect to the proportion of participants that are in Major Molecular Response (MMR) at Week 48 and Week 96 To compare the efficacy of asciminib versus Investigator selected TKI, within the stratum of participants with imatinib as the pre- randomization selected TKI, with | Long-term efficacy, including long-term response rates, progression-free survival, and overall survival. | Further characterizatio n of the safety and tolerability profile of asciminib [acute pancreatitis (including isolated pancreatic enzyme elevations), myelosuppress ion, QTc prolongation, hepatotoxicity, hepatitis B virus infection reactivation], | Final report submission                                              | 30-Sep-2031                                                          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Study , Status                                                                                                                                                       | Summary of Objectives                                                                                                                                                                                                                       | Efficacy uncertainties addressed                                                                                                                                     | Safety concerns addressed                                                                                                                                            | Milestones                                                                                                                                                           | Due Date                                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                      | respect to the proportion of participants that are in MMR at Week 48 and Week 96 To characterize the safety and tolerability profile of asciminib versus 2G TKIs (nilotinib, dasatinib, or bosutinib) during the course of study treatment. |                                                                                                                                                                      | Long-term Safety]                                                                                                                                                    |                                                                                                                                                                      |                                                                                                                                                                      |
| Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                        | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                 |                                                                                                                                                                                                                                             |                                                                                                                                                                      |                                                                                                                                                                      |                                                                                                                                                                      |                                                                                                                                                                      |

## Risk minimisation measures

Table Error! No text of specified style in document. -96  Summary of pharmacovigilance activities and risk minimization activities by safety concerns

| Safety concern                                                       | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks                                           | Important identified risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Important identified risks                                                                                                                                                                                                                                                                                                                      |
| Acute pancreatitis (including isolated pancreatic enzyme elevations) | Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPC Section 4.4 where description of the risk along with monitoring and treatment guidance are added. SmPC Section 4.8 where the adverse reactions related to acute pancreatitis (including isolated pancreatic enzyme elevations) are listed. PL Section 2 where precautions, monitoring and treatment are described. PL Section 4 where possible side effects of asciminib are described. Legal status: Medical prescription only product Additional risk minimization measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2301 (Final report submission: 31-Jul- 2025), CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- 2028) |
| Myelosuppression                                                     | Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPC Section 4.4 where description of the risk along with monitoring and treatment guidance are added. SmPC Section 4.8 where the adverse reactions related to myelosuppression are listed. PL Section 2 where precautions, monitoring and treatment are described. PL Section 4 where possible side effects of asciminib are described. Legal status: Medical prescription only product                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2301 (Final report submission: 31-Jul- 2025), CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- 2028) |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Safety concern                           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| QTc prolongation                         | None Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPC Section 4.4 where description of the risk along with monitoring and treatment guidance are added. SmPC Section 4.5 where precaution while administrating asciminib with medicinal products with known risk of torsades de pointes is added. SmPC Section 4.8 where adverse reactions related to QTc prolongation are listed. SmPC Section 5.1 where effect of asciminib in cardiac electrophysiology is described. PL Section 2 where precautions, monitoring and treatment are described. PL Section 4 where possible side effects of asciminib are described. Legal status: Medical prescription only product Additional risk minimization | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2301 (Final report submission: 31-Jul- 2025), CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- 2028) |
| Important potential risks                | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Important potential risks                                                                                                                                                                                                                                                                                                                       |
| Hepatotoxicity                           | Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPC Section 4.8 where the adverse reactions related to hepatotoxicity are listed. SmPC Section 5.2 where PK of asciminib in patients with hepatic impairment is described. PL Section 4 where possible side effects of asciminib are described. Legal status: Medical prescription only product Additional risk minimization measures None Routine risk minimization measures                                                                                                                                                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2301 (Final report submission: 31-Jul- 2025), CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- 2028) |
| Hepatitis B virus infection reactivation | SmPC Section 4.4 where description of the risk along with monitoring and treatment guidance are added. PL Section 2 where precautions, monitoring and treatment are described. Legal status: Medical prescription only product Additional risk minimization measures None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- 2028)                                                       |
| Reproductive toxicity                    | Routine risk minimization measures SmPC Section 4.6 where effects of asciminib in fertility, pregnancy and lactation are described.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Follow-up using a targeted checklist.                                                                                                                                                                                                              |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Safety concern                          | Risk minimization measures                                                                                                                                                                                                                         | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                         | PL Section 2 where precautions, monitoring and treatment are described. Legal status: Medical prescription only product Additional risk minimization measures                                                                                      | None                                                                                                                                                                                                                                                                                                                                      |
| Missing information                     | Missing information                                                                                                                                                                                                                                | Missing information                                                                                                                                                                                                                                                                                                                       |
| Long-term safety                        | Routine risk minimization measures SmPC: None PL: None Additional risk minimization measures None                                                                                                                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from studies CABL001A2301 (Final report submission: 31-Jul- 2025), CABL001A2302 (Final report submission: 11-Mar- 2027), and CABL001A2001B (Final report submission: 31-Dec- |
| Use in patients with renal impairment   | Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPCSection 5.2 where PKof asciminib in patients with renal impairment is described. Additional risk minimization measures None     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from Study CABL001A2302 (Final report submission: 11-Mar-2027)                                                                                                               |
| Use in patients with hepatic impairment | Routine risk minimization measures SmPC Section 4.2 where posology and method of administration are described. SmPC Section 5.2 where PK of asciminib in patients with hepatic impairment is described. Additional risk minimization measures None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities Evaluation of data from Study CABL001A2302 (Final report submission: 11-Mar-2027)                                                                                                               |

## 2.7. Update of the Product information

As a consequence of this new indication and posology, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

Compared to the already approved PIL submitted with the MAA which underwent user testing, there are only limited updates in the currently proposed PIL.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).

## 3.1.2. Available therapies and unmet medical need

The two main goals of CML-CP treatment are to normalise survival and to achieve durable deep molecular remissions (DMR, including MR4 and MR4.5 lasting for 2-5+ years) allowing for treatmentfree remission (TFR).

There are four TKIs approved in the EU for the treatment of newly diagnosed CML-CP (1 st  generation: imatinib; 2 nd  generation: nilotinib, dasatinib, bosutinib).

Asciminib (ABL001), administered orally, is a potent allosteric inhibitor of ABL/BCR-ABL1 tyrosine kinase by specifically targeting the ABL myristoyl pocket (STAMP). Asciminib was approved in the EU for adults after treatment with two or more TKIs on 25 August 2022.

The choice of the TKI depends on 1) the patient's age and comorbidities 2) the CML risk profile 3) the cost and affordability of the TKI and 4) the treatment goal, as imatinib is considered to be equally effective for prolongation of survival to 2nd generation TKI. Achievement of deep molecular remissions is potentially faster with 2nd generation TKI, possibly reaching the criteria for a discontinuation attempt in a TFR faster.

A respectable number of patients fail to reach or maintain deep remissions due to primary or secondary resistance or have difficulties in the tolerability of the drug.

## 3.1.3. Main clinical studies

Three clinical studies were presented in this application.

## I. Study CABL001J12301 (ASC4FIRST):

Ongoing pivotal randomised-controlled phase III clinical trial comparing asciminib 80 mg QD monotherapy with investigator's selected TKI (imatinib 400 mg QD, nilotinib 300 mg BID, dasatinib 100 mg QD or bosutinib 400 mg QD) in 405 patients with CML-CP. Stratification was applied according to ELTS score (low vs. intermediate vs. high) and PRS-IKI (imatinib vs. 2G TKI). Primary endpoints were a comparison of MMR rates at week 48 for the overall population (FAS) and for the imatinib stratum (FASIMA); key secondary endpoints were a comparison of MMR rate at week 96 for the overall population (FAS) and for the imatinib stratum (FASIMA). The efficacy comparison between asciminib and 2G TKI was addressed by a secondary endpoint. Further secondary endpoints included different molecular levels and duration of the response at different time points up to week 96 (CHR, MR2.0, MR3.0 (MMR), MR4.0 and MR4.5 at all scheduled data collection time points), time to treatment failure and event free survival.

## II. Study CABL001AUS08 / ASC2ESCALATE:

Supportive evidence for the 2 nd  line efficacy of asciminib in CML-CP comes from the 2 nd  line cohort of the ongoing, uncontrolled, open-label, single-arm, dose escalation, multicentre phase II study AUS08 in participants with CML-CP receiving asciminib 80 mg QD monotherapy with response levels as

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

endpoints. The study has completed enrolment with 101 2 nd  line patients, of which 63 were efficacy evaluable with MMR rates at week 24 at DCO 15 November 2024. After a request for supplementary information, results with data-cut off of 16 May 2025 were provided.

## III. Study CABL001A2302 (ASC4OPT):

Supportive clinical evidence for the new posology of 80 mg QD for the 3 rd  or later line comes from an ongoing phase III, non-comparative, open-label, multi-centre, treatment optimisation study with 168 patients 1:1 randomised to asciminib 40 mg BID or asciminib 80 mg QD in CML-CP patients after two or more lines of therapy. MMR rate at week 48 is the primary endpoint, aiming at a statistically significant difference to MMR rate at week 48 of 23% in the overall population. No stratification was applied. No direct comparison was planned or conducted between both groups and no margin for equivalence/non-inferiority was pre-specified.

## 3.2. Favourable effects

## I. Extension of indication to patients with newly diagnosed CML-CP

MMR rate at week 48 (co-primary endpoints 1+2): The differences in MMR rates at week 48 are

- in the overall population (FAS) Δ 18.9 % (95% CI: 9.59, 28.17; one sided p &lt;0.001) with 67.7% vs. 49.0% MMR rate at week 48 in the ASC arm vs. IS-TKI arm, respectively.
- in the imatinib stratum (FAS IMA ) Δ 29.6% (95% CI: 16.9, 42.2; one -sided p &lt; 0.001) with 69.3% vs. 40.2% MMR rate at week 48 in the ASC IMA  population vs. IS-TKI IMA  population, respectively.

MMR rate at week 96 (key secondary endpoints 1+2): The differences in MMR rates at week 96 are

- in the overall population (FAS) Δ 22.4% (95% CI: 13.6, 31.3; one sided p &lt;0.001) with 74.1% vs 52.0% MMR rate at week 96 in the ASC arm vs. IS-TKI arm.
- in the imatinib stratum (FAS IMA ) Δ 29.7% ( 95% CI, 17.6, 41.8; one sided p&lt;0.001) with 76.2% vs 47.1% MMR rate at week 96 in the ASC IMA  population vs. IS-TKI IMA  population.

Regarding MR2.0 rate, the numerical difference between arms by week 48 was 22.0% (95% CI: 11.95, 32.06; 91.1% vs. 69.6%) for the FAS IMA  and 9.67% (95% CI: 1.45, 17.89; 94.0% vs. 84.3%) for the FAS 2G  in favour of asciminib.

Regarding MR4.0 rate, the numerical difference between arms by week 48 was 30.2% (95% CI: 18.61, 41.83; 56.4% vs. 28.4%) for the FAS IMA  and 7.54% (95% CI; -4.77, 19.86; 36.0% vs. 28.4%) for the FAS 2G  in favour of asciminib.

Regarding MR4.5 rate, the numerical difference between arms by week 48 was 16.2% (95% CI: 7.01, 25.29; 21.8% vs. 5.9%) for the FAS IMA  and 0.33% (95% CI; -10.03, 10.69; 18.0% vs. 17.7%) for the FAS 2G  in favour of asciminib.

The KM probability of treatment failure was numerically lower in the asciminib arm compared to the ISTKI arm (HR=0.37; 95% CI: 0.25, 0.55), by one year the KM estimated probability of being treatment failure-free is higher in the asciminib arm (88.0%, 95% CI: 82.6, 91.8) compared to the IS-TKI arm (74.1%, 95% CI: 67.5, 79.6).

## II. Extension of the indication to 2nd line CML-CP treatment

Responses at week 24: BCR::ABL1&lt;=10% rate was 90.5% (95%CI: 80.4%, 96.4%) MR2 rate 82.5% (95%CI: 70.9%, 91.0%), MMR (MR3) rate 44.4% (95%CI: 31.9%, 57.5%), MR4.0 rate 25.4%

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

(95%CI: 15.3%, 37.9%) and MR4.5 rate 9.5% (95% CI: 3.6%, 19.6%). MMR rate at week 36 is 52.4% (36.4, 68.0). MMR rate at week 48: 55.6% (40/72; 95% CI: 43.4; 67.3%).

- III. New posology of 80 mg QD for the 3 rd  or later line, 40 mg BID in earlier lines The study met its primary endpoint, for participants without MMR at baseline, the overall rate of MMR at Week 48 in FAS was 38.5% (95% CI: 31.09, 46.24).

Post- hoc comparison: The rate of MMR at Week 48 was 42.4% (95% CI: 31.70, 53.55) vs. 34.5% (95% CI: 24.48, 45.69) for the asciminib 40 mg BID group vs. asciminib 80 mg QD group, respectively. The numerical difference in MMR rate is 7.8% in favour of 40 mg BID.

The performed post-hoc propensity score weighting according to baseline characteristics led to a reduced difference of 2.43 (95% CI: -12.71, 17.56) in favour of asciminib 40 mg BID.

Supportive evidence comes from efficacy and activity with 80 mg QD dosing in newly diagnosed CMLCP (study J12301) and 2 nd  line CML-CP (study AUS08).

## 3.3. Uncertainties and limitations about favourable effects

## I. Extension of indication to patients with newly diagnosed CML-CP

The results of the long-term (&gt;96 weeks) outcomes of this potentially lifelong therapy are pending. The MAH committed to provide (Annex IID condition) a follow up of 8 years to judge the durability of responses, particularly in terms of the number of TFRs achieved, the duration of TFI, and more mature EFS data, since PFS and OS data are unlikely to mature. As the predictiveness of responses for clinical endpoints has been established for CML based on ATP-binding site-targeting TKIs, the translation of responses to clinical endpoints for the myristoyl pocket-targeting agent while be further confirmed with the long term results (see Annex II).

## II. Extension of the indication to 2nd line CML-CP treatment

The interpretability of the data is hampered due to the uncontrolled nature of the trial, however taken altogether the results support the efficacy in 2 nd  line treatment of CML-CP.

## III. New posology of 80 mg QD for the 3 rd or later line, 40 mg BID in earlier lines

The study design implemented a 1:1 randomisation between the two regimens of 40 mg BID and 80 mg QD, as the study was planned as a post-authorisation study for treatment optimisation. The objectives, however, were formally not aligned for a comparison between the two arms. The post-hoc defined propensity score weighting addressing putative imbalances in baseline characteristics for studies A2301 and A2302 is not justified, adequate or reliable. Following a request for supplementary information the applicant conducted the requested analyses. The difference in MMR rate at week 48 of -7.8% (95% CI: -22.45, 6.79) in the unadjusted analysis is considered clinically relevant. It is not possible to conclude on the equivalence/similarity of the two posologies based on overlapping confidence intervals, nor on superiority of one of the dosing regimen in the absence of statistical significant superiority of 40 mg BID dosing in comparison to 80 mg QD. The potential lower efficacy with 80 mg QD is reflected in section 4.4 of the SmPC.

## 3.4. Unfavourable effects

## I. Extension of indication to newly diagnosed Ph+ CML-CP

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The safety profile of asciminib in CML -CP 1 st  line is based on data (DCO 22 October 2024) from RCT J12301 in 200 asciminib-exposed patients with a median exposure of 115.8 weeks. Overall, estimated cumulative post-marketing exposure of asciminib contains 7601 patient treatment years (PTY).

The risk of study treatment discontinuation due to AEs at week 96 was a predefined endpoint and statistically significantly lower in the asciminib group compared to 2G TKI (TTDAE, HR = 0.463; 95% CI: 0.215, 0.997; adjusted one sided p-value: 0.0246) and numerically lower compared to the imatinib group (HR = 0.381; 95% CI: 0.178, 0.818). Most common reasons for discontinuation of asciminib (for more than two patients) by PT were 'lipase increased' or 'thrombocytopenia'.

The overall incidence of AE was comparable to IS-TKI (&gt;95%), however, after adjustment for exposure numerically favourable for asciminib. Furthermore, the incidence of Grade ≥ 3 AEs (44.5% vs. 54.7%), SAE (14.5% vs. 20.4%) AE leading to dose adjustment and/or interruption (33.0% vs. 41.4%) or treatment discontinuation (5.0% vs. 13.1%) was numerically lower in the asciminib group. The effect was found in comparison to imatinib and to 2G TKI. Until DCO, no on treatment death had occurred.

The applicant defined 14 AESI derived from the current safety profile. Asciminib showed lower rates for myelosuppression, hypersensitivity and edema/fluid retention in comparison to imatinib and lower rates for myelosuppression, GI toxicity hypersensitivity hepatotoxicity, haemorrhage (potential sequala of thrombocytopenia, 6.5% vs. 11.8%) and edema/ fluid retention in comparison to 2G-TKI.

However, vascular disorders, including hypertension (16.5% vs. 8.5%), increase in body weight ≥ 10% (32.0% vs. 20.4%) and thrombocytopenia (13.5 vs. 15.4% G3/4: 8.0 vs. 5.5%) were reported more frequently in the asciminib group (16.5% vs. 8.5%).

## II. Extension of indication to 2nd line CML-CP

Incidence of AEs in the SAT is 95.0% (G3-5: 31.7%), SAEs 3.0% (G3-5: 3.0%) and AE leading to dose adjustment 26.7% in 2L cohort of study AUS08. No on-treatment death occurred. Common AESI were GI toxicity (51.5%), hypersensitivity (21.8%), acute pancreatitis (ink. isolated enzyme elevations) with 16.8%. No AOE events occurred. No new safety signal was detected.

## III. New posology of 80 mg QD for the 3rd or later line, 40 mg BID in earlier lines

Study A2302 is a randomised (1:1) open- label phase IIIB trial, including 168 patients with asciminib either 40mg BID or 80mg QD, data cut-off was 12 March 2024 after a mean exposure of 68.3 weeks.

Patient exposure was comparable with median 67.3 (40 mg BID) vs. 68.6 (80 mg QD) weeks. The treatment was ongoing for 80 vs. 81% of patients. The number of patients reporting AEs irrespective of grade is equal (88 vs. 90%), while for &gt;= G3 events, numerically more patients from the 80 mg QD arm report events (25.0 vs. 34.5%, Δ 8 patients from various PT). The occurrence of AEs leading to discontinuation of study treatment was low and numerically higher in the 40 mg BID arm (7.1% vs. 4.8%). The most frequently reported AE leading to dose adjustment and/or interruption were neutropenia (8.3% vs. 3.6%) and thrombocytopenia (4.8% vs. 7.1%) for the 40 mg BID vs. 80 mg QD arm, respectively. One death occurred on treatment in the 80 mg QD arm by stroke who already had a history of stroke. The event was not suspected to be related to the study drug.

Some AESI were numerically less often reported in 40-mg-BID than in 80-mg-QD patients: GI toxicity (23.8 vs. 29.8%); myelosuppression (13.1 vs. 17.9%) and hypersensivity (9.5 vs. 13.1%), ischaemic conditions (3.6 vs. 9.5%), other AESI were numerically more often observed in the 40 mg -BID patients as acute pancreatitis (including isolated enzyme elevations 10.7 vs. 8.3%) and haemorrhage (4.8 vs. 3.6%). Further comparison of haematology, clinical chemistry including liver enzymes and ECG leads for QTcF interval prolongation did not show major imbalances between the two dosing regimens in study A2302.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The treatment of 168 patients with either 40 mg BID or 80 mg QD did not show any further safety signal.

## 3.5. Uncertainties and limitations about unfavourable effects

## I. Extension of indication to newly diagnosed Ph+ CML-CP

From 200 asciminib exposed patients, only 10 patients were older than 74 years of age. In this age group, rates for AE by PT hypertension, constipation, diarrhoea, nausea, arthralgia, pain in extremities, pruritus and headache are higher compared to younger patients. Further follow- up is required to assess the safety profile in the older population.

For a potentially lifelong therapy, exposure and follow-up is still considered limited, especially regarding the experience with serious emerging safety signals in later follow up of other BCR-ABL targeting agents (esp. AOE). Long-term safety (including in the elderly population) will be collected and reported in the final CSR for study J12301 (see Annex II)

## II. Extension of indication to 2nd line CML-CP

The median duration of exposure at DCO is only 26.1 weeks. Furthermore, no clear comparability is given due to a lack of a control arm, cross - study comparisons are difficult.

- III. New posology of 80 mg QD for the 3rd or later line, 40 mg BID in earlier lines N/A.

## 3.6. Effects Table

Table 97: Effects Table for asciminib in study J12301, data cut-off 28 November 2023

| Effect                         | Short description                 | Population           | Treatment            | Control              | Strength of evidence/ Uncertainties (95% CI)   |                      |
|--------------------------------|-----------------------------------|----------------------|----------------------|----------------------|------------------------------------------------|----------------------|
| Favourable Effects             | Favourable Effects                | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                             | Favourable Effects   |
|                                |                                   |                      | Asciminib 80 mg QD   | IS-TKI               |                                                |                      |
| Major molecular response (MMR) | MMR rate at week 48 (vs IS-TKIs)  | FAS                  | 67.66%               | All: 49.02%          | 18.88% 95% CI (9.59, 28.17); p<0.001           |                      |
| MMR                            | MMR rate at week 48 (vs imatinib) | FAS IMA              | 69.31%               | Imatinib: 40.2%      | 29.55% 95% CI (16.91, 42.18); p< 0.001.        |                      |
| MMR                            | MMR rate at week 96 (va IS-TKIs)  | FAS                  | 74.13%               | 51.96%               | 22.42% 95%CI (13.6, 31.3); p< 0.001            |                      |
| MMR                            | MMR rate at week 96 (vs imatinib) | FAS IMA              | 76.24%               | 47.06%               | 29.76% 95% CI (17.6, 41.8); p<0.001            |                      |
| Unfavourable Effects           | Unfavourable Effects              | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                           | Unfavourable Effects |
| Study J12301                   |                                   |                      | Asciminib n=200      | 2G TKI n=102         |                                                |                      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Effect                                               | Short description    | Population   | Treatment   | Control   | Control   | Strength of evidence/ Uncertainties (95% CI)   |
|------------------------------------------------------|----------------------|--------------|-------------|-----------|-----------|------------------------------------------------|
| AE                                                   | All grade% Grade ≥3% |              | 95.5 44.5   | 100 59.8  | 97 49.5   |                                                |
| SAE                                                  | All grade% Grade ≥3% |              | 14.5 11.5   | 14.5 11.5 | 16.2 14.1 |                                                |
| Myelosuppression                                     | All grade% Grade ≥3% |              | 43.5 20.0   | 63.7 33.3 | 51.5 24.2 |                                                |
| GI toxicity                                          | All grade% Grade ≥3% |              | 39.0 0.5    | 52.0 4.9  | 43.4 0    |                                                |
| Acute pancreatitis (ink. isolated enzyme elevations) | All grade% Grade ≥3% |              | 14.5 3.5    | 17.6 5.9  | 16.2 3.0  |                                                |
| Haemorrhage                                          | All grade% Grade ≥3% |              | 6.5 0       | 11.8 2.9  | 10.1 1.0  |                                                |
| Arterial-occlusive events                            | All grade% Grade ≥3% |              | 2.0 0.5     | 2.9 1.0   | 0 0       |                                                |

Abbreviations: AE=adverse events, GI=gastrointestinal, SAE=serious adverse event,. MMR=major molecular response, defined as BCR-ABL1 &gt; 0.1%

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

## I. Extension of indication to patients with newly diagnosed CML-CP

The phase III study J12301 demonstrated a statistically significant superiority for asciminib monotherapy compared to investigator's selected TKI in newly diagnosed CML-CP patients. The primary endpoint, MMR rate after 48 weeks resembling an 'optimal response' milestone according to current guidelines (NCCN, ELN) showed a 18.9% (95% CI: 9.59, 28.17) improvement for the overall population. The effect was conclusively present against the imatinib stratum too and, although in a lower extent, the 2G-TKI stratum as well and supported by statistical superior results at week 96, numerically higher rates of response for EMR, MR2.0, DMR. Subgroup analyses according to risk profile and age group support the effect. The results of the long-term (&gt;96 weeks) outcomes of this potentially lifelong therapy are pending (the MAH has committed to provide them via an Annex IID condition).

No new safety concerns arose until the data cut-off. The reported events suggest a manageable safety profile for CML-CP first-line treatment, consistent with previous descriptions. Thrombocytopenia was more common in patients treated with asciminib; however, this did not result in a higher bleeding rate. Hypertension and weight gain were observed more frequently with asciminib.

Compared to imatinib, the safety profile shows more vascular events, including hypertension, as well as more constipation and abdominal pain. However, there are fewer cases of diarrhoea, anaemia, leukopenia, muscle spasms and oedema.

Compared to 2G-TKIs, asciminib shows more vascular events, including hypertension, but fewer events are reported for cardiac disorders, anaemia, neutropenia, oedema, pleural effusions and hepatic toxicity, as well as nausea and diarrhoea.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## II. Extension of the indication to 2nd line CML-CP treatment

Results from the SAT in 2nd line CML-CP patients provide reasonable evidence for activity of asciminib after one previous TKI therapy. MMR rate achieved in this population lays in between rates in newly diagnosed or &gt;= third line patients with asciminib monotherapy.

The safety of asciminib after one line of therapy is also consistent with the so far established safety profile. No new safety signals were detected.

## III. New posology of 80 mg QD for the 3 rd or later line, 40 mg BID in earlier lines

In general, evidence for the new posology comes from demonstrated activity and efficacy of asciminib 80 mg QD in CML-CP 1 st  and 2 nd  line patients. Of note, adherence/ relative dose intensity might be worse for the 40 mg BID in daily practice due to food restrictions compared to the study.

Supportive clinical evidence, RCT A2302 (ASC4OPT) in 169 patients, for the evaluation of efficacy of the two dosing regimens in 3 rd  line treatment was provided. The difference in MMR rate at week 48 was 7.83% (95% CI: -22.45, 6.79 ) in favour of 40 mg BID. No equivalence margin was predefined, however, the difference of 7.8% is considered to be clinically relevant. This potential for lower efficacy of the 80 mg QD posology is addressed in Section 4.4 of the SmPC.

Safety of the two posologies appears comparable in RCT A2102 (ASC4OPT), hence both regimen are recommended in section 4.2 thus providing different options to the patient.

Notably, the proposed posology of 80 mg QD is useful for patients with impaired adherence or for whom a twice daily intake in fasting conditions is not feasible (such as patients with food restrictions like diabetes mellitus, with difficulties to swallow or patients in need of care who only have nursing aid once a day). In order to make an informed treatment decision, prescribers should be able to base their decision on the information available. The results of study A2302 (ASC4OPT) have therefore been added to the SmPC (results are reported in section 5.1 and a warning has been added to section 4.4).

## 3.7.2. Balance of benefits and risks

## I. Extension of indication to patients with newly diagnosed CML-CP

The efficacy of asciminib monotherapy compared with investigator's selected TKI has been demonstrated in the pivotal RCT J12301. The safety profile was generally consistent with that previously described, with no new safety concerns identified.

## II. Extension of the indication to 2nd line CML-CP treatment

The benefit-risk balance for patients with CML-CP in the second-line treatment setting is considered to be similar to that in the first- and third/later-line disease settings.

## III. New posology of 80 mg QD for the 3 rd or later line, 40 mg BID in earlier lines

Efficacy of 80 mg QD has been shown in newly diagnosed CML-CP compared to investigator's selected TKI and activity was demonstrated with 80 mg QD in CML-CP 2 nd line treatment.

However, clinical data provided from the ASC4OPT study does not support the equivalence of different regimens in the 3 rd or later-line treatment of chronic myeloid leukaemia (CML), with clinically relevant lower major molecular response (MMR) rates at week 48 with the 80 mg once-daily (QD) dosing regimen.

The proposed posology of 80 mg QD is however considered useful for patients with impaired adherence or for whom a twice daily intake in fasting conditions is not feasible (i.e. patients with food restrictions

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

such as diabetes mellitus, with difficulties to swallow or patients in need of care who only have nursing aid once a day). In order to make an informed treatment decision, the results of study A2302 (ASC4OPT) have been added to the SmPC (section 5.1 and a warning has been added to section 4.4) .

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of Scemblix is positive.

The following measures are considered necessary to address remaining uncertainties related to long term efficacy and safety:

In order to further evaluate the long-term efficacy and safety of asciminib in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP), the MAH should submit the final CSR of study CABL001J12301 (ASC4FIRST), see Annex II.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                                                         | Type              |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| C.I.6.a               | C.I.6.a Addition of a new therapeutic indication or modification of an approved one                                                                         | Variation type II |
| C.I.4                 | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data | Variation type II |

A grouped application consisting of:

C.I.6.a: Extension of indication to include treatment of adult patients with Philadelphia chromosomepositive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) for SCEMBLIX.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. RMP version 4.2 has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.

C.I.4: Update of sections 4.2, 4.5, 5.1, 5.2 and 5.3 of the SmPC in order to introduction of a new posology regimen of 80 mg QD. The Package Leaflet is updated accordingly. RMP version 4.2 has also been submitted.

The group of variations leads to amendments to the annexes I, II and IIIB and to the Risk Management Plan (RMP).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

This recommendation is subject to the following new condition:

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## · Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                  | Due date    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Post-authorisation efficacy study (PAES): In order to further evaluate the long-term efficacy and safety of asciminib in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP), the MAH should submit the final CSR of study CABL001J12301 (ASC4FIRST). | 30-Sep-2031 |

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 1).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this &lt;group of variations&gt;&lt;variation. In particular the 'EPAR-Procedural steps taken and scientific information after authorisation' will be updated as follows:

## Scope

Please refer to the Recommendations section above.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Summary

Please refer to Scientific Discussion 'Scemblix-H-C-5605-II-VR/0000265010.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_